Generated by All in One SEO v4.9.8, this is an llms.txt file, used by LLMs to index the site.

# nlvpartners

Funding the healthcare revolution.

## Sitemaps

- [XML Sitemap](https://www.nlvpartners.com/sitemap.xml): Contains all public & indexable URLs for this website.

## Posts

- [News | May 20, 2026](https://www.nlvpartners.com/news-may-20-2026/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”May 20, 2026″ _builder_version=”4.27.0″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]MemorialCare Heart & Vascular Institute Becomes First Hospital in Los Angeles County to Offer Cleerly AI-Powered Heart Disease Analysis, Quantifying Total Plaque Volume and Soft Plaque Systemwide launch brings AI powered assessment
- [News | March 20, 2026](https://www.nlvpartners.com/news-march-20-2026/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”March 20, 2026″ _builder_version=”4.27.0″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]Cleerly AI-QCT Demonstrates High Agreement With Invasive IVUS in INVICTUS Registry Multicenter INVICTUS Registry Demonstrates Strong Correlation Between Noninvasive AI-QCT and Invasive IVUS for Coronary Plaque Quantification March 20, 2026 (DENVER, CO)
- [News | May 12, 2026](https://www.nlvpartners.com/news-may-12-2026/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”May 12, 2026″ _builder_version=”4.27.0″ _module_preset=”default” global_colors_info=”{}”]Bluesight Launches Prism, an AI Platform Built for Health Systems, Debuting with Prism Assistant By Adam Rosenberg Prism Assistant, the first product within Bluesight’s new AI platform, is now available in ControlCheck and cuts
- [News | May 5, 2026](https://www.nlvpartners.com/news-may-5-2026/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||” theme_builder_area=”post_content”][et_pb_text admin_label=”May 5, 2026″ _builder_version=”4.27.0″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” theme_builder_area=”post_content” sticky_enabled=”0″]Electra Therapeutics Announces First Patient Dosed in Phase 1 Study of Ipsoprubart (ELA026) in T Cell Malignancies Phase 1 study builds on early signals of anti-tumor activity in
- [News | April 21, 2026](https://www.nlvpartners.com/news-april-21-2026/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||” theme_builder_area=”post_content”][et_pb_text admin_label=”April 21, 2026″ _builder_version=”4.27.0″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” theme_builder_area=”post_content” sticky_enabled=”0″]STAR THERAPEUTICS RECEIVES FDA RARE PEDIATRIC DISEASE AND BREAKTHROUGH THERAPY DESIGNATIONS FOR VGA039 IN VON WILLEBRAND DISEASE PROPHYLAXIS VGA039 is a once monthly, subcutaneously self-administered investigational therapy for
- [News | June 1, 2026](https://www.nlvpartners.com/news-june-1-2026-2/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||” theme_builder_area=”post_content”][et_pb_text admin_label=”June 1, 2026″ _builder_version=”4.27.0″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” theme_builder_area=”post_content” sticky_enabled=”0″]Edgewise Therapeutics Announces Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline — Edgewise to Receive $1.55 Billion in
- [News |  June 1, 2026](https://www.nlvpartners.com/news-june-1-2026/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||” theme_builder_area=”post_content”][et_pb_text admin_label=”June 1, 2026″ _builder_version=”4.27.0″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” theme_builder_area=”post_content” sticky_enabled=”0″]Rallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Generation Oncology Therapies and $215 Million Concurrent Private Placement Combined company to operate as Avenzo Therapeutics, advancing a
- [News | March 18, 2026](https://www.nlvpartners.com/news-march-18-2026/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”March 18, 2026″ _builder_version=”4.27.0″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson’s Disease Treated for 28 Days – ARV-102 reduced endolysosomal and neuroinflammatory
- [News | February 23, 2026](https://www.nlvpartners.com/news-february-23-2026/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”February 23, 2026″ _builder_version=”4.27.0″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]TigerConnect Launches AI-Powered Operator Console To Modernize Hospital Communications Cloud-Native Smart Switchboard Replaces Legacy Operator Consoles EL SEGUNDO, CA, February 23, 2026 — TigerConnect, the leader in healthcare communication orchestration, today announced
- [News | December 6, 2025](https://www.nlvpartners.com/news-december-6-2025/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”December 6, 2025″ _builder_version=”4.27.0″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]STAR THERAPEUTICS PRESENTS INTERIM DATA FROM PHASE 1/2 MULTIDOSE STUDY OF VGA039 IN VON WILLEBRAND DISEASE, DEMONSTRATING SUBSTANTIAL BLEED REDUCTIONS IN ALL PATIENTS, AT ASH ANNUAL MEETING VGA039 is a once monthly,
- [News | March 2, 2026](https://www.nlvpartners.com/news-march-2-2026/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”March 2, 2026″ _builder_version=”4.27.0″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]Rallybio Corporation and Candid Therapeutics Announce Merger Agreement Combined company to operate as Candid Therapeutics, advancing a leading portfolio of T-cell engager therapeutics for autoimmune diseases Concurrent significantly oversubscribed and upsized financing
- [News | March 10, 2026](https://www.nlvpartners.com/news-march-10-2026/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”March 10, 2026″ _builder_version=”4.27.0″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]Qlaris Bio Appoints Fred Guerard, Pharm.D., as President and Chief Executive Officer DEDHAM, Mass., March 10, 2026 – Qlaris Bio, Inc., (“Qlaris”), a clinical-stage biotechnology company developing first-in-class therapies for glaucoma, today
- [News | February 26, 2026](https://www.nlvpartners.com/news-february-26-2026/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”February 26, 2026″ _builder_version=”4.27.0″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]Havas Health and BrightInsight Forge Exclusive Alliance to Tackle Pharma’s $500B+ Patient Problem NEW YORK, NY [February 26, 2026] – Havas Health today announced an exclusive, strategic partnership with BrightInsight, the leading
- [News | March 3, 2026](https://www.nlvpartners.com/news-january-6-2026-2/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”March 3, 2026″ _builder_version=”4.27.0″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]Flosonics Medical Receives Vizient Innovative Technology Contract for FloPatch Wearable Doppler UltrasoundContract recognizes FloPatch’s unique potential to improve fluid management decisions and patient outcomes in sepsis care LOS ANGELES, CALIF., March 3,
- [News | January 6, 2026](https://www.nlvpartners.com/news-january-6-2026/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”January 6, 2026″ _builder_version=”4.27.0″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]Aetna Approves Coverage for Cleerly’s AI Cardiovascular Imaging Analysis Major Insurer Joins UnitedHealthcare, Cigna, and Humana in Covering Cleerly’s AI-QCT Technology as Industry Momentum Builds with 86+ Million Lives Now Covered January
- [News | December 4, 2025](https://www.nlvpartners.com/news-december-4-2025/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||” theme_builder_area=”post_content”][et_pb_text admin_label=”December 4, 2025″ _builder_version=”4.27.0″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” theme_builder_area=”post_content” sticky_enabled=”0″]Sunbird Bio Presents New Clinical Data Supporting the Accuracy of its Blood-Based Alpha-Synuclein Assay for Parkinson’s Disease Detection– The sunbird αSyn™ assay accurately classified Parkinson’s disease-positive blood samples
- [News |  October 22, 2025](https://www.nlvpartners.com/news-october-22-2025/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||” theme_builder_area=”post_content”][et_pb_text admin_label=”October 22, 2025″ _builder_version=”4.27.0″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” theme_builder_area=”post_content” sticky_enabled=”0″]Electra Therapeutics Announces $183 Million Series C Financing to Advance First-in-Class SIRP-Targeted Therapies for Immune Disorders and Cancer Proceeds will fund a global pivotal trial of lead product
- [News |  September 30, 2025](https://www.nlvpartners.com/news-september-30-2025/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”September 30, 2025″ _builder_version=”4.27.0″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]STAR THERAPEUTICS ANNOUNCES OVERSUBSCRIBED $125 MILLION SERIES D FINANCING Proceeds to support continued clinical advancement of lead program, VGA039, a first-in-class antibody targeting protein S for the treatment of bleeding disorders, starting
- [News | October 1, 2025](https://www.nlvpartners.com/news-october-1-2025/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||” theme_builder_area=”post_content”][et_pb_text admin_label=”October 1, 2025″ _builder_version=”4.27.0″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” theme_builder_area=”post_content” sticky_enabled=”0″]Kyruus Health and Healthgrades Partner to Improve Patient Access and Digital Presence for Healthcare Providers BOSTON, Mass., Oct. 1, 2025 — Kyruus Health, the leading care access platform,
- [News | June 26, 2025](https://www.nlvpartners.com/news-june-26-2025/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||” theme_builder_area=”post_content”][et_pb_text admin_label=”June 26, 2025″ _builder_version=”4.27.0″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” theme_builder_area=”post_content” sticky_enabled=”0″]Edgewise Therapeutics Reports Positive Results on Sevasemten Program for Becker and Duchenne Muscular Dystrophies – New open label data in Becker demonstrated sustained disease stabilization up to three
- [News |  September 23, 2025](https://www.nlvpartners.com/news-september-23-2025/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||” theme_builder_area=”post_content”][et_pb_text admin_label=”September 23, 2025″ _builder_version=”4.27.0″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” theme_builder_area=”post_content” sticky_enabled=”0″]RevSpring to Acquire Kyruus Health, Creating a Connected Care Journey from Search to Final Payment Unified platform will support whole-person engagement while simplifying operations and improving financial outcomes
- [News | October 23, 2025](https://www.nlvpartners.com/news-october-23-2025/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”October 23, 2025″ _builder_version=”4.27.0″ _module_preset=”default” global_colors_info=”{}”]CuraSen Therapeutics Doses First Patient with CuraAX (CST-3056) in Phase 2a Neurogenic Orthostatic Hypotension (nOH) Study CuraAX aims to address debilitating blood pressure drops and cognitive symptoms of nOH San Carlos, CA, – October
- [News | October 7, 2025](https://www.nlvpartners.com/news-october-7-2025/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||” theme_builder_area=”post_content”][et_pb_text admin_label=”October 7, 2025″ _builder_version=”4.27.0″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” theme_builder_area=”post_content” sticky_enabled=”0″]TigerConnect Secures FDA 510(K) Clearance For Industry’s First Cloud-Native Alarm Management Solution The solution helps hospitals combat alarm fatigue, improve response times, and support patient safety initiatives with
- [News | September 4, 2025](https://www.nlvpartners.com/news-september-4-2025/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||” theme_builder_area=”post_content”][et_pb_text admin_label=”September 4, 2025″ _builder_version=”4.27.0″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” theme_builder_area=”post_content” sticky_enabled=”0″]TigerConnect Launches Patient Coordination Product To Streamline Interfacility Transfer New solution combines real-time coordination and communication to streamline transfers and post-discharge transport—driving faster care, higher staff efficiency, and
- [News | August 26, 2025](https://www.nlvpartners.com/news-august-26-2025/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||” theme_builder_area=”post_content”][et_pb_text admin_label=”May 14, 2025″ _builder_version=”4.27.0″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” theme_builder_area=”post_content” sticky_enabled=”0″]TigerConnect Acquires EVideon To Power The Next-Generation Of Smart Room Solutions Acquisition Accelerates Smart Room Innovation to Drive Nurse Efficiency, Patient Experience, and Cost Optimization SANTA MONICA, CA.,
- [News | May 1, 2025](https://www.nlvpartners.com/news-may-1-2025/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”May 1, 2025″ _builder_version=”4.27.0″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]TigerConnect Appoints Sean O’Neal as CEO, Marking a Bold New Chapter of Innovation and Growth Strategic leadership transition signals TigerConnect’s continued commitment to transform healthcare collaboration through an expanded, unified communications platform
- [News | May 13, 2025](https://www.nlvpartners.com/news-may-13-2025/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”May 13, 2025″ _builder_version=”4.27.0″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]TigerConnect Strengthens Global Presence with New Mexico City Office Strategic regional expansion aims to attract local talent and enhance delivery of the company’s unified healthcare communications solutions TigerConnect, the leading unified healthcare
- [News | May 31, 2025](https://www.nlvpartners.com/news-may-31-2025/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”May 31, 2025″ _builder_version=”4.27.0″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]Arvinas and Pfizer’s Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer – Pivotal Phase 3 VERITAC-2 clinical trial results presented at ASCO demonstrate 2.9-month improvement in median
- [News | May 14, 2025](https://www.nlvpartners.com/news-may-14-2025/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||” theme_builder_area=”post_content”][et_pb_text admin_label=”May 14, 2025″ _builder_version=”4.27.0″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” theme_builder_area=”post_content” sticky_enabled=”0″]Kalderos Names Healthcare Industry Veteran Daryl Todd as Chief Strategy Officer — Data infrastructure and analytics company Kalderos, creator of the world’s first Drug Discount Management platform, today
- [News | March 11, 2025](https://www.nlvpartners.com/news-march-11-2025/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”March 11, 2025″ _builder_version=”4.27.0″ _module_preset=”default” global_colors_info=”{}”]Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial – VERITAC-2 achieved its primary endpoint in the estrogen receptor 1-mutant population, demonstrating statistically significant and clinically meaningful improvement in progression-free
- [News | April 2, 2025](https://www.nlvpartners.com/news-april-2-2025-2/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”April 2, 2025″ _builder_version=”4.27.0″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]Edgewise Therapeutics Announces Positive Top-Line Results from Phase 2 CIRRUS-HCM Four-Week Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) – Phase 2 trial of EDG-7500 demonstrated rapid and clinically meaningful reductions in LVOT
- [News | March 31, 2025](https://www.nlvpartners.com/march-31-2025/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”March 31, 2025″ _builder_version=”4.27.0″ _module_preset=”default” global_colors_info=”{}”]Cleerly Unveils Groundbreaking Late-Breaking Clinical Trial Results Demonstrating AI-QCT’s Predictive Power for Women’s Cardiovascular Risk at ACC.25 New Findings from the CONFIRM2 Registry Reveal Significant Gender Disparities in Coronary Plaque Features and Associated Risks
- [News | April 2, 2025](https://www.nlvpartners.com/news-april-2-2025/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”April 2, 2025″ _builder_version=”4.27.0″ _module_preset=”default” global_colors_info=”{}”]Edgewise Therapeutics Announces Pricing of $200 Million Underwritten Offering of Common Stock BOULDER, Colo., April 2, 2025 /PRNewswire/ — Edgewise Therapeutics, Inc. (NASDAQ: EWTX), a leading muscle disease biopharmaceutical company, today announced the pricing
- [News | February 27, 2025](https://www.nlvpartners.com/news-february-27-2025/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”February 27, 2025″ _builder_version=”4.27.0″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]TigerConnect to Launch Pre-Hospital and Transfer Solutions to Streamline Emergency Care Coordination and Improve Patient Throughput at HIMSS 25 New solutions combined with feature enhancements to the current portfolio, including the addition
- [News | February 13, 2025](https://www.nlvpartners.com/news-february-13-2025/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”February 13, 2025″ _builder_version=”4.27.0″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]Kyruus Health and aha! Announce Partnership to Enhance Patient Access and Engagement UCI Health Leads the Way in Patient-Centric Digital Experiences with Kyruus Health and aha! Partnership BOSTON, MA – FEB. 13,
- [News | February 20, 2025](https://www.nlvpartners.com/news-february-20-2025/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||” theme_builder_area=”post_content”][et_pb_text admin_label=”February 20, 2025″ _builder_version=”4.27.0″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” theme_builder_area=”post_content” sticky_enabled=”0″]CuraSen Therapeutics Announces First Subject Treated with CuraAX (CST-3056) in a Phase 1 Clinical Trial CuraAX Designed to Treat Neurogenic Orthostatic Hypotension (nOH) and Cognitive Impairment San Carlos,
- [News | February 5, 2025](https://www.nlvpartners.com/news-february-5-2025-2/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||” theme_builder_area=”post_content”][et_pb_text admin_label=”February 5, 2025″ _builder_version=”4.27.0″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” theme_builder_area=”post_content” sticky_enabled=”0″]Kyruus Health Achieves Record Growth as Searches for Care Surpass 1 Billion Care access leader adds 12M health plan members and 100 new provider organizations to its platform
- [News | December 9, 2024](https://www.nlvpartners.com/news-december-9-2024-2/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”December 9, 2024″ _builder_version=”4.27.0″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]Crinetics Announces FDA Acceptance of New Drug Application for Paltusotine for Adult Patients with Acromegaly FDA Assigns a Prescription Drug User Fee Act Target Action Date of September 25, 2025 SAN DIEGO,
- [News | January 6, 2025](https://www.nlvpartners.com/news-january-6-2025/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”Janaury 6, 2025″ _builder_version=”4.27.0″ _module_preset=”default” global_colors_info=”{}”]Star Therapeutics Receives FDA Fast Track Designation for VGA039 in Von Willebrand Disease (VWD) VGA039 is potentially the first subcutaneous therapy that addresses all types of VWD and has a convenient dosing regimen SOUTH
- [News | January 9, 2025](https://www.nlvpartners.com/news-january-9-2025/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”Janaury 9, 2025″ _builder_version=”4.27.0″ _module_preset=”default” global_colors_info=”{}”]Bluesight Expands Compliance Capabilities and Strengthens Platform through Acquisition of Protenus ALEXANDRIA and BALTIMORE, January 9, 2025 – Bluesight, the leading provider of inventory management, procurement, and compliance solutions for health systems and hospital
- [News | February 11, 2025](https://www.nlvpartners.com/news-february-11-2025/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”February 11, 2025″ _builder_version=”4.27.0″ _module_preset=”default” global_colors_info=”{}”]Rallybio Announces Initiation of Dosing in RLYB212 Phase 2 Clinical Trial – Key Data Readouts from Sentinel Participant Expected in 2Q 2025 and 3Q 2025 – NEW HAVEN, Conn.–(BUSINESS WIRE)–Feb. 11, 2025– Rallybio Corporation
- [News | February 5, 2025](https://www.nlvpartners.com/news-february-5-2025/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||” theme_builder_area=”post_content”][et_pb_text admin_label=”February 5, 2025″ _builder_version=”4.27.0″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” theme_builder_area=”post_content” sticky_enabled=”0″]Qlaris Bio Announces Positive Topline Data From Two Phase II Trials Of QLS-111 In Patients With Primary Open Angle Glaucoma And Ocular Hypertension QLS-111 met all primary and
- [News | December 9, 2024](https://www.nlvpartners.com/news-december-9-2024/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||” theme_builder_area=”post_content”][et_pb_text admin_label=”Cogent” _builder_version=”4.27.0″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” theme_builder_area=”post_content” sticky_enabled=”0″]Cogent Biosciences Announces Updated Clinical Results from SUMMIT, Showcasing Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients 56% mean improvement in Total Symptom Score (TSS) at 24 weeks with 76%
- [News | December 10, 2024](https://www.nlvpartners.com/news-december-10-2024/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||” theme_builder_area=”post_content”][et_pb_text admin_label=”Arvinas” _builder_version=”4.27.0″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” theme_builder_area=”post_content” sticky_enabled=”0″]Arvinas and Pfizer Announce Initial Phase 1b Data from the TACTIVE-U Sub-Study of Vepdegestrant in Combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium – Vepdegestrant in combination with
- [News | December 4, 2024](https://www.nlvpartners.com/news-december-4-2024/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”Cleerly” _builder_version=”4.27.0″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]Cleerly Raises $106 Million in Funding Led by Insight Partners to Revolutionize Heart Disease Care December 4, 2024 (DENVER) – Today Cleerly, a leader in advanced cardiovascular imaging, announced the successful closure of its
- [News | October 25, 2024](https://www.nlvpartners.com/news-october-25-2024/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||” theme_builder_area=”post_content”][et_pb_text admin_label=”Iterum Therapeutics” _builder_version=”4.27.0″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” theme_builder_area=”post_content” sticky_enabled=”0″]Iterum Therapeutics Receives U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections ORLYNVAH™ is the first oral penem approved for use in the
- [News |  September 3, 2024](https://www.nlvpartners.com/news-september-3-2024/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||” theme_builder_area=”post_content”][et_pb_text admin_label=”Passage Bio” _builder_version=”4.27.0″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” theme_builder_area=”post_content” sticky_enabled=”0″]Cogent Biosciences Announces Phase 3 PEAK Trial in Patients with Gastrointestinal Stromal Tumors (GIST) Has Completed Enrollment and Advanced Past Interim Futility Analysis -413 patients enrolled in PEAK Phase
- [News | August 1, 2024](https://www.nlvpartners.com/news-august-1-2024/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”Passage Bio” _builder_version=”4.27.0″ _module_preset=”default” global_colors_info=”{}”]Passage Bio Out-licenses Three Pediatric Gene Therapy Programs to GEMMA Biotherapeutics and Enters New Research Collaboration Granted exclusive, worldwide rights for the development and commercialization of PBGM01 for GM1 gangliosidosis, PBKR03 for Krabbe disease, and
- [News | August 2, 2024](https://www.nlvpartners.com/news-august-2-2024/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”Iterum” _builder_version=”4.27.0″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]Iterum Therapeutics Broadens Patent Estate for Oral Sulopenem DUBLIN and CHICAGO, Aug. 02, 2024 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), a clinical-stage pharmaceutical company focused on developing next generation oral and
- [News | May 7, 2024](https://www.nlvpartners.com/news-may-7-2024/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”BrightInsight” _builder_version=”4.27.0″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]BrightInsight Expands its Partnership with Google Cloud to Enhance the Patient Journey Through Generative AI BrightInsight is modernizing its development processes and patient companion apps with Google’s Gemini models, MedLM, and Vertex AI SAN
- [News | July 22, 2024](https://www.nlvpartners.com/news-july-22-2024/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”Iterum” _builder_version=”4.27.0″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]Iterum Therapeutics Commences Rights Offering DUBLIN and CHICAGO, July 22, 2024 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics
- [News | July 16, 2024](https://www.nlvpartners.com/news-july-16-2024-2/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”Passage Bio” _builder_version=”4.27.0″ _module_preset=”default” global_colors_info=”{}”]Passage Bio Announces Positive Feedback from FDA on Expansion of upliFT-D Trial of PBFT02 to Include FTD-C9orf72 Patients Agency feedback from Type C meeting process supports the company’s proposed clinical development plans to expand the
- [News | July 30, 2024](https://www.nlvpartners.com/news-july-30-2024/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||” theme_builder_area=”post_content”][et_pb_text admin_label=”TigerConnect” _builder_version=”4.27.0″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” theme_builder_area=”post_content” sticky_enabled=”0″]TigerConnect Dominates G2’s Summer 2024 Rankings, Securing Top Positions in Healthcare Technology SANTA MONICA, CA., July 30, 2024 — TigerConnect, the leading clinical collaboration platform in healthcare, has once again
- [News | June 21, 2024](https://www.nlvpartners.com/news-june-21-2024-2/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||” theme_builder_area=”post_content”][et_pb_text admin_label=”Iterum” _builder_version=”4.27.0″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” theme_builder_area=”post_content” sticky_enabled=”0″]Iterum Therapeutics Announces FDA Advisory Committee Meeting to discuss NDA for Oral Sulopenem for the treatment of Uncomplicated Urinary Tract Infections Proposed Date for Advisory Committee meeting is September 9,
- [News | July 16, 2024](https://www.nlvpartners.com/news-july-16-2024/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”Kyruus” _builder_version=”4.25.1″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]XO Health Powers Provider Search and Improved Transparency with Kyruus Health BOSTON, MA – JULY 16, 2024 – XO Health, an innovative health care services organization designed by and for self-insured employers, has
- [News | June 27, 2024](https://www.nlvpartners.com/news-june-27-2024/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”Cogent” _builder_version=”4.25.1″ _module_preset=”default” global_colors_info=”{}”]Cogent Biosciences Announces Positive FDA Meeting and Alignment on MS2D2, a Novel Patient Reported Outcome Measure for the SUMMIT Trial Enrollment in SUMMIT Part 2 remains on track for completion in Q2 2025 with top-line results
- [News | June 21, 2024](https://www.nlvpartners.com/news-june-21-2024/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||” theme_builder_area=”post_content”][et_pb_text admin_label=”Arvinas” _builder_version=”4.25.1″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” theme_builder_area=”post_content” sticky_enabled=”0″]Arvinas Announces Presentations for Two of its PROTAC® Investigational Programs Targeting BCL6 and LRRK2 – Preclinical data for ARV-393 presented at the European Hematology Association 2024 Annual Congress showed anti-tumor
- [News | June 26, 2024](https://www.nlvpartners.com/news-june-26-2024/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||” theme_builder_area=”post_content”][et_pb_text admin_label=”Star Therapeutics” _builder_version=”4.25.1″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” theme_builder_area=”post_content” sticky_enabled=”0″]Star Therapeutics Presents Clinical Data for VGA039, a Subcutaneous Therapy for the Treatment of Von Willebrand Disease (VWD) VGA039 clinical data supports favorable safety profile in healthy volunteers and
- [News | June 16, 2024](https://www.nlvpartners.com/news-june-16-2024/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”Electra Therapeutics” _builder_version=”4.25.1″ _module_preset=”default” global_colors_info=”{}”]Electra Therapeutics Presents Late-Breaking Clinical Data at EHA2024 from Ongoing Phase 1b Study of ELA026 in Secondary Hemophagocytic Lymphohistiocytosis (sHLH) ELA026 demonstrated a high overall response rate (ORR) across a range of sHLH patients and
- [News | June 14, 2024](https://www.nlvpartners.com/news-june-14-2024/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||” theme_builder_area=”post_content”][et_pb_text admin_label=”Cogent” _builder_version=”4.25.1″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” theme_builder_area=”post_content” sticky_enabled=”0″]COGENT BIOSCIENCES ANNOUNCES ADDITIONAL CLINICAL DATA FROM PART 1 OF ITS ONGOING SUMMIT TRIAL EVALUATING BEZUCLASTINIB IN PATIENTS WITH NONADVANCED SYSTEMIC MASTOCYTOSIS (NONADVSM) Patients treated with 100 mg bezuclastinib showed
- [News | May 14, 2024](https://www.nlvpartners.com/may-14-2024/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||” theme_builder_area=”post_content”][et_pb_text admin_label=”Truveris” _builder_version=”4.25.0″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” theme_builder_area=”post_content” sticky_enabled=”0″]Truveris Secures $15 Million in Series E Funding ThroughCanaan Partners and New Leaf Venture Partners New funding by existing investors will support company’s next stage of development and core business
- [News | May 16, 2024](https://www.nlvpartners.com/news-may-16-2024/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”Arvinas” _builder_version=”4.25.0″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®) – After six months of additional follow-up, clinical benefit rate (63%), overall response rate (41.9%), median
- [News |  April 29, 2024](https://www.nlvpartners.com/news-april-29-2024/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”Iterum” _builder_version=”4.23″ _module_preset=”default” global_colors_info=”{}”]Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem –First Oral Penem in the U.S. and Second New Oral Treatment for uUTIs in Over 25 Years, if approved– –Potential Approval
- [News | April 29, 2024](https://www.nlvpartners.com/news-april-29-2024-2/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||” theme_builder_area=”post_content”][et_pb_text admin_label=”Deciphera” _builder_version=”4.23″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” theme_builder_area=”post_content” sticky_enabled=”0″]Deciphera Pharmaceuticals to be Acquired by ONO Pharmaceutical For $2.4 Billion Deciphera Shareholders to Receive $25.60 per Share in Cash Deciphera’s Kinase Inhibitor Expertise and Established Commercialization Platform in Key
- [News | April 10, 2024](https://www.nlvpartners.com/news-april-10-2024/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||” theme_builder_area=”post_content”][et_pb_text admin_label=”Rallybio” _builder_version=”4.23″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” theme_builder_area=”post_content” sticky_enabled=”0″]Rallybio Announces Collaboration to Advance Therapeutic Solutions for Pregnant Individuals at Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) – Rallybio to Receive Funding for FNAIT Awareness Initiative and Equity
- [News | April 11, 2024](https://www.nlvpartners.com/april-11-2024/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||” theme_builder_area=”post_content”][et_pb_text admin_label=”Arvinas” _builder_version=”4.23″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” theme_builder_area=”post_content” sticky_enabled=”0″]Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate
- [News | March 5, 2024](https://www.nlvpartners.com/news-march-5-2024/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||” theme_builder_area=”post_content”][et_pb_text admin_label=”Cleerly” _builder_version=”4.23″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” theme_builder_area=”post_content” sticky_enabled=”0″]Cleerly® Receives FDA Breakthrough Device Designation for Heart Disease Risk Staging SystemCompany’s AI-enabled technology for future heart attack risk assessment accepted into FDA’s TAP Pilot and to be validated in
- [News | March 7, 2024](https://www.nlvpartners.com/news-march-7-2024/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||” theme_builder_area=”post_content”][et_pb_text admin_label=”Curasen” _builder_version=”4.23″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” theme_builder_area=”post_content” sticky_enabled=”0″]CuraSen Therapeutics Announces Oral Presentation of Additional Positive Phase 2a Data with CST-2032/CST-107 in Patients with Alzheimer’s or Parkinson’s Disease at AD/PD™ 2024 International Conference Drug Combination’s Unique Mechanism of
- [News | March 5, 2024](https://www.nlvpartners.com/news-march-5-2024-2/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”Sunbird Bio” _builder_version=”4.23″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]New Data Demonstrate Sunbird Bio’s APEX Diagnostic Test Accurately Differentiates Key Alzheimer’s Disease Biomarker in Blood– Blood-based diagnostic effectively discriminated between patients who were positive versus negative for amyloid beta on PET scans
- [News | March 11, 2024](https://www.nlvpartners.com/news-march-11-2024/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||” theme_builder_area=”post_content”][et_pb_text admin_label=”Harpoon Therapeutics” _builder_version=”4.23″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” theme_builder_area=”post_content” sticky_enabled=”0″]Merck Completes Acquisition of Harpoon Therapeutics, Inc. Acquisition broadens oncology pipeline with a portfolio of novel T-cell engagers including HPN328 (MK-6070), an investigational delta-like ligand 3 (DLL3) targeting T-cell
- [News | January 8, 2024](https://www.nlvpartners.com/news-january-8-2024/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||” theme_builder_area=”post_content”][et_pb_text admin_label=”Harpoon Therapeutics” _builder_version=”4.23″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” theme_builder_area=”post_content” sticky_enabled=”0″]Merck to Acquire Harpoon Therapeutics, Further Diversifying Oncology Pipeline Acquisition includes HPN328, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager being evaluated in certain patients with small cell
- [News | February 22, 2024](https://www.nlvpartners.com/news-february-22-2024/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||” theme_builder_area=”post_content”][et_pb_text admin_label=”Cogent” _builder_version=”4.23″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” theme_builder_area=”post_content” sticky_enabled=”0″]COGENT BIOSCIENCES ANNOUNCES POSITIVE PART 1B DATA FROM SUMMIT TRIAL EVALUATING BEZUCLASTINIB IN PATIENTS WITH NONADVANCED SYSTEMIC MASTOCYTOSIS Registration-enabling SUMMIT Part 2 initiated and actively enrolling at 40 sites globally;
- [News | February 15, 2024](https://www.nlvpartners.com/news-february-15-2024/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”Kyruus” _builder_version=”4.23″ _module_preset=”default” global_colors_info=”{}”]New collaboration with Kyruus Health to advance care access and outcomes for patients at Nicklaus Children’s Health System BOSTON, MA – Feb. 15, 2024 – Kyruus Health, the leading care access platform, and Nicklaus Children’s Health
- [News | February 7, 2024](https://www.nlvpartners.com/news-february-7-2024-2/) - TigerConnect is a 2024 Best in KLAS Award Winner for Clinical Communications TigerConnect ranked as a leading provider in the ambulatory and post-acute care categories SANTA MONICA, Calif., February 7, 2024 — TigerConnect, healthcare’s most trusted clinical collaboration platform, today proudly announced its Clinical Collaboration Platform is a 2024 Best in KLAS Awards winner for
- [News | February 7, 2024](https://www.nlvpartners.com/news-february-7-2024/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||” theme_builder_area=”post_content”][et_pb_text admin_label=”Bluesight” _builder_version=”4.23″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” theme_builder_area=”post_content” sticky_enabled=”0″]Bluesight Demonstrates Industry-Leading Performance in Drug Diversion Detection; New Data Highlights 6.6X Advantage Over Competitors Bluesight’s ControlCheck delivers hard outcomes by identifying a diverter every two days ALEXANDRIA, Va., Feb.
- [News | February 20, 2024](https://www.nlvpartners.com/news-february-20-2024/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”Arvinas” _builder_version=”4.23″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]Arvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC® Protein Degrader for Neurodegenerative Disease – ARV-102 is a novel oral PROTAC® protein degrader designed to cross the blood-brain barrier and target leucine-rich repeat kinase 2
- [News | February 14, 2024](https://www.nlvpartners.com/news-february-14-2024/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”Cogent” _builder_version=”4.23″ _module_preset=”default” global_colors_info=”{}”]COGENT BIOSCIENCES ANNOUNCES OVERSUBSCRIBED $225 MILLION PRIVATE PLACEMENT Pro-forma cash, cash equivalents and marketable securities expected to fund the Company into 2027 and through clinical readouts from ongoing SUMMIT, PEAK and APEX registration-directed trials Cogent to
- [News | February 6, 2024](https://www.nlvpartners.com/news-february-6-2024/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”Arvinas” _builder_version=”4.23″ _module_preset=”default” global_colors_info=”{}”]Arvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast Cancer — Vepdegestrant is an investigational PROteolysis Targeting Chimera (PROTAC®) protein degrader designed to target and degrade
- [News | December 11, 2023](https://www.nlvpartners.com/news-december-11-2023/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||” theme_builder_area=”post_content”][et_pb_text admin_label=”Cogent” _builder_version=”4.23″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” theme_builder_area=”post_content” sticky_enabled=”0″]COGENT BIOSCIENCES ANNOUNCES POSITIVE DATA FROM ONGOING PHASE 2 APEX TRIAL EVALUATING BEZUCLASTINIB IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS (ADVSM) 56% ORR in TKI-naïve patients, including 86% ORR by PPR
- [News | December 9, 2023](https://www.nlvpartners.com/news-december-9-2023/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”Cogent” _builder_version=”4.23″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]COGENT BIOSCIENCES ANNOUNCES POSITIVE INITIAL DATA FROM PHASE 2 SUMMIT TRIAL EVALUATING BEZUCLASTINIB IN PATIENTS WITH NONADVANCED SYSTEMIC MASTOCYTOSIS (NONADVSM) Rapid and ongoing improvement in patient symptoms, with 57% median best improvement on MC-QoL
- [News | December 7, 2023](https://www.nlvpartners.com/news-december-7-2023/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||” theme_builder_area=”post_content”][et_pb_text admin_label=”Cogent” _builder_version=”4.23″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” theme_builder_area=”post_content” sticky_enabled=”0″]COGENT BIOSCIENCES PRESENTS NEW PRECLINICAL DATA HIGHLIGHTING POTENTIAL BEST-IN-CLASS POTENCY AND SELECTIVITY OF ERBB2 AND PI3KΑ INHIBITOR PROGRAMS AT THE SAN ANTONIO BREAST CANCER SYMPOSIUM Novel EGFR-sparing, brain-penetrant ErbB2 inhibitor
- [News | December 5, 2023](https://www.nlvpartners.com/news-december-5-2023/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.23″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” admin_label=”Arvinas” sticky_enabled=”0″]Arvinas and Pfizer Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®) and Plans to Expand Vepdegestrant Development Program – Overall response rate of 42% and median progression-free survival
- [News | November 11, 2023](https://www.nlvpartners.com/new-november-11-2023/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.23″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]Cleerly, Partners Announce TRANSFORM Trial to Evaluate Personalized Heart Disease Care Strategies at AHA 2023 Cleerly, Partners Announce TRANSFORM Trial to Evaluate Personalized Heart Disease Care Strategies at American Heart Association 2023 Data from randomized
- [News | November 27, 2023](https://www.nlvpartners.com/news-november-27-023/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.23″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]Arvinas Announces Oversubscribed $350 Million Private Placement NEW HAVEN, Conn., Nov. 27, 2023 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation,
- [News | October 26, 2023](https://www.nlvpartners.com/news-october-26-2023/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.23″ _module_preset=”default” global_colors_info=”{}”]Bluesight Appoints Jason Vander Meer as Chief Product Officer to Expand Medication Intelligence Suite New leader of product strategy and development to drive innovation, support company’s growth plans ALEXANDRIA, Va., Oct. 26, 2023 — Bluesight, the leader
- [News |  October 23, 2023](https://www.nlvpartners.com/news-october-23-2023/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.23″ _module_preset=”default” global_colors_info=”{}”]HARPOON THERAPEUTICS ANNOUNCES UP TO $150 MILLION PRIVATE PLACEMENT SOUTH SAN FRANCISCO, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) — Harpoon Therapeutics, Inc. (NASDAQ: HARP) (the “Company”), a clinical-stage immunotherapy company developing novel T cell engagers, today announced
- [News | September 20, 2023](https://www.nlvpartners.com/news-september-20-2023/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.23″ _module_preset=”default” global_colors_info=”{}”]Kalderos names veteran healthcare leader Angie Franks as new CEORedefining how the business of healthcare performs.™ (PRNewsfoto/Kalderos) Experienced chief executive brings growth mindset,strong vision to Drug Discount Management solution leader CHICAGO, Sept. 20, 2023 /PRNewswire/ — Data
- [News | September 23, 2023](https://www.nlvpartners.com/news-september-23-2023/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.23″ _module_preset=”default” hover_enabled=”0″ sticky_enabled=”0″]Kalderos Adds Powerful Features to Commercial Drug Discount Monitoring SolutionRedefining how the business of healthcare performs.™ (PRNewsfoto/Kalderos) Drug Discount Management Leader Delivers New Tools to Tackle Billions in Overpaid Commercial Rebates CHICAGO, Sept. 14, 2023 /PRNewswire/
- [News | October 30, 2023](https://www.nlvpartners.com/news-october-30-2023/) - [et_pb_section fb_built=”1″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”October 30, 2023″ _builder_version=”4.23″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″] Deciphera Pharmaceuticals Announces Positive Top-line Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) and Updated Results from Phase 1/2 Study of Vimseltinib
- [News | August 9, 2023](https://www.nlvpartners.com/news-august-9-2023/) - [et_pb_section fb_built=”1″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”August 9, 2023″ _builder_version=”4.19.5″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]Lilly Completes Acquisition of DICE Therapeutics INDIANAPOLIS, Aug. 9, 2023 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of DICE Therapeutics, Inc. (NASDAQ: DICE).
- [News | August 7, 2023](https://www.nlvpartners.com/news-august-7-2023/) - [et_pb_section fb_built=”1″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”August 7, 2023″ _builder_version=”4.19.5″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”]PASSAGE BIO ANNOUNCES PROMISING INTERIM CLINICAL DATA FROM FIRST EIGHT PATIENTS WITH GM1 GANGLIOSIDOSIS IN IMAGINE-1 STUDY Interim safety data up to 28 months showed Dose 1 and 2 of PBGM01 were well tolerated
- [News | August 17, 2023](https://www.nlvpartners.com/news-august-17-2023/) - [et_pb_section fb_built=”1″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”August 17, 2023″ _builder_version=”4.19.5″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”]Abcuro Announces $155 Million Oversubscribed Series B Financing to Further Advance Autoimmune Pipeline Financing co-led by Redmile Group and Bain Capital Life Sciences Proceeds to support completion of Phase 2/3 registrational trial of ABC008,
- [News | June 26, 2023](https://www.nlvpartners.com/news-june-26-2023/) - [et_pb_section fb_built=”1″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”June 26, 2023″ _builder_version=”4.19.5″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”]Edgewise Therapeutics Announces Positive 12-Month Topline Results From The ARCH Open Label Study Of EDG-5506 In Adults With Becker Muscular Dystrophy (BMD) – Sustained positive trend in North Star Ambulatory Assessment (NSAA) scores relative
- [News | May 23, 2023](https://www.nlvpartners.com/news-may-23-2023/) - [et_pb_section fb_built=”1″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”May 23, 2023″ _builder_version=”4.19.5″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”]Vega Therapeutics Receives FDA Orphan Drug Designation for VGA039 for the Treatment of von Willebrand Disease SOUTH SAN FRANCISCO, CA, May 23, 2023 – Vega Therapeutics, Inc., a clinical stage biotechnology company developing novel
- [News | June 27, 2023](https://www.nlvpartners.com/news-june-27-2023/) - [et_pb_section fb_built=”1″ _builder_version=”4.16″ global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_row _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||” theme_builder_area=”post_content”][et_pb_text admin_label=”June 22, 2023″ _builder_version=”4.19.5″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ global_colors_info=”{}” theme_builder_area=”post_content” sticky_enabled=”0″]HARPOON THERAPEUTICS ANNOUNCES COMPLETION OF PLANNED PATIENT ENROLLMENT IN PHASE 1 STUDY OF HPN217 IN RELAPSED/REFRACTORY MULTIPLE MYELOMA SOUTH SAN FRANCISCO, Calif., June 27, 2023 (GLOBE NEWSWIRE) —
- [News | June 20, 2023](https://www.nlvpartners.com/news-june-20-2023-2/) - [et_pb_section fb_built=”1″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”June 20, 2023″ _builder_version=”4.19.5″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”]Silver Cross Hospital Expands Use of Kyruus’ Award-Winning Online Scheduling Solution Across Specialties and Services 348-Bed Community Hospital Builds on Success of Preventive and Diagnostic Care Scheduling Impact Boston, MA – June 20, 2023
- [News | July 17, 2023](https://www.nlvpartners.com/news-july-17-2023/) - [et_pb_section fb_built=”1″ _builder_version=”4.16″ global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_row _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||” theme_builder_area=”post_content”][et_pb_text admin_label=”July 17, 2023″ _builder_version=”4.19.5″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ global_colors_info=”{}” theme_builder_area=”post_content” sticky_enabled=”0″]Thoma Bravo Announces Strategic Growth Investment in Bluesight to Support the Company’s Acquisition of MedacistCombination Creates Leading Hospital Pharmacy Software Platform ALEXANDRIA, Va. and CHESHIRE, Conn. and SAN
- [News | June 20, 2023](https://www.nlvpartners.com/news-june-20-2023/) - [et_pb_section fb_built=”1″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”June 20, 2023″ _builder_version=”4.19.5″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]Lilly to Acquire DICE Therapeutics to Advance Innovation in Immunology INDIANAPOLIS and SOUTH SAN FRANCISCO, Calif., June 20, 2023 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and DICE Therapeutics, Inc. (NASDAQ:
- [News | June 8, 2023](https://www.nlvpartners.com/news-june-8-2023/) - [et_pb_section fb_built=”1″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”June 8, 2023″ _builder_version=”4.19.5″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]Arvinas Announces Interim Data from the ARV-766 Phase 1/2 Dose Escalation and Expansion Trial Showing Promising Signals of Efficacy in Late-line mCRPC, Including in Patients with AR L702H Mutations – 42% of
- [News | June 3, 2023](https://www.nlvpartners.com/news-june-3-2023/) - [et_pb_section fb_built=”1″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”June 3, 2023″ _builder_version=”4.19.5″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]COGENT BIOSCIENCES ANNOUNCES POSITIVE LEAD-IN DATA FROM ONGOING PHASE 3 PEAK TRIAL EVALUATING BEZUCLASTINIB IN COMBINATION WITH SUNITINIB IN PATIENTS WITH GASTROINTESTINAL STROMAL TUMORS (GIST) – Data presented at ASCO annual meeting
- [News | May 10, 2023](https://www.nlvpartners.com/news-may-10-2023/) - [et_pb_section fb_built=”1″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”May 10, 2023″ _builder_version=”4.19.5″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]CostCheck From Bluesight Wins 2023 MedTech Breakthrough Award MedTech Breakthrough Recognizes Bluesight’s CostCheck as a Standout Digital Health & Medical Technology Product ALEXANDRIA, Va., – May 10, 2023 – BluesightⓇ, The Medication
- [News | June 6, 2023](https://www.nlvpartners.com/news-june-6-2023/) - [et_pb_section fb_built=”1″ _builder_version=”4.16″ global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_row _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||” theme_builder_area=”post_content”][et_pb_text admin_label=”June 6, 2023″ _builder_version=”4.19.5″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ global_colors_info=”{}” theme_builder_area=”post_content” sticky_enabled=”0″]COGENT BIOSCIENCES ANNOUNCES PRICING OF UPSIZED PUBLIC OFFERING OF SHARES OF COMMON STOCK WALTHAM, Mass. and BOULDER, Colo., June 06, 2023 (GLOBE NEWSWIRE) — Cogent Biosciences, Inc. (Nasdaq:
- [News | June 1, 2023](https://www.nlvpartners.com/news-june-1-2023/) - [et_pb_section fb_built=”1″ _builder_version=”4.16″ global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_row _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||” theme_builder_area=”post_content”][et_pb_text admin_label=”June 1, 2023″ _builder_version=”4.19.5″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ global_colors_info=”{}” theme_builder_area=”post_content” sticky_enabled=”0″]Cleerly Partners with ProScan Imaging to Transform the Standard of Care for Heart Disease PreventionProScan’s imaging centers in two major regions will now leverage Cleerly’s AI-enabled approach to
- [News | May 2, 2023](https://www.nlvpartners.com/news-may-2-2023/) - [et_pb_section fb_built=”1″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”May 2, 2023″ _builder_version=”4.19.5″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]Arvinas and Quantum Leap Healthcare Announce Clinical Study to Evaluate Vepdegestrant (ARV-471) in I-SPY-2 Endocrine Optimization Platform (EOP) Clinical Trial NEW HAVEN, Conn. and SAN FRANCISCO, May 2, 2023 /PRNewswire/ — Arvinas,
- [News | April 6, 2023](https://www.nlvpartners.com/news-april-6-2023/) - [et_pb_section fb_built=”1″ _builder_version=”4.16″ global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_row _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||” theme_builder_area=”post_content”][et_pb_text admin_label=”April 6, 2023″ _builder_version=”4.19.5″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ global_colors_info=”{}” theme_builder_area=”post_content” sticky_enabled=”0″]Rallybio Announces Clinical Proof-of-Concept Results for RLYB211, an Anti-HPA-1a Polyclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT), Published in the Journal of Thrombosis and
- [News | April 3, 2023](https://www.nlvpartners.com/news-april-3-2023/) - [et_pb_section fb_built=”1″ _builder_version=”4.16″ global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_row _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||” theme_builder_area=”post_content”][et_pb_text admin_label=”April 3, 2023″ _builder_version=”4.19.5″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ global_colors_info=”{}” theme_builder_area=”post_content” sticky_enabled=”0″]Rallybio Announces Acceptance of Abstract for RLYB212 at the 31st Congress of the International Society on Thrombosis and Haemostasis (ISTH) NEW HAVEN, Conn.–(BUSINESS WIRE)–Apr. 3, 2023– Rallybio Corporation
- [News | March 6, 2023](https://www.nlvpartners.com/news-march-6-2023/) - [et_pb_section fb_built=”1″ _builder_version=”4.16″ global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_row _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||” theme_builder_area=”post_content”][et_pb_text admin_label=”March 6, 2023″ _builder_version=”4.19.5″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ global_colors_info=”{}” theme_builder_area=”post_content” sticky_enabled=”0″]Rallybio Announces Proof-of-Concept Achieved for RLYB212, a Novel Monoclonal anti-HPA-1a Antibody to Prevent Fetal and Neonatal Alloimmune Thrombocytopenia — RLYB212 Showed Rapid Elimination of Transfused, HPA-1a Positive Platelets
- [News | March 14, 2023](https://www.nlvpartners.com/news-march-14-2023/) - [et_pb_section fb_built=”1″ _builder_version=”4.16″ global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_row _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||” theme_builder_area=”post_content”][et_pb_text admin_label=”March 14, 2023″ _builder_version=”4.19.5″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ global_colors_info=”{}” theme_builder_area=”post_content” sticky_enabled=”0″]Deciphera Pharmaceuticals Announces QINLOCK® Included in NCCN Guidelines® for the Treatment of Second-Line GIST Patients and FDA Grants Breakthrough Therapy Designation for QINLOCK in Second-Line GIST Patients with
- [News | April 17, 2023](https://www.nlvpartners.com/news-april-17-2023/) - [et_pb_section fb_built=”1″ _builder_version=”4.16″ global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_row _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||” theme_builder_area=”post_content”][et_pb_text admin_label=”April 27, 2023″ _builder_version=”4.19.5″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ global_colors_info=”{}” theme_builder_area=”post_content” sticky_enabled=”0″]COGENT BIOSCIENCES PRESENTS PRECLINICAL DATA AT AACR ANNUAL MEETING HIGHLIGHTING PRECISION THERAPY PIPELINE AND ANNOUNCES INITIATION OF PART 2 OF THE REGISTRATION-ENABLING APEX TRIAL WITH BEZUCLASTINIB IN ADVANCED
- [News | February 27, 2023](https://www.nlvpartners.com/news-february-27-2023/) - [et_pb_section fb_built=”1″ _builder_version=”4.16″ global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_row _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||” theme_builder_area=”post_content”][et_pb_text admin_label=”February 27, 2023″ _builder_version=”4.19.5″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ global_colors_info=”{}” theme_builder_area=”post_content” sticky_enabled=”0″]Kalderos Introduces New Product Suite to Better Serve Manufacturers Navigating Drug Discount Programs CHICAGO, Feb. 27, 2023 /PRNewswire/ — Data infrastructure and analytics company Kalderos, creator of the
- [News | March 24, 2023](https://www.nlvpartners.com/news-march-24-2023/) - [et_pb_section fb_built=”1″ _builder_version=”4.16″ global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_row _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||” theme_builder_area=”post_content”][et_pb_text admin_label=”March 24, 2023″ _builder_version=”4.19.5″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ global_colors_info=”{}” theme_builder_area=”post_content” sticky_enabled=”0″]TigerConnectAppoints Two SaaS Leaders to Drive Product Enhancements and Revenue Growth Veteran leaders bring extensive experience to accelerate TigerConnect’s mission to optimize healthcare workflows with real-time communication and
- [News | January 9, 2023](https://www.nlvpartners.com/news-january-9-2023/) - [et_pb_section fb_built=”1″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”January 9, 2023″ _builder_version=”4.19.5″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”]Kyruus Reports Landmark Year, Cementing Position as a Foundational Digital Health Platform Leading Healthcare SaaS Company Continues Rapid Growth Fueled by Expansion into New Markets BOSTON, Mass. – Jan. 9, 2023 – Kyruus, the
- [News | April 5, 2023](https://www.nlvpartners.com/news-april-5-2023/) - [et_pb_section fb_built=”1″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”April 5, 2023″ _builder_version=”4.19.5″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”]Intermountain Health Expands Relationship with Kyruus to Create Foundation for Rebranded Digital Experience 33-Hospital Health System Partners with Kyruus to Streamline Data and Inventory Management and Convert Demand Online Boston, MA – April 5th,
- [News | February 22, 2023](https://www.nlvpartners.com/news-february-22-2023/) - [et_pb_section fb_built=”1″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”February 23, 2023″ _builder_version=”4.19.5″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”]BrightInsight Welcomes ixlayer to the BrightInsight Ecosystem to Streamline Diagnosis and Improve Therapy Matching Companies partner to pair the power of drug companion apps with convenient diagnostic testing SAN JOSE, Calif. – February 22,
- [News | March 20, 2023](https://www.nlvpartners.com/news-march-20-2023/) - [et_pb_section fb_built=”1″ _builder_version=”4.16″ global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_row _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||” theme_builder_area=”post_content”][et_pb_text admin_label=”February 23, 2023″ _builder_version=”4.19.5″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ global_colors_info=”{}” theme_builder_area=”post_content” sticky_enabled=”0″]BrightInsight Named to Fierce Medtech’s 2022 Fierce 15 List SAN JOSE, Calif. – March 20, 2023 (Globe Newswire) – BrightInsight, Inc., provider of the leading global platform for
- [News | January 24, 2023](https://www.nlvpartners.com/news-january-24-2023-2/) - [et_pb_section fb_built=”1″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”January 24, 2023″ _builder_version=”4.19.5″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]Deciphera Pharmaceuticals Presents Results from ctDNA Analysis of INTRIGUE Phase 3 Clinical Study at the American Society of Clinical Oncology Plenary Series Session – Second-Line GIST Patients with Mutations in KIT Exon
- [News | January 24, 2023](https://www.nlvpartners.com/news-january-24-2023/) - [et_pb_section fb_built=”1″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”January 24, 2023″ _builder_version=”4.19.5″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares WALTHAM, Mass.–(BUSINESS WIRE)–Jan. 24, 2023– Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical
- [News | December 15, 2022](https://www.nlvpartners.com/news-december-15-2022-2/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″ global_colors_info=”{}”][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”December 15, 2022″ _builder_version=”4.14.7″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]Rallybio Announces Publication of Data Highlighting the Ability of HPA-1a-Specific Antibodies to Prevent Alloimmunization in an Authentic Mouse Model of FNAIT — Data Demonstrates that HPA-1a Alloimmunization can be Prevented with Prophylactic
- [News | December 5, 2022](https://www.nlvpartners.com/news-december-5-2022/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″ global_colors_info=”{}”][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”December 5, 2022″ _builder_version=”4.14.7″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]Medication Intelligence Leader Kit CheckⓇ Rebrands as BluesightⓇ The shift redefines Bluesight from a point solution to a suite of Medication Intelligence™ software products that provides a complete picture of the pharmaceutical
- [News | December 14, 2022](https://www.nlvpartners.com/news-december-14-2022/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″ global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||” theme_builder_area=”post_content”][et_pb_text admin_label=”December 14, 2022″ _builder_version=”4.14.7″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ global_colors_info=”{}” theme_builder_area=”post_content” sticky_enabled=”0″]PASSAGE BIO ANNOUNCES POSITIVE INTERIM CLINICAL DATA FROM FIRST SIX PATIENTS WITH GM1 GANGLIOSIDOSIS IN IMAGINE-1 STUDY Interim safety data up to 20 months showed the low and
- [News | November 22, 2022](https://www.nlvpartners.com/news-november-22-2022/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”3.22″ global_colors_info=”{}”][et_pb_row admin_label=”row” _builder_version=”4.14.7″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.14.7″ _module_preset=”default” admin_label=”November 22, 2022″ hover_enabled=”0″ sticky_enabled=”0″]Arvinas Announces ARV-471 Achieves a Clinical Benefit Rate of 38% in Evaluable Patients and Continues to Show a Favorable Tolerability Profile in its Phase 2 Expansion Trial (VERITAC) ARV-471 continues to
- [News | December 1, 2022](https://www.nlvpartners.com/news-december-1-2022/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″ global_colors_info=”{}”][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”December 1, 2022″ _builder_version=”4.14.7″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]AbCellera and Rallybio Announce Strategic Alliance to Discover, Develop, and Commercialize Novel Antibody-Based Therapeutics for Rare Diseases VANCOUVER, British Columbia & NEW HAVEN, Conn.–(BUSINESS WIRE)–Dec. 1, 2022– AbCellera (Nasdaq: ABCL) and Rallybio
- [News | December 15, 2022](https://www.nlvpartners.com/news-december-15-2022/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″ global_colors_info=”{}”][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”December 15, 2022″ _builder_version=”4.14.7″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]Iterum Therapeutics announces Issuance of Allowance for a U.S. Patent Covering Oral Sulopenem DUBLIN, Ireland and CHICAGO, Dec. 15, 2022 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum”),
- [News | December 11, 2022](https://www.nlvpartners.com/news-december-11-2022/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″ global_colors_info=”{}”][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”December 11, 2022″ _builder_version=”4.14.7″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”]HARPOON THERAPEUTICS PRESENTS UPDATED INTERIM RESULTS AT ASH 2022 FOR NOVEL T CELL ENGAGER HPN217 IN RELAPSED/REFRACTORY MULTIPLE MYELOMA Clinically active across a wide dose range (2.15 to 24 mg) in a Phase 1
- [News | October 25, 2022](https://www.nlvpartners.com/news-october-25-2022/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″ global_colors_info=”{}”][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”October 25, 2022″ _builder_version=”4.14.7″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”]Glympse to Present Data Demonstrating Sensitive Detection of Hepatocellular Carcinoma at AASLD The Liver Meeting 2022 -Data demonstrating novel platform to measure protease activity accurately differentiates patients with hepatocellular carcinoma (HCC) vs. patients with
- [News | November 10, 2022](https://www.nlvpartners.com/news-november-10-2022/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″ global_colors_info=”{}”][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”November 10, 2022″ _builder_version=”4.14.7″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]Rallybio Announces Pricing of $50 Million Public Offering Rallybio Corporation (“Rallybio”) (Nasdaq: RLYB) today announced the pricing of an underwritten public offering of 5,000,001 shares of its common stock at a price
- [News | November 17, 2022](https://www.nlvpartners.com/news-november-17-2022/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″ global_colors_info=”{}”][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”November 17, 2022″ _builder_version=”4.14.7″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”]Cleerly Partners With Heartbeat Health for Increased Access to Early Cardiac Evaluations New alliance combines Cleerly’s AI-enabled approach to identifying early signs of heart disease with Heartbeat Health’s nationwide footprint of virtual cardiologists and
- [News | October 31, 2022](https://www.nlvpartners.com/news-october-31-2022/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″ global_colors_info=”{}”][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”October 31, 2022″ _builder_version=”4.14.7″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]Cleerly’s Proxy solution improves heart disease imaging workflows Cleerly introduces Proxy solution to improve heart disease imaging workflowsProxy allows for seamless data transmission and improved AI-based plaque analysis Cleerly, the company creating
- [News | November 14, 2022](https://www.nlvpartners.com/news-november-14-2022/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″ global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||” theme_builder_area=”post_content”][et_pb_text admin_label=”November 14, 2022″ _builder_version=”4.14.7″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ global_colors_info=”{}” theme_builder_area=”post_content” sticky_enabled=”0″]BrightInsight Inks Enterprise Agreement with CSL Behring for Digital Health Solutions Across Brand Portfolio Following success of Hizentra App, CSL Behring and BrightInsight expand partnership to build apps
- [News | November 16, 2022](https://www.nlvpartners.com/news-november-16-2022/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″ global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||” theme_builder_area=”post_content”][et_pb_text admin_label=”November 16, 2022″ _builder_version=”4.14.7″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ global_colors_info=”{}” theme_builder_area=”post_content” sticky_enabled=”0″]BrightInsight Ranked 217th Fastest-Growing Company in North America on the 2022 Deloitte Technology Fast 500™ 701% revenue growth underscores BrightInsight’s position as the de facto digital health platform
- [News | September 27, 2022](https://www.nlvpartners.com/news-october-20-2022-2/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″ global_colors_info=”{}”][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”October 20, 2022″ _builder_version=”4.14.7″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]BrightInsight Adds Xealth, Woebot Health and Claritas Rx to the BrightInsight EcosystemCompanies Will Collaborate to Drive Digital Innovation, Adoption and Engagement BrightInsight, Inc., provider of the leading global platform for biopharma and
- [News | October 20, 2022](https://www.nlvpartners.com/news-october-20-2022/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″ global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||” theme_builder_area=”post_content”][et_pb_text admin_label=”October 20, 2022″ _builder_version=”4.14.7″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ global_colors_info=”{}” theme_builder_area=”post_content” sticky_enabled=”0″]Iterum Announces First Patient Dosed in REASSURE, a Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections — NDA resubmission expected in Second Half of
- [News | June 16, 2022](https://www.nlvpartners.com/news-june-16-2022/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″ global_colors_info=”{}”][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”June 16, 2022″ _builder_version=”4.14.7″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]TigerConnect Appoints Melissa Bell Company’s First President The appointment comes on the heels of a strategic investment in growth from Vista Equity Partners SANTA MONICA, Calif., June 16, 2022 —TigerConnect, healthcare’s most
- [News | August 10, 2022](https://www.nlvpartners.com/news-august-10-2022/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″ hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”August 10, 2021″ _builder_version=”4.14.7″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]Deciphera Pharmaceuticals, Inc. Announces Publication of INTRIGUE Phase 3 Clinical Study Results in Journal of Clinical Oncology – Efficacy Observed with QINLOCK® was Comparable to Sunitinib with a More Favorable
- [News | June 10, 2022](https://www.nlvpartners.com/news-june-10-2022-2/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″ global_colors_info=”{}”][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”June 10, 2022″ _builder_version=”4.14.7″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]Kit Check Recognized as Industry-Leading Vendor for Kit and Tray Management. 65% of participants consider Kit Check to be the top industry leader Washington, D.C. – (June 10, 2022) – Kit Check,
- [News | May 18, 2022](https://www.nlvpartners.com/news-may-18-2022/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″ global_colors_info=”{}”][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”May 18, 2022″ _builder_version=”4.14.7″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”]Qlaris Bio Reports Phase 2 Clinical Trial Results Demonstrating Favorable Safety and Tolerability Profile and Positive Efficacy Signal for QLS-101 Findings from First-in-Human Study Support Continued Clinical Development of Investigational IOP-lowering Therapy; New Trials
- [News | July 25, 2022](https://www.nlvpartners.com/news-july-25-2022/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″ global_colors_info=”{}”][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”July 25, 2022″ _builder_version=”4.14.7″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]Heart Health Innovator Cleerly Closes Series C Funding Round with $223 Million High-profile investors led by T. Rowe Price and Fidelity back a new standard of care for cardiovascular disease This press
- [News | June 8, 2022](https://www.nlvpartners.com/news-june-8-2022/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″ global_colors_info=”{}”][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”June 8, 2022″ _builder_version=”4.14.7″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]Glympse to Present Two Posters Demonstrating Novel Protease Biosensor Diagnostic PlatformDetection of Hepatocellular Carcinoma at EASL ILC 2022 -Analysis demonstrating highly accurate detection (AUC ≥ 0.94) of HCC vs. Healthy in two
- [News | June 14, 2022](https://www.nlvpartners.com/news-june-14-2022/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″ global_colors_info=”{}”][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”June 14, 2022″ _builder_version=”4.14.7″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]Kyruus Wins Google Cloud Healthcare & Life Sciences 2021 Customer Award BOSTON, MA – June 14, 2022 – Kyruus, the leader in provider search and scheduling solutions for healthcare organizations, today announced
- [News | June 29, 2022](https://www.nlvpartners.com/news-june-29-2022/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″ global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||” theme_builder_area=”post_content”][et_pb_text admin_label=”June 29, 2022″ _builder_version=”4.14.7″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ global_colors_info=”{}” theme_builder_area=”post_content” sticky_enabled=”0″]Kyruus Announces Paul Merrild as Company’s First President Leadership Team Expansion Follows Year of Accelerated Growth BOSTON, MA – June 29, 2022 – Kyruus, the leader in provider
- [New | July 12, 2022](https://www.nlvpartners.com/new-july-12-2022/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″ global_colors_info=”{}”][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”July 12, 2022″ _builder_version=”4.14.7″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]AiCure and Defense Health Agency to Develop Targeted PTSD Treatment for Service Members and VeteransAiCure, an artificial intelligence (AI) and advanced data analytics company focused on improving clinical trials, today announced the
- [News | July 11, 2022](https://www.nlvpartners.com/news-july-11-2022/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″ global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||” theme_builder_area=”post_content”][et_pb_text admin_label=”July 11, 2022″ _builder_version=”4.14.7″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ global_colors_info=”{}” theme_builder_area=”post_content” sticky_enabled=”0″]Iterum Therapeutics Announces Special Protocol Assessment (SPA) Agreement With the FDA –SPA supports protocol for Phase 3 Clinical Trial of Oral Sulopenem for the treatment of Uncomplicated Urinary
- [News | May 10, 2022](https://www.nlvpartners.com/news-may-10-2022/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″ global_colors_info=”{}”][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”May 10, 2022″ _builder_version=”4.14.7″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”]Rallybio Announces In-Licensing of Potential First-In-Class Preclinical Antibody Candidate from Sanofi –Expands pipeline focus on rare benign hematological disorders– –Licensing agreement marks first business development transaction since IPO– NEW HAVEN, Conn.–(BUSINESS WIRE)–May 10, 2022–
- [News | June 10, 2022](https://www.nlvpartners.com/news-june-10-2022/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″ global_colors_info=”{}”][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”June 10, 2021″ _builder_version=”4.14.7″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]Cogent Biosciences Announces Positive Initial Clinical Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) June 10, 2022 at 7:00 AM EDT All patients treated
- [News | February 16, 2022](https://www.nlvpartners.com/news-february-16-2022-2/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″ global_colors_info=”{}”][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”February 16, 2022″ _builder_version=”4.14.7″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]Star Therapeutics emerges from stealth mode raising $100M in financing since inception to be an innovation engine for rare disease therapies Drug discovery approach uncovers novel biology for treatments that can
- [News | March 10, 2022](https://www.nlvpartners.com/news-march-10-2022/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″ global_colors_info=”{}”][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”March 10, 2022″ _builder_version=”4.14.7″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]WellHive Announces Partnership with Kyruus to Integrate Systems and Optimize Care Navigation for Veterans Melbourne, FL – WellHive, the leader in digital care navigation within the federal government, today announced a novel
- [News | March 9, 2022](https://www.nlvpartners.com/news-march-9-2022/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″ global_colors_info=”{}”][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”March 9, 2022″ _builder_version=”4.14.7″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”]UPMC and Kyruus Launch Strategic Partnership to Transform Digital Patient Access and Care Navigation World-Renowned Healthcare Provider and Insurer Deepens Relationship through Direct Investment and Collaboration with Leading Digital Health Company Boston, MA –
- [News | April 13, 2022](https://www.nlvpartners.com/news-april-13-2022/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″ global_colors_info=”{}”][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”April 13, 2022″ _builder_version=”4.14.7″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”]GSK Reaches Agreement to Acquire Late-Stage Biopharmaceutical Company Sierra Oncology For $1.9bn Sierra Oncology’s differentiated momelotinib has the potential to address the critical unmet medical needs of myelofibrosis patients with anaemia Momelotinib complements GSK’s
- [News | February 16, 2022](https://www.nlvpartners.com/news-february-16-2022/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″ global_colors_info=”{}”][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”February 16, 2022″ _builder_version=”4.14.7″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”]Electra Therapeutics announces $84 million Series B financing and unveils its novel SIRP targeted therapies for immunological diseases and cancer Company’s first-in-class approach to targeting of signal regulatory proteins (SIRP) enables specific depletion
- [News | March 15, 2022](https://www.nlvpartners.com/news-march-15-2022/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″ global_colors_info=”{}”][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”March 15, 2022″ _builder_version=”4.14.7″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”]PASSAGE BIO PROVIDES UPDATE ON STRATEGIC PRIORITIES AND EXTENDS CASH RUNWAY Company to reduce workforce and prioritize research and development programs to reduce operating expenses Continued focus on execution of three ongoing clinical trials
- [News | March 29, 2022](https://www.nlvpartners.com/news-march-29-2022/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″ global_colors_info=”{}”][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”March 29, 2022″ _builder_version=”4.14.7″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”]PASSAGE BIO ANNOUNCES PUBLICATION OF PRECLINICAL DATA THAT SUPPORT ONGOING CLINICAL STUDY OF PBKR03 IN KRABBE DISEASE Preclinical studies conducted with University of Pennsylvania’s Gene Therapy Program demonstrate biologic effects of vector-optimized gene therapy
- [News | April 21, 2022](https://www.nlvpartners.com/news-april-21-2022/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″ global_colors_info=”{}”][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”April 21, 2022″ _builder_version=”4.14.7″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”]Kyruus and Upfront Partner to Enable Healthcare Organizations to Maximize Digital Patient Acquisition and Retention Partnership Offers Consumer-Centric Search and Scheduling Options While Closing Gaps in Care through Personalized Digital Outreach to Patients Boston,
- [News | April 12, 2022](https://www.nlvpartners.com/news-april-12-2022/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″ global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||” theme_builder_area=”post_content”][et_pb_text admin_label=”April 12, 2021″ _builder_version=”4.14.7″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ global_colors_info=”{}” theme_builder_area=”post_content” sticky_enabled=”0″]Deciphera Pharmaceuticals Presents Preclinical Data from DCC-3116 Program at the AACR Annual Meeting – ULK Inhibitor DCC-3116 Shown to Inhibit KRASG12C Inhibitor-induced Autophagy in Mutant KRASG12C NSCLC Cell
- [News | April 7, 2022](https://www.nlvpartners.com/news-april-7-2022/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″ global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||” theme_builder_area=”post_content”][et_pb_text admin_label=”April 7, 2022″ _builder_version=”4.14.7″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ global_colors_info=”{}” theme_builder_area=”post_content” sticky_enabled=”0″]Pfizer to Acquire ReViral and Its Respiratory Syncytial Virus Therapeutic Candidates Proposed acquisition strengthens Pfizer’s capabilities in infectious disease research and development with a complementary strategy to help
- [News | March 8, 2022](https://www.nlvpartners.com/news-march-8-2022/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″ global_colors_info=”{}”][et_pb_row _builder_version=”4.14.7″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ global_colors_info=”{}” width=”100%” sticky_enabled=”0″][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”March 8, 2022″ _builder_version=”4.14.7″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”]BrightInsight and UCB Partner to Build Digital Care Solutions for Rare Diseases UCB’s Digital Care Solutions for Myasthenia Gravis to be Built on the BrightInsight Platform SAN JOSE, Calif. – March
- [News | February 14, 2022](https://www.nlvpartners.com/news-february-14-2022/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″ global_colors_info=”{}”][et_pb_row _builder_version=”4.14.7″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ global_colors_info=”{}” width=”100%” sticky_enabled=”0″][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”February 14, 20221″ _builder_version=”4.9.5″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]Arvinas Announces New Data from Completed Phase 1 Dose Escalation and Ongoing Phase 2 ARDENT Expansion Cohort with Novel PROTAC® Degrader Bavdegalutamide (ARV-110) to be Presented at 2022 ASCO
- [News | February 17, 2022](https://www.nlvpartners.com/news-february-17-2022/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″ global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||” theme_builder_area=”post_content”][et_pb_text admin_label=”February 17, 2021″ _builder_version=”4.14.7″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ global_colors_info=”{}” theme_builder_area=”post_content” sticky_enabled=”0″]Arvinas PROTAC® Protein Degrader Bavdegalutamide (ARV-110) Continues to Demonstrate Clinical Benefit in Men with Metastatic Castration-Resistant Prostate Cancer – Bavdegalutamide treatment demonstrated robust activity in molecularly defined tumors
- [News | February 8, 2022](https://www.nlvpartners.com/news-february-8-2022-2/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text admin_label=”February 8, 2022″ _builder_version=”4.9.5″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ sticky_enabled=”0″]Kit Check’s Bluesight® for Controlled Substances is Named Best in KLAS for the 3rd Consecutive YearFor the third year running, Bluesight for Controlled Substances takes top marks in all product categories and receives a score of
- [News | January 20, 2022](https://www.nlvpartners.com/news-january-20-2022/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text admin_label=”January 20, 2022″ _builder_version=”4.9.5″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ sticky_enabled=”0″]Kit Check Launches Webinar Series Focused on RFID Innovation in HealthcareKit Check launches educational webinar series focused on supporting ASHP’s Enhancing Adoption of RFID Technology Research Grant Alexandria, VA, January 20, 2022: Kit Check, the market
- [News | February 3, 2022](https://www.nlvpartners.com/news-february-3-2022/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text admin_label=”February 2, 2022″ _builder_version=”4.9.5″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ sticky_enabled=”0″]Kyruus Announces Record-Breaking Customer Growth in 2021, Welcoming HealthSparq and Connecting Millions of People with CareLeading Digital Health Company Expands Provider and Payer Customer Base as Demand for Patient Access Solutions Accelerates Across the Healthcare Industry
- [News | January 12, 2022](https://www.nlvpartners.com/news-january-12-2022-2/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text admin_label=”January 12, 2022″ _builder_version=”4.9.5″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ sticky_enabled=”0″]Atlantic Health System Takes Consumer Convenience to the Next Level with Online Scheduling from KyruusNew Jersey-Based Health System Sees Increase in Online Appointment Bookings Boston, MA – January 12, 2022 – Kyruus, the leader in provider
- [News | February 2, 2022](https://www.nlvpartners.com/news-february-2-2022/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text admin_label=”February 2, 2022″ _builder_version=”4.9.5″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ sticky_enabled=”0″]CLEERLY NAMED TO NYC DIGITAL HEALTH 100 BY NEW YORK CITY HEALTH BUSINESS LEADERSOrganization recognizes the most promising and innovative health startups in New York NEW YORK, February 2, 2022 — Cleerly, the company creating a
- [News | February 8, 2022](https://www.nlvpartners.com/news-february-8-2022/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text admin_label=”February 8, 2022″ _builder_version=”4.9.5″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”]CLEERLY TAKES PRECISION HEART CARE TO THE NEXT LEVEL WITH CLEERLY 2.2.0Cleerly 2.2.0 includes UX updates and three high-value tools to better evaluate heart disease NEW YORK, February 8, 2022 — Cleerly, the company creating a new standard
- [News | January 25, 2022](https://www.nlvpartners.com/news-january-25-2022/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text admin_label=”January 25, 2022″ _builder_version=”4.9.5″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ sticky_enabled=”0″]Sierra Oncology Announces Momelotinib Achieved Statistically Significant Benefit on Symptoms, Anemia and Splenic Size in the Pivotal MOMENTUM Study for Myelofibrosis —New Drug Application submission planned for second quarter of 2022— —Full data set to be
- [News | January 26, 2022](https://www.nlvpartners.com/news-january-26-2022/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text admin_label=”January 26, 2022″ _builder_version=”4.9.5″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ sticky_enabled=”0″]Sierra Oncology Announces Pricing of Upsized Public Offering of Securities SAN MATEO, Calif.–(BUSINESS WIRE)– Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, today announced the pricing of
- [News | January 27, 2022](https://www.nlvpartners.com/news-january-27-2022/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.9.5″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ admin_label=”January 27, 2022″ sticky_enabled=”0″]PDS Biotech Announces Preclinical Data for PDS0202 Universal Influenza VaccinePDS0202 (Infectimune™ + COBRA Influenza Antigens) neutralized multiple strains of the flu and provided effective protection against infection in preclinical studies FLORHAM PARK, N.J., Jan. 27, 2022
- [News | January 12, 2022](https://www.nlvpartners.com/news-january-12-2022/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text admin_label=”January 12, 2022″ _builder_version=”4.9.5″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”]State of Minnesota Selects Truveris to Help Optimize its Pharmacy Benefits ProgramState to use Truveris’ proprietary truBid® technology for PBM procurement and ongoing oversight of all pharmacy claims. NEW YORK, JANUARY 12, 2022 – Truveris, the leader in pharmacy
- [News | January 11, 2022](https://www.nlvpartners.com/news-january-11-2022/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text admin_label=”January 11, 2022″ _builder_version=”4.9.5″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ sticky_enabled=”0″]TigerConnect Secures Strategic Growth Investment from Vista Equity PartnersPartnership will expand TigerConnect’s ability to deliver software to support healthcare organizations and professionals in their mission of improving patient health outcomes SANTA MONICA, Calif. — January 11,
- [News | January 10, 2022](https://www.nlvpartners.com/news-january-10-2022/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text admin_label=”January 10, 2022″ _builder_version=”4.9.5″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ sticky_enabled=”0″]BrightInsight Announces Partnership with Sanofi to Bring to Market a Next Generation Digital Companion ApplicationBrightInsight’s Platform has been selected to Accelerate Continuous Development of one of Sanofi’s Best-In-Class Software as a Medical Device SAN JOSE, Calif.
- [News | January 5, 2022](https://www.nlvpartners.com/news-january-5-2022/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.9.5″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ admin_label=”January 5, 2022″ sticky_enabled=”0″]Edgewise Therapeutics Announces Positive Topline Results From the EDG-5506 Phase 1b Clinical Trial in Adults With Becker Muscular Dystrophy (BMD) – EDG-5506 was well tolerated with no serious adverse events observed – – Pharmacokinetic (PK) data
- [News | December 21, 2021](https://www.nlvpartners.com/news-december-21-2021/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text admin_label=”April 16, 2021″ _builder_version=”4.9.5″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”]Deciphera Announces Approval of QINLOCK® in the United Kingdom for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor – QINLOCK Significantly Reduced the Risk of Disease Progression or Death by 85% and Showed Clinically Meaningful Overall Survival in the
- [News | December 10, 2021](https://www.nlvpartners.com/news-december-10-2021/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text admin_label=”December 10, 2021″ _builder_version=”4.9.5″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ sticky_enabled=”0″]Arvinas and Pfizer Announce PROTAC® Protein Degrader ARV-471 Continues to Demonstrate Encouraging Clinical Benefit Rate in Patients with Locally Advanced or Metastatic ER+/HER2- Breast Cancer – ARV-471 continues to show a favorable tolerability profile and robust
- [News | December 8, 2021](https://www.nlvpartners.com/news-december-8-2021-2/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text admin_label=”December 8, 2021″ _builder_version=”4.9.5″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”]Kit Check and Fagron Partner to Launch RFID-tagged 503B Products in February 2022 503B Compounder Set to Manufacture Products Embedded with RFID tags Compatible with Kit Check Scanning Technology ARLINGTON, Va., Dec. 8, 2021 /PRNewswire/ — Kit Check,
- [News | December 8, 2021](https://www.nlvpartners.com/news-december-8-2021/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text admin_label=”December 8, 2021″ _builder_version=”4.9.5″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”]CLEERLY NAMED TO THE 2021 CB INSIGHTS DIGITAL HEALTH 150List of Most Innovative Digital Health Startups NEW YORK, December 8, 2021 — CB Insights today named Cleerly to its third annual Digital Health 150, which showcases the 150
- [News | December 7, 2021](https://www.nlvpartners.com/news-november-29-2021-2/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text admin_label=”December 7, 2021″ _builder_version=”4.9.5″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ sticky_enabled=”0″]Ochsner Health Makes Finding the Right Provider Easier with Solutions from Kyruus Louisiana’s Largest Healthcare Provider Has Implemented a New Provider Directory and Enhanced Search Capabilities to Simplify Patient Access Boston, MA – December 7, 2021–
- [News | November 29, 2021](https://www.nlvpartners.com/news-november-29-2021/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text admin_label=”November 29, 2021″ _builder_version=”4.9.5″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ sticky_enabled=”0″]Neurana Pharmaceuticals Completes Patient Enrollment in Phase 3 RESUME-1 StudySAN DIEGO, Calif., November 29, 2021 — Neurana Pharmaceuticals, a biotechnology company focused on the treatment of neuromuscular conditions, today announced it has completed enrollment of its
- [News | November 22, 2021](https://www.nlvpartners.com/news-november-22-2021/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text admin_label=”November 22, 2021″ _builder_version=”4.9.5″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ sticky_enabled=”0″]Deciphera Receives European Commission Approval of QINLOCK® for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor – QINLOCK Significantly Reduced the Risk of Disease Progression or Death by 85% and Showed Clinically Meaningful Overall Survival in the
- [News | November 8, 2021](https://www.nlvpartners.com/news-november-8-2021/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text admin_label=”November 8, 2021″ _builder_version=”4.9.5″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ sticky_enabled=”0″]PDS Biotechnology Licenses Protein for the Treatment of Acute Myeloid Leukemia, Prostate and Breast Cancers from National Cancer Institute Advances Next Phase of Versamune® Oncology Pipeline FLORHAM PARK, N.J., Nov. 08, 2021 (GLOBE NEWSWIRE) — PDS
- [News | October 27, 2021](https://www.nlvpartners.com/news-october-27-2021/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text admin_label=”October 27, 2021″ _builder_version=”4.9.5″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ sticky_enabled=”0″]Aptinyx Completes Enrollment in Phase 2b Study of NYX-2925 in Painful Diabetic Peripheral Neuropathy Results from the Phase 2b study are expected in early to mid 2Q 2022 EVANSTON, Ill.–(BUSINESS WIRE)– Aptinyx Inc. (Nasdaq: APTX), a
- [News | September 22, 2021](https://www.nlvpartners.com/news-september-22-2021/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text admin_label=”September 22, 2021″ _builder_version=”4.9.5″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ sticky_enabled=”0″]Kit Check Enters into a Reseller Agreement with Govplace to allow Government Hospitals to increase Pharmacy Visibility with RFID Enabled Kit and Tray Processing to Increase Medication Intelligence WASHINGTON (September 22, 2021) — Kit Check, the
- [News | October 26, 2021](https://www.nlvpartners.com/news-october-26-2021/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text admin_label=”October 26, 2021″ _builder_version=”4.9.5″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ sticky_enabled=”0″]TigerConnect’s Alarm Management and Event Notification Solution Mitigates “Alarm Fatigue” in Demanding Clinical Environments FDA-cleared solution enables converged healthcare communication and collaboration for providers struggling with staffing shortages and caregiver burnout SANTA MONICA, Calif., Oct. 26,
- [News | October 5, 2021](https://www.nlvpartners.com/news-october-5-2021/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text admin_label=”October 5, 2021″ _builder_version=”4.9.5″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ sticky_enabled=”0″]Privia Health Uses Kyruus’ Digital Patient Access Platform to Help Empower Consumers and Drive Practice Growth Boston, MA – October 5, 2021– Kyruus, the leader in provider search and scheduling solutions for healthcare organizations, today announced
- [News | October 18, 2021](https://www.nlvpartners.com/news-october-18-2021/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text admin_label=”October 18, 2021″ _builder_version=”4.9.5″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ sticky_enabled=”0″]CLEERLY APPOINTS JIM HARTMAN AS CHIEF REVENUE OFFICERSales strategy expert brings industry success to leverage growth. NEW YORK – October 18, 2021 – Cleerly, the company creating a new standard of care for heart disease, announced
- [News | October 12, 2021](https://www.nlvpartners.com/news-october-12-2021/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text admin_label=”October 12, 2021″ _builder_version=”4.9.5″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ sticky_enabled=”0″]Deciphera Announces Approval of QINLOCK® in Switzerland for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor – Seventh Approval Worldwide for QINLOCK and First European Approval – WALTHAM, Mass.–(BUSINESS WIRE)–Oct. 12, 2021– Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH),
- [News | October 7, 2021](https://www.nlvpartners.com/news-october-7-2021-2/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text admin_label=”Occtober 7, 2021″ _builder_version=”4.9.5″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ sticky_enabled=”0″]Deciphera Presents Preclinical Data from DCC-3116 Program at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics – DCC-3116 Shown to Inhibit EGFR and EGFR Family Inhibitor-induced Autophagy in Multiple EGFR-mutant Non-Small Cell Lung Cancer
- [News | October 7, 2021](https://www.nlvpartners.com/news-october-7-2021/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text admin_label=”October 7, 2021″ _builder_version=”4.9.5″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ sticky_enabled=”0″]Cogent Biosciences Presents New Preclinical Data Demonstrating Bezuclastinib as a Differentiated KIT Inhibitor with Minimal Brain PenetrationOctober 7, 2021 at 9:00 AM EDT Currently enrolling APEX, a Phase 2 clinical study of bezuclastinib (CGT9486) for patients
- [News | September 17,  2021](https://www.nlvpartners.com/news-september-17-2021/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text admin_label=”September 17, 2021″ _builder_version=”4.9.5″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ sticky_enabled=”0″]Deciphera Pharmaceuticals Presents New Clinical Study Results Across Pipeline at the European Society for Medical Oncology (ESMO) Congress 2021 – Rebastinib in Combination with Paclitaxel Demonstrated Progression Free Survival of 9.1 months in Heavily Pretreated Patients
- [News | September 14, 2021](https://www.nlvpartners.com/news-september-14-2021/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text admin_label=”September 14, 2021″ _builder_version=”4.9.5″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”]DICE Therapeutics Announces Pricing of Upsized Initial Public Offering SOUTH SAN FRANCISCO, Calif., Sept. 14, 2021 (GLOBE NEWSWIRE) — DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel
- [News | August 5, 2021](https://www.nlvpartners.com/news-august-5-2021/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text admin_label=”August 5, 2021″ _builder_version=”4.9.5″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”]TigerConnect Announces Expanded Product Suite to Revolutionize Clinical Collaboration and Cut Care CostsIntuitive Communication Capabilities Designed Around and For Today’s Healthcare Worker SANTA MONICA, Calif. — August 5, 2021 — TigerConnect, healthcare’s most adopted platform for advanced care
- [News | August 30, 2021](https://www.nlvpartners.com/news-august-30-2021/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text admin_label=”August 30, 2021″ _builder_version=”4.9.5″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”]Kit Check Hires New Chief Technology Officer WASHINGTON, August 30 – Kit Check today announced the addition of Vijay Venkatesh as Chief Technology Officer. Mr. Venkatesh brings vast expertise leading technology teams that have used new data sets
- [News | September 9, 2021](https://www.nlvpartners.com/news-september-9-2021/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text admin_label=”September 9, 2021″ _builder_version=”4.9.5″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ sticky_enabled=”0″]PDS Biotech Completes Enrollment of Lead-In Safety Cohort in VERSATILE-002 Phase 2 Combination Trial of PDS0101-KEYTRUDA® in Recurrent or Metastatic Head and Neck Cancer FLORHAM PARK, N.J., Sept. 09, 2021 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation
- [News | July 2, 2021](https://www.nlvpartners.com/news-july-2-2021/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text admin_label=”July 2, 2021″ _builder_version=”4.9.5″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ sticky_enabled=”0″]Rallybio Announces Clinical Proof of Concept for RLYB211, an Anti-HPA-1a Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) — Data to be Presented at the International Society on Thrombosis and Haemostasis (ISTH) 2021
- [News | July 28, 2021](https://www.nlvpartners.com/news-july-28-2021/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text admin_label=”July 28, 2021″ _builder_version=”4.9.5″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”]Rallybio Corporation Announces Pricing of Initial Public Offering NEW HAVEN, Conn.–(BUSINESS WIRE)–Jul. 28, 2021– Rallybio Corporation (Rallybio), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases,
- [News | June 21, 2021](https://www.nlvpartners.com/news-june-21-2021-2/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text admin_label=”June 21, 2021″ _builder_version=”4.9.5″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ sticky_enabled=”0″]Cleerly Launches with $43 Million Series B to Provide a New Standard of Care for the Leading Cause of Death – Heart Disease Resulting from More than a Decade of Clinical Research, Company Unveils Non-Invasive Approach
- [News | July 22, 2021](https://www.nlvpartners.com/news-july-22-2021/) - Arvinas and Pfizer Announce Global Collaboration to Develop and Commercialize PROTAC® Protein Degrader ARV-471 – Collaboration combines Arvinas’ investigational estrogen receptor-targeting breast cancer therapy with Pfizer’s deep experience in breast oncology therapeutics – – ARV-471 is currently in Phase 2 development for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer –
- [News | June 29, 2021](https://www.nlvpartners.com/news-june-29-2021/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text admin_label=”June 29, 2021″ _builder_version=”4.9.5″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ sticky_enabled=”0″]ADDEX THERAPEUTICS INITIATES PIVOTAL PHASE 2B/3 STUDY WITH DIPRAGLURANT FOR DYSKINESIA ASSOCIATED WITH PARKINSON’S DISEASE Geneva, Switzerland, June 29, 2021 – Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug
- [News | June 21, 2021](https://www.nlvpartners.com/news-june-21-2021/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text admin_label=”June 21, 2021″ _builder_version=”4.9.5″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ sticky_enabled=”0″]Sierra Oncology Announces Completion of Enrollment for MOMENTUM Phase 3 Trial—Topline data anticipated in Q1 2022 with NDA filing to follow in H2 2022— SAN MATEO, Calif., June 21, 2021 /CNW/ – Sierra Oncology, Inc. (NASDAQ:
- [News | June 15, 2021](https://www.nlvpartners.com/news-june-15-2021-2/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text admin_label=”April 16, 2021″ _builder_version=”4.9.5″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ sticky_enabled=”0″] Braeburn Resubmits New Drug Application for BRIXADI™ (buprenorphine) Extended-Release Subcutaneous Injection for Moderate to Severe Opioid Use Disorder Plymouth Meeting, Pa. – June 15, 2021 – Braeburn announces that today the New Drug Application (NDA)
- [News | June 15, 2021](https://www.nlvpartners.com/news-june-15-2021/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text admin_label=”April 16, 2021″ _builder_version=”4.9.5″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ sticky_enabled=”0″] Aptinyx Provides Update on NYX-783 Development Program for the Treatment of Post-Traumatic Stress Disorder Finalizes design for Phase 2b program, which remains on track to commence in 4Q 2021 Corrects statistical analysis from previous exploratory
- [News | June 4, 2021](https://www.nlvpartners.com/news-june-4-2021-2/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text admin_label=”April 16, 2021″ _builder_version=”4.9.5″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ sticky_enabled=”0″] Deciphera Pharmaceuticals Presents Data from QINLOCK® and Rebastinib Programs at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting – Exploratory Analysis of the INVICTUS Phase 3 Study Showed QINLOCK Dose Escalation After Disease
- [News | June 7, 2021](https://www.nlvpartners.com/news-june-7-2021/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text admin_label=”April 16, 2021″ _builder_version=”4.9.5″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ sticky_enabled=”0″] ADDEX STARTS PHASE 2 CLINICAL STUDY OF ADX71149 FOR EPILEPSY First patients enrolled into multi-center U.S. study Geneva, Switzerland, June 7, 2021 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering
- [News | June 7, 2021](https://www.nlvpartners.com/news-june-7-2021-2/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text admin_label=”April 16, 2021″ _builder_version=”4.9.5″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ sticky_enabled=”0″] Neurana Pharmaceuticals Announces 50% Enrollment in Phase 3, RESUME-1 Study SAN DIEGO, Calif., June 7, 2021 — Neurana Pharmaceuticals, a biotechnology company focused on the treatment of neuromuscular conditions, today announced that 500 of its
- [News | April 14, 2021](https://www.nlvpartners.com/news-june-4-2021/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text admin_label=”April 16, 2021″ _builder_version=”4.9.5″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ sticky_enabled=”0″]Qlaris Bio Enrolls First Patient in Phase 1/2 Studies of QLS-101, an Investigational Therapy Designed to Lower Episcleral Venous Pressure (EVP) in Patients with Glaucoma – Phase 1/2 Initiation Follows FDA Acceptance of Investigational New Drug
- [News | April 15, 2021](https://www.nlvpartners.com/news-april-15-2021/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text admin_label=”April 16, 2021″ _builder_version=”4.5.1″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″] Qlaris Bio Enrolls First Patient in Phase 1/2 Studies of QLS-101, an Investigational Therapy Designed to Lower Episcleral Venous Pressure (EVP) in Patients with Glaucoma – Phase 1/2 Initiation Follows FDA Acceptance of Investigational New Drug
- [News | April 6, 2021](https://www.nlvpartners.com/news-april-6-2021/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text admin_label=”April 6, 2021″ _builder_version=”4.5.1″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″] Aptinyx Recommences Phase 2 Study of NYX-458 in Patients with Cognitive Impairment Associated with Parkinson’s Disease Dementia and Dementia with Lewy Bodies Patient screening has resumed following temporary suspension due to escalation of the COVID-19 pandemic
- [News | March 30, 2021](https://www.nlvpartners.com/news-march-30-2021/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text admin_label=”March 30, 2021″ _builder_version=”4.5.1″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″] BrightInsight Announces $101M in Series C Funding led by General Catalyst The Financing will Fuel BrightInsight’s Hypergrowth as the Leading Global Regulated Digital Health Platform for Biopharma and MedtechSAN JOSE, Calif., March 30, 2021 – BrightInsight,
- [News | March 25, 2021](https://www.nlvpartners.com/news-march-25-2021/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text admin_label=”March 25, 2021″ _builder_version=”4.5.1″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″] Edgewise Therapeutics Announces Pricing of Initial Public Offering BOULDER, Colo.–(BUSINESS WIRE)– Edgewise Therapeutics, Inc. (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for rare muscle disorders, announced today the pricing
- [News | March 16, 2021](https://www.nlvpartners.com/news-march-16-2021/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text admin_label=”March 16, 2021″ _builder_version=”4.5.1″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″] BrightInsight and AstraZeneca Collaborate to Enhance Disease Management BrightInsight Accelerates Time to Market for the AstraZeneca AMAZE Disease Management Platform Within a Regulatory-Compliant Environment SAN JOSE, Calif., March 16, 2021 – BrightInsight, Inc., provider of the
- [News | March 2, 2021](https://www.nlvpartners.com/news-march-2-2021-2/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text admin_label=”March 2, 2021″ _builder_version=”4.5.1″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”] ReViral and LianBio Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Sisunatovir in China London and Research Triangle Park, N.C., and Shanghai and Princeton, N.J., March 2, 2021 – ReViral Ltd., a clinical-stage biopharmaceutical company
- [News | February 3, 2021](https://www.nlvpartners.com/news-february-3-2021-2/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text admin_label=”February 3, 2021″ _builder_version=”4.5.1″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″] Kit Check®’s Bluesight® for Controlled Substances is Announced as Best in KLAS for Drug Diversion Monitoring in 2021 Best in KLAS Report For the second year running, Bluesight for Controlled Substances takes top marks in all
- [News | January 20, 2021](https://www.nlvpartners.com/news-january-20-2021/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text admin_label=”January 20, 2021″ _builder_version=”4.5.1″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″] TRUVERIS EXPANDS LEADERSHIP TEAM WITH KEY APPOINTMENTS New CCO, CMO and Senior Industry Leaders to Further Accelerate Company Growth NEW YORK, January 20, 2021 – Truveris, a leading digital health company focused on reducing costs and
- [News | March 2, 2021](https://www.nlvpartners.com/news-march-2-2021/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text admin_label=”March 2, 2021″ _builder_version=”4.5.1″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″] Rallybio Reveals Details of Two Pipeline Programs with the Potential to Transform the Lives of Patients with Rare Diseases RLYB212: A Novel Monoclonal HPA-1a Antibody for the Prevention of a Potentially Life-Threatening Rare Disease that Impacts
- [News | February 8, 2021](https://www.nlvpartners.com/news-february-8-2021/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text admin_label=”February 8, 2020″ _builder_version=”4.5.1″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″] FDA Clears IND Application for Passage Bio’s Gene Therapy Candidate PBKR03 for Treatment of Patients with Early Infantile Krabbe Disease, A Rare Pediatric Disorder with No Approved Disease-Modifying Treatment Options – Phase 1/2 trial expected to
- [News | February 9, 2021](https://www.nlvpartners.com/news-february-9-2021/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text admin_label=”February 9, 2020″ _builder_version=”4.5.1″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”] Iterum Therapeutics plc Announces $35.0 Million Registered Direct Offering of Ordinary Shares Priced At-the-Market under Nasdaq Rules DUBLIN, Ireland and CHICAGO, Feb. 09, 2021 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical
- [News | February 3, 2021](https://www.nlvpartners.com/news-february-3-2021/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text admin_label=”February 3, 2021″ _builder_version=”4.5.1″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″] Iterum Therapeutics plc Increases Previously Announced Bought Deal Public Offering of Ordinary Shares to $40.0 Million DUBLIN, Ireland and CHICAGO, Feb. 03, 2021 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical
- [News | February 1, 2021](https://www.nlvpartners.com/news-february-1-2021/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text admin_label=”February 1, 2020″ _builder_version=”4.5.1″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″] Iterum Therapeutics Announces Collaboration with EVERSANA to Support Oral Sulopenem Launch DUBLIN, Ireland and CHICAGO, Feb. 01, 2021 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next
- [News| January 7, 2021](https://www.nlvpartners.com/news-january-7-2021/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.5.1″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″] ADDEX ANNOUNCES PRICING OF $10.0 MILLION GLOBAL OFFERING Geneva, Switzerland, January 7, 2021 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today the pricing of an
- [News | January 6, 2021](https://www.nlvpartners.com/news-january-6-2021/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.5.1″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”] HARPOON THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK SOUTH SAN FRANCISCO, Calif., Jan. 06, 2021 (GLOBE NEWSWIRE) — Harpoon Therapeutics, Inc. (Nasdaq: HARP), announced today the pricing of an underwritten public offering of 5,882,352 shares of its common
- [News | January 4, 2021](https://www.nlvpartners.com/news-january-4-2021-2/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.5.1″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″] HARPOON THERAPEUTICS DOSES FIRST PATIENT WITH HPN328, AN ANTI-DLL3 T CELL ENGAGER FOR TREATMENT OF SMALL CELL LUNG CANCER AND OTHER DLL3-ASSOCIATED TUMORS HPN328, Harpoon’s fourth TriTAC® T cell engager, enters clinical development SOUTH SAN FRANCISCO, Calif., Jan. 04,
- [News | January 4, 2021](https://www.nlvpartners.com/news-january-4-2021/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.5.1″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″] Passage Bio Receives FDA Clearance of IND Application for Lead Gene Therapy Candidate PBGM01 for Treatment of Infantile GM1 Gangliosidosis FDA clearance marks second regulatory authorization for global Phase 1/2 clinical trial, Imagine-1 study, expected to dose first patient
- [News | December 14, 2020](https://www.nlvpartners.com/news-december-14-2020/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.5.1″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″] Arvinas Releases Interim Clinical Data Further Demonstrating the Powerful Potential of PROTAC® Protein Degraders ARV-471 and ARV-110 – ARV-471 demonstrates evidence of anti-tumor activity, and potential for best-in-class safety, and estrogen receptor (ER) degradation profile and robust efficacy signals
- [News | December 15, 2020](https://www.nlvpartners.com/news-december-15-2020/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.5.1″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″] Arvinas, Inc. Announces Pricing of $400 Million Public Offering of Common Stock NEW HAVEN, Conn., Dec. 15, 2020 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein
- [News | November 30, 2020](https://www.nlvpartners.com/news-november-30-2020-2/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.5.1″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″] Deciphera Pharmaceuticals Completes Target Enrollment in the INTRIGUE Phase 3 Clinical Study of QINLOCK® (Ripretinib) in Patients with Second-Line Gastrointestinal Stromal Tumor – Top-line Results Expected in Second Half of 2021 –– Study Designed to Evaluate the Efficacy and
- [News | December 8, 2020](https://www.nlvpartners.com/news-december-8-2020-4/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.5.1″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″] Kit Check Launches Streamlined Mobile Pharmacy to Boost EfficiencyLucas McCanna December 8, 2020Medication management easily accessible through stocked medication cart WASHINGTON (December 8, 2020) — Kit Check, the leader in automated and intelligent medication management solutions for hospitals, announces
- [News | December 17, 2020](https://www.nlvpartners.com/news-december-17-2020/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.5.1″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″] Kyruus and HealthSparq Come Together to Transform Care Navigation Through Novel Payer-Provider Collaboration Kyruus Acquisition of HealthSparq from Cambia Health Solutions Provides Unparalleled Digital Access Platform to Connect People to the Right Care for Their Needs Boston, MA and
- [News | December 8, 2020](https://www.nlvpartners.com/news-december-8-2020-2/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.5.1″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″] HARPOON THERAPEUTICS REPORTS CLINICAL PROGRESS ACROSS ALL FOUR TRITAC® PIPELINE DEVELOPMENT PROGRAMS HPN424 has shown confirmed partial response in treatment of metastatic castration-resistant prostate cancer in highest fixed dose cohort (160 ng/kg) of continuing Phase 1/2a dose escalation trial
- [News | December 8, 2020](https://www.nlvpartners.com/news-december-8-2020-3/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.5.1″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″] Kyruus Named Winner of the Powerhouse Healthcare Company Category at New England Venture Capital Association’s 2020 NEVY Awards NEVY Award 2020 BOSTON — December 8, 2020— Recently, in homes all over New England, the New England Venture Capital Association
- [News | December 21, 2020](https://www.nlvpartners.com/news-december-21-2020/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.5.1″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″] Neurana Pharmaceuticals Announces First Patient Enrolled in Phase 3, RESUME-1 Study SAN DIEGO, Calif., December 21, 2020 — Neurana Pharmaceuticals, a biotechnology company focused on the treatment of neuromuscular conditions, today announced that the first patient has been enrolled
- [News | December 8, 2020](https://www.nlvpartners.com/news-december-8-2020/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.5.1″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″] Edgewise Therapeutics Completes $95 Million Series C Financing to Advance Clinical Development of Muscular Dystrophy Program – Financing Round Led by Viking Global Investors – – Proceeds will fund ongoing clinical development of EDG-5506, a novel, oral drug candidate
- [News | November 30, 2020](https://www.nlvpartners.com/news-november-30-2020/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.5.1″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″] Iterum Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem –First Oral Penem in the U.S. and First New Oral Treatment for uUTIs in Over 20 Years, if approved– –Potential Approval Q3 2021 with
- [News | November 13, 2020](https://www.nlvpartners.com/news-november-13-2020/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.5.1″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″] First-In-Human Data Supporting the Safety of Glympse Bio’s Biosensors are Presented at the AASLD 2020 Annual MeetingNoninvasive biosensors are developed for the detection and monitoring of NASH CAMBRIDGE, Mass., Nov. 13, 2020 – Glympse Bio (Glympse), a biotechnology company
- [News | October 29, 2020](https://www.nlvpartners.com/news-october-29-2020/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.5.1″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″] Study: Telehealth Achieves Nearly 90% Customer Satisfaction TigerConnect Research Reveals Seven in 10 Healthcare Providers Say Telehealth Is Here to Stay; Broad Bipartisan Support for Telehealth Adoption SANTA MONICA, California — October 29, 2020 — TigerConnect, healthcare’s most widely
- [News | November 11, 2020](https://www.nlvpartners.com/news-november-11-2020-3/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.5.1″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”] Edgewise Therapeutics Initiates Phase 1 Clinical Trial of EDG-5506 in Becker Muscular Dystrophy – EDG-5506 is a novel, oral, small molecule drug candidate with the potential to promote muscle function in patients with muscular dystrophy – Boulder, Colo., (November 11,
- [News | November 11, 2020](https://www.nlvpartners.com/news-november-11-2020-2/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.5.1″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″] Deciphera Presents Updated Preliminary Data from DCC-3014, its CSF1R Inhibitor Program, in Tenosynovial Giant Cell Tumor Patients at the Connective Tissue Oncology Society (CTOS) 2020 Virtual Annual Meeting – Preliminary Results Showed 41% (9 of 22 Patients) Objective Response
- [News | November 11, 2020](https://www.nlvpartners.com/news-november-11-2020/) - [et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.5.1″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″] Deciphera Presents Data from QINLOCK® (Ripretinib) Program at the Connective Tissue Oncology Society (CTOS) 2020 Virtual Annual Meeting – Deciphera Presents the First and Largest Baseline Genomic Analysis by Tumor and Liquid Biopsy in Fourth-line Patients with GIST –
- [News | October 19, 2020](https://www.nlvpartners.com/news-october-19-2020/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”3.22″][et_pb_row admin_label=”row” _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text admin_label=”October 19, 2020″ _builder_version=”4.5.1″ _module_preset=”default”] Aptinyx Reports Positive, Statistically Significant, Top-line Data From Phase 2 Study of NYX-783 in Patients With Post-Traumatic Stress Disorder Clinically meaningful and statistically significant improvement on CAPS-5 Arousal and Reactivity Score observed with NYX-783 Clinically meaningful improvement
- [News | October 26, 2020](https://www.nlvpartners.com/news-october-26-2020/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”3.22″][et_pb_row admin_label=”row” _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text admin_label=”October 26, 2020″ _builder_version=”4.5.1″ _module_preset=”default” hover_enabled=”0″] Aptinyx Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option EVANSTON, Ill.–(BUSINESS WIRE)– Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous
- [News  | September 28, 2020](https://www.nlvpartners.com/news-september-28-2020/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”3.22″][et_pb_row admin_label=”row” _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text admin_label=”September 28, 2020″ _builder_version=”4.5.1″ _module_preset=”default” hover_enabled=”0″] Aptinyx Recommences Patient Recruitment in Phase 2 Study of NYX-2925 in Patients with Fibromyalgia Resuming study following suspension of enrollment due to escalation of COVID-19 pandemic Data readout expected in 1H 2022 Also on track to
- [News | October 14, 2020](https://www.nlvpartners.com/news-october-14-2020/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”3.22″][et_pb_row admin_label=”row” _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text admin_label=”October 14, 2020″ _builder_version=”4.5.1″ _module_preset=”default” hover_enabled=”0″] Arvinas Announces Pipeline Programs Targeting Validated and Classically “Undruggable” Disease-Causing Proteins NEW HAVEN, Conn., Oct. 14, 2020 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on
- [News | October 8, 2020](https://www.nlvpartners.com/news-october-8-2020/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”3.22″][et_pb_row admin_label=”row” _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.5.1″ _module_preset=”default” hover_enabled=”0″ admin_label=”October 8, 2020″] TigerConnect Closes $45M Series D To Meet Soaring DemandCare Team Collaboration Platform Revenue Grew 30% Since COVID-19 Onset, Added 1,000 Hospital Systems SANTA MONICA, California — October 8, 2020 — TigerConnect, healthcare’s most widely adopted care
- [News | September 1, 2020](https://www.nlvpartners.com/news-september-1-2020-2/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”3.22″][et_pb_row admin_label=”row” _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.5.1″ _module_preset=”default” hover_enabled=”0″] Kit Check Extends Partnership with Premier Inc. in Multi-Year Contract to Further Advance Pharmacy Visibility with Diversion Detection Software and Medication Management WASHINGTON, D.C.–(BUSINESS WIRE)–Kit Check, the leader in automated and intelligent medication management solutions, today announced that Premier
- [News | September 15, 2020](https://www.nlvpartners.com/news-september-15-2020-2/) - [et_pb_section][et_pb_row][et_pb_column type=”4_4″][et_pb_text] CuraSen Therapeutics Announces First Subjects Dosed in Phase 1 Clinical Trial with First Proprietary Compound, CST-2032, Targeting Neurodegenerative Disease Novel Approach Aimed at Restoring Brain Functionality September 15, 2020 — San Mateo, Calif.—CuraSen Therapeutics, Inc., a privately held clinical-stage biotechnology company, announced that it has dosed its first subjects in a multi-part, Phase
- [News | October 1, 2020](https://www.nlvpartners.com/october-1-2020/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”3.22″][et_pb_row admin_label=”row” _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.5.1″ _module_preset=”default”] Kit Check and Sandoz Collaborate to Launch RFID-tagged Generic Injectables in October 2020 DoseID members, Kit Check and Sandoz, have agreed to launch RFID-tagged injectable medicines Two NDCs of Sandoz RFID-tagged medicines will be available in October 2020, with several
- [News | September 1, 2020](https://www.nlvpartners.com/news-september-1-2020/) - TigerConnect Acquires Call Scheduler, Launches Fully-Integrated TigerSchedule™ to Simplify Physician On-Call Scheduling Acquisition bolsters collaboration across complex healthcare teams to drive efficiency in the COVID-19 era SANTA MONICA, Calif. — Sept. 1, 2020 — TigerConnect, healthcare’s most advanced, reliable, and widely adopted care team collaboration solution, today announced the acquisition of Adjuvant’s Call Scheduler solution
- [News | September 15, 2020](https://www.nlvpartners.com/news-september-15-2020/) - Adventist Health Enhances Online Access for Both New and Existing Patients with Kyruus and Cerner Collaboration by Kyruus, on Sep 15, 2020 9:00:00 AM California-Based Health System is First to Offer Kyruus ProviderMatch® Integrated with the Cerner Consumer FrameworkTM Boston, MA – September 15, 2020 – Kyruus, the leader in provider search and scheduling solutions
- [News | August 10, 2020](https://www.nlvpartners.com/news-august-10-2020/) - Saniona successfully raises USD 65 million (approximately SEK 567 million) in a directed issue of shares NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL
- [News | September 14, 2020](https://www.nlvpartners.com/news-september-14-2020/) - ESCAPE BIO CLOSES $73 MILLION IN CROSSOVER FINANCING TO ADVANCE CLINICAL DEVELOPMENT OF PRECISION NEUROLOGY MEDICINES FOR GENETIC NEURODEGENERATION – ESCAPE BIO SOUTH SAN FRANCISCO, September 14, 2020 — ESCAPE Bio, a clinical stage company developing novel, precisely targeted therapeutics for genetic neurodegenerative diseases, today announced the closing of a $73M financing led by Wellington
- [News | August 17, 2020](https://www.nlvpartners.com/news-august-17-2020/) - Sanofi to acquire Principia Biopharma Further strengthens core R&D areas of autoimmune and allergic diseases Provides full control of brain-penetrant BTK inhibitor SAR442168 in multiple sclerosis (MS), making commercialization more efficient and eliminating future royalty payments Allows expansion of SAR442168 development program into other central nervous system diseases and therapeutic areas Adds clinically advanced oral
- [News | August 4, 2020](https://www.nlvpartners.com/news-august-4-2020/) - ReViral Announces FDA Fast Track Designation Granted to Sisunatovir For The Treatment of Serious Respiratory Syncytial Virus Infection London, UK, and Research Triangle Park, NC, August 4, 2020 – ReViral Ltd., a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics that target respiratory syncytial virus (RSV), today announced that the U.S. Food
- [News | July 24, 2020](https://www.nlvpartners.com/news-july-24-2020/) - Approval based on Phase III ETHOS trial which showed a statistically significant reduction in the rate of exacerbations compared with dual-combination therapies AstraZeneca’s Breztri Aerosphere (budesonide/glycopyrrolate/formoterol fumarate) has been approved in the US for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). The approval by the US Food and Drug Administration (FDA)
- [News | July 15, 2020](https://www.nlvpartners.com/news-july-15-2020/) - Glympse Bio Announces $46.7 Million Series B Financing Proceeds Support PMA-Enabling Study of Glympse Technology in NASH Patients CAMBRIDGE, Mass., July 15, 2020 – Glympse Bio (Glympse), a biotechnology company advancing the way diseases are understood, tracked, and treated, has closed an oversubscribed $46.7 million Series B financing. The proceeds from the financing will support
- [News | June 30, 2020](https://www.nlvpartners.com/news-june-30-2020/) - Iterum Therapeutics Announces $5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules DUBLIN, Ireland and CHICAGO, June 30, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral antibiotics to treat infections caused by multi-drug resistant pathogens in community settings, today announced that it has
- [News | June 8, 2020](https://www.nlvpartners.com/news-june-8-2020/) - Neurana Pharmaceuticals Announces First Patient Enrolled in CNS Effects Clinical Study SAN DIEGO, Calif., June 8, 2020 – Neurana Pharmaceuticals, Inc., a biotechnology pharmaceutical company focused on the treatment of neuromuscular conditions, today announced that the first patient has been enrolled in the Phase 1 central nervous effects (CNS) clinical study of tolperisone, a novel
- [News | July 8, 2020](https://www.nlvpartners.com/news-july-8-2020/) - KLAS Rates TigerConnect Among Top Advanced Clinical Communication Platforms KLAS recognizes TigerConnect for its highly customer-centric, very large customer base across inpatient and non-inpatient care settings, delivering nimble development and “most extensive breadth of workflows for advanced users SANTA MONICA, Calif., July 8, 2020 PRNewswire – TigerConnect, healthcare’s most advanced, reliable, and widely adopted care
- [News | June 18, 2020](https://www.nlvpartners.com/news-june-18-2020/) - Aptinyx Completes Enrollment in Phase 2 Exploratory Study of NYX-783 in Post-Traumatic Stress Disorder EVANSTON, Ill., June 18, 2020 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the completion of enrollment in its ongoing Phase 2 exploratory study
- [News | June 29, 2020](https://www.nlvpartners.com/news-june-29-2020/) - Iterum Therapeutics Announces Topline Results from its Phase 3 Clinical Trial of Oral Sulopenem for the Treatment of Uncomplicated Urinary Tract Infections Sulopenem demonstrates superiority in treatment of patients with quinolone resistant pathogens Company to discuss NDA filing with FDA DUBLIN, Ireland and CHICAGO, June 29, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM),
- [News | June 23, 2020](https://www.nlvpartners.com/june-23-2020/) - Principia Announces First Patient Enrolled in Sanofi’s Phase 3 Trial of SAR442168 in Relapsing Multiple Sclerosis Dosing of Patient Will Trigger $50 Million Milestone Payment SOUTH SAN FRANCISCO, Calif., June 23, 2020 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing treatments for immune-mediated diseases, today announced that the
- [News | June 23, 2020](https://www.nlvpartners.com/news-june-23-2020/) - BrightInsight Raises $40M in Series B Funding to Cement our Position as the Leading Global Regulated Digital Health Platform for Biopharma and Medtech It’s a big day for BrightInsight. Today we announced a Series B funding round of $40M led by global venture capital and private equity firm, Insight Partners, with participation from Series A
- [News | June 16, 2020](https://www.nlvpartners.com/news-june-16-2020/) - Inspira Health Enables More Streamlined and Seamless Access to Care with Kyruus New Jersey-Based Health System is Leveraging the Kyruus Platform to Better Manage its Network and Connect Consumers to the Right Care Boston, MA – June 16, 2020 – Kyruus, the leader in provider search and scheduling solutions for health systems, today announced that
- [News | June 10, 2020](https://www.nlvpartners.com/news-june-10-2020/) - Kyruus Secures $30 Million Investment from Francisco Partners New Funding Will Accelerate Company’s Ability to Support Healthcare Organizations Caring for Patients During Unprecedented Time Boston, MA and San Francisco, CA – June 10, 2020 – Kyruus, the leader in provider search and scheduling solutions for health systems, today announced that it has obtained $30 million
- [News | June 15, 2020](https://www.nlvpartners.com/news-june-15-2020/) - New Research Sheds Light on Intentional Non-adherence in Clinical Trials First-of-its-kind study leverages objective adherence data collected by AiCure to illustrate scope of intentional non-adherence Study findings help inform best practices to lower non-adherence and reduce trial timelines and enrollment volume New York, N.Y. – While medication non-adherence in clinical trials has been widely recognized
- [News |  June 12, 2020](https://www.nlvpartners.com/news-june-12-2020-2/) - Principia Announces Positive Data from its Phase 2 Part B Trial in Pemphigus Clear dose-response combined with decreased daily corticosteroid usage Response rate increased with extended duration of treatment to six months while maintaining a favorable safety profile SOUTH SAN FRANCISCO, Calif., June 12, 2020 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage
- [News |  June 12, 2020](https://www.nlvpartners.com/news-june-12-2020/) - Principia Presents Updated Positive Data of Rilzabrutinib for Immune Thrombocytopenia in Ongoing Phase 1/2 Trial Oral BTK inhibitor reaches primary endpoint in 50 percent of patients treated > 12 weeks; demonstrates fast onset and durable responses Principia to initiate pivotal Phase 3 trial in ITP SOUTH SAN FRANCISCO, Calif., June 12, 2020 (GLOBE NEWSWIRE) --
- [News | May 13, 2020](https://www.nlvpartners.com/news-may-13-2020/) - Neurana Pharmaceuticals Announces Publication of Driving Study SAN DIEGO, Calif., May 12, 2020 – Neurana Pharmaceuticals, Inc., a biotechnology pharmaceutical company focused on the treatment of neuromuscular conditions, today announced the publication of a driving study which demonstrates the tolerability and safety of tolperisone in the peer-reviewed Journal of Clinical Pharmacy and Therapeutics. The publication,
- [News | May 4, 2020](https://www.nlvpartners.com/news-may-4-2020/) - Kit Check Announces New Sanitization Feature and Medication Tagging Milestone Company’s RFID solution, now with Sanitization Check feature to better support COVID-19 frontline providers, reaches 100 million medications tagged WASHINGTON (May 4, 2020) — Kit Check™, the leader in automated and intelligent medication management solutions, today announced that on the heels of tracking its 100
- [News | May 19, 2020](https://www.nlvpartners.com/news-may-19-2020/) - Rallybio Completes $145 Million Series B Financing and Announces Plans to Advance Lead Product Candidate into the Clinic in 2H 2020 — Financing Led by Pivotal bioVenture Partners — Company Announces Lead Product Candidate for the Prevention of a Potentially Life-Threatening Rare Disease that Impacts Fetuses and Newborns — Portfolio Expansion Planned for 2020 NEW
- [News |  May 15, 2020](https://www.nlvpartners.com/news-may-15-2020/) - FDA Grants Full Approval of Deciphera Pharmaceuticals’ QINLOCK™ (ripretinib) for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor -QINLOCK Significantly Improved Progression-Free Survival and Showed Clinically Meaningful Overall Survival in INVICTUS Phase 3 Study- -NDA Approved 3 Months Prior to Action Date Under FDA’s Real Time Oncology Review (RTOR)- -Deciphera to Host Conference Call Today at
- [News | May 6, 2020](https://www.nlvpartners.com/news-may-6-2020/) - BrightInsight and CSL Behring Announce Global Digital Health Partnership to Improve Treatment Experience for Patients with Rare Diseases CSL Behring selects the BrightInsight Platform to build and manage its digital health solutions within a regulatory-compliant environment SAN JOSE, Calif. and KING OF PRUSSIA, Pa., May 6, 2020 – BrightInsight, Inc, the provider of the leading
- [News | April 27, 2020](https://www.nlvpartners.com/news-april-27-2020/) - HARPOON THERAPEUTICS DOSES FIRST PATIENT WITH HPN217, A BCMA TARGETING TRITAC, FOR MULTIPLE MYELOMA Initiation of the clinical trial triggers $50 million milestone payment from AbbVie SOUTH SAN FRANCISCO, Calif., April 27, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced
- [News | April 16, 2020](https://www.nlvpartners.com/news-april-16-2020/) - TigerConnect Launches TigerTouch Video and Voice Telehealth Features to Help Hospitals Combat COVID-19 TigerTouch simplifies telehealth for patients with video, voice, and text messaging in a single smartphone-friendly user experience SANTA MONICA, California — April 16, 2020 — TigerConnect, healthcare’s most advanced, reliable and widely adopted care team collaboration solution, today launched TigerTouch to help
- [News | April 6, 2020](https://www.nlvpartners.com/news-april-6-2020/) - BrightInsight Named 2019 Google Cloud Technology Partner of the Year for the Healthcare Industry for Second Year in Row Built on Google Cloud Platform, the BrightInsight Platform supports and optimizes regulated drugs, devices and software through integrated data and actionable insights SAN JOSE, Calif, April 6, 2020 – BrightInsight, Inc, provider of a leading regulated
- [News | March 31, 2020](https://www.nlvpartners.com/news-march-31-2020/) - Iterum Therapeutics Provides Update on Phase 3 Clinical Trials of Sulopenem in Complicated Urinary Tract Infection (cUTI) and Uncomplicated Urinary Tract Infection (uUTI) Topline results from uUTI and cUTI clinical trials to be announced in Q2 2020 Iterum Therapeutics maintaining business operations amid COVID-19 public health crisis DUBLIN, Ireland and CHICAGO, March 31, 2020 (GLOBE
- [News | February 19, 2020](https://www.nlvpartners.com/news-4/) - Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock WALTHAM, Mass.--(BUSINESS WIRE)--Feb. 19, 2020-- Deciphera Pharmaceuticals, Inc. (Nasdaq:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced the closing of its previously announced registered underwritten public offering. 3,181,818 shares of the Company’s common stock at a price to
- [News | February 12, 2020](https://www.nlvpartners.com/news-february-12-2020/) - Deciphera Pharmaceuticals Announces U.S. Food and Drug Administration Acceptance of New Drug Application and Priority Review for Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumors - FDA Grants Priority Review and sets PDUFA Date of August 13, 2020 - WALTHAM, Mass.--(BUSINESS WIRE)--Feb. 12, 2020-- Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced that the U.S. Food and
- [News | January 30, 2020](https://www.nlvpartners.com/news-january-30-2020/) - Aptinyx Announces Publication of Data in Movement Disorders Demonstrating Reversal of Cognitive Deficits with NYX-458 in Primate Model of Parkinson’s Disease NYX-458 is currently under evaluation in a Phase 2 study in patients with mild cognitive impairment associated with Parkinson’s disease EVANSTON, Ill., Jan. 30, 2020 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage
- [News | January 10, 2020](https://www.nlvpartners.com/news-january-10-2020/) - Aptinyx Announces Pricing of Public Offering of Common Stock EVANSTON, Ill., Jan. 10, 2020 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the pricing of its public offering of 10,166,666 shares of its common stock at a public offering
- [New | January 31, 2020](https://www.nlvpartners.com/new-january-31-2020/) - Kit Check’s Bluesight for Controlled Substances™ Named Category Leader for Drug Diversion Monitoring in 2020 Best in KLAS Report KLAS report ranks Kit Check as the top performer with 93.9 rating for consistently delivering on product support, customer loyalty and quality of operations. WASHINGTON (January 31, 2020) — Kit Check™, the leader in automated and
- [News | March 25, 2020](https://www.nlvpartners.com/news-march-25-2020/) - BrightInsight Announces Global Digital Health Partnership with AstraZeneca AstraZeneca selects the BrightInsight Platform to build and manage its digital health solutions within a regulatory-compliant environment SAN JOSE, Calif., March 25, 2020 (GLOBE NEWSWIRE) -- BrightInsight, Inc., provider of the leading regulated Internet of Things (IoT) platform for biopharma and medtech, announced today a global digital
- [News | January 29, 2020](https://www.nlvpartners.com/news-january-29-2020/) - Key customer wins, rapidly growing customer base, and bold product vision accelerate TigerConnect’s role as a force of change for Healthcare collaboration SANTA MONICA, California — Jan. 29, 2020 — TigerConnect, healthcare’s most advanced, reliable, and widely adopted care team collaboration solution, closed out the decade with a year of record revenue and customer growth.
- [News | March 13, 2020](https://www.nlvpartners.com/news-march-13-2020/) - TigerConnect extends patient communication platform, tools during coronavirus pandemic Originally posted in BeckersHospitalReview.com by Jackie Drees (March 13, 2020) TigerConnect, a clinical communication platform, is offering U.S. hospitals and health systems free use of its text messaging network to help support COVID-19 related communications, according to a March 12 blog post. TigerConnect will offer U.S.
- [News | January 17, 2020](https://www.nlvpartners.com/news-january-17-2020/) - Iterum Therapeutics Announces $52 Million Private Placement with New and Existing Investors DUBLIN, Ireland and CHICAGO, Jan. 17, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital
- [News | January 13, 2020](https://www.nlvpartners.com/news-january-13-2020/) - Deciphera Pharmaceuticals Provides Corporate Update and Highlights Key 2020 Milestones - Ripretinib Marketing Applications Submitted to Health Canada and Australia’s Therapeutic Goods Administration for Patients with Advanced GIST via the U.S. FDA’s Project Orbis Pilot Program - - Commercial Preparations Underway to Support Potential Approval and Launch of Ripretinib in the U.S. for Patients with
- [News | January 7, 2020](https://www.nlvpartners.com/news-january-7-2020/) - Principia Announces Expanded Development Program to Broaden BTK Footprint in Immune-Mediated Diseases Company’s lead candidate PRN1008 receives generic name -- rilzabrutinib Rilzabrutinib to enter clinical trial in IgG4-Related Disease SOUTH SAN FRANCISCO, Calif., Jan. 07, 2020 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing treatments for immune-mediated diseases,
- [News | December 31, 2019](https://www.nlvpartners.com/news-december-31-2019/) - Principia Updates PRN1008 Pemphigus Clinical Program Accelerated enrollment of company’s Phase 3 pivotal trial anticipating final results in second half of 2021 SOUTH SAN FRANCISCO, Calif., Dec. 30, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in
- [News | December 16, 2019](https://www.nlvpartners.com/news-december-16-2019/) - Kit Check’s Bluesight for Controlled Substances Solution Implemented at 10 OhioHealth Hospitals Rapid cloud-based implementation for nationally recognized health system committed to addressing drug diversion and the opioid crisis already yielding results WASHINGTON (December 16, 2019) —Kit Check, the leader in automated medication management solutions for hospitals, today announced that OhioHealth, a nationally recognized health
- [News | December 9, 2019](https://www.nlvpartners.com/news-december-9-2019/) - Omnicell and Kit Check Partner to Offer Cloud-based Solution for Tracking of Controlled Substances Medication intelligence software solution supports critical need for hospitals and health systems to identify drug diversion to combat national opioid crisis MOUNTAIN VIEW, Calif.—December 9, 2019—Omnicell, Inc. (NASDAQ:OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems
- [News | December 6, 2019](https://www.nlvpartners.com/news-december-6-2019/) - MPI Label Systems Partners With Kit Check To Provide Custom RFID Tags for Medication Inventory Tracking Label leader engineers top RFID tags for pharmaceuticals, follows FDA guidelines for best labeling practice WASHINGTON (December 06, 2019) – Kit Check, the leader in automated medication management solutions for hospitals, today announced an expansion of their continued partnership
- [News | November 18, 2019](https://www.nlvpartners.com/news-november-18-2019-2/) - Phase 2a Study Published in Antimicrobial Agents and Chemotherapy Shows Potential of Sisunatovir (RV521) to Combat Respiratory Syncytial Virus Infection London, UK, November 18, 2019 – ReViral Ltd., a clinical-stage company focused on developing novel, antiviral compounds that target respiratory syncytial virus (RSV), today announced that Antimicrobial Agents and Chemotherapy (AAC) has published results from
- [News | November 12, 2019](https://www.nlvpartners.com/news-november-12-2019/) - Aptinyx Initiates Two Phase 2 Studies of NYX-2925 in Patients with Chronic Centralized Pain Conditions 200-patient painful diabetic peripheral neuropathy study and 300-patient fibromyalgia study build on previous compelling data obtained in these indications Top-line efficacy and safety data anticipated in late 2020 or early 2021 for painful DPN and 1H 2021 for fibromyalgia Studies
- [News | October 23, 2019](https://www.nlvpartners.com/news-october-23-2019/) - ARVINAS PRESENTS A PLATFORM UPDATE, INCLUDING INITIAL DATA FROM THE FIRST TWO CLINICAL TRIALS OF PROTAC® TARGETED PROTEIN DEGRADERS -Data from initial cohorts suggest that Arvinas’ PROTAC® platform has the potential to create safe and well-tolerated orally bioavailable drugs for the treatment of certain cancers -Conference call to be held at 8:30 AM ET today
- [News | November 21, 2019](https://www.nlvpartners.com/news-november-21-2019/) - HARPOON THERAPEUTICS AND ABBVIE ANNOUNCE LICENSING AND OPTION COLLABORATION TO ADVANCE HPN217, HARPOON’S BCMA-TARGETING TRITAC®, AND EXPAND EXISTING DISCOVERY COLLABORATION Harpoon grants AbbVie option to license worldwide rights to HPN217 (BCMA), a TriTAC for the treatment of multiple myeloma planned for IND filing this year Expanded TriTAC discovery collaboration includes up to six additional targets
- [News | November 18, 2019](https://www.nlvpartners.com/news-november-18-2019/) - Iterum Therapeutics Announces Completion of Enrollment in Phase 3 Clinical Trial of Oral and IV Sulopenem in Complicated Urinary Tract Infection Topline results expected in Q1 2020 DUBLIN, Ireland and CHICAGO, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics
- [News | November 5, 2019](https://www.nlvpartners.com/news-november-5-2019/) - New Patient Access Survey Shows Consumers Are Increasingly Self-Empowered in Their Care Decisions and Place a Growing Premium on Convenience Third Annual Survey from Kyruus Underscores the Need for Health Systems to Meet Patient Demand for Streamlined Access and Digitally-Enabled Experiences BOSTON, MA—November 5, 2019—Kyruus today announced findings from its third annual survey of 1,000
- [News | November 7, 2019](https://www.nlvpartners.com/news-november-7-2019-2/) - Neurana Pharmaceuticals Appoints Randall Kaye, M.D., Chief Medical Officer SAN DIEGO, Calif., November 7, 2019 – Neurana Pharmaceuticals, a biotechnology pharmaceutical company focused on the treatment of neuromuscular conditions, today announced that it has appointed Randall Kaye, M.D., as Chief Medical Officer (CMO). In this new role, Dr. Kaye will lead the clinical development of
- [News | November 6, 2019](https://www.nlvpartners.com/news-november-6-2019/) - ARVINAS, INC. ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK NEW HAVEN, Conn., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the pricing of an underwritten public offering of 4,545,455 shares of its common stock at a
- [News | October 28, 2019](https://www.nlvpartners.com/news-october-28-2019/) - Aptinyx Announces Results of Phase 2 Fibromyalgia Study of NYX-2925 Have Been Selected for Late-Breaking Presentation at the American College of Rheumatology Annual Meeting Study met primary and secondary endpoints – statistically significant effects on neuroimaging biomarkers and patient-reported measures ePoster to be presented at ACR Annual Meeting on Tuesday, November 12 EVANSTON, Ill., Oct.
- [News | November 20, 2019](https://www.nlvpartners.com/news-november-20-2019/) - Sierra Oncology Launches the MOMENTUM Phase 3 Clinical Trial for Patients with Myelofibrosis - MOMENTUM trial designed to confirm the unique benefits of momelotinib on all three hallmarks of myelofibrosis: symptoms, anemia and enlarged spleen - - Targeting enrollment of 180 symptomatic and anemic patients previously treated with a JAK inhibitor – - Top-line data
- [News | November 7, 2019](https://www.nlvpartners.com/news-november-7-2019/) - Sierra Oncology Announces Pricing of $103 Million Public Offering of Convertible Preferred Stock and Warrants VANCOUVER, Nov. 7, 2019 /CNW/ - Sierra Oncology, Inc. (Nasdaq: SRRA), a late-stage drug development company focused on the development and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treatment of
- [News | October 29, 2019](https://www.nlvpartners.com/news-october-29-2019/) - Deciphera Pharmaceuticals Presents Updated Data from Ripretinib and DCC-3014 Programs at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - Median Progression Free Survival (mPFS) of 46 Weeks for the Second-Line Gastrointestinal Stromal Tumors (GIST) Cohort from the Phase 1 Study of Ripretinib in Patients Receiving 150 mg QD as Starting Dose -
- [News | October 15, 2019](https://www.nlvpartners.com/news-october-15-2019-2/) - PRINCIPIA ANNOUNCES POSITIVE PRELIMINARY DATA OF PRN1008 FOR IMMUNE THROMBOCYTOPENIA IN ONGOING PHASE 1/2 TRIAL Preliminary results from trial have been accepted as an oral presentation at upcoming American Society of Hematology Annual Meeting SOUTH SAN FRANCISCO, Calif., October 15, 2019 – Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing novel
- [News | October 15, 2019](https://www.nlvpartners.com/6920-2/) - PRINCIPIA ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK SOUTH SAN FRANCISCO, Calif., Oct. 15, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing novel therapies for immune mediated diseases, today announced the pricing of its underwritten public offering of 7,500,000 shares of its common stock at a price to the public
- [News | October 10, 2019](https://www.nlvpartners.com/news-october-10-2019/) - PRINCIPIA ANNOUNCES POSITIVE PRELIMINARY DATA OF PRN1008 FROM ITS ONGOING PHASE 2 PART B TRIAL IN PEMPHIGUS Consistent efficacy and safety profile for pemphigus patients observed Confirms 400mg twice daily dose in Phase 3 trial Principia to host investor conference call at 8:00 am Eastern time SOUTH SAN FRANCISCO, Calif., Oct. 10, 2019 (GLOBE NEWSWIRE)
- [News | September 23, 2019](https://www.nlvpartners.com/news-september-23-2019/) - Neurana Pharmaceuticals Announces Positive Topline Results from Phase 2 STAR Study of Tolperisone in Acute Muscle Spasms of the Back Tolperisone shown to be effective in treating pain due to acute back muscle spasm • Tolperisone was well-tolerated and did not increase sleepiness over placebo • STAR Study results enable Neurana to advance tolperisone to
- [News | September 30, 2019](https://www.nlvpartners.com/news-september-30-2019/) - Deciphera Pharmaceuticals Announces Late-Breaking Oral Presentation at the ESMO 2019 Congress Demonstrating Positive Results from INVICTUS Pivotal Phase 3 Study of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumors WALTHAM, Mass.--(BUSINESS WIRE)--Sep. 30, 2019-- Deciphera Pharmaceuticals, Inc. (Nasdaq:DCPH), a clinical-stage biopharmaceutical company addressing key mechanisms of tumor drug resistance, today announced the late-breaking presentation of
- [News | October 2, 2019](https://www.nlvpartners.com/news-october-2-2019-2/) - ARVINAS STRENGTHENS SCIENTIFIC ADVISORY BOARD WITH LEADERS IN ONCOLOGY AND NEUROLOGICAL DISORDERS NEW HAVEN, Conn., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, announced that six new thought leaders will join the company’s scientific advisory board (SAB). The new
- [News | October 1, 2019](https://www.nlvpartners.com/news-october-1-2019/) - BAYER AND ARVINAS UNVEIL TARGETED PROTEIN DEGRADATION JOINT VENTURE, OERTH BIO - Oerth Bio to utilize Arvinas’ PROTAC® technology to develop innovative new agricultural products to improve crop yields - John Dombrosky Announced as CEO of Oerth Bio - Transaction had been formally closed on July 15, 2019 MONHEIM, Germany and BOSTON and NEW HAVEN,
- [News | September 26, 2019](https://www.nlvpartners.com/news-september-26-2019/) - Three Recent Preclinical Publications Highlight NMDA Receptor Activation Facilitated by Aptinyx’s NYX-2925 Data published across three peer-reviewed journals elucidate novel mechanism leading to enhanced synaptic plasticity EVANSTON, Ill., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today
- [News | October 15, 2019](https://www.nlvpartners.com/news-october-15-2019/) - Bozeman Health Engages Kyruus to Support its Digital Transformation and Integrate Patient Access System-wide Montana-Based Health System to Enhance Access and Convenience for Rising Patient Population with Kyruus ProviderMatch® Boston, MA – October 15, 2019 – Kyruus, the leader in provider search and scheduling solutions for health systems, today announced that Bozeman Health, Southwest Montana’s leading health system, has
- [News | October 7, 2019](https://www.nlvpartners.com/6888-2/) - Lafayette General Health to Elevate Consumer Digital Experience and Launch Online Scheduling with Kyruus Louisiana-Based Health System Looking to Simplify Patient Access and Enhance Patient-Provider Matching for Growing Population Boston, MA – October 7, 2019 – Kyruus, the leader in provider search and scheduling solutions for health systems, today announced that Lafayette General Health (LGH), a leading non-profit
- [News | October 2, 2019](https://www.nlvpartners.com/news-october-2-2019/) - Kyruus Named to the 2019 CB Insights Digital Health 150 List of Most Innovative Digital Health Startups Kyruus recognized for achievements in provider search and scheduling for health systems New York, NY, October 2, 2019 -- CB Insights today named Kyruus to the inaugural Digital Health 150 ranking, showcasing the 150 most promising private digital
- [News | October 3, 2019](https://www.nlvpartners.com/news-october-3-2019/) - Kit Check’s Agreement with Vizient Extended in Multi-Year Contract, Providing Better Visibility in Drug Diversion and Medication Tracking WASHINGTON (October 3, 2019) — Kit Check, the leader in automated medication management solutions for hospitals, today announced that Vizient has extended its agreement with the company for its Bluesight for Controlled Substances (BCS) as well as
- [News | September 17, 2019](https://www.nlvpartners.com/news-september-17-2019/) - Edgewise Therapeutics Closes $50 Million Series B Financing – Financing to Support Advancing Company’s Lead Product Candidate for Muscular Dystrophy- Boulder, Colo., (September 17, 2019) – Edgewise Therapeutics, a preclinical company developing small molecule therapies for musculoskeletal diseases, has announced the closing of a $50 million Series B financing round. The round was co-led by
- [News | September 5, 2019](https://www.nlvpartners.com/news-september-5-2019/) - BrightInsight Raises Significant Capital to Enhance its Regulated Digital Health Platform and Accelerate Global Commercialization Today we announced the exciting news that BrightInsight raised significant capital from top healthcare venture capital firm, New Leaf Venture Partners, and leading technology venture capital firm, Eclipse Ventures. It has been an incredibly busy few months leading up to
- [News | August 14, 2019](https://www.nlvpartners.com/news-august-14-2019/) - Deciphera Pharmaceuticals Announces Pricing of Public Offering of Common Stock WALTHAM, Mass.--(BUSINESS WIRE)--Aug. 14, 2019-- Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced the pricing of its previously announced registered underwritten public offering of 10,810,810 shares of its common stock at a price to the public
- [News | August 13, 2019](https://www.nlvpartners.com/news-august-13-2019/) - Deciphera Pharmaceuticals Reports Positive Updated Phase 1 Data for Ripretinib in Gastrointestinal Stromal Tumors - Data from Phase 1 Study Supports Ongoing INTRIGUE Phase 3 Clinical Study in Patients with Second-line GIST – - Median Progression Free Survival (mPFS) Sustained across All Cohorts - - Additional Phase 1 Results Expected to be Presented at Upcoming
- [News | July 29, 2019](https://www.nlvpartners.com/news-july-29-2019-2/) - ARVINAS APPOINTS RONALD PECK, M.D. AS CHIEF MEDICAL OFFICER NEW HAVEN, Conn., July 29, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, announced today the appointment of Ronald Peck, M.D. to the newly created position of Chief Medical Officer (CMO). Dr.
- [News | August 1, 2019](https://www.nlvpartners.com/news-august-1-2019/) - Neuronetics® Announces First TMS Patient Treated Under New Japan Reimbursement Policy Reimbursement for Company's non-drug depression treatment, NeuroStar® Advanced Therapy, enables access for depression sufferers in Japan MALVERN, Pa., Aug. 1, 2019 /PRNewswire/ -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality
- [News | July 29, 2019](https://www.nlvpartners.com/news-july-29-2019/) - Neuronetics® Launches TrakStar® Plus Patient Data Management System to Maximize Physician Time with Patients Enhanced software efficiencies include user-friendly mobile interface and data export to electronic medical records capability MALVERN, Pa., July 29, 2019 /PRNewswire/ -- Neuronetics, Inc. (NASDAQ: STIM), the developer of NeuroStar® Advanced Therapy, the market leader in transcranial magnetic stimulation (TMS) for
- [News | June 26, 2019](https://www.nlvpartners.com/news-june-26-2019/) - Aptinyx Presents Preclinical Data Demonstrating Robust Activity of NYX-783 on Alcohol-Seeking Behavior and Relapse-Like Behavior in Multiple Models of Alcohol Use Disorder EVANSTON, Ill., June 26, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the presentation of preclinical data on its
- [News | July 1, 2019](https://www.nlvpartners.com/news-july-1-2019/) - Kit Check Announces the Latest Bluesight for Controlled Substances Feature, Investigation Portfolios Jenny Harlett July 1, 2019 Workflow collaboration tool helps hospitals locate possible diverters with accuracy Washington DC, June 25, 2019 — Kit Check, the leader in automated medication management solutions for hospitals, today announced the addition of a new feature to its Bluesight
- [News | June 27, 2019](https://www.nlvpartners.com/news-june-27-2019/) - Kit Check and Sandoz agree to a commercialization collaboration that helps improve hospital medication administration safety Jenny HarlettJune 27, 2019 Implementation of Kit Check RFID technology enables accuracy and visibility of hospital medications, from the production line to the patient Washington DC, June 27, 2019 — Kit Check, the leader in automated medication management solutions
- [News | June 11, 2019](https://www.nlvpartners.com/news-june-11-2019/) - Kit Check Brings Next-Generation Medication Tracking Mainstream with FDA Pilot Jenny HarlettJune 11, 2019 Pilot looks to implement tech that improves the tracking of powerful drugs and interoperability of software throughout the supply chain Group initiative brings together industry leaders such as Nephron Pharmaceuticals, Sandoz, Coral Gables Hospital and Hackensack University Medical Center Washington DC,
- [News |  August 6, 2019](https://www.nlvpartners.com/news-august-6-2019/) - Kyruus ProviderMatch® Patient Access Platform Now Powering Patient-Provider Matching at Norton Healthcare Kyruus Platform Aims to Help Kentucky Health System Empower Consumers and Streamline Access Boston, MA – August 6, 2019 – Kyruus, the leader in provider search and scheduling solutions for health systems, today announced that Norton Healthcare, a leading not-for-profit health system based
- [News | July 30, 2019](https://www.nlvpartners.com/news-july-30-2019/) - OHSU to Become First Health System in Oregon to Implement Kyruus ProviderMatch® Oregon’s Only Academic Health Center Enhances Online Offerings for Patients with Kyruus Provider Data Management and Search Solutions Boston, MA – July 30, 2019 – Kyruus, the leader in provider search and scheduling solutions for health systems, today announced that OHSU in Portland,
- [News | June 10, 2019](https://www.nlvpartners.com/news-june-10-2019-2/) - Deciphera Pharmaceuticals, Inc. Expands Pipeline with Potential First-in-Class Autophagy Inhibitor to Treat Mutant RAS Cancers -DCC-3116 Selectively Targets ULK Kinase, an Initiating Protein that Activates Autophagy - -Company to Host a Webcast on Tuesday, June 18, 2019 at 8 a.m. ET to Discuss Autophagy Inhibition and the Treatment of Mutant RAS Cancers - WALTHAM, Mass.--(BUSINESS
- [News | June 10, 2019](https://www.nlvpartners.com/news-june-10-2019/) - Aptinyx Reports Positive Top-line Data from Phase 2 Study of NYX-2925 in Patients with Fibromyalgia, Demonstrating Significant Effects on Both Biomarkers and Patient-Reported Pain NYX-2925 demonstrated statistically significant effects on a range of neuroimaging biomarkers and patient-reported outcomes, including pain scores Neuroimaging biomarkers correlated with patient-reported pain improvements NYX-2925 was well tolerated with no serious
- [News | April 4, 2019](https://www.nlvpartners.com/news-april-4-2019/) - TigerConnect Named a Top Technology Company in Santa Monica 04.25.19 In the News Home / Newsroom /TigerConnect Named a Top Technology Company in Santa Monica Originally posted in The Tech Tribune Best Technology Company in Santa MonicaThe Tech Tribune staff has compiled a list of the best technology companies in Santa Monica, California. In doing
- [News |  May 29, 2019](https://www.nlvpartners.com/news-may-29-2019/) - ARVINAS RECEIVES FAST TRACK DESIGNATION FOR ITS TARGETED PROTEIN DEGRADER ARV-110 AS A TREATMENT FOR MEN WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER ARV-110 is Arvinas' first clinical-stage drug in the innovative field of targeted protein degradation, and is currently being evaluated in a Phase 1 clinical trial NEW HAVEN, Conn., May 29, 2019 (GLOBE NEWSWIRE) --
- [News | April 30, 2019](https://www.nlvpartners.com/news-april-30-2019/) - Aptinyx Reports Positive Data from Phase 1 Study of Novel NMDA Receptor Modulator, NYX-458, in Healthy Volunteers Favorable overall safety, tolerability, and pharmacokinetic profile—no serious adverse events reported across wide dose range Achieved ample CNS exposure consistent with exposure observed at preclinically efficacious doses Expect to initiate Phase 2a study in patients with cognitive impairment
- [News | May 15, 2019](https://www.nlvpartners.com/news-may-15-2019/) - TigerConnect Names Sarah Shillington SVP of Client Success Shillington Brings 25 Years of Healthcare Experience Overseeing Client Success at Large-Scale, Global Enterprise Companies SANTA MONICA, CA – May 15, 2019 – TigerConnect, provider of healthcare’s most advanced, reliable, and widely adopted clinical communication and collaboration (CC&C) solution, today announced Sarah Shillington has joined the company
- [News |  April 17, 2019](https://www.nlvpartners.com/news-april-17-2019/) - Newly-Formed Prisma Health Selects Kyruus Solutions to Optimize Patient Access and Provider Network Management Post-Merger South Carolina’s Largest Health System to Leverage Digital Solutions to Drive Systemness Boston, MA – Kyruus, a leader in provider search and scheduling solutions for health systems, today announced that Prisma Health, now South Carolina’s largest health system – formed
- [News | May 20, 2019](https://www.nlvpartners.com/news-may-20-2019/) - PRINCIPIA PRESENTS PHASE 1 DATA OF PRN1371 IN PATIENTS WITH METASTATIC BLADDER CANCER -- FGFR inhibitor PRN1371 well tolerated in 36 patients in dose-escalation phase; dose expansion in metastatic urothelial carcinoma patients ongoing -- SOUTH SAN FRANCISCO, Calif., May 20, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company dedicated to
- [News | June 3, 2019](https://www.nlvpartners.com/news-june-3-2019/) - NeuroStar® Advanced Therapy Receives National Reimbursement Listing in Japan Transformative, non-drug treatment offers new solution for country’s underserved depression sufferers MALVERN, Pa., June 03, 2019 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer
- [News | May 14, 2019](https://www.nlvpartners.com/news-may-14-2019/) - PRINCIPIA BIOPHARMA ANNOUNCES FIRST PATIENT DOSED IN SANOFI’S PHASE 2B TRIAL OF SAR442168 IN MULTIPLE SCLEROSIS, TRIGGERING $30 MILLION MILESTONE SOUTH SAN FRANCISCO, Calif., May 14, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and
- [News | April 18, 2019](https://www.nlvpartners.com/news-april-18-2019/) - HARPOON THERAPEUTICS DOSES FIRST PATIENT WITH A MESOTHELIN-TARGETING T CELL ENGAGER (HPN536) IN PHASE 1/2A CLINICAL TRIAL FOR OVARIAN AND OTHER SOLID TUMOR CANCERS HPN536 is the second TriTAC T cell engager to enter clinical development from the Harpoon pipeline Trial initiated at Sarah Cannon Research Institute in Nashville, Tenn. - a leading drug development
- [News |  March 18, 2019](https://www.nlvpartners.com/news-march-18-2019/) - PDS Biotechnology Completes Merger with Edge Therapeutics Shares of Combined Company to Commence Trading on Nasdaq Capital Market under New Symbol “PDSB” on March 18, 2019 PRINCETON, N.J., March 18, 2019 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (“PDS Biotechnology”), a clinical-stage immuno-oncology company pioneering the development of novel multifunctional immunotherapeutic products, today announced the closing
- [News | February 4, 2019](https://www.nlvpartners.com/news-3/) - Neurana Pharmaceuticals Announces First Patient Enrolled in the STAR Study Neurana Pharmaceuticals Announces First Patient Enrolled in the “STAR Study,” a Phase 2 Dose Ranging Study of Tolperisone in Acute Muscle Spasms of the Back SAN DIEGO, February 4th, 2019 -- Neurana Pharmaceuticals, a specialty pharmaceutical company focused on the treatment of neuromuscular conditions, today
- [News | March 2, 2019](https://www.nlvpartners.com/news-march-2-2019/) - PRINCIPIA BIOPHARMA ANNOUNCES POSITIVE DATA FROM PHASE 2 PEMPHIGUS VULGARIS TRIAL AT 2019 AMERICAN ACADEMY OF DERMATOLOGY ANNUAL MEETING IN LATE-BREAKING PRESENTATION Reached primary endpoint of Control of Disease Activity at four weeks in 54 percent of patients on low dose corticosteroids Median Anti-DSG antibodies reduced by up to 65 percent with 12 weeks of
- [News | January 2, 2019](https://www.nlvpartners.com/news-january-2-2019/) - HARPOON THERAPEUTICS ANNOUNCES PRELIMINARY SAFETY AND PHARMACOLOGY DATA FROM ITS HPN424 PHASE 1 TRIAL IN PROSTATE CANCER Initial data shows HPN424 serum exposure supports weekly dosing Changes in blood-derived tumor cell and serum biomarkers consistent with T cell activation HPN424 dose escalation proceeding to identify Phase 2 therapeutic dose South San Francisco, CA – January
- [News | February 7, 2019](https://www.nlvpartners.com/news-february-7-2019/) - HARPOON THERAPEUTICS ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Harpoon Therapeutics, Inc. (“Harpoon”), a clinical-stage immunotherapy company developing a novel class of T cell engagers, announced today the pricing of its initial public offering of 5,400,000 shares of its common stock at a price to the public of $14.00 per share. The
- [News | December 3, 2018](https://www.nlvpartners.com/news-december-3-2018-2/) - Aptinyx Reports Positive Data from Interim Analysis of Exploratory Study of NYX-2925 in Subjects with Fibromyalgia December 03, 2018 Achieved statistical significance on primary imaging-based endpoint, changes in markers of central pain processing, in 11 subjects Observed corresponding trends of improvement on multiple secondary endpoints, including average daily pain scores and the Revised Fibromyalgia Impact
- [News | December 3, 2018](https://www.nlvpartners.com/news-december-3-2018/) - Kit Check Announces “Works with Kit Check” Certification Program for Hospital Pharmacy Vendors Ava MutchlerDecember 3, 2018 The program, which includes nine launch partners, provides assurance of Kit Check compatibility with hospital solutions ANAHEIM, CA (December 3, 2018) – Kit CheckTM, the leader in automated medication management solutions for hospitals, today announced “Works with Kit
- [News | October 1, 2018](https://www.nlvpartners.com/news-october-1-2018/) - Kit Check Closes the Diversion Gap with Launch of Bluesight IRIS and Reveals Which Hospital Employees Exhibit Behaviors Consistent with Controlled Substance Theft Ava Mutchler Leading Automated Medication Solutions Provider for Hospital Pharmacies Leverages Machine Learning to Enhance Diversion Identification and Curb Opioid Misuse in Hospitals WASHINGTON (October 1, 2018) – Kit Check, the leader
- [News | November 26, 2018](https://www.nlvpartners.com/news-november-26-2018/) - Edge Therapeutics Enters into Merger Agreement with PDS Biotechnology to Form Clinical-Stage Cancer Immunotherapy Company -Merger would create publicly-traded immuno-oncology biotechnology company developing novel products for treating early- and late-stage cancer- -Growing product pipeline utilizing Versamune®, a novel, versatile, multi-functional platform- -Phase 1/2 clinical data on lead product candidate PDS0101 suggests immunotherapeutic anti-cancer activity and
- [News | November 29, 2018](https://www.nlvpartners.com/news-november-29-2018/) - PRINCIPIA BIOPHARMA REPORTS POSITIVE PRN1008 PHASE 2 TOP-LINE RESULTS AND INITIATES PHASE 3 PEMPHIGUS PROGRAM November 29, 2018 at 4:01 PM EST - Achieved Phase 2 primary endpoint – over 50% of patients attained Control of Disease Activity within four weeks of starting PRN1008 - - Demonstrated sustained clinical efficacy at 12 weeks of therapy,
- [News | November 9, 2018](https://www.nlvpartners.com/news-november-9-2018/) - HARPOON THERAPEUTICS UNVEILS PROTRITAC PLATFORM: A NOVEL, PROTEASE-ACTIVATED T CELL ENGAGER PLATFORM DESIGNED TO ACCESS A BROAD LANDSCAPE OF SOLID TUMOR TARGETS Preclinical Proof-of-Concept Data Presented at the 2018 Society for Immunotherapy of Cancer (SITC) Annual Meeting First ProTriTAC Product Candidate Expected to Enter IND-Enabling Studies in 2019 Washington, DC – November 9, 2018 – Harpoon
- [News | November 11, 2018](https://www.nlvpartners.com/news-november-11-2018/) - HARPOON THERAPEUTICS ANNOUNCES CLOSING OF $70M SERIES C FINANCING Proceeds to Advance Pipeline of Cancer Immunotherapies South San Francisco, CA – November 11, 2018 – Harpoon Therapeutics, Inc. (“Harpoon”), a clinical-stage immunotherapy company developing a novel class of T cell engagers, announced today the closing of a $70 million Series C equity financing. OrbiMed served as
- [News | November 12, 2018](https://www.nlvpartners.com/news-november-12-2018/) - Aptinyx Exploratory Clinical Studies Provide First Evidence that NYX-2925 Elicits Rapid, Persistent, NMDAr-Mediated Pharmacodynamic Activity in Humans Studies in Healthy Human Volunteers Reinforce Mechanism of Action Observed in Preclinical Studies EVANSTON, Ill., Nov. 12, 2018 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous
- [News | November 1, 2018](https://www.nlvpartners.com/news-november-1-2018/) - Aptinyx Completes Enrollment in Phase 2 Study of NYX-2925 for Painful Diabetic Peripheral Neuropathy Top-line Data Expected Early in the First Quarter of 2019 EVANSTON, Ill., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced enrollment completion for
- [News | October 24, 2018](https://www.nlvpartners.com/news-october-24-2018/) - PRINCIPIA BIOPHARMA APPOINTS DOLCA THOMAS, M.D. AS CHIEF MEDICAL OFFICER - Succession designed to lead Principia through next phase of growth as a clinical-stage company - SOUTH SAN FRANCISCO, Calif., Oct. 24, 2018 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a clinical-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant
- [News | October 19, 2018](https://www.nlvpartners.com/news-october-19-2018/) - PRINCIPIA BIOPHARMA ANNOUNCES PRN1008 RECEIVES ORPHAN-DRUG DESIGNATION FROM FDA FOR TREATMENT OF IMMUNE THROMBOCYTOPENIC PURPURA SOUTH SAN FRANCISCO, Calif., Oct. 19, 2018 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a clinical-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology, today announced that PRN1008,
- [News | October 16, 2018](https://www.nlvpartners.com/news-october-16-2018/) - PRINCIPIA ACHIEVES $10 MILLION IN ADDITIONAL MILESTONES RELATED TO DEVELOPMENT OF PRN2246/SAR442168 -- Additional milestones achieved under the Sanofi collaboration which is focused on treating diseases of the central nervous system -- SOUTH SAN FRANCISCO, Calif., October 16, 2018 – Principia Biopharma Inc. (Nasdaq: PRNB), a clinical-stage biopharmaceutical company dedicated to bringing transformative oral therapies
- [News | October 17, 2018](https://www.nlvpartners.com/news-october-17-2018/) - CuraSen Therapeutics Announces $54.5 Million Series A Financing with Industry Veterans at Helm to Develop Drugs Targeting Novel Mechanism for the Treatment of Neurodegenerative Diseases Kathleen Sereda Glaub Appointed Executive Chair and Anthony Ford, PhD, Named Chief Executive Officer New Leaf Venture Partners Leads Top-Tier Investor Syndicate SAN MATEO, Calif., Oct. 17, 2018 /PRNewswire/ --
- [News | October 3, 2018](https://www.nlvpartners.com/news-october-3-2018/) - HARPOON THERAPEUTICS ANNOUNCES APPOINTMENT OF NATALIE R. SACKS, M.D., AS CHIEF MEDICAL OFFICER South San Francisco, CA – October 3, 2018 – Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company developing a new class of T cell engaging therapeutics, announced today that it has appointed Natalie R. Sacks, M.D., as Chief Medical Officer. “We are thrilled
- [News | September 17, 2018](https://www.nlvpartners.com/news-september-17-2018/) - UNUM THERAPEUTICS ANNOUNCES ABSTRACT ACCEPTED FOR PRESENTATION AT THE FOURTH CRI-CIMT-EATI-AACR INTERNATIONAL CANCER IMMUNOTHERAPY CONFERENCE - Complete Responses Observed in Three of Six Patients with relapsed or refractory CD20-positive B cell non-Hodgkin Lymphoma at Dose Level 1 of the ATTCK-20-03 Phase I Study - - No SAEs of Cytokine Release Syndrome or Neurotoxicity Observed in
- [News | September 26, 2018](https://www.nlvpartners.com/news-september-26-2018/) - ARVINAS ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING NEW HAVEN, Conn., Sept. 26, 2018 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies to degrade disease-causing proteins, today announced the pricing of its initial
- [News | September 18, 2018](https://www.nlvpartners.com/news-september-18-2018-3/) - PRINCIPIA BIOPHARMA ANNOUNCES CLOSING OF INITIAL PUBLIC OFFERING AND FULL EXERCISE OF UNDERWRITERS’ OPTION TO PURCHASE ADDITIONAL SHARES SOUTH SAN FRANCISCO, Calif., Sept. 18, 2018 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Principia or the Company) (Nasdaq: PRNB), a clinical-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in
- [News | September 18, 2018](https://www.nlvpartners.com/news-september-18-2018-2/) - HARPOON THERAPEUTICS ANNOUNCES APPOINTMENTS TO BOARD OF DIRECTORS AND MANAGEMENT TEAM Jonathan Drachman, M.D., former CMO of Seattle Genetics, Brings Immuno-Oncology Expertise to Board South San Francisco, CA – September 18, 2018 – Harpoon Therapeutics, Inc., a clinical-stage immuno-oncology company developing a new class of T cell engaging therapeutics, announced today that it has appointed Jonathan
- [News | September 14, 2018](https://www.nlvpartners.com/news-september-14-2018/) - Aptinyx Presents Preclinical Data on NMDA Receptor Modulator NYX-2925 at the International Association for the Study of Pain’s 17th World Congress on Pain EVANSTON, Ill., Sept. 14, 2018 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the presentation of two
- [News | September 18, 2018](https://www.nlvpartners.com/news-september-18-2018/) - Iterum Initiates SURE 2 and SURE 3 Phase 3 Clinical Trials of IV and Oral Sulopenem in Complicated Urinary Tract and Complicated Intra-abdominal Infections Remaining two of three planned Phase 3 pivotal trials now underway for Iterum’s lead antibiotic product candidate sulopenem Potential to be first and only oral and IV penem antibiotic available globally
- [News | August 9, 2018](https://www.nlvpartners.com/news-august-9-2018/) - Iterum Initiates SURE 1, a Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections First of three planned Phase 3 pivotal trials now underway for Iterum’s oral antibiotic Oral sulopenem, if approved, could be the first antibiotic for uncomplicated urinary tract infections in over 20 years Top-line results expected in 2H 2019
- [News | August 2, 2018](https://www.nlvpartners.com/news-august-2-2018/) - Aptinyx Initiates Phase 1 Study of NYX-458 Development in Parkinson’s Disease Cognitive Impairment Planned EVANSTON, Ill., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced initiation of Phase 1 clinical development of NYX-458, its third novel product
- [News | August 6, 2018](https://www.nlvpartners.com/news-august-6-2018/) - Harpoon Therapeutics treats first patient with HPN424 in phase I clinical trial of metastatic castration-resistant prostate cancer (mCRPC) patients. HPN424, First-in-Class TriTAC™ T Cell Redirection Therapy, Targets Prostate-Specific Membrane Antigen (PSMA) Clinical Data Expected in 2019 South San Francisco – August 6, 2018 – (BUSINESS WIRE) – Harpoon Therapeutics, an immuno-oncology company pioneering a new
- [News | August 7, 2018](https://www.nlvpartners.com/news-august-7-2018/) - Rallybio Further Expands Drug Acquisition and Development Capabilities Rallybio Welcomes Laura Ekas, PhD and Eric Watsky, MD, Further Expanding Rallybio’s Drug Acquisition and Development Capabilities FARMINGTON, Connecticut, August 7, 2018 – Rallybio LLC, a development-stage biotechnology company, today announced that it has further expanded its drug acquisition and development capabilities with the addition of Laura Ekas,
- [News | August 1, 2018](https://www.nlvpartners.com/news-august-1-2018/) - ReViral announces Series B investment ReViral announces US$55 million series B fundraising to advance RSV clinical studies London, UK – 1st August 2018: ReViral, an antiviral drug discovery and development company, focused on diseases caused by the Respiratory Syncytial Virus (RSV), today announced the successful completion of a US$55 million Series B financing. The new
- [News | June 28, 2018](https://www.nlvpartners.com/news-june-28-2018/) - Neuronetics, Inc., Maker of NeuroStar® Advanced Therapy, Announces Pricing of Initial Public Offering MALVERN, Pa., June 28, 2018 (GLOBE NEWSWIRE) -- Neuronetics, Inc., a commercial-stage medical device company focused on designing, developing, and manufacturing products that improve the quality of life for patients who suffer from psychiatric disorders and the maker of the NeuroStar® Advanced
- [News | June 12, 2018](https://www.nlvpartners.com/6276-2/) - Truveris Expands Audit Capabilities with Launch of TruAudit™ Solution allows clients to track PBM performance by implementing several new audits NEW YORK--(BUSINESS WIRE)--Truveris, Inc. today announced new audit capabilities geared towards further increasing transparency in the pharmacy benefit space. TruAudit™ allows clients to track PBM contract performance with a diverse audit portfolio, expanding Truveris’ comprehensive
- [News | June 11, 2018](https://www.nlvpartners.com/news-june-11-201/) - Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock WALTHAM, Mass.--(BUSINESS WIRE)--Jun. 11, 2018-- Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced the closing of its previously announced underwritten public offering of 4,300,000 shares of its common stock at a public offering price
- [News | May 24, 2018](https://www.nlvpartners.com/news-may-24-2018/) - Iterum Therapeutics Announces Pricing of Initial Public Offering DUBLIN and CHICAGO, May 24, 2018 /PRNewswire/ -- Iterum Therapeutics plc (NASDAQ:ITRM), a clinical-stage pharmaceutical company developing anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens, today announced the pricing of its initial public offering of 6,150,000 ordinary shares at a price to the public
- [News | May 5, 2018](https://www.nlvpartners.com/news-may-5-2018/) - NeuroStar® Advanced Therapy Reaches Monumental Milestone of 1.7 Million Treatments in the US Non-drug, non-invasive NeuroStar has become a mainstream option for depression patients, and is now covered by most insurance companies and available in 49 states MALVERN, Pa., May 5, 2018 /PRNewswire/ -- NeuroStar® Advanced Therapy, the established leader in transcranial magnetic stimulation (TMS), announced
- [News | June 2, 2018](https://www.nlvpartners.com/news-june-2-2018/) - Deciphera Pharmaceuticals Reports Updated Interim Phase 1 Clinical Study Results with DCC-2618 at The 2018 American Society of Clinical Oncology Annual Meeting (ASCO) and Provides Additional Clinical and Regulatory Updates on DCC-2618 - Initial Objective Response Rates and Disease Control Rates in Second and Third Line GIST Patients Exceed Previously Published Results of Registrational Trials
- [News | May 29, 2018](https://www.nlvpartners.com/news-may-29-201/) - Deciphera Pharmaceuticals Appoints Stephen B. Ruddy, Ph.D. as Chief Technical Officer Senior Executive with Global Pharmaceutical Development and Manufacturing Experience WALTHAM, Mass.--(BUSINESS WIRE)--May 29, 2018-- Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that it has appointed Stephen B. Ruddy, Ph.D. as Chief Technical
- [News | June 4, 2018](https://www.nlvpartners.com/news-june-4-2018/) - New Leaf Ventures Names Martin Mackay, Ph.D., as Senior Advisor Seasoned Biopharma R&D Executive Brings More Than 30 Years of Expertise to New Leaf and Its Portfolio of Healthcare and Technology Companies NEW YORK--(BUSINESS WIRE)--New Leaf Venture Partners (NLV Partners) today announced the appointment of Martin Mackay, Ph.D., as Senior Advisor, effective immediately. Dr. Mackay
- [News | May 7, 2018](https://www.nlvpartners.com/news-may-7-2018/) - Neurana Pharmaceuticals Announces Completion of $60 Million Series A Financing Funding to advance novel drug for acute, painful muscle spasms and spasticity without sedation SAN DIEGO, California May 7, 2018 – Neurana Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the treatment of neuromuscular conditions, announced the completion of a $60 million Series A financing
- [News | March 15, 2018](https://www.nlvpartners.com/news-march-25-2018/) - Aptinyx Presents Data on NMDA Receptor Modulator NYX-458 in a Preclinical Model of Parkinson’s Cognitive Impairment at the AAT-AD/PD Focus Meeting 2018 Evanston, Ill., March 15, 2018 – Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative therapies for challenging neurologic disorders, today announced the presentation of preclinical data that supports advancing the development of a
- [News | April 17, 2018](https://www.nlvpartners.com/6218-2/) - Preclinical Data Demonstrate That Deciphera Pharmaceuticals' DCC-2618 Exhibits Broader Inhibition Profile Against Primary and Secondary Drug-Resistant Mutations in Gastrointestinal Stromal Tumors (GIST) Compared to Approved and Investigational Agents Pre-Clinical Data Presented at 2018 American Association for Cancer Research (AACR) Annual Meeting Confirms A Broad Spectrum of Potent Inhibition of KIT and PDGFRα Mutations in Gastrointestinal
- [News | April 24, 2018](https://www.nlvpartners.com/news-april-24-2018/) - by Jeff Fryer | Apr 24, 2018 Rallybio Completes $37.0M Series A Financing Rallybio Established by Industry Leaders with $37.0 Million in Series A Financing to Develop Transformative Therapies for Patients with Severe and Rare Diseases FARMINGTON, CT, April 25, 2018 – Rallybio, LLC, a biotechnology company established to identify and accelerate the development of
- [News | April 16, 2018](https://www.nlvpartners.com/news-april-16-2018/) - Harpoon Therapeutics Launches Immuno-Oncology Pipeline with Compelling Data from Lead Programs at the 2018 American Association for Cancer Research (AACR) Annual Meeting Preclinical Data Showcase New T Cell Engaging Platform (TriTAC™) and Lead Drugs, HPN424 and HPN536, Targeting Prostate Cancer and Other Solid Tumors Chicago, IL – April 16, 2018 – (BUSINESS WIRE) – Harpoon
- [News | April 4, 2018](https://www.nlvpartners.com/news-april-4-2018/) - Arvinas Completes $55 Million Series C Financing to Advance Protein Degradation Platform Financing round led by Nextech Invest. Proceeds to advance lead oncology programs into the clinic and broaden early-stage pipeline NEW HAVEN, CT, April 4, 2018 – Arvinas LLC, a private biotechnology company creating a new class of drugs based on protein degradation, today
- [News | March 7, 2018](https://www.nlvpartners.com/news-march-7-2018/) - TigerConnect Teams with QGenda Joint clients can now benefit from the full force of TigerConnect’s clinical communication platform driven by QGenda’s powerful, proven provider scheduling solution SANTA MONICA, Calif. – March 7, 2018 – TigerConnect, formerly TigerText, provider of healthcare’s most advanced, reliable, and widely adopted clinical communication platform, and QGenda the market leader of
- [News | March 6, 2018](https://www.nlvpartners.com/news-march-6-2018/) - TigerText Renames As TigerConnect to Welcome a New Era of Clinical Communication SANTA MONICA, CA – March 1, 2018 – TigerText, provider of healthcare’s most advanced, reliable, and widely adopted clinical communication and collaboration (CC&C) solution, today announced that it has officially changed its corporate name to TigerConnect. The new name more accurately reflects the
- [News | March 20, 2018](https://www.nlvpartners.com/news-march-20-2018-2/) - Truveris Appoints Sally Welborn, former head of Walmart Global Benefits to Board of Directors Brings deep industry experience to the leading pharmaceutical data analytics firm focused on providing everyone with greater access to affordable medications NEW YORK, NY—March 20, 2018—Truveris, Inc. today announced that Sally Welborn, the former senior vice president of global benefits at
- [News | March 5, 2018](https://www.nlvpartners.com/news-march-5-2018/) - Kyruus Announces Collaboration with IBM to Leverage IBM Watson Virtual Agent with Kyruus ProviderMatch™ to Enable AI-Assisted Patient-Provider Matching and Scheduling Boston, MA - Kyruus, a leader in provider search and scheduling solutions for health systems, today announced a collaboration with IBM to integrate IBM’s Watson Virtual Agent with Kyruus ProviderMatch’s smart search and appointment
- [News | March 20, 2018](https://www.nlvpartners.com/news-march-20-2018/) - Partners HealthCare Expands Use of Kyruus Technology Across Its Network to Enhance Patient Access Leading Health System to Operationalize Enterprise-Wide Provider Data Management and Facilitate Precise Patient-Provider Matching Across Call Centers Boston, MA - Kyruus, a leader in provider search and scheduling solutions for health systems today announced that Partners HealthCare has expanded its use
- [News | February 20, 2018](https://www.nlvpartners.com/news-february-20-2018/) - Iterum Announces the appointment of Jeff Schaffnit as Chief Commercial Officer Industry Veteran To Lead Commercialization of Potential New Oral and IV Antibiotic DUBLIN and CHICAGO, Feb. 20, 2018 /PRNewswire/ -- Iterum Therapeutics Limited, a clinical-stage pharmaceutical company developing anti-infectives for patients with infectious diseases and other acute illnesses, today announced the appointment of Jeff
- [News | January 4, 2018](https://www.nlvpartners.com/news-january-4-2018/) - Deciphera Pharmaceuticals Initiates Phase 3 Clinical Study with DCC-2618 in Patients with Advanced Gastrointestinal Stromal Tumors (“INVICTUS” study) - Pivotal Study to Evaluate the pan-KIT and PDGFRα inhibitor, DCC-2618, in Heavily Pretreated Patients with GIST, for Whom There Are No Approved Treatment Options - - Top-line Data from the invictus Study Expected in 2019 -
- [News | February 9, 2018](https://www.nlvpartners.com/news-february-9-2018/) - Arvinas Presents New Preclinical Data on Oral Androgen Receptor PROTAC® ARV-110 at ASCO 2018 Genitourinary Cancers Symposium Data show complete degradation of androgen receptor in models of enzalutamide-resistant prostate cancer NEW HAVEN, CT, February 9, 2018 – Arvinas LLC, a private biotechnology company creating a new class of drugs based on protein degradation, today announced
- [News | January 4, 2018](https://www.nlvpartners.com/news-january-4-2018-2/) - Arvinas Announces Research Collaboration and License Agreement with Pfizer Inc. for the Discovery and Development of Protein Degradation Drug Candidates $830 million in upfront and potential milestone payments to Arvinas across multiple PROTAC programs NEW HAVEN, CT., January 4, 2018 – Arvinas LLC, a private biotechnology company focused on creating a new class of drugs
- [News | January 9, 2018](https://www.nlvpartners.com/news-january-9-2018/) - Kyruus Joins the Epic App Orchard with Direct Scheduling Solution Integration Brings ProviderMatch DirectBook Capabilities to Epic Customers Boston, MA - Kyruus, a leader in provider search and scheduling solutions for health systems, announced today that it has joined the Epic App Orchard to enable seamless scheduling for its customers on Epic’s EHR platform. The Kyruus ProviderMatch™ suite of patient
- [News | January 30, 2018](https://www.nlvpartners.com/news-january-30-2018/) - Kyruus Reports Record-Breaking Success in 2017 with Almost 400 Hospitals Across the U.S. Now on the ProviderMatch Platform Company Doubles Revenue Amid Rapidly Growing Demand for Enterprise-Wide Patient Access Solutions Boston, MA - Kyruus, a leader in provider search and scheduling solutions for health systems, today announced its 2017 results, highlighting a monumental year for the
- [News | November 21, 2017](https://www.nlvpartners.com/news-november-21-2017/) - Arvinas and Macroceutics Establish DEL Screening Collaboration on Undruggable Targets NEW HAVEN, Conn. and Monmouth Junction New Jersey, November 21, 2017 – Arvinas LLC, a private biotechnology company creating a new class of drugs based on protein degradation, and Macroceutics, Inc., today announced the establishment of a multi-target collaboration intended to deliver new chemical matter
- [News | December 13, 2017](https://www.nlvpartners.com/news-december-13-2017/) - Principia Biopharma initiates clinical trial for PRN1008 in patients with Immune Thrombocytopenia Purpura Preclinical Data Presented at American Society of Hematology Annual Meeting Support ITP Indication SOUTH SAN FRANCISCO, CALIF., December 13, 2017 Principia Biopharma, a private, clinical-stage biopharmaceutical company, today announced that it has initiated a clinical trial for PRN1008, a reversible covalent Bruton’s
- [News | December 7, 2017](https://www.nlvpartners.com/news-december-7-2017/) - CRISPR Therapeutics Submits First Clinical Trial Application for a CRISPR Gene-Edited Therapy, CTX001 in β-thalassemia -Phase 1/2 trial in β-thalassemia expected to begin in 2018- ZUG, Switzerland and CAMBRIDGE, Mass., Dec. 07, 2017 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP) today announced the submission of a Clinical Trial Application (CTA) for CTX001 in β-thalassemia. CTX001 is
- [News | October 3, 2017](https://www.nlvpartners.com/news-october-3-2017/) - Ultragenyx Enters into Definitive Agreement to Acquire Dimension for $6.00 Per Share in Cash in a Transaction Valued at Approximately $151 Million Based on Currently Outstanding Shares Combined Company will be Strongly Positioned to Bring Needed New Therapies to Market NOVATO, Calif., and CAMBRIDGE, Mass., Oct. 03, 2017 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)
- [News | November 15, 2017](https://www.nlvpartners.com/news-november-15-2017-2/) - Arvinas Expands Strategic License Agreement with Genentech Expansion of 2015 agreement brings total deal value to potentially exceed $650 million NEW HAVEN, Conn., November 15, 2017 – Arvinas LLC, a private biotechnology company creating a new class of drugs based on protein degradation, today announced it has expanded its ongoing license agreement with Genentech, a
- [News | November 15, 2017](https://www.nlvpartners.com/news-november-15-2017/) - Jefferson Health Selects Kyruus’ Solutions to Support Its Expansion and Enhance Patient Access Growing Health System to Build Comprehensive Provider Directory and Optimize Patient-Provider Matching Boston, MA - Kyruus, a leader in provider search and scheduling solutions for health systems, today announced that Jefferson Health, a leading academic health system in Pennsylvania and New Jersey, will
- [News | November 09, 2017](https://www.nlvpartners.com/news-november-09-2017/) - SANOFI, PRINCIPIA AGREE TO DEVELOP MULTIPLE SCLEROSIS DRUG CANDIDATE Clinical-stage oral drug candidate (PRN2246) with the potential to treat multiple sclerosis Principia to receive $40 million upfront payment, future milestone payments could total $765 million Paris, France and South San Francisco, Calif - November 9, 2017 - Sanofi will develop Principia Biopharma Inc.'s experimental oral treatment that
- [News | October 9, 2017](https://www.nlvpartners.com/news-october-9-2017/) - Neuronetics Named 2017 Health Care Innovator by Philadelphia Business Journal Recognized for company’s breakthrough non-drug depression treatment, NeuroStar® Advanced Therapy Malvern, Pa., October 9, 2017 – Neuronetics, Inc., a privately held medical device company widely recognized as the market-leader in transcranial magnetic stimulation (TMS) with its NeuroStar Advanced Therapy for depression, has been named a
- [News | October 18, 2017](https://www.nlvpartners.com/news-october-18-2017/) - AbbVie and Harpoon Therapeutics Announce Immuno-Oncology Research Collaboration NORTH CHICAGO, Ill. and SOUTH SAN FRANCISCO, Calif. – Oct. 18, 2017 – AbbVie (NYSE: ABBV), a global biopharmaceutical company, and Harpoon Therapeutics, a biotechnology company developing novel T-cell recruiting biologic therapies, announced today that they have entered an immuno-oncology research collaboration. The goal of the collaboration
- [News | September 15, 2017](https://www.nlvpartners.com/news-september-15-2017/) - Alysha Fluno Joins Truveris as Chief Pharmacy Officer Alysha Fluno has joined Truveris as Chief Pharmacy Officer where she will be involved in developing thought leadership programs and in strategic account management. Fluno is an experienced clinical professional with a diverse background in the pharmacy industry. Before joining Truveris, she served as a pharmacist and
- [News | September 26, 2017](https://www.nlvpartners.com/news-september-26-2017/) - Kyruus ProviderMatch™ to Help Emory Healthcare Raise the Bar on Patient Access by Kyruus, on Sep 26, 2017 8:20:23 AM Leading Health System Will Implement Multi-Channel Patient Access Solution to Enhance the Patient Experience and Boost Operational Efficiency Boston, MA - Kyruus, a leader in provider search and scheduling solutions for health systems, today announced that Emory
- [News | October 16, 2017](https://www.nlvpartners.com/news-october-16-2017/) - Neuronetics, Inc. Partners with Teijin Pharma Limited, a Leading Healthcare Company in Japan, to Distribute NeuroStar Advanced Therapy Partnership expands access to transformative, non-drug depression treatment to millions MALVERN, Pa., Oct. 16, 2017 /PRNewswire/ -- Neuronetics, Inc., a privately held medical device company widely recognized as the market-leader in transcranial magnetic stimulation (TMS), announced today it
- [News | October 11, 2017](https://www.nlvpartners.com/news-october-11-2017/) - NeuroStar® Advanced Therapy Approved as a Life-Changing Depression Treatment to Help Conquer Depression in Japan Proven, breakthrough non-drug treatment provides safe and effective option to the country's critical public health issue Proven, breakthrough non-drug treatment provides safe and effective option to the country's critical public health issue News provided by NeuroStar Advanced Therapy MALVERN, Pa.,
- [News | August 23, 2017](https://www.nlvpartners.com/news-august-23-2017/) - Unum Therapeutics Announces Active Investigational New Drug (IND) Application for ACTR087 in Combination with SEA-BCMA in Patients with Relapsed/Refractory Multiple Myeloma - First ACTR Combination Therapy Under Unum’s Collaboration with Seattle Genetics – - Company Plans to Initiate Patient Dosing in a Multi-center, Phase 1 Trial in Q1 2018 – CAMBRIDGE, MA, August 23, 2017 --(BUSINESS
- [News | August 22, 2017](https://www.nlvpartners.com/news-august-22-2017/) - CRISPR Therapeutics Announces Collaboration with Massachusetts General Hospital to Research Use of CRISPR/Cas9 in T Cell Cancer Therapies Collaboration expands CRISPR Therapeutics’ efforts in immuno-oncology ZUG, Switzerland and CAMBRIDGE, Mass., Aug. 22, 2017 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, and Massachusetts General Hospital
- [News | August 15, 2017](https://www.nlvpartners.com/news-august-15-2017-2/) - Oxford Immunotec Global PLC Announces Pricing of Underwritten Public Offering of Ordinary Shares OXFORD, United Kingdom and MARLBOROUGH, Mass., August 15, 2017 (GLOBE NEWSWIRE) — Oxford Immunotec Global PLC (Nasdaq: OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced the pricing of
- [News | August 15, 2017](https://www.nlvpartners.com/news-august-15-2017/) - Binary Fountain and Kyruus Announce Partnership to Enhance Patient Acquisition and Engagement for Health Systems by Kyruus, on Aug 15, 2017 8:55:42 AM The seamless integration of Binary Star Ratings and Kyruus ProviderMatch for Consumers will enable health systems to better educate, inform, and engage their patients online Boston, MA - Binary Fountain, the leading provider
- [News | August 1, 2017](https://www.nlvpartners.com/news-august-1-2017/) - Aptinyx Initiates Phase 2 Clinical Studies Evaluating NYX-2925 in Two Chronic Pain Conditions Evanston, Ill., August 1, 2017 – Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative therapies for challenging neurologic disorders, today announced the first subjects have been randomized in a Phase 2 clinical study evaluating the company’s lead product candidate, NYX-2925, a novel
- [News | September 5, 2015](https://www.nlvpartners.com/news-september-5-2015/) - Deciphera Pharmaceuticals Announces FDA Orphan Drug Designation for DCC-2618 for the Treatment of Glioblastoma Multiforme and Anaplastic Astrocytoma Waltham, MA – September 5, 2017 – Deciphera Pharmaceuticals, a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that the U.S. Food and Drug Administration (“FDA”) has granted orphan drug designation
- [News | September 27, 2017](https://www.nlvpartners.com/news-september-28-2017/) - Deciphera Pharmaceuticals Announces Pricing of Initial Public Offering WALTHAM, Mass., Sept. 27, 2017 (GLOBE NEWSWIRE) -- Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced the pricing of its initial public offering of 7,500,000 shares of common stock at a public offering price of $17.00
- [News | September 18, 2017](https://www.nlvpartners.com/news-september-18-2017/) - Karus Therapeutics Announces First Cancer Patients Dosed with KA2507, a Small Molecule HDAC6-Selective Inhibitor, in a Phase I Clinical Trial Oxfordshire, UK, 18th September 2017 – Karus Therapeutics Ltd (‘Karus’), a leader in the design and development of innovative medicines with breakthrough potential in the treatment of cancer, today announced that the first patients have
- [News | July 25, 2017](https://www.nlvpartners.com/news-july-25-2017/) - Iterum Gains Important Support for Development of Novel Oral Antibiotic, Sulopenem • CARB-X selects Iterum’s sulopenem to receive $1.5 million investment • Funding recognizes urgent need for new therapies against resistant bacteria DUBLIN, IRELAND – July 25th, 2017 – Iterum Therapeutics Limited, a clinical-stage pharmaceutical company focused on the development and commercialization of drugs to
- [News | July 13, 2017](https://www.nlvpartners.com/news-july-13-2017/) - Baylor Scott & White Health Selects Kyruus’ Solutions to Enhance Provider Data Management and Patient Access Leading Texas Health System to Leverage the KyruusOne™ Platform and ProviderMatch APIs to Create a Comprehensive Provider Directory and Improve Access to Its Providers Boston, MA – Kyruus, a leader in provider search and scheduling solutions for health systems, today announced
- [News | July 5, 2017](https://www.nlvpartners.com/news-july-5-2017/) - NJEA: Union-led Effort Nets $1.6 Billion in Prescription Savings The State of New Jersey School Employees Health Benefits Program (SEHBP) and State Health Benefits Program (SHBP) announced the results of a Pharmacy Benefits Manager bidding process using Truveris reverse auction technology. State, policy holders save big with new online bidding process Following a long advocacy effort,
- [News | June 22, 2017](https://www.nlvpartners.com/news-june-22-2017/) - Oxford Immunotec Announces National Reimbursement For The T-SPOT®.TB Test In France OXFORD, United Kingdom and MARLBOROUGH, Mass., June 22, 2017 (GLOBE NEWSWIRE) — Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced a decision from the French Ministry
- [News | June 13, 2017](https://www.nlvpartners.com/news-june-13-2017-2/) - Kyruus Enhances Its Clinical Leadership with New Chief Medical Officer, Erin Jospe, M.D. Boston, MA - Kyruus, a leader in provider search and scheduling solutions for health systems, announced today that Erin Jospe, M.D., has joined its leadership team as the company’s Chief Medical Officer. Dr. Jospe brings over 15 years of clinical and healthcare
- [News | June 6, 2017](https://www.nlvpartners.com/news-june-6-2017/) - Neuronetics, Inc. Raises $15 Million in Series G Equity Financing, Led by Ascension Ventures Capital will help expand clinical adoption of NeuroStar® Advanced Therapy, the company's market-leading transcranial magnetic stimulation (TMS) treatment MALVERN, Pa.June 6, 2017 /PRNewswire/ -- Neuronetics, Inc., a privately held medical device company widely recognized as the market-leader in transcranial magnetic stimulation (TMS)
- [News | June 13, 2017](https://www.nlvpartners.com/news-june-13-2017/) - AbbVie and Principia Annouce Collaboration on Oral Immunoproteasome Inhibitors NORTH CHICAGO, Ill. and SOUTH SAN FRANCISCO, Calif., June 13, 2017 – AbbVie (NYSE: ABBV), a global biopharmaceutical company, and Principia Biopharma Inc., a private, clinical-stage biopharmaceutical company, announced today that they have entered a collaboration for the development of oral immunoproteasome inhibitors. The collaboration is aimed at
- [News | June 15, 2017](https://www.nlvpartners.com/news-june-15-2017/) - Oxford Immunotec Announces Favorable Claim Construction Ruling in Patent Infringement Litigation OXFORD, United Kingdom and MARLBOROUGH, Mass., June 15, 2017 (GLOBE NEWSWIRE) — Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced a favorable Markman claim construction ruling
- [News | June 1, 2017](https://www.nlvpartners.com/news-june-1-2017/) - Deciphera Pharmaceuticals Announces $52 Million Series C Financing to Advance Novel Clinical-stage Oncology Pipeline Waltham, MA | June 1, 2017 Deciphera Pharmaceuticals, a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that it closed a $52 million Series C financing led by Viking Global Investors LP, Redmile Group, and
- [News | May 25, 2017](https://www.nlvpartners.com/news-may-25-2017/) - Harpoon Therapeutics Announces Completion Of $45M Series B Financing MPM Capital, Arix Bioscience, New Leaf Venture Partners and Taiho Ventures Participate in Immuno-Oncology Financing South San Francisco, CA—May 25, 2017-Harpoon Therapeutics, a biotechnology company developing novel T-cell recruiting biologic therapies for the treatment of cancer, today announced the completion of a $45M Series B financing,
- [News | May 23, 2017](https://www.nlvpartners.com/news-may-23-2017/) - Bioverativ to Acquire Clinical-Stage Rare Disease Biotechnology Company, True North Therapeutics - Strengthens pipeline with lead candidate TNT009 in cold agglutinin disease, a rare and chronic autoimmune hemolytic anemia with no approved therapies - TNT009 granted breakthrough therapy designation by FDA; late-stage development planning underway - Advances Bioverativ’s vision of becoming the leading rare disease
- [News | May 22, 2017](https://www.nlvpartners.com/news-march-22-2017/) - Versartis Presents 3-Year Somavaratan Safety and Efficacy Data and Pediatric Program Baseline Demographics at the 19th European Congress of Endocrinology MENLO PARK, Calif., May 22, 2017 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan, a novel, long-acting form of recombinant human growth hormone (rhGH) for growth hormone deficiency (GHD),
- [News | May 19, 2017](https://www.nlvpartners.com/news-may-19-2017/) - Iterum Secures $65 Million in Series B Financing Funding to support the Phase 3 clinical development of oral penem antibiotic DUBLIN, IRELAND, and CHICAGO –May 19, 2017 – Iterum Therapeutics Limited, an Irish clinical-stage pharmaceutical company focused on the development and commercialization of anti-infectives for patients with infectious diseases and other acute illnesses, today announced
- [News | April 28, 2017](https://www.nlvpartners.com/news-april-28-2017/) - Truveris selected by New Jersey to implement reverse auction and price transparency platform for pharmaceutical benefits Apr 28, 2017 Truveris will use our innovative, proprietary technology to measure the value of New Jersey’s public employee benefits contracts. The pricing transparency provided by our data analysis will enable the state’s benefits plan managers to realize savings of more
- [News | April 11, 2017](https://www.nlvpartners.com/news-april-11-2017/) - Banner Health Selects Kyruus for Its Patient Access and Provider Data Management Solutions by Kyruus, on Apr 11, 2017 9:03:00 AM The Deployment of ProviderMatch Throughout the System’s Call Centers and Websites Will Enhance Patient-Provider Matching Across the Network Boston, MA – Kyruus, a leader in provider search and scheduling solutions for health systems, today announced that
- [News | March 6, 2017](https://www.nlvpartners.com/news-march-6-2017/) - Deciphera Pharmaceuticals Initiates a Phase 1 Clinical Trial of DCC-3014 Waltham, MA | March 6, 2017 DCC-3014 – A Highly-Selective Small Molecule CSF1R Immunokinase Inhibitor with Potent Macrophage Checkpoint Inhibition Activity Deciphera Pharmaceuticals, a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, announced today that it has initiated a multi-center Phase
- [News | February 17, 2017](https://www.nlvpartners.com/news-february-17-2017-2/) - Mercy Health and Kyruus Forge Strategic Partnership to Further Enterprise-Wide Patient Access by Kyruus, on Feb 17, 2017 9:20:00 AM BOSTON, MA – Kyruus, a leader in provider search and scheduling solutions for health systems, announced today that Mercy Health (based in Cincinnati, Ohio) has entered into a strategic partnership with the company. The largest health system
- [News | February 17, 2017](https://www.nlvpartners.com/news-february-17-2017/) - Arvinas Presents New Preclinical Data on Oral Androgen Receptor PROTAC at ASCO 2017 Genitourinary Cancers Symposium Data shows robust degradation of androgen receptor in vitro and in vivo NEW HAVEN, Conn., February 17, 2017 – Arvinas LLC, a private biotechnology company creating a new class of drugs based on protein degradation, today announced the presentation
- [News | February 16, 2017](https://www.nlvpartners.com/news-february-16-2017/) - TigerText Launches Role-based Scheduling Automation Feb 16, 2017 TigerText Automated role assignments and dynamic scheduling speed clinical communication among teams, enabling faster shift transitions and patient handoffs Power of Role-based Scheduling showcased through the Amazon Echo® to intelligently route verbal bedside requests to the appropriate care provider SANTA MONICA, CA (February 16, 2017) – Ahead of
- [News | February 3, 2017](https://www.nlvpartners.com/news-february-3-2017/) - Intarcia Announces FDA Filing Acceptance of New Drug Application (NDA) for ITCA 650 for the Treatment of Type 2 Diabetes Boston, MA – February 3, 2017 – Intarcia Therapeutics, Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for active review its New Drug Application (NDA) for ITCA 650, an investigational
- [News | January 31, 2017](https://www.nlvpartners.com/news-•-january-31-2017/) - Dimension Announces Interim Topline Results from Ongoing Phase 1/2 Clinical Program for DTX101, Dimension’s Lead AAV Product Candidate in Development for Adult Patients with Moderate/Severe to Severe Hemophilia B Evidence of High-Efficiency Liver Transduction with AAVrh10 Vector Sub-clinical, Asymptomatic Elevations of ALT Observed in 5 of 6 Patients CAMBRIDGE, Mass., Jan. 31, 2017 (GLOBE NEWSWIRE)
- [News | January 9, 2017](https://www.nlvpartners.com/news-january-9-2017/) - Intarcia and Calibr Announce Collaboration and In-Licensing Deal Aimed at Delivering a Next Generation Combination Product for Diabetes and Obesity Collaboration aims to develop a novel peptide therapeutic derived from Calibr’s Stapled-Peptide Technology Platform that can be combined with ITCA 650, Intarcia’s late stage investigational GLP-1 therapy for type 2 diabetes The Calibr deal expands
- [News | January 5, 2017](https://www.nlvpartners.com/news-january-5-2017/) - Arvinas Appoints Dr. John Houston as President of Research and Development and Chief Scientific Officer NEW HAVEN, Conn., January 5, 2017 – Arvinas LLC, a private biotechnology company creating a new class of drugs based on protein degradation, today announced that it has appointed Dr. John Houston as President of Research and Development and Chief
- [News | January 4, 2017](https://www.nlvpartners.com/news-january-4-2017/) - Piedmont Healthcare Selects Kyruus' Suite of Patient-Provider Matching Solutions by Kyruus, on Jan 4, 2017 9:37:03 AM BOSTON, MA – Kyruus, a leader in provider search and scheduling solutions for health systems, announced today that Piedmont Healthcare, a not-for-profit health system serving nearly two million patients in Georgia, has selected its suite of solutions to enhance
- [News | December 29, 2016](https://www.nlvpartners.com/news-december-29-2016/) - Intarcia Secures Second Close of the Series EE Equity Financing for an Additional $206M; As Part of the Financing and a New Strategic Initiative, Intarcia Now Aims Its Medici Technology Towards Preventing HIV ? The Bill & Melinda Gates Foundation is committing up to $140M in grants and equity with the intent to develop the
- [News | December 13, 2016](https://www.nlvpartners.com/news-december-13-2016/) - Dimension Therapeutics Announces FDA Acceptance of Investigational New Drug Application for DTX301 to Treat OTC Deficiency On Track to Initiate Phase 1/2 Global, Multi-Center Clinical Trial by Year End 2016 Most Advanced of Five Inherited Metabolic Disease Programs Progressing Towards Clinical Testing CAMBRIDGE, Mass., Dec. 13, 2016 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a
- [News | December 6, 2016](https://www.nlvpartners.com/news-december-6-2016/) - Arvinas Collaborators Present Data on BET PROTAC Degraders at 2016 ASH Annual Meeting NEW HAVEN, Conn., December 6, 2016 – Arvinas LLC, a private biotechnology company creating a new class of drugs known as PROTACs which function via targeted protein degradation, today announced that preclinical data were presented by three Arvinas collaborators at the 2016
- [News | December 1, 2016](https://www.nlvpartners.com/news-december-1-2016-2/) - Deciphera Pharmaceuticals Reports Encouraging Clinical Results with DCC-2618 in Genetically-defined Cancers with Drug Resistant Mutations Waltham, MA | December 1, 2016 Advanced Kinase Inhibitors with Improved Tumor Targeting Offer Potential for Durable Responses in Difficult-to-Treat Cancers Late-breaking Oral Presentation of Clinical Data for Pan-KIT Switch Control Inhibitor, DCC-2618, Presented at EORTC-NCI-AACR Symposium on Molecular Targets
- [News | December 1, 2016](https://www.nlvpartners.com/news-december-1-2016/) - AiCure’s Artificial Intelligence Platform Wins 2016 Scrip Award Using artificial intelligence to optimize patient behavior NEW YORK, Dec. 1, 2016 /PRNewswire/ — AiCure, which uses artificial intelligence (AI) on mobile devices to visually confirm medication ingestion, today announced that they are the winners of the 2016 Scrip Award in the category of Best Technological Development
- [News | November 29, 2016](https://www.nlvpartners.com/news-november-29-2016/) - Arvinas Presents Data on its BET PROTAC Degraders at 2016 EORTC-NCI-AACR Symposium NEW HAVEN, Conn., November 29, 2016 – Arvinas LLC, a private biotechnology company creating a new class of drugs based on protein degradation, today announced that data were presented by Dr. Kevin Coleman, Vice President of Exploratory Biology, during an oral presentation at
- [News | November 21, 2016](https://www.nlvpartners.com/news-november-21-2016/) - Intarcia Submits New Drug Application (NDA) to FDA for U.S. Marketing Approval of ITCA 650 in Type 2 Diabetes The NDA submission reflects more than 10 years of innovation and clinical development of ITCA 650 to respond to pressing unmet needs in type 2 diabetes. ITCA 650 is the first investigational drug to use Intarcia’s
- [News | November 14, 2016](https://www.nlvpartners.com/news-november-14-2016/) - UAB Medicine Selects Kyruus for Patient-Provider Matching and Provider Data Management on Nov 14, 2016 12:54:00 PM BOSTON, MA – Kyruus, a leader in provider search and scheduling solutions for health systems, announced today that UAB Medicine, one of the top four largest academic medical centers in the U.S., has selected ProviderMatchTM for Access Centers and KyruusOneTM
- [News | November 16, 2016](https://www.nlvpartners.com/news-november-16-2016/) - Truveris Ranked Number 131 Fastest Growing Company in North America on Deloitte’s 2016 Technology Fast 500™ Nov 16, 2016 Truveris ranked 131 on Deloitte’s Technology Fast 500™, a ranking of the 500 fastest growing technology, media, telecommunications, life sciences and energy tech companies in North America. Truveris grew 677 percent from 2012-2015. Overall, 2016 Technology Fast 500™ companies achieved revenue growth
- [News | November 7, 2016](https://www.nlvpartners.com/news-november-7-2016/) - Versartis Presents Safety, Efficacy and IGF-I Data for Somavaratan in Pediatric Growth Hormone Deficiency at the 2016 Congress of the GRS & IGF Society Increasing somavaratan dose to the 3.5mg/kg twice-monthly now used in Phase 3 safely improved IGF-I SDS and height velocity from year 1 to year 2 MENLO PARK, Calif., Nov. 07, 2016
- [News | October 26, 2016](https://www.nlvpartners.com/news-october-26-2016/) - The Ohio State University Wexner Medical Center Implements Kyruus ProviderMatch to Optimize Patient Access by Kyruus, on Oct 26, 2016 9:05:48 AM BOSTON, MA – Kyruus, a leader in provider search and scheduling solutions, announced today that The Ohio State University Wexner Medical Center has selected Kyruus ProviderMatch™ to enhance patient-provider matching and appointment access. The medical
- [News | October 18, 2016](https://www.nlvpartners.com/news-october-18-2016-2/) - CRISPR Therapeutics Announces Pricing of Initial Public Offering BASEL, Switzerland and CAMBRIDGE, Mass., Oct. 18, 2016 (GLOBE NEWSWIRE) -- CRISPR Therapeutics AG (Nasdaq:CRSP), a biopharmaceutical company focused on translating CRISPR/Cas9 gene-editing technology into transformative medicines, today announced the pricing of its initial public offering of 4,000,000 common shares at a public offering price of $14.00
- [News | October 20, 2016](https://www.nlvpartners.com/news-october-20-2016/) - TigerText Introduces TigerFlow, The Next Evolution In Clinical Communications Oct 20, 2016 TigerText Advancing well beyond secure messaging, TigerFlow delivers a sweeping, first-of-its-kind, workflow-centric clinical communication solution that brings together an enterprise-wide platform, integration with clinical systems of record, an engaging user experience, and intelligent workflow mapping for better care team collaboration. SANTA MONICA, CA
- [News | October 13, 2016](https://www.nlvpartners.com/news-october-13-2016/) - True North Therapeutics Receives FDA Orphan Drug Designation for TNT009 for the Treatment of Autoimmune Hemolytic Anemia, Including Cold Agglutinin Disease (CAD) South San Francisco, CA, October 13, 2016 — True North Therapeutics, a clinical stage biotechnology company developing novel product candidates that selectively inhibit the Complement system to treat certain rare diseases, today announced
- [News | October 18, 2016](https://www.nlvpartners.com/news-october-18-2016/) - True North Therapeutics Announces $45 Million Series D Financing Financing Follows Encouraging Interim Clinical Data Announced for Lead Product Candidate, TNT009, in Cold Agglutinin Disease South San Francisco, CA, October 18, 2016 — True North Therapeutics, a clinical stage biotechnology company developing novel products that selectively inhibit the Complement system to treat certain rare diseases,
- [News | October 12, 2016](https://www.nlvpartners.com/news-october-12-2016/) - Oxford Immunotec Acquires Immunetics, Inc. OXFORD, United Kingdom and MARLBOROUGH, Mass., October 12, 2016 (GLOBE NEWSWIRE) – Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of under-served immune-regulated conditions, announced it has today closed a transaction to acquire Immunetics, Inc., a Massachusetts-based diagnostics company focused on developing specialized tests
- [News | October 7, 2016](https://www.nlvpartners.com/news-october-7-2016/) - Kyruus Appoints John Downey as Senior Vice President of Sales by Kyruus, on Oct 7, 2016 8:59:00 AM Kyruus, a leader in provider search and scheduling solutions for health systems, announced today that John Downey has joined the company as Senior Vice President of Sales. A proven sales leader within healthcare IT, Downey represents a
- [News | October 3, 2016](https://www.nlvpartners.com/news-october-3-2016/) - Oxford Immunotec Announces Favorable Decision from U.S. District Court of Massachusetts in Patent Infringement Litigation OXFORD, United Kingdom and MARLBOROUGH, Mass., October 3, 2016 (GLOBE NEWSWIRE) – Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of under-served immune-regulated conditions, today announced that the U.S. District Court for the District
- [News | October 4, 2016](https://www.nlvpartners.com/news-october-4-2016/) - Oxford Immunotec Announces Closing of $40 Million in Debt Financing OXFORD, United Kingdom and MARLBOROUGH, Mass., October 4, 2016 (GLOBE NEWSWIRE) – Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of under-served immune-regulated conditions, today announced that it has entered into an agreement with MidCap Financial (“MidCap”) that provides
- [News | September 26, 2016](https://www.nlvpartners.com/news-september-26-2016/) - Versartis Initiates Phase 3 Trial of Somavaratan in Japan for Children with Growth Hormone Deficiency Following Completion of Phase 2 MENLO PARK, Calif., Sept. 26, 2016 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting form of recombinant human growth hormone (rhGH) for growth hormone deficiency
- [News | September 22, 2016](https://www.nlvpartners.com/news-september-22/) - Truveris Strengthens Leadership Team with Appointment of Faisal Mushtaq as Chief Executive Officer Company seeks to make prescription drug ecosystem more efficient by providing transparency through data-driven solutions NEW YORK – THURSDAY, SEPTEMBER 22, 2016 – Truveris, a leading provider of solutions across the prescription drug ecosystem, today announced the appointment of Faisal Mushtaq as the chief executive
- [News | September 15, 2016](https://www.nlvpartners.com/news-september-15-2016-2/) - Intarcia Completes First Close of a Major Equity Financing; Poised for ITCA 650 NDA Filing for Type 2 Diabetes, Commercial Readiness and Pipeline Progression First close secured subscriptions of $215 million, a second larger close is expected in 4Q; Company pleased with solid support from existing investors and ability to attract new long-term institutional investors
- [News | September 15, 2016](https://www.nlvpartners.com/news-september-15-2016/) - Kit Check Adds Former QSI/NextGen Healthcare Sales Leader Gary Voydanoff as New Chief Commercial Officer Washington, DC – Kit Check, the leader in hospital pharmacy medication tracking software and drug spend optimization analytics, announced today that Gary Voydanoff, formerly EVP Sales and Marketing of QSI/NextGen Healthcare, has joined the company as Chief Commercial Officer. In
- [News | September 12, 2016](https://www.nlvpartners.com/news-september-12-2016/) - Versartis Presents Data From Up to 30 Months of Somavaratan Treatment for Pediatric Growth Hormone Deficiency at the 2016 ESPE Annual Meeting MENLO PARK, Calif., Sept. 12, 2016 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting form of recombinant human growth hormone (rhGH) for growth
- [News | August 8, 2016](https://www.nlvpartners.com/news-august-8-2016/) - ReShape Medical® Announces the Appointment of Michael J. Mangano as President and Chief Executive Officer SAN CLEMENTE, CALIF.—August 8, 2016—ReShape Medical Inc. today announced the appointment of Michael J. Mangano as President and Chief Executive Officer. Mr. Mangano, whose 20 year career in the medical device field has included numerous commercial leadership roles, joins ReShape
- [News | August 22, 2016](https://www.nlvpartners.com/news-august-22-2016/) - Versartis Announces Completion of Enrollment in Phase 3 VELOCITY Trial of Somavaratan in Pediatric GHD Total of 137 patients enrolled; top-line results expected in Q3 2017 MENLO PARK, Calif., Aug. 22, 2016 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting form of recombinant human growth
- [News | August 7, 2016](https://www.nlvpartners.com/news-august-1-2016/) - Kit Check Names Cameron Ferroni as Chief Product Officer Washington, DC – Kit Check™ (https://kitcheck.com), the leader in hospital pharmacy kit restocking and medication tracking software, today announced Cameron Ferroni as Chief Product Officer. Ferroni will lead the product and engineering teams in enhancing Kit Check’s product portfolio, including the recently released Narc Check solution
- [News | August 2, 2016](https://www.nlvpartners.com/news-august-2-2016/) - Edge Therapeutics Announces Closing of $20 Million Debt Facility with Hercules Capital, Inc. BERKELEY HEIGHTS, N.J., Aug. 02, 2016 (GLOBE NEWSWIRE) -- Edge Therapeutics, Inc. (Nasdaq:EDGE), a clinical-stage biotechnology company developing novel hospital-based therapies in the management of acute, life-threatening conditions, today announced the closing of a $20 million dual-tranche term loan with Hercules Capital,
- [News | July 13, 2016](https://www.nlvpartners.com/news-july-13-2016/) - Aptinyx Initiates Dosing in Phase 1 Clinical Study of Lead NMDA-Receptor Modulator, NYX-2925 Evanston, Ill., July 13, 2016 – Aptinyx Inc., a biopharmaceutical company developing novel modulators of the N-methyl-D-aspartate (NMDA) receptor for the treatment of challenging neurologic disorders, today announced the initiation of dosing in a Phase 1, first-in-human study for its lead therapeutic
- [News | August 9, 2016](https://www.nlvpartners.com/news-august-9-2016/) - Teijin Limited and Versartis Enter Strategic Alliance for Commercialization of Somavaratan Long-Acting Growth Hormone in Japan Teijin's regulatory and commercial infrastructure ideally suited to capitalize on somavaratan, which is positioned to be the first potential long-acting form of recombinant growth hormone (rhGH) to enter the Japanese market Teijin to receive exclusive license to commercialize and
- [News | July 29, 2016](https://www.nlvpartners.com/news-july-29-2016/) - Edge Therapeutics Announces First Patient Treated in Phase 3 NEWTON 2 Study of EG-1962 in Adult Patients with Aneurysmal Subarachnoid Hemorrhage Pivotal, double-blind, placebo-controlled global study will compare EG-1962 to standard of care oral nimodipine BERKELEY HEIGHTS, N.J., July 29, 2016 (GLOBE NEWSWIRE) -- Edge Therapeutics, Inc. (Nasdaq:EDGE), a clinical-stage biotechnology company developing novel hospital-based
- [News | July 27, 2016](https://www.nlvpartners.com/news-july-27-2016/) - TigerText Earns Prestigious HITRUST CSF Certification 3rd-party certification from U.S. healthcare industry’s premier security testing agency confirms TigerText’s place as the most trusted name in healthcare communications SANTA MONICA, Calif. (July 27, 2016) – TigerText, the healthcare industry’s largest and most recognized secure messaging provider, today announced it has earned Certified status for information security
- [News | July 6, 2016](https://www.nlvpartners.com/news-july-6-2016-2/) - Edge Therapeutics Announces Appointment of Harry J. Sacks, M.D., FAAP, as Vice President, Clinical Development BERKELEY HEIGHTS, N.J., July 06, 2016 (GLOBE NEWSWIRE) -- Edge Therapeutics, Inc. (Nasdaq:EDGE), a clinical-stage biotechnology company developing novel hospital-based therapies in the management of acute, life-threatening conditions, today announced that Harry J. Sacks, M.D., FAAP, has joined Edge as
- [News |  July 7, 2016](https://www.nlvpartners.com/news-july-7-2016/) - Aptuit LLC and Dimension Therapeutics Enter Strategic Partnership to Advance Select Dimension Programs Toward IND Filing GREENWICH, Connecticut and CAMBRIDGE, Massachusetts, July 7, 2016 /PRNewswire/ -- Aptuit LLC, a premier global drug discovery and development CRO, and Dimension Therapeutics, a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting the liver, a key organ
- [News | July 21, 2016](https://www.nlvpartners.com/news-july-21-2016/) - CardioKinetix Announces the 500th Parachute Heart Failure Device Implantation July 21, 2016 Menlo Park, Calif. – July 21, 2016— CardioKinetix Inc., a medical device company pioneering a catheter-based treatment for heart failure, today announced that 500 patients have received the company’s Parachute® Ventricular Partitioning Device for heart failure. Patients have been treated in more than
- [News | July 6, 2016](https://www.nlvpartners.com/news-july-6-2016/) - Bio-Techne Announces Agreement to Acquire Advanceed Cell Diagnostics July 06, 2016 Minneapolis/July 6, 2016/--Bio-Techne Corporation (NASDAQ: TECH) announced today that it has agreed to acquire Advanced Cell Diagnostics (ACD) for $250 million in cash plus contingent consideration of $75 million due upon the achievement of certain milestones. The transaction is expected to close on or about August 1,
- [News | June 24, 2016](https://www.nlvpartners.com/news-june-24-2016/) - CRISPR Therapeutics Raises Additional $38M as Part of Series B Financing Funding to Support the Development of its CRISPR/Cas9 Gene-Editing Platform and Programs BASEL, Switzerland and Cambridge, Massachusetts – CRISPR Therapeutics, a biopharmaceutical company focused on translating CRISPR/Cas9 gene-editing technology into transformative medicines, today announced an additional $38 million closing of its Series B financing. This additional
- [News | June 20, 2016](https://www.nlvpartners.com/news-june-20-2016-a/) - Unum Therapeutics Announces Active Investigational New Drug (IND) Application for ACTR087 in Patients with Relapsed/Refractory B-cell Lymphoma Company Focused on Initiating Multi-center, Phase 1 Trial in Second Half of 2016 - CAMBRIDGE, MA, June 20, 2016 – a clinical stage biopharmaceutical company developing a universal cellular immunotherapy to treat multiple cancers, today announced that the investigational
- [News | June 20, 2016](https://www.nlvpartners.com/news-june-20-2016/) - Kit Check Closes $15 Million Series C Round Baxter Ventures Leads Round; Black Granite Capital, Kaiser Permanente Ventures, Rex Health Ventures, New Leaf Venture Partners, Easton Capital Management, LionBird and Sands Capital Ventures Participate Kit Check™(https://kitcheck.com), the leader in hospital pharmacy medication tracking and restocking automation software, announced a $15 million Series C funding round
- [News | June 7, 2016](https://www.nlvpartners.com/news-june-7-2016/) - Arvinas Publishes First Peer-Reviewed, In Vivo Data from its Proprietary PROTAC Technology PROTACs demonstrated to degrade oncology target BET proteins, causing cell death in prostate cancer cells and tumor growth inhibition or regression in mouse models of prostate cancer NEW HAVEN, Conn., June 7, 2016 /PRNewswire/ -- Arvinas LLC, a private biotechnology company creating a new
- [News | June 9, 2016](https://www.nlvpartners.com/news-june-9-2016/) - Merck to Acquire Afferent Pharmaceuticals KENILWORTH, N.J. & SAN MATEO, Calif., June 9, 2016 – Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Afferent Pharmaceuticals announced today that the two companies have signed a definitive agreement under which Merck will acquire this privately held pharmaceutical company. Afferent Pharmaceuticals is a leader
- [News | June 2, 2016](https://www.nlvpartners.com/news-june-2-2016/) - TigerText and Honeywell Collaborate to Increase Healthcare Organizational Efficiency and Enhance Patient Experience New Dolphin CT50h Clinical Smartphone Offers Customized HIPAA-Compliant Messaging Solution to Improve Productivity and Lower Hospital Costs SANTA MONICA, Calif., June 2, 2016 – TigerText, the leading provider of secure messaging for the healthcare industry, is working with Honeywell to customize the
- [News | May 12, 2016](https://www.nlvpartners.com/news-may-12-2016/) - TigerConnect Healthcare Bot Set to Automate the Future of Healthcare Information Bot-driven technology puts a “care coach” in the pocket of every patient in America Opens door to auto-diagnoses, drug interaction alerts, medication reminders, billing questions, and appointment scheduling, all from a single secure messaging app SANTA MONICA, Calif. (May 12, 2016) – TigerText, maker
- [News | May 16, 2016](https://www.nlvpartners.com/news-may-16-2016/) - Afferent Pharmaceuticals Presents Updated Positive Results with AF-219 from Phase 2B Chronic Cough Study at the 2016 American Thoracic Society (ATS) International Conference Treatment with AF-219 reduced cough frequency by 50% or more at 50 mg BID dose in half of responding patients San Francisco, CA – May 16, 2016 –Afferent Pharmaceuticals, a leader in the
- [News | May 10, 2016](https://www.nlvpartners.com/news-may-10-2016/) - Aptinyx Raises $65 Million in Series A Financing to Advance Therapies for Neurological Disorders Evanston, Ill., May 10, 2016 – Aptinyx Inc., a biopharmaceutical company developing novel modulators of the N-methyl-D-aspartate (NMDA) receptor for the treatment of challenging neurological disorders, today announced the completion of a $65 million Series A financing. The funds will support
- [News | May 6, 2016](https://www.nlvpartners.com/news-may-6-2016/) - Intarcia Announces Successful Cardiovascular Safety Results in Phase 3 FREEDOM-CVO Trial for ITCA 650, an Investigational Therapy for Type 2 Diabetes Company also Reports New $75 Million Financing for Manufacturing Scale-Up and Inventory Build for Anticipated Global Launch of ITCA 650 ? FREEDOM-CVO Phase 3 safety trial in more than 4,000 patients meets its primary
- [News | April 28, 2016](https://www.nlvpartners.com/news-april-28-2016-2/) - IRHYTHM TECHNOLOGIES EXPANDS ZIO® SERVICE TO INCLUDE TRUE ATRIAL FIBRILLATION DURATION REPORTING SAN FRANCISCO, CA –April 28, 2016 –– iRhythm Technologies, Inc., a leading digital health care company focused on the advancement of cardiac care, announced today a significant enhancement of ZIO® Reports. The report now includes True Atrial Fibrillation (AFib) Duration, the validated amount
- [News | April 28, 2016](https://www.nlvpartners.com/news-april-28-2016/) - MedStar Health Selects Kyruus to Build Patient Access Experience by Kyruus, on Apr 28, 2016 8:30:00 AM Leading mid-Atlantic health system to use ProviderMatch™ software platform to create consistency and engagement across the patient journey BOSTON, April 28, 2016 – Kyruus, Inc., a leading provider of patient access and referral management solutions, announced today that
- [News | April 19, 2016](https://www.nlvpartners.com/news-april-19-2016/) - New Hampshire Health Information Organization Upgrades Communication System, Selects TigerText Secure Messaging Platform SANTA MONICA, Calif., April 19, 2016 – TigerText, the leading provider of secure messaging for healthcare, today announced that the New Hampshire Health Information Organization (NHHIO), New Hampshire’s network for the digital exchange of patient health information, has selected TigerText as a
- [News | April 18, 2016](https://www.nlvpartners.com/news-april-18-2016/) - TigerText to Offer Secure Messaging Services to U.S. Cellular Customers Secure Messaging Solution Now Available to U.S. Cellular Customers Protects Confidential Conversations and Accelerates Workflows SANTA MONICA, Calif., April 18, 2016 – TigerText today announced they have begun offering its secure messaging enterprise technology, to the customers of U.S. Cellular (NYSE: USM). This secure messaging
- [News | April 13, 2016](https://www.nlvpartners.com/news-april-13-2016/) - Karos Pharmaceuticals Advances Development of KAR5585 to Treat Pulmonary Arterial Hypertension into the Clinic First-in-class small molecule candidate designed to alter course of disease through selective modulation of peripheral serotonin April 13, 2016 08:00 AM Eastern Daylight Time NEW HAVEN, Conn.--(BUSINESS WIRE)--Karos Pharmaceuticals, a privately held, clinical-stage biopharmaceutical company focused on orphan indications, including fibrotic,
- [News | March 30, 2016](https://www.nlvpartners.com/news-march-30-2016/) - Versartis Appoints Colin Hislop, M.D., as Chief Medical Officer MENLO PARK, Calif., March 30, 2016 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting form of recombinant human growth hormone (rhGH) for growth hormone deficiency (GHD), today announced that it has appointed Colin Hislop, M.D. as
- [News | April 1, 2016](https://www.nlvpartners.com/news-april-1-2016/) - Versartis Presents Confirmatory 18-Month Adherence Data from Ongoing Somavaratan Extension Study at Late-Breaker Session at ENDO Annual Meeting MENLO PARK, Calif., April 01, 2016 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting form of recombinant human growth hormone (rhGH) for growth hormone deficiency (GHD), announced
- [News | February 16, 2016](https://www.nlvpartners.com/news-february-16-2016/) - Kaiser's Zion Medical Center Wins IHA 2016 Award SAN DIEGO – February 16, 2016 – Awarepoint Corporation, a leader in real-time locating systems (RTLS), announced today that its customer and innovation partner Kaiser Permanente’s Zion Medical Center in San Diego has won the IHA 2016 Award for Innovative Healthcare.?The IHA annual awards identify and recognize
- [News | February 23, 2016](https://www.nlvpartners.com/news-february-23-2016/) - Beaumont Health and Kyruus Partner to Provide an “Omnichannel” Experience for Patients by Kyruus, on Feb 23, 2016 8:30:00 AM Michigan-based system to implement ProviderMatchTM across multiple access channels to improve patient experience and care coordination Boston, MA, February 23, 2016 – Kyruus, Inc., a leading provider of patient access and referral management solutions, announced today
- [News | March 1, 2016](https://www.nlvpartners.com/news-march-1-2016-2/) - Awarepoint Showcases the Industry’s First Wi-Fi Managed BLE Beacon ?Real time locating systems (RTLS) based on Bluetooth Low Energy (BLE)/Wi-Fi is quickly becoming a driving force behind the Internet of Things (IoT) in healthcare. Awarepoint is the first in the market with a RTLS BLE/Wi-Fi platform. The company will showcase its Location as a Service
- [News | March 17, 2016](https://www.nlvpartners.com/news-march-17-2016-2/) - Kit Check Tracks 10 Million Hospital Medications to Become Largest Scale IoT and Cloud Software Solution in Healthcare by Ava Mutchler March 17 2016, WASHINGTON – Kit Check™ (http://kitcheck.com), the leader in hospital pharmacy kit restocking automation and medication tracking software, today announced that 10 million medications have been tracked by hospital pharmacies using the
- [News | March 22, 2016](https://www.nlvpartners.com/news-march-22-2016/) - New Study Suggests High Burden of Atrial Fibrillation is Associated with Lower Cognitive Function Use of iRhythm Technologies' ZIO Patch Helps Determine True Atrial Fibrillation Burden SAN FRANCISCO, March 22, 2016 /PRNewswire/ -- iRhythm Technologies, Inc. announced today that study results showed an association between a high burden of atrial fibrillation (AFib) and lower cognitive function. Previous
- [News | March 17, 2016](https://www.nlvpartners.com/news-march-17-2016/) - Dimension Therapeutics Receives Positive Opinion for European Orphan Drug Designation for DTX301 for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency CAMBRIDGE, Mass., March 17, 2016 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, liver-directed treatments for diverse rare diseases based on an adeno-associated virus (AAV) gene delivery technology, today announced that
- [News | March 14, 2016](https://www.nlvpartners.com/news-march-14-2016/) - Versartis Announces Two Abstracts from Ongoing Pediatric Extension Study of Somavaratan Selected for Late-Breaker Presentations at the Endocrine Society's 98th Annual Meeting MENLO PARK, Calif., March 14, 2016 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting form of recombinant human growth hormone (rhGH) for growth
- [News | March 2, 2016](https://www.nlvpartners.com/new-march-2-2016/) - Arvinas Appoints Angela Shen as Chief Medical Officer NEW HAVEN, CT, March 2, 2016 – Arvinas LLC, a biotechnology company creating a new class of oncology drugs based on protein degradation, announced the appointment of Angela Shen, M.D., M.B.A, as chief medical officer of the company. Dr. Shen brings extensive experience in clinical development, medical
- [News | March 1, 2016](https://www.nlvpartners.com/news-march-1-2016/) - Summa Health Selects ProviderMatch to Power Access for Clinically Integrated Network Leading health system will leverage Kyruus’ suite of solutions to optimize physician care coordination across Ohio’s largest CIN Boston, MA, March 1, 2016 – Kyruus, Inc., a leading provider of patient access and referral management solutions, announced today that Summa Health System – one
- [News | February 29, 2016](https://www.nlvpartners.com/news-february-29-2016/) - TigerText Announces Deeper Integration with BOX to Provide Healthcare Teams with Secure Messaging Capabilities for DICOM Image Collaboration New Integration Enhances Patient Care Communication and Alleviates Data Interoperability Issues for Healthcare Organizations SANTA MONICA, Calif., Feb. 29, 2016 – TigerText, the secure communications leader in healthcare, today announced a deeper integration with Box, the leading
- [News | February 19, 2016](https://www.nlvpartners.com/news-february-19-2016/) - Edge Therapeutics Announces New Data Highlighting the Potential Pharmacoeconomic Impact of EG-1962 in Aneurysmal Subarachnoid Hemorrhage • Reduced length of ICU stay by 3.5 days, hospital stay by 2.5 days versus standard of care • Builds on efficacy data from Phase 1/2 clinical study, where EG-1962 doubled chances of favorable clinical outcomes • Initiation of
- [News | February 2, 2016](https://www.nlvpartners.com/news-february-2-2016/) - Versartis Reports Confirmatory Top-Line Two-Year Data from Ongoing Extension Study of Somavaratan in GHD Children Safe and well tolerated over two years Height velocity (HV) in second year comparable to published US rhGH daily dosing data; further confirms Phase 3 dose and schedule Extremely high rate of adherence to dosing schedule in Extension Study (18
- [News | January 11, 2016](https://www.nlvpartners.com/news-january-11-2016/) - AiCure's Artificial Intelligence Platform Draws $12.25 Million Series A (New York, NY) - January 11, 2016 - AiCure, an artificial intelligence company connecting the world's patients to better treatments and improved health, has closed a Series A fundraising round with $12.25 million. The consortium is led by New Leaf Venture Partners, with additional participation from
- [News | November 11, 2015](https://www.nlvpartners.com/news-november-11-2015/) - TigerText Closes on $50 Million in Financing to Accelerate Growth; Launches TigerText Anywhere Initiative Industry’s most widely adopted secure messaging platform unveils new apps for desktop and Apple Watch and introduces Low Connectivity Protocol (LCP) for areas with poor reception SANTA MONICA, Calif. – November 11, 2015 – TigerText, a provider of secure communications and workflow
- [News | November 11, 2015](https://www.nlvpartners.com/news-november-13-2015/) - WAVE Life Sciences Announces Pricing of Initial Public Offering CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 11, 2015-- WAVE Life Sciences Ltd. (NASDAQ: WVE), a preclinical biopharmaceutical company using its proprietary chemistry platform to design, develop and commercialize a broad pipeline of first-in-class or best-in-class stereopure nucleic acid therapeutics candidates, today announced the pricing of its initial public offering of 6,375,000
- [News | December 1, 2015](https://www.nlvpartners.com/news-december-1-2015/) - Acelity Acquires SNaP® Disposable Negative Pressure Wound Therapy System to Expand Offering in Portable, Non-Powered NPWT Technology Acquisition accelerates Acelity’s strategy in the disposable negative pressure wound therapy market SAN ANTONIO, Dec. 1, 2015 – Acelity, a global wound care and regenerative medicine company, announced it has acquired the SNaP® Therapy System, a disposable negative
- [News | December 3, 2015](https://www.nlvpartners.com/news-december-3-2015/) - True North Therapeutics Announces $40 Million Series C Financing Company to Advance Clinical Program for Lead Complement Inhibitor, TNT009, in Cold Agglutinin Disease and Other Rare Diseases South San Francisco, CA, December 3, 2015— True North Therapeutics, a biotechnology company developing novel therapies that selectively inhibit the Complement system to treat rare diseases, announced today
- [News | November 18, 2015](https://www.nlvpartners.com/news-november-18-2015/) - iRhythm Technologies Launches New iOS App Enabling Patients to Report Irregular Heartbeat Symptoms for Physician Diagnosis iRhythm myZIO™ smartphone app and website to increase patient engagement with company's leading arrhythmia detection service SAN FRANCISCO, Nov. 18, 2015 /PRNewswire/ -- iRhythm Technologies, Inc., a leading digital health care solutions company focused on advancing cardiac care, announced today
- [News | December 1, 2015](https://www.nlvpartners.com/news-december-1-2015-2/) - QPID Health to Showcase New Approach to Quality Reporting at the IHI Forum on Quality Improvement in Healthcare Company to demonstrate software that streamlines reporting processes and finds more patient data to improve performance Boston – December 1, 2015 – QPID Health, which helps hospitals and medical groups achieve their quality goals with software that generates
- [News | December 8, 2015](https://www.nlvpartners.com/news-december-8-2015/) - Afferent Pharmaceuticals Advances Novel Molecule, AF-130, to Phase 1 Clinical Trial Second Candidate from Company’s P2X3 Development Pipeline to Enter the Clinic San Mateo, CA – December 8, 2015 – Afferent Pharmaceuticals, a leader in the development of small molecule compounds for the treatment of poorly managed and common neurogenic disorders, announced today initiation of the
- [News  |  January 5, 2016](https://www.nlvpartners.com/news-•-january-5-2016/) - Waltham, MA | Jan 5, 2016 Deciphera Pharmaceuticals Increases Size of Series B Financing to over $90 Million with Addition of SV Life Sciences Michael Ross, Managing Director of SV Life Sciences, to join Deciphera Board of Directors Deciphera Pharmaceuticals, a clinical-stage biotechnology company focused on developing advanced kinase inhibitor treatments, today announced that it
- [News | December 16, 2015](https://www.nlvpartners.com/news-december-16-2015/) - Versartis' VRS-317 6-Month Data Published in The Journal of Clinical Endocrinology & Metabolism Results Show Positive Safety and Efficacy Data With Similar Outcomes Across Three Dosing Regimens MENLO PARK, Calif., Dec. 16, 2015 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting form of recombinant human
- [News | January 6, 2016](https://www.nlvpartners.com/news-•-january-6-2016/) - Dimension Therapeutics Announces Orphan Drug Designation of DTX301 for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency CAMBRIDGE, Mass., Jan. 06, 2016 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a leading gene therapy company advancing novel, liver-directed treatments for diverse rare diseases, today announced that the U.S. Food and Drug Administration (FDA) granted orphan drug designation
- [News | January 7, 2016](https://www.nlvpartners.com/news-january-7-2016/) - Dimension Therapeutics Announces Initiation of Phase 1/2 Study for DTX101 for the Treatment of Hemophilia B Receives Positive Opinion on European Orphan Drug Designation CAMBRIDGE, Mass., Jan. 07, 2016 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a leading gene therapy company advancing novel, liver-directed treatments for diverse rare diseases, today announced the initiation of a
- [News | January 7, 2016](https://www.nlvpartners.com/news-january-7-2016-2/) - Principia Biopharm advances BTK inhibitor program in autoimmune disease and FGFR inhibitor program in oncology Initiates Phase 2 clinical trial of BTK inhibitor PRN1008 in orphan autoimmune disease Advances Phase 1 clinical trial of FGFR1-4 inhibitor PRN1371 in solid tumors SOUTH SAN FRANCISCO, Calif., January 7, 2016 Principia Biopharma Inc., a private clinical-stage biopharmaceutical company,
- [News | September 21, 2015](https://www.nlvpartners.com/news-september-21-2015/) - Sharp HealthCare Selects QPID Health for PQRS Compliance Leading California health system to use QPID Health’s technology to streamline mandated quality reporting and ensure reports are consistent with high standards of care Boston – September 21, 2015 – QPID Health, which helps hospitals and medical groups complete quality and registry reporting more efficiently and thoroughly, today announced
- [News | October 20, 2015](https://www.nlvpartners.com/news-october-20-2015/) - QPID Health Announces Groupers for Epic New content subscription service reduces cost of developing and maintaining Groupers Boston – October 20, 2015 – QPID Health, which helps hospitals and medical groups achieve their quality goals with software that generates actionable information from electronic health records, today announced the availability of QPID Groupers for Epic. The company’s
- [News | October 19, 2015](https://www.nlvpartners.com/news-october-19-2015/) - U.S. News & World Report and Kyruus Team Up to Help Patients Book Doctor Appointments Washington, D.C., October 19, 2015 – U.S. News & World Report, publisher of Best Hospitals, today announced new first-in-class physician search and scheduling capabilities for its Best Hospital and Doctor Finder sites through a collaboration with Kyruus. Patients researching care
- [News | October  21, 2015](https://www.nlvpartners.com/news-october-21-2015/) - Kit Check Adds Children’s Hospital of Orange County as 200th Hospital Customer Washington, DC – Kit Check™ (http://kitcheck.com), the leader in hospital pharmacy kit restocking and medication tracking software, announced that Children’s Hospital of Orange County (CHOC Children’s) became the 200th hospital to adopt the company’s cloud software and RFID technology solution. More than 10,000
- [News | October 21, 2015](https://www.nlvpartners.com/news-october-21-2015-•-2/) - Unum Therapeutics Expands Leadership Team by Appointing Dr. Michael J. Vasconcelles as Chief Medical Officer Former SVP at Millennium/Takeda Fills Newly Created Position to Advance Unum’s Expanding Immunotherapy Clinical Program CAMBRIDGE, MA, October 21, 2015 – Unum Therapeutics, a company developing a universal cellular immunotherapy to treat multiple cancers, announced today that it has named
- [News | October 21, 2015](https://www.nlvpartners.com/news-october-21-2015-•-3/) - Dimension Therapeutics Announces Pricing of Initial Public Offering CAMBRIDGE, MASS, October 21, 2015– Dimension Therapeutics, Inc. (“Dimension” or the “Company”), a leading gene therapy company advancing novel, liver-directed treatments for diverse rare diseases, today announced the pricing of its initial public offering of 5,500,000 shares of its common stock at a public offering price of $13.00
- [News | October 21, 2015](https://www.nlvpartners.com/news-october-21-2015-•-4/) - RELYPSA ANNOUNCES FDA APPROVAL OF VELTASSA(TM) (PATIROMER) FOR ORAL SUSPENSION FOR THE TREATMENT OF HYPERKALEMIA First new medicine for the treatment of hyperkalemia, or high blood potassium levels, in more than 50 years Approximately 3 million people with chronic kidney disease (CKD) and/or heart failure in the United States have hyperkalemia In clinical trials, Veltassa
- [News | October 21, 2015](https://www.nlvpartners.com/news-oct-21-2015-•-5/) - Arvinas Secures $41.6M Series B Financing – Appoints New Board Members New Haven, CT – October 21, 2015 – Arvinas LLC (“Arvinas”), a private biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that it has closed a Series B financing round of $41.6 million. All of the initial
- [News | October 28, 2015](https://www.nlvpartners.com/news-october-28-2015/) - KLAS Report Names TigerText Most Widely Adopted Solution For Secure Messaging – Clear Leader In Market Share And Mindshare Prospects consider TigerText 2X more often than next largest competitor – KLAS calls it a “proven solution” with simplicity cited as a key driver of adoption SANTA MONICA, CA (October 28, 2015) – TigerText, the leader
- [News | November 2, 2015](https://www.nlvpartners.com/news-november-2-2015/) - ReShape Medical, Inc. Builds Momentum with Next Generation Integrated Dual Balloon System at ObesityWeek 2015 Following FDA Approval, Company Focused on Physician Training and Comprehensive Patient Care LOS ANGELES and SAN CLEMENTE, Calif., Nov. 2, 2015 /PRNewswire/ -- (Booth #529) -- ReShape Medical, Inc. announced today that the company will focus on physician education and training, as well as
- [News | June 11, 2015](https://www.nlvpartners.com/news-june-11-2015-2/) - Unum Therapeutics Announces $65 Million Series B Financing Round Proceeds from the oversubscribed funding round will support the expansion of Unum’s proprietary pipeline and development of ACTR therapies for a broad range of hematological and solid tumor indications CAMBRIDGE, MA – June 11, 2015 –Unum Therapeutics, a biotechnology company developing a universal, antibody-directed cellular immunotherapy,
- [News | June 11, 2015](https://www.nlvpartners.com/news-june-11-2015-3/) - Tioga Pharmaceuticals Announces Initiation of Phase 2 Clinical Study of Asimadoline in Patients with Pruritus Associated with Atopic Dermatitis SAN DIEGO – June 11, 2015 - Tioga Pharmaceuticals, a clinical stage biotechnology company, today announced the initiation of a Phase 2 clinical study of asimadoline, a novel, well-studied kappa-opioid receptor specific agonist, for the treatment
- [News | January 12, 2015](https://www.nlvpartners.com/news-january-12-2015/) - Kit Check Raises $12 Million Series B Kaiser Permanente Ventures Leads Round; New Leaf, Sands, Easton, Lionbird and Rex Health Ventures Participate Quick Facts • Total Series B Funding Round: $12 Million (closed 1/12/15) • Lead: Kaiser Permanente Ventures • Also Participating: New Leaf Venture Partners, Sands Capital Ventures, Easton Capital Investment Group, Lionbird, Rex
- [News | January 5, 2015](https://www.nlvpartners.com/news-january-5-2015/) - Relypsa Announces Assignment of October 21, 2015 PDUFA Date for New Drug Application for Patiromer for Oral Suspension FDA Not Currently Planning to Hold an Advisory Committee Meeting Company to Host Webcasted Analyst Day in New York on January 8, 2015 REDWOOD CITY, Calif., Jan. 5, 2015 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), today announced
- [News | December 15, 2014](https://www.nlvpartners.com/news-december-15-2014/) - Karyopharm Announces Addition to the NASDAQ Biotechnology Index NEWTON, Mass., Dec. 15, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced today that it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq:NBI). The addition to the NASDAQ Biotechnology Index will become effective upon market open on Monday,
- [News | December 8, 2014](https://www.nlvpartners.com/news-december-8-2014/) - VaxInnate Initiates Phase 1b/2 Clinical Trial of Quadrivalent Seasonal Influenza Vaccine Candidate, VAX2012Q, in Elderly Study to assess safety and immunogenicity in high-priority, at-risk population; top-line results expected in second quarter of 2015 CRANBURY, NJ, December 8, 2014 – VaxInnate Corporation, a biotechnology firm pioneering a breakthrough vaccine technology platform, today announced the initiation of
- [News | December 2, 2014](https://www.nlvpartners.com/news-december-2-2014/) - MEI Pharma Completes Enrollment in Phase II Study of Pracinostat in Front Line Acute Myeloid Leukemia Interim Data from 33 Evaluable Patients to be Presented at ASH on Saturday SAN DIEGO, Dec. 2, 2014 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced
- [News | December 8, 2014](https://www.nlvpartners.com/news-december-8-2014-2/) - CareFusion and Kit Check to Help Providers Save Time and Improve Medication Safety from the Pharmacy to the OR ANAHEIM, Calif., December 8, 2014 – Kit Check™ (kitcheck.com), the leader in hospital pharmacy kit processing and medication tracking software, and carefusionCareFusion (carefusion.com), the health care industry leader in medication dispensing, inventory management and medication administration,
- [News | November 12, 2014](https://www.nlvpartners.com/news-november-12-2014-4/) - Spiracur Secures $16M from GE Capital to Expand Sales and R&D Efforts SUNNYVALE, Calif., Nov. 12, 2014 – Spiracur Inc., developer of the only mechanically powered advanced wound care solution with the proven efficacy of Negative Pressure Wound Therapy (NPWT), today announced that it has closed a $16 million round of debt financing with GE
- [News | November 12, 2014](https://www.nlvpartners.com/news-november-12-2014-3/) - TigerText Announces Integration with MobileIron to Deliver Secure Messaging Alliance brings TigerText secure enterprise messaging to MobileIron AppConnect ecosystem. Santa Monica, CA (November 12, 2014) – TigerText, the leader in secure real-time messaging for the enterprise, today announced it has officially joined the MobileIron AppConnect ecosystem. TigerText’s integration enables MobileIron customers to now securely text
- [News | November 12, 2014](https://www.nlvpartners.com/news-november-12-2014-2/) - Intarcia and Servier Sign Ex-U.S. Partnership for ITCA 650 in Diabetes; Intarcia Retains Independence & Full Control of the U.S. & Japan • Intarcia grants Servier exclusive rights to ITCA 650 in ex-U.S./Japan territories; Intarcia retains full control of ITCA 650 in the United States and plans another partner in Japan. • Intarcia upfront and
- [News | November 3, 2014](https://www.nlvpartners.com/news-november-3-2014-2/) - Chimerix Names Two New Executives: Peter Payne as Senior Vice President, Business Development and Corporate Strategy, and Roberto Guzman, JD, MBA, MCLFS, as Vice President, Corporate Compliance DURHAM, N.C., Nov. 3, 2014 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals, today announced the appointments of Peter Payne as Senior Vice
- [News | October 6, 2014](https://www.nlvpartners.com/news-october-6-2014/) - Actavis to Acquire Durata Therapeutics, Inc. - Lead Product DALVANCE™ a Novel Antibiotic for Unmet Medical Need in Hospital and Outpatient Settings - Enhances Actavis' Long-term Growth Profile 2015+ - Experienced Development and Commercial Team Bolsters Actavis' Infectious Disease Expertise - Leverages Actavis' Hospital Sales and Marketing Capabilities DUBLIN, Ireland and CHICAGO, Oct. 6, 2014
- [News | September 17, 2014](https://www.nlvpartners.com/news-september-17-2014-2/) - Concert Pharmaceuticals Announces Initiation of CTP-730 Phase 1 Clinical Trial Under Celgene Collaboration LEXINGTON, Mass.--(Sep 17, 2014)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has initiated a Phase 1 clinical trial of CTP-730, a novel product candidate that is being developed under its strategic collaboration with Celgene Corporation. Concert will conduct the randomized,
- [News | September 9, 2014](https://www.nlvpartners.com/news-september-9-2014/) - Kit Check Passes 100 Hospital Customer Mark Washington, DC – September 9, 2014 - Kit Check™ (http://kitcheck.com), the leader in hospital pharmacy kit processing and medication tracking software, today announced that over 100 hospitals are using its cloud-based software solution. Today, Kit Check supports more than 3,800 hospital users tracking more than 11,000 pharmacy kits.
- [News | September 3, 2014](https://www.nlvpartners.com/news-september-3-2014-2/) - Kit Check Tracks Two Million Hospital Medications With RFID Great Falls, MT – September 3, 2014 – Kit Check™ (http://kitcheck.com), the leader in hospital pharmacy kit processing and medication tracking software, today announced that hospital users have tracked two million medications using the company’s RFID-based solution. The medication receiving RFID tag number two million was
- [News | September 2, 2014](https://www.nlvpartners.com/news-september-2-2014-3/) - MEI Pharma Completes Enrollment In Randomized Phase II Clinical Trial Of Pracinostat In Front Line Myelodysplastic Syndrome Data from Multi-Center, Placebo-Controlled Study Anticipated in Q1 2015 SAN DIEGO, Sept. 2, 2014 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that it
- [News | September 2, 2014](https://www.nlvpartners.com/news-september-2-2014-2/) - Chimerix and BARDA Announce Continued Partnership in the Development of Brincidofovir for Smallpox $17.0 Million Awarded in Latest Contract Extension DURHAM, N.C., Sept. 2, 2014 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals, today announced an award of $17.0 million through the extension of its contract with the Biomedical Advanced
- [News | July 8, 2014](https://www.nlvpartners.com/news-july-8-2014/) - Awarepoint awareAssets version 3.0 Now Available Healthcare RTLS leader announces updates to asset tracking software, enhancing resource management, efficiency and compliance SAN DIEGO – July 8, 2014 – Awarepoint Corporation, the largest real-time location system (RTLS) corporation dedicated exclusively to healthcare, announces the availability of its enterprise-wide asset tracking and workflow optimization tool, awareAssets 3.0.
- [News | July 8, 2014](https://www.nlvpartners.com/news-july-8-2014-2/) - Chimerix Announces Three Abstracts to be Presented at the 2014 World Transplant Congress DURHAM, N.C., July 8, 2014 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced the presentation of three abstracts on its investigational broad-spectrum antiviral, brincidofovir (BCV, CMX001), at the
- [News | June 2, 2014](https://www.nlvpartners.com/news-june-2-2014-2/) - Relypsa Secures Loan Facility of Up to $35 Million Company Restructures Debt and Reduces Debt Service Costs REDWOOD CITY, Calif., June 2, 2014 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced it has secured a loan facility of up to $35 million with Oxford Finance LLC ("Oxford") and Silicon Valley Bank ("SVB").
- [News | April 2, 2014](https://www.nlvpartners.com/news-april-2-2014-3/) - Cardinal Health Expands Portfolio of Physician Preference Items Company to Acquire AccessClosure, a Leading U.S. Manufacturer of Extravascular Closure Devices - Expands Cardinal Health portfolio of preferred products that meet increasing demand for high quality, cost-efficient solutions - Provides entrance to U.S. interventional cardiology area - Further aligns Cardinal Health with market forces and customers’
- [News | April 2, 2014](https://www.nlvpartners.com/news-april-2-2014-2/) - Premier, Inc. Identifies Kit Check as "Technology Breakthrough Product" – awards exclusive agreement for pharmacy kit medication tracking solution Washington, DC – April 2, 2014 - Premier, Inc., a leading healthcare improvement company uniting an alliance of more than 2,900 U.S. hospitals and nearly 100,000 other providers, has awarded a group purchasing agreement to Kit
- [News | April 1, 2014](https://www.nlvpartners.com/news-april-1-2014/) - Spiracur Announces FDA Clearance of its SNaP Wound Care System Dressings with Hyperbaric Oxygen Therapy SUNNYVALE, Calif., April 1, 2014 – Spiracur today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the SNaP® Wound Care Dressing (with fittings and cartridge removed) for use in a hyperbaric oxygen therapy (HBOT) chamber for the treatment
- [News | April 1, 2014](https://www.nlvpartners.com/news-april-1-2014-2/) - Intarcia Secures Second Landmark Private Financing of $200 Million – Strengthens Position To Complete Phase 3, Prepare For Launch, and Build Pipeline - Promising first interim phase 3 data for ITCA 650 in type 2 diabetes, combined with robust execution against key milestones and the addition of key talent - Last two private financings have
- [News | March 31, 2014](https://www.nlvpartners.com/news-march-31-2014-2/) - Convergence and Evotec form integrated pain alliance Cambridge, UK, 31 March 2014: Convergence Pharmaceuticals Holdings Limited (“Convergence”), the company focused on the development of novel and high value analgesic medicines for the treatment of chronic pain, today announces that it has entered into a research alliance with Evotec, a drug discovery alliance and development partnership
- [News | March 20, 2014](https://www.nlvpartners.com/news-march-20-2014-2/) - Versartis Announces Pricing of Its Initial Public Offering REDWOOD CITY, Calif., March 20, 2014 (GLOBE NEWSWIRE) -- Versartis, Inc., (Nasdaq:VSAR) an endocrine-focused biopharmaceutical company, today announced the pricing of its initial public offering of 6,000,000 shares of its common stock at a public offering price of $21 per share, before underwriting discounts and commissions. The
- [News | February 13, 2014](https://www.nlvpartners.com/news-february-13-2014/) - Awarepoint Drives Growth and Moves Client Base to Next Generation Platform Healthcare RTLS leader reports significant movement in client base toward next generation platform, continued growth SAN DIEGO – February 13, 2014 – Awarepoint Corporation, the largest real-time location system (RTLS) corporation dedicated exclusively to healthcare, announced the close of a strong year with sales
- [News | January 9, 2014](https://www.nlvpartners.com/news-january-9-2014-2/) - Direct Flow Medical®, Inc. Receives CE Mark For First Fully Repositionable 29 mm Transcatheter Aortic Valve System SANTA ROSA, Calif., January 9, 2014 – Direct Flow Medical®, Inc., a transcatheter heart valve innovator focused on improving patient outcomes, announced today it has received CE Mark for the first fully repositionable 29mm transcatheter aortic heart valve,
- [News | December 18, 2013](https://www.nlvpartners.com/news-december-18-2013/) - Chimerix Appoints Linda M. Richardson as Chief Commercial Officer DURHAM, N.C., Dec. 18, 2013 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced the appointment of Linda M. Richardson as Chief Commercial Officer. Ms. Richardson brings more than 25 years of pharmaceutical
- [News | November 5, 2013](https://www.nlvpartners.com/news-november-5-2013-2/) - Advanced Cell Diagnostics Announces Genoptix® as their First CLIA Certified RNAscope® Service Provider Advanced Cell Diagnostic expands RNAscope® technology access through CLIA Service Provider Program HAYWARD, CA, November 5, 2013—Advanced Cell Diagnostics, Inc. (ACD), a leader in the field of molecular pathology and developer of cell and tissue-based analysis tools, today announced that it has
- [News | October 14, 2013](https://www.nlvpartners.com/news-october-14-2013/) - CardioKinetix Announces First Heart Failure Patients Treated in China with Novel Minimally Invasive Structural Heart Device Menlo Park, Calif. – October 14, 2013 - CardioKinetix Inc., a medical device company pioneering a catheter-based treatment for heart failure, today announced a new first with two patients successfully treated this week with the new catheter-based Parachute® Ventricular
- [News | October 8, 2013](https://www.nlvpartners.com/news-october-8-2013-2/) - Versartis Closes $20 Million Series D Venture Financing New Capital Will Support Preparations for Phase 3 Trial of Long-Acting Human Growth Hormone in Pediatric Patients Redwood City, CA – October 8, 2013 – Versartis, Inc., an emerging biotechnology company developing novel therapeutics for patients with endocrine disorders, today announced completion of a $20 million Series
- [News | October 2, 2013](https://www.nlvpartners.com/news-october-2-2013-2/) - Durata Therapeutics Presents New Comprehensive Review of the Efficacy and Safety Data of Dalbavancin and New In Vitro Findings at IDWeek 2013™ SAN FRANCISCO, Oct. 2, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today announced a comprehensive review of the efficacy, safety and microbiology data of the company's lead product candidate, dalbavancin, for the
- [News | September 26, 2013](https://www.nlvpartners.com/news-september-26-2013-2/) - Durata Therapeutics Announces NDA Submission for Dalbavancin for the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) CHICAGO, Sept. 26, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX), an emerging specialty pharmaceutical company, today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration
- [News | September 24, 2013](https://www.nlvpartners.com/news-september-24-2013/) - TigerText Provides Integrated, Secure Communication Network for Hartford HealthCare and UConn’s School of Medicine Residency Program Hartford HealthCare and the University of Connecticut’s School of Medicine Residency rely on TigerText to stay HIPAA-complaint, coordinate care, and facilitate secure communication between its staff and resident physicians across five major health care facilities. SANTA MONICA, CA (September
- [News _ September 10, 2013](https://www.nlvpartners.com/news-_-september-10-2013-6/) - Catalyst Pharmaceutical Partners, Inc. Closes Previously Announced $15.1 Million Registered Direct Offering CORAL GABLES, Fla., Sept. 10, 2013 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) today reported that it has closed its previously announced offering of 8.8 million shares of its common stock in a registered direct public offering. The offering price was $1.72
- [News | September 10, 2013](https://www.nlvpartners.com/news-september-10-2013-5/) - MEI Pharma Acquires PWT143, A Highly Selective PI3-Kinase Delta Inhibitor Acquisition Expands Pipeline of Drug Candidates, Footprint in Hematologic Cancers San Diego – September 10, 2013 - MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that it has acquired exclusive worldwide rights to
- [News | September 10, 2013](https://www.nlvpartners.com/news-september-10-2013-4/) - Relypsa Reports Positive Top-Line Results for the First Part of Its Two-Part Pivotal Phase 3 Trial of Patiromer Redwood City, CA, September 10, 2013 – Relypsa, Inc., a clinical-stage biopharmaceutical company, today announced positive top-line results on both the primary and secondary efficacy endpoints of Part A, the patiromer treatment part, of its two-part pivotal
- [News | September 10, 2013](https://www.nlvpartners.com/news-september-10-2013-3/) - New Treato Pharma Release Brings Real-time "Patient Voice" Intelligence into the Executive Suite YEHUD, Israel, September 10, 2013 – Treato, the source of "patient voice" intelligence from across the social web, today announced the new version of its flagship Treato Pharma platform for pharmaceutical companies and agencies. Treato's proprietary big data technology platform extracts real-time
- [News | September 10, 2013](https://www.nlvpartners.com/news-september-10-2013-2/) - Durata Therapeutics Presents New Pivotal Phase 3 Clinical Results and New In Vitro Data on Dalbavancin at ICAAC DENVER, Sept. 10, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today presented clinical trial results from its two Phase 3 DISCOVER ("Dalbavancin for Infections of the Skin COmpared to Vancomycin at an Early Response") 1 and
- [News | September 9, 2013](https://www.nlvpartners.com/news-september-9-2013-3/) - Afferent Pharmaceuticals Reports Positive Phase 2 Clinical Data for the Company’s Lead P2X3 Antagonist, AF-219 - Study Showed AF-219 Reduced Daytime Cough Frequency by 75% in Patients with Treatment-Refractory Chronic Cough - New Findings Featured in Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Annual Congress 2013 in Barcelona, Spain - AF-219 Also Being
- [News  | September 9, 2013](https://www.nlvpartners.com/news-september-9-2013-2/) - New Leaf Venture Partners Affirms Its Support of Roumell Asset Management’s Letter to Transcept Pharmaceuticals' Board New York, NY September 9, 2013 – New Leaf Venture Partners (NLV Partners) announced that the Company has submitted today a letter to the Board of Directors of Transcept Pharmaceuticals, Inc., concurring with a 13D filing by Roumell Asset
- [News | August 14, 2013](https://www.nlvpartners.com/news-august-14-2013-2/) - Korea Approves NeuroStar TMS for Treating Depression Neuronetics Partners with BR Holdings to Make Non-Invasive, Non-Drug Treatment System Available to 50 Million People MALVERN, PA, August 14, 2013 – Neuronetics, Inc., the established market leader in Transcranial Magnetic Stimulation technology for the treatment of Major Depressive Disorder, announced today that the South Korea Ministry of
- [News | June 10, 2013](https://www.nlvpartners.com/news-june-10-2013-2/) - Pearl Therapeutics to be Acquired by AstraZeneca for up to $1.15 Billion REDWOOD CITY, CALIF., June 10, 2013 - Pearl Therapeutics Inc. today announced that it has entered into a definitive merger agreement under which the Company will be acquired by AstraZeneca. The acquisition will bring together Pearl’s pipeline of inhaled bronchodilator products for the
- [News | May 22, 2013](https://www.nlvpartners.com/news-may-22-2013-2/) - Direct Flow Medical Transcatheter Aortic Valve System Demonstrates Excellent 30 Day Outcomes Following Full Enrollment of DISCOVER CE Mark Trial Results Presented in Oral Presentation at EuroPCR PARIS, France, May 22, 2013 – Direct Flow Medical®, Inc., a transcatheter heart valve innovator focused on improving patient outcomes, today announced that it has met its primary
- [News | May 16, 2013](https://www.nlvpartners.com/news-may-16-2013-2/) - Direct Flow Medical® Receives IDE Approval for U.S. Salus Trial of Transcatheter Aortic Heart Valve System SANTA ROSA, Calif., May 16, 2013 – Direct Flow Medical®, Inc., a transcatheter heart valve company focused on improving patient outcomes, today announced that it has received approval from the United States Food and Drug Administration (FDA) for an
- [News | May 13, 2013](https://www.nlvpartners.com/news-may-13-2013-2/) - Relypsa Completes Patient Enrollment in Pivotal Phase 3 Program for the Treatment of Hyperkalemia Redwood City, CA, May 13, 2013 – Relypsa, Inc., a clinical-stage biopharmaceutical company, today announced that the company has completed enrollment of its pivotal phase 3 program of patiromer for the treatment of hyperkalemia in patients with chronic kidney disease (CKD).
- [News | April 11, 2013](https://www.nlvpartners.com/news-april-11-2013-2/) - Chimerix Announces Pricing of Initial Public Offering RESEARCH TRIANGLE PARK, N.C., April 11, 2013 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, announced today the pricing of its initial public offering of 7,320,000 shares of its common stock at a price to the
- [News | April 10, 2013](https://www.nlvpartners.com/news-april-10-2013-2/) - MEI Pharma’s Mitochondrial Inhibitor Drug Candidate ME-344 Delays Tumor Growth in Recurrent Ovarian Cancer Model New Pre-Clinical Data Presented at AACR Annual Meeting in Washington, DC San Diego – April 10, 2013 - MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced the presentation of
- [News | March 19, 2013](https://www.nlvpartners.com/news-march-19-2013/) - NeuroStar TMS Therapy, a Non-Drug Depression Treatment, Demonstrates Statistically Significant Benefits on Patient-Reported Pain Outcomes Study Participants Experienced Improvement in Pain and Well-Being that Persisted Through One Year SAN DIEGO, March 19, 2013 – New data released today at the annual meeting of the American Academy of Neurology show that transcranial magnetic stimulation (TMS) administered
- [News | February 25, 2013](https://www.nlvpartners.com/news-february-25-2013/) - ReShape Medical Completes Enrollment of Pivotal Clinical Trial for Weight Loss Device SAN CLEMENTE, CA – February 25, 2013 – ReShape Medical® Inc announced today that it has completed enrollment in the pivotal clinical trial for the ReShape Duo® Intragastric Balloon, one of the first non-surgical weight loss devices developed for the U.S. market. The
- [News | February 25, 2013](https://www.nlvpartners.com/news-february-25-2013-2/) - Durata Therapeutics Announces Preliminary, Topline Phase 3 Clinical Trial Results for Dalbavancin in the Treatment of ABSSSI DISCOVER 2 Study Meets Primary & Secondary Endpoints Conference Call and Webcast Today at 8:30 A.M. EST to Discuss Results CHICAGO, Feb. 25, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today announced preliminary, top-line results for its
- [Portfolio News | April 12, 2007](https://www.nlvpartners.com/portfolio-news-april-12-2007/) - Affymax(R) Announces Results From Phase 2 Clinical Trial of Hematide(TM) for the Treatment of Anemia in Dialysis Patients PALO ALTO, Calif., Apr 12, 2007 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) today announced that results available from its Phase 2 clinical trial of Hematide(TM) dosed monthly in dialysis patients were presented this week at the National
- [News | August 18, 2015](https://www.nlvpartners.com/news-august-18-2015-•-2/) - Intarcia Announces New Top-Line Phase 3 Results for Investigational Therapy ITCA 650 in Type 2 Diabetes: Freedom-2 Comparative Trial Demonstrates Superior & Sustained Glucose Control and Weight Reduction vs Januvia Over 52 Weeks • Patients treated with ITCA 650 60mcg experienced superior reductions in HbA1c versus those treated with Januvia® (sitagliptin) 100mg (-1.5% versus -0.8%;
- [News | September 21, 2015](https://www.nlvpartners.com/news-september-21-2015-2/) - Waltham, MA | Sep 21, 2015 Deciphera Pharmaceuticals Announces $75 Million Series B Financing to Advance Novel Oncology Pipeline Multiple Clinical Programs for Switch Control Kinase Inhibitor Drug Candidates to Reach Key Milestones in Next 12 months Deciphera Pharmaceuticals, a clinical-stage biotechnology company focused on developing advanced kinase inhibitor treatments targeting the tumor cell and
- [News | September 17, 2015](https://www.nlvpartners.com/news-september-17-2015-•-2/) - Dimension Therapeutics Announces FDA Fast Track Designation for Lead Candidate DTX101 in Patients with Hemophilia B CAMBRIDGE, MASS, September 17, 2015 – Dimension Therapeutics, Inc. (“Dimension” or the “Company”), a leading gene therapy platform company focused on discovering and developing new therapeutic products for people living with rare diseases associated with the liver, today announced that the
- [News | December 23, 2013](https://www.nlvpartners.com/news-december-23-2013/) - European Medicines Agency Accepts Marketing Authorization Application for Dalbavancin CHICAGO, Dec. 23, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today announced that the European Medicines Agency (EMA) has accepted for review a Marketing Authorization Application (MAA) for dalbavancin. Durata is seeking approval for the marketing and sale of dalbavancin for the treatment of patients
- [News | October 6, 2015](https://www.nlvpartners.com/news-october-6-2015/) - Edge Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Over-Allotment Option BERKELEY HEIGHTS, N.J., Oct. 06, 2015 (GLOBE NEWSWIRE) -- Edge Therapeutics, Inc. (Nasdaq:EDGE) (“Edge”) today announced the closing of its initial public offering of 8,412,423 shares of its common stock at an initial public offering price of $11.00 per share, before
- [News | October  1, 2015](https://www.nlvpartners.com/news-october-1-2015/) - Versartis Presents Confirmatory 18-Month Data From Ongoing Somavaratan Extension Study at Late-Breaker Session at ESPE Annual Meeting Data From Ongoing Pediatric Extension Study Confirms Dose Used in VELOCITY Phase 3 Trial Provides Stable Second Year Growth Rates and Similar Safety Profile to Daily Treatment MENLO PARK, Calif., Oct. 1, 2015 (GLOBE NEWSWIRE) -- Versartis, Inc.
- [News | September 28, 2015](https://www.nlvpartners.com/news-september-28-2015/) - Afferent Pharmaceuticals Announces Positive Results in Phase 2b Chronic Cough Trial AF-219 Treatment Significantly Reduces Cough Frequency in Patients SAN MATEO, Calif.—September 28, 2015 — Afferent Pharmaceuticals, a leader in the development of small molecule compounds targeting P2X3 for the treatment of poorly managed and common neurogenic disorders, such as chronic cough, today announced positive top-line results
- [News | September 18, 2015](https://www.nlvpartners.com/september-18-2015/) - Versartis Announces Confirmatory 18-Month Data From Ongoing Extension Study of Somavaratan in GHD Children Late-Breaking Data Show 3.5 mg/kg Twice-Monthly Dosing Increased Mean Peak IGF-I SDS and Stabilized 12 to 18 Month Mean Height Velocity While Maintaining Safety Profile MENLO PARK, Calif., Sept. 18, 2015 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company
- [News | September 16, 2015](https://www.nlvpartners.com/news-september-16-2015/) - September 16, 2015 Intarcia Presents Results from Two Successful Phase 3 Trials for ITCA 650, Its Investigational Therapy in Type 2 Diabetes, at 51st EASD Both Phase 3 clinical trials (FREEDOM-1 and FREEDOM-1 HBL) met the primary and secondary clinical endpoints, with significant and clinically meaningful reductions in blood glucose levels, weight reduction, and percent
- [News | September 17, 2015](https://www.nlvpartners.com/news-september-17-2015/) - Kyruus Raises $25 million to Accelerate Market Adoption of Its Patient Access Platform for Hospital Systems by Kyruus, on Sep 17, 2015 8:30:00 AM SaaS-Based Referral Coordination Platform Addresses Unmet Patient Access Needs Kyruus, a leading enterprise software company that helps hospitals optimize patient access and referral management, has raised $25 million in funding to
- [News | September 10, 2015](https://www.nlvpartners.com/news-september-10-2015/) - Versartis Initiates Phase 2 Trial (VITAL) of Monthly Somavaratan in Adults With Growth Hormone Deficiency MENLO PARK, Calif., Sept. 10, 2015 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting form of recombinant human growth hormone (rhGH) for growth hormone deficiency (GHD), today announced the initiation
- [News | September 2, 2015](https://www.nlvpartners.com/news-september-2-2015/) - Holyoke Medical Center Selects QPID Health for Quality Initiative Hospital will use QPID Health technology to expedite review and improve care for behavioral health patients at risk for revolving emergency visits and readmissions Boston – September 2, 2015 – QPID Health, which helps hospitals and medical groups achieve their quality goals with software that locates
- [News | August 26, 2015](https://www.nlvpartners.com/news-august-26-2015/) - ReShape Medical, Inc. Completes $38 Million Series D Financing Round Led by HealthCor Partners Management, L.P. and Endeavour Vision SA to Support U.S. Commercialization of ReShape™ Integrated Dual Balloon System Following Recent Approval by the FDA SAN CLEMENTE, Calif., August 26, 2015 – ReShape Medical® today announced that it has completed a Series D financing
- [News | August 19, 2015](https://www.nlvpartners.com/news-august-19-2015/) - Edge Therapeutics Reports Positive Top-Line Phase 1/2 NEWTON Trial Results of EG-1962 in Aneurysmal Subarachnoid Hemorrhage - Efficacy results show 60% favorable outcome vs. only 28% for standard of care - EG-1962 met primary and secondary safety endpoint targets BERKELEY HEIGHTS, N.J. – August 19, 2015 – Edge Therapeutics, Inc. (the “Company”) today announced that
- [News | August 18, 2015](https://www.nlvpartners.com/news-august-18-2015/) - WAVE Life Sciences Raises $66 Million in Series B Financing - Genetic medicine company continues to expand breadth of potential therapeutic applications for novel stereopure synthetic chemistry platform to treat rare diseases - Pipeline to span multiple modalities, including RNAi, antisense and exon-skipping, among others BOSTON, Mass., August 18, 2015 – WAVE Life Sciences, a
- [News | August 11, 2015](https://www.nlvpartners.com/news-august-11-2015/) - QPID Health to Deploy at Providence Health & Services Health system to implement QPID Health to support quality improvement initiatives Boston – August 11, 2015 – QPID Health, which helps hospitals and medical groups complete quality and registry reporting more efficiently and thoroughly, today announced that Providence Health & Services has selected QPID Health’s software
- [News | August 10, 2015](https://www.nlvpartners.com/news-august-10-2015/) - Relypsa Enters Two-Year Detailing Agreement With Sanofi in the United States REDWOOD CITY, Calif., Aug. 10, 2015 (GLOBE NEWSWIRE) -- Relypsa Inc. (NASDAQ:RLYP), a biopharmaceutical company, today announced it has entered a two-year detailing agreement with Sanofi for Patiromer for Oral Suspension (Patiromer FOS). Patiromer FOS is Relypsa's investigational medicine that is currently under review
- [News | August 5, 2015](https://www.nlvpartners.com/news-august-5-2015/) - New App Helps Consumers Find More Ways to Save on Prescription Drugs OneRx® is the First App to Provide Instant Access to Co-pays, Coupons and Discounts to Reduce Patients' Rx Costs NEW YORK - WEDNESDAY, AUGUST 5, 2015 - As prescription prices and out-of-pocket costs continue to skyrocket, newly launched app OneRx enables consumers to
- [News | July 23, 2015](https://www.nlvpartners.com/news-july-23-2015/) - Chimerix Announces Positive Topline Results From Brincidofovir Pivotal Study in Animal Model for Smallpox Data Demonstrated Statistically Significant Survival Benefit DURHAM, N.C., July 23, 2015 (GLOBE NEWSWIRE) -- Chimerix, Inc. (NASDAQ:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced that its investigational antiviral brincidofovir showed a survival
- [News | July 28, 2015](https://www.nlvpartners.com/news-july-28-2015/) - FDA Approves The ReShape™ Integrated Dual Balloon System, a First-Of-Its-Kind Non-Surgical Weight Loss Procedure for People with Mild to Moderate Obesity - Next generation dual balloon designed to create a feeling of fullness while providing patient comfort and safety - Proven to provide more than twice the weight loss of diet and exercise alone -
- [Portfolio News | March 22, 2012](https://www.nlvpartners.com/portfolio-news-march-22-2012/) - Durata Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering MORRISTOWN, NJ — (BUSINESS WIRE) — March 22, 2012 — Durata Therapeutics, Inc. announced today that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission relating to the proposed initial public offering of its common stock. BofA Merrill
- [News | July 8, 2015](https://www.nlvpartners.com/news-july-8-2015/) - Afferent Pharmaceuticals Raises $55 Million in Oversubscribed Crossover Financing - Funds to advance pipeline, and clinical lead AF-219 for the treatment of pathologic cough, including in idiopathic pulmonary fibrosis (IPF) patients - SAN MATEO, Calif.—July 8, 2015 — Afferent Pharmaceuticals, a leader in the development of novel small molecule drugs for the treatment of neurogenic
- [News | July 22, 2015](https://www.nlvpartners.com/news-july-22/) - QPID Health sequences the “digital DNA” in your health record Alvin Yu, MD, Clinical Content Engineer - July 22, 2015 - As an engineer turned physician who returned to engineering as a QPID clinical content engineer (yes, it’s confusing!), I’ve been fielding a lot of questions from friends and family about the exciting problems our
- [News | July 28, 2015](https://www.nlvpartners.com/new-july-28-2015/) - FDA Approves The ReShape™ Integrated Dual Balloon System, a First-Of-Its-Kind Non-Surgical Weight Loss Procedure for People with Mild to Moderate Obesity - Next generation dual balloon designed to create a feeling of fullness while providing patient comfort and safety - Proven to provide more than twice the weight loss of diet and exercise alone -
- [New Leaf News | September 9, 2013](https://www.nlvpartners.com/new-leaf-news-september-9-2013/) - New Leaf Venture Partners Affirms Its Support of Roumell Asset Management’s Letter to Transcept Pharmaceuticals' Board New York, NY September 9, 2013 – New Leaf Venture Partners (NLV Partners) announced that the Company has submitted today a letter to the Board of Directors of Transcept Pharmaceuticals, Inc., concurring with a 13D filing by Roumell Asset
- [New Leaf News | April 30, 2012](https://www.nlvpartners.com/new-leaf-news-april-30-2012/) - New Leaf Venture Partners’ Liam Ratcliffe, M.D., Ph.D., Elected to Array BioPharma’s Board of Directors New York, NY, April 30, 2012 –New Leaf Venture Partners (NLV Partners) announced today that General Partner Liam Ratcliffe, M.D., Ph.D., has been elected as Independent Director to the Board of Directors of Array BioPharma Inc. Dr. Ratcliffe has extensive
- [New Leaf News | January 7, 2011](https://www.nlvpartners.com/new-leaf-news-january-7-2011/) - New Leaf Venture Partners Names Reza Zadno, Ph.D., as Venture Partner NEW YORK--(BUSINESS WIRE)-- New Leaf Venture Partners (NLV Partners) announced today the appointment of Reza Zadno, Ph.D., as venture partner, effective immediately. Dr. Zadno was the founder, president and CEO of Visiogen (now part of Abbott Medical Optics) and, following the company’s acquisition by
- [New Leaf News | January 16, 2009](https://www.nlvpartners.com/new-leaf-news-january-16-2009/) - New Leaf Venture Partners Appoints Dr. Srinivas Akkaraju as Managing Director and Lead of the Firm’s West Coast Biopharmaceuticals Practice NEW YORK--(BUSINESS WIRE)-- New Leaf Venture Partners (NLV Partners) announced today the appointment of Srinivas Akkaraju, M.D., Ph.D., as Managing Director and lead of NLV Partners’ West Coast biopharmaceuticals practice. Dr. Akkaraju’s appointment is effective
- [New Leaf News | September 2, 2008](https://www.nlvpartners.com/new-leaf-news-september-2-2008/) - New Leaf Venture Partners Expands Leadership Team, Naming Liam Ratcliffe, M.D., Ph.D., as Venture Partner NEW YORK--(BUSINESS WIRE)—Sept. 2, 2008 -- New Leaf Venture Partners (NLV Partners) announced today the appointment of Liam Ratcliffe, M.D., Ph.D., as venture partner. Dr. Ratcliffe recently served as Senior Vice President and Global Head of Clinical Research and Development
- [New Leaf News | October 10, 2007](https://www.nlvpartners.com/new-leaf-news-october-10-2007/) - New Leaf Venture Partners Closes $450 Million Healthcare Fund NEW YORK & MENLO PARK, Calif.--Oct. 10, 2007--New Leaf Venture Partners, L.L.C. ("NLV Partners") today announced the closing of New Leaf Ventures II, L.P. ("NLV-II"), a $450 million venture capital fund dedicated to healthcare technologies. With strong support from existing investors and a limited number of
- [New leaf News | April 16, 2007](https://www.nlvpartners.com/new-leaf-news-april-16-2007/) - New Leaf Venture Partners Names Milton B. McColl, M.D. as Venture Partner NEW YORK & MENLO PARK, Calif. – April 16, 2007 – New Leaf Venture Partners (NLV Partners) announced today the appointment of Milton B. McColl, M.D. as a venture partner. Dr. McColl most recently served as President of Boston Scientific’s Neurovascular division. Dr.
- [New Leaf News | August 9, 2005](https://www.nlvpartners.com/new-leaf-news-august-9-2005/) - New Leaf Venture Partners Closes $310 Million Healthcare Fund; Focus on Clinical-Stage Biopharmaceutical Products, Early-Stage Medical Devices, and Molecular Diagnostics NEW YORK & MENLO PARK, Calif. Aug. 9, 2005 -- New Leaf Venture Partners (NLV Partners) announced today that the company has closed a $310 million venture capital fund dedicated to healthcare technologies. The company
- [Portfolio News | August 2, 2006](https://www.nlvpartners.com/portfolio-news-august-2-2006/) - Cerexa Reports Positive Top-Line Results for Phase 2 Clinical Trial of Ceftaroline Broad-Spectrum Anti-Infective Achieves Excellent Clinical, Microbiological Cure Rates for cSSSI Compared to Standard Therapy ALAMEDA, Calif., Aug. 2, 2006 -- Cerexa Inc. today announced positive top-line results for the Phase 2 clinical trial of Ceftaroline for the treatment of complicated skin and skin
- [Portfolio News | March 14, 2012](https://www.nlvpartners.com/portfolio-news-march-14-2012/) - Neuronetics Announces NeuroStar TMS Therapy Will be Featured On The Dr. Oz Show Segment to air during March 14th episode Watch: Part 1 Part 2 Neuronetics, Inc. is pleased to announce that TMS (transcranial magnetic stimulation) Therapy will be featured on an upcoming episode of The Dr. Oz Show. The episode, which is scheduled to
- [Portfolio News | September 22, 2008](https://www.nlvpartners.com/portfolio-news-september-22-2008/) - NxStage Named Fastest Growing Company in Massachusetts LAWRENCE, Mass., Sept. 22 /PRNewswire-FirstCall/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced that for the second consecutive year it has been recognized as the Fastest Growing Company in Massachusetts by the Boston Business Journal. NxStage's Chief Executive Officer, Jeffrey H.
- [Portfolio News | May 1, 2008](https://www.nlvpartners.com/portfolio-news-may-1-2008/) - FDA Calls for Physician Action in Reporting Adverse Drug Events (ePocrates) Agency Taps Epocrates to Educate Clinicians on Importance and Ease of Reporting SAN MATEO, CALIF., - May 1, 2008 - Adverse drug events (ADEs) occur commonly in the healthcare system with more than 100,000 hospitalized patients experiencing fatal drug reactions, according to estimates1. The
- [Portfolio News | December 19, 2007](https://www.nlvpartners.com/portfolio-news-december-19-2007/) - Prometheus Laboratories Plans IPO NEW YORK - 12.19.07 - Prometheus Laboratories Inc., which is developing diagnostic tests and drugs to help doctors individualize patient care, plans an initial public offering of common stock, according to a Securities and Exchange Commission filing Wednesday. The San Diego-based company did not disclose the expected size or price range
- [Portfolio News | July 16, 2007](https://www.nlvpartners.com/portfolio-news-july-16-2007/) - Affymax® Announces Phase 3 Development Plan for Hematide™ PALO ALTO, Calif., Jul 16, 2007 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) today announced that it plans to initiate Phase 3 clinical studies with Hematide(TM) in chronic renal failure patients following recent discussions with the United States Food and Drug Administration (FDA) on the design of the
- [Portfolio News | April 12, 2007](https://www.nlvpartners.com/portfolio-news-april-12-2007-2/) - Intarcia Therapeutics Announces Final Results From A Phase 2 Study Of Injectable Omega Interferon plus Ribavirin for the Treatment of Hepatitis C Genotype-1 Potent synergy, activity and patient tolerance support development of Omega DUROS® continuous delivery therapy Barcelona, Spain — April 12, 2007 — Intarcia Therapeutics, Inc., a privately held biopharmaceutical company, today announced final
- [Portfolio News | March 27, 2007](https://www.nlvpartners.com/portfolio-news-march-27-2007/) - Barrier Therapeutics Announces Azoline (Pramiconazole) Dose Ranging Study in Tinea Versicolor Meets Primary and Secondary Endpoints Oral Formulation of Novel Antifungal Agent Shown to Be Highly Effective PRINCETON, NJ, Mar 27, 2007 (MARKET WIRE via COMTEX News Network) -- Barrier Therapeutics, Inc. (NASDAQ: BTRX), a pharmaceutical company that develops and markets dermatology products, today announced
- [Portfolio News | March 8, 2007](https://www.nlvpartners.com/portfolio-news-march-8-2007/) - Barrier Therapeutics Receives Regulatory Approval to Market Xolegel(TM) in Canada PRINCETON, NJ, Mar 08, 2007 (MARKET WIRE via COMTEX News Network) -- Barrier Therapeutics, Inc. (NASDAQ: BTRX), a pharmaceutical company that develops and markets dermatology products, today announced that Health Canada's Therapeutic Products Directorate granted marketing approval to Xolegel(TM) (ketoconazole, topical gel, 2% w/w) for
- [Portfolio News | February 8, 2007](https://www.nlvpartners.com/portfolio-news-february-8-2007/) - ISTA Pharmaceuticals Announces Positive Preliminary Xibrom(TM) Once-daily Formulation Clinical Results From U.S. Phase III Trials IRVINE, Calif., Feb. 8 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), today announced highly statistically significant results from its initial analysis of the Company's U.S. Phase III clinical trials of Xibrom(TM) (bromfenac sodium ophthalmic solution) once-daily formulation. The multi-center studies
- [Portfolio News | February 7, 2007](https://www.nlvpartners.com/portfolio-news-february-7-2007/) - NxStage(R) Medical and DaVita Announce Agreement for Home Hemodialysis Using the NxStage System One(TM) LAWRENCE, Mass., Feb. 7 /PRNewswire-FirstCall/ -- NxStage Medical, Inc. (Nasdaq: NXTM), the manufacturer of the NxStage System One(TM) portable kidney dialysis machine, today announced a multi-year, national agreement with certain market rights, under which the two companies will collaborate on expanding
- [Portfolio News | December 20, 2006](https://www.nlvpartners.com/portfolio-news-december-20-2006/) - Affymax(R) Announces Completion of Common Stock Offering PALO ALTO, Calif., Dec 20, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Affymax, Inc. (Nasdaq: AFFY), a clinical-stage pharmaceutical company, today announced the completion of its initial public offering of 3.7 million shares of its common stock and the exercise by the underwriters of their option to purchase
- [Portfolio News | October 12, 2006](https://www.nlvpartners.com/portfolio-news-october-12-2006/) - eHealth, Inc. Announces Pricing of its Initial Public Offering of Common Stock MOUNTAIN VIEW, California - October 12, 2006 - eHealth, Inc. today announced the pricing of its initial public offering of 5,000,000 shares of common stock at a price of $14.00 per share. eHealth has also granted the underwriters a 30-day option to purchase
- [Portfolio News | May 19, 2006](https://www.nlvpartners.com/portfolio-news-may-19-2006/) - Quest Diagnostics to Acquire Focus Diagnostics, Inc., A World Leader in Infectious Disease Testing LYNDHURST, N.J., and HERNDON, Va., May 19 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, has agreed to acquire Focus Diagnostics, Inc., the premier infectious disease testing provider, in a cash transaction
- [Portfolio News | October 27, 2005](https://www.nlvpartners.com/portfolio-news-october-27-2005/) - NxStage Medical, Inc. Sets Price For Initial Public Offering Lawrence, MA – October 27, 2005 : NxStage Medical, Inc. today announced the initial public offering of 5,500,000 shares of its common stock at a price of $10.00 per share, before underwriting discounts and commissions. Shares of NxStage’s common began trading on the Nasdaq National Market
- [News | March 20, 2014](https://www.nlvpartners.com/news-march-20-2014/) - Kit Check Hires Elizabeth Thomas as Director of Marketing Washington, DC – March 20, 2014 - Kit Check™ (http://kitcheck.com), the leader in hospital pharmacy kit processing automation, today announced that healthcare industry executive Elizabeth Thomas has joined the company as Director of Marketing. Ms. Thomas joins Kit Check after five years with telehealth industry leader,
- [News | March 19, 2014](https://www.nlvpartners.com/news-march-19-2014/) - VaxInnate Begins Phase I Clinical Trial to Evaluate Quadrivalent Vaccine for Prevention of Seasonal Flu CRANBURY, NJ, March 19, 2014 – VaxInnate Corporation today announced that enrollment has commenced in a Phase 1 clinical trial to evaluate VAX2012Q, a recombinant quadrivalent vaccine in development for the prevention of seasonal influenza. VaxInnate is a biotechnology firm
- [News | March 11, 2014](https://www.nlvpartners.com/news-march-11-2014/) - Chimerix to Provide Brincidofovir to Josh Hardy as First Patient in New Open-Label Study in Patients With Adenovirus Infections Company Worked With FDA to Create Path Forward DURHAM, N.C., March 11, 2014 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX) today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) for the
- [News | February 26, 2014](https://www.nlvpartners.com/news-february-26-2014/) - Intarcia Appoints Jay Smith Head of Customer Experience & Outcomes Smith takes-on innovative CXO role to optimize customer experiences and consistently deliver the best possible outcomes for patients, payors and providers BOSTON, MA – February 26, 2014 – Intarcia Therapeutics, Inc. today formally announced the appointment of Jay Smith as Head of Customer Experience &
- [News | February 19, 2014](https://www.nlvpartners.com/news-february-19-2014/) - Optum Acquires Majority Interest in Audax Health Solutions Optum’s investment seeks to expand the breadth and reach of Audax’s multichannel digital platform, providing greater resources for consumers to better manage their health MINNEAPOLIS – (Feb. 19, 2014) – Optum and Audax Health Solutions, Inc., today announced that Optum has acquired a majority stake in Audax.
- [News | February 18, 2014](https://www.nlvpartners.com/news-february-18-2014/) - Versartis Secures $55 Million in Series E Financing REDWOOD CITY, CA - Feb 18, 2014 - Versartis, Inc., an endocrine-focused biopharmaceutical company that is developing a novel, long-acting form of recombinant human growth hormone (rhGH) for the treatment of growth hormone deficiency (GHD), today announced that it has completed a $55 million Series E financing.
- [News | February 13, 2014](https://www.nlvpartners.com/news-february-13-2014-2/) - Concert Pharmaceuticals Announces Pricing of Initial Public Offering LEXINGTON, Mass.-- Feb 13, 2014 --Concert Pharmaceuticals, Inc. today announced the pricing of its initial public offering of 6,000,000 shares of its common stock at a public offering price of $14.00 per share, before underwriting discounts. In addition, Concert has granted the underwriters a 30-day option to
- [News | January 28, 2014](https://www.nlvpartners.com/news-january-28-2014/) - VaxInnate Receives $2.1 million from New Jersey’s Technology Business Tax Certificate Transfer Program EDA LogoCRANBURY, NJ, January 28, 2014 – VaxInnate Corporation, a biotechnology firm pioneering a breakthrough technology platform for the development of novel vaccines, announced today that it has received $2.1 million in non-dilutive financing through New Jersey’s Technology Business Tax Certificate Transfer
- [News | January 27, 2013](https://www.nlvpartners.com/news-january-27-2013/) - TigerText Caps Record Year with $21 Million Series B Investment to Accelerate Market Penetration With sales more than quadrupling in 2013, company closes Series B funding for its secure, enterprise messaging solution. SANTA MONICA, CA (January 27, 2013) – TigerText, the leader in secure, real-time messaging for the enterprise, today announced it closed a $21
- [News | January 14, 2014](https://www.nlvpartners.com/news-january-14-2014/) - Spiracur Secures TGA Approval for SNaP Wound Care System and Announces Distribution Partnership in Australia Spiracur and AinsCorp Team up to Bring Proven, Advanced Wound Care System to Australia and New Zealand SUNNYVALE, Calif., Jan. 14, 2014 – Spiracur Inc., developer of the only mechanically powered advanced wound care solution with the proven efficacy of
- [News | January 9, 2014](https://www.nlvpartners.com/news-january-9-2014/) - Direct Flow Medical®, Inc. Completes Enrollment In U.S. Salus Feasibility Trial Of Transcatheter Aortic Heart Valve System SANTA ROSA, Calif., January 9, 2014 – Direct Flow Medical®, Inc., a transcatheter heart valve innovator focused on improving patient outcomes, today announced it has completed enrollment in the U.S. SALUS trial of the Direct Flow Medical Transcatheter
- [News | January 8, 2014](https://www.nlvpartners.com/news-january-8-2014/) - Convergence Pharmaceuticals and Consortium Partners Win European Commission FP7 Grant for the PROPANE Project Cambridge, UK, 8 January 2014: Convergence Pharmaceuticals Limited ("Convergence"), the company focused on the development of novel and high value analgesic medicines for the treatment of chronic pain, today announces the award of a prestigious Framework Project 7 (FP7) grant, worth
- [News | January 2, 2014](https://www.nlvpartners.com/news-january-2-2014/) - ZIO® Service Identifies Significantly More Cardiac Arrhythmias Than the Traditional Holter Monitor, According to Study Published Online in the American Journal of Medicine SAN FRANCISCO – January 2, 2014 – iRhythm Technologies, a healthcare information services company, today announced that a prospective study by Scripps Translational Science Institute (STSI) has found that use of the
- [News | December 19, 2013](https://www.nlvpartners.com/news-december-19-2013/) - Audax Health Names David Ko President and Chief Operating Officer WASHINGTON, D.C. (DECEMBER 19, 2013) — Audax Health, a digital health development company that empowers consumers to lead healthier lives, today announced that board member David Ko will assume the role of president and chief operating officer, effective immediately. Ko, who will be based in
- [News | December 18, 2013](https://www.nlvpartners.com/news-december-18-2013-2/) - US FDA Grants Orphan Drug Designation to Versartis’ Treatment for Growth Hormone Deficiency Redwood City, CA – December 18, 2013 – Versartis, Inc., an endocrine-focused biopharmaceutical company, has received US Food and Drug Administration (FDA) orphan drug designation for its product candidate VRS-317 for the treatment of growth hormone deficiency (GHD) at once-a-month dosing. The
- [News | December 9, 2013](https://www.nlvpartners.com/news-december-9-2013/) - Kit Check launches Anesthesia Check to automate Operating Room Syringe Labeling and Medication Tracking Orlando, FL – December 9, 2013 - Kit Check™, the leader in hospital pharmacy kit automation, today announced the launch of Anesthesia Check™, a new cloud-hosted software tool to manage and track medications in the operating room (OR). Anesthesia Check brings
- [News | December 3, 2013](https://www.nlvpartners.com/news-december-3-2013/) - Kit Check Announces a Pharmacy Kit Accelerator Program with No Cost for Software and Hardware Washington, DC – December 3, 2013 - Kit Check™ today announced the Pharmacy Kit Accelerator Program that provides pharmacy kit automation software and hardware free of charge. Users only purchase tags as needed to track medications. Kit Check pre-configures the
- [News | November 26, 2013](https://www.nlvpartners.com/news-november-26-2013/) - Durata Therapeutics Announces FDA's Acceptance for Priority Review of NDA for Dalvance™ (dalbavancin hydrochloride) CHICAGO, Nov. 26, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today announced that the New Drug Application (NDA) for its investigational drug, Dalvance™ (dalbavancin hydrochloride) for injection, has been accepted for priority review by the U.S. Food and Drug Administration
- [News | November 22, 2013](https://www.nlvpartners.com/news-november-22-2013/) - Oxford Immunotec Global PLC Announces Pricing of Initial Public Offering Oxford, UK and Marlborough, MA, November 22, 2013 – Oxford Immunotec Global PLC (NASDAQ: OXFD) (the "Company") announced today that its initial public offering of 5,360,000 ordinary shares priced at $12.00 per share. The Company has granted the underwriters the option to purchase up to
- [News | November 14, 2013](https://www.nlvpartners.com/new-november-14-2013/) - Relypsa, Inc. Announces Pricing of Initial Public Offering REDWOOD CITY, Calif., Nov. 14, 2013 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a clinical-stage biopharmaceutical company, today announced the pricing of its initial public offering of 6,850,000 shares of its common stock at a price to the public of $11.00 per share. The shares are expected to
- [News | November 7, 2013](https://www.nlvpartners.com/news-november-7-2013/) - ReShape Medical® Successfully Meets Endpoints in Weight Loss Device Pivotal Trial ReShape Duo® is First to Achieve Important Milestone in the U.S. SAN CLEMENTE, CA, November 7, 2013 –ReShape Medical,® Inc. today announced that its REDUCE Trial for the ReShape Duo® Intragastric Balloon, a non-surgical treatment for weight loss, has met its primary efficacy endpoints.
- [News | November 5, 2013](https://www.nlvpartners.com/news-november-5-2013/) - Karyopharm Therapeutics Announces Pricing of Initial Public Offering NATICK, Mass., Nov. 5, 2013 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company focused on developing novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, today announced the pricing of its initial public offering of 6,800,000 shares
- [News | October 29, 2013](https://www.nlvpartners.com/news-october-29-2013/) - Direct Flow Medical® Transcatheter Aortic Valve System Continues To Demonstrate Excellent Outcomes at Six Months in Discover CE Mark Trial Results Featured in Oral Presentation at 25th Annual Transcatheter Cardiovascular Therapeutics (TCT) Conference SAN FRANCISCO, Calif., October 29, 2013 – Direct Flow Medical®, Inc., a transcatheter heart valve innovator focused on improving patient outcomes, today
- [News | October 23, 2013](https://www.nlvpartners.com/news-october-23-2013/) - Advanced Cell Diagnostics and Kindstar Global Announce Partnership to Launch Cancer Diagnostic Tests in China HAYWARD, CA & WUHAN, CHINA, Oct. 23, 2013—Advanced Cell Diagnostics, Inc. (ACD) and Kindstar Global (Kindstar) today announced that Kindstar will begin validating and implementing ACD’s RNAscope® technology-based molecular diagnostic assays in its clinical laboratories. The initial suite of tests
- [News | October 17, 2013](https://www.nlvpartners.com/news-october-17-2013/) - Relypsa Reports Positive Topline Results for its 52-Week Phase 2b Trial of Patiromer Redwood City, CA, October 17, 2013 – Relypsa, Inc., a clinical-stage biopharmaceutical company, today announced that its Phase 2b trial studying the safety and efficacy of patiromer as a treatment for hyperkalemia has met the primary efficacy endpoint for the trial. Additionally,
- [News | October 14, 2013](https://www.nlvpartners.com/news-october-14-2013-2/) - Spiracur and Century Medical Announce Multiple SNaP System Sales in Japan After Ministry of Health, Labor and Welfare Grants Reimbursement Proven Advanced Wound Care Device Offers Patients in Japan Effective, Non-powered Treatment for Chronic, Acute Wounds; Improves Quality of Life SUNNYVALE, Calif., and TOKYO, Oct. 14, 2013 – Spiracur Inc. and Century Medical, Inc. (CMI)
- [News | October 8, 2013](https://www.nlvpartners.com/news-october-8-2013/) - Chimerix Announces Proposed Public Offering of Common Stock All Shares to be Sold by Existing Shareholders DURHAM, N.C., Oct. 8, 2013 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced that it has filed a registration statement with the U.S. Securities and
- [News | October 3, 2013](https://www.nlvpartners.com/news-october-3-2013/) - TigerText Goes Freemium; Launches Next Generation of its Secure Enterprise Messaging App for BYOD Fourth-generation TigerText app allows anyone to instantly create their own enterprise messaging mobile network; More than 10,000 businesses already signed up. SANTA MONICA, CA (October 3, 2013) – TigerText, the leader in secure, real-time messaging for the enterprise, today introduced its
- [News | October 2, 2013](https://www.nlvpartners.com/news-october-2-2013/) - Treato Expands US Presence and Leadership Team with New Senior Executive Hires Healthcare Industry Veterans, Ezra Ernst and Gerhard Gallwitz, Join Treato Management Team to Accelerate Company US Growth YEHUD, Israel, October 2, 2013 /PRNewswire/ -- Treato, the source of "patient voice" intelligence from across the social web, today announced the appointment of healthcare industry
- [News | September 26, 2013](https://www.nlvpartners.com/news-september-26-2013/) - Chimerix Announces Publication of Positive Phase 2 Results of Brincidofovir (CMX001) in the New England Journal of Medicine Phase 2 Trial Evaluated Brincidofovir for the Prevention of Cytomegalovirus (CMV) Infection in Hematopoietic Cell Transplant Recipients DURHAM, N.C., Sept. 26, 2013 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas
- [News | September 25, 2013](https://www.nlvpartners.com/news-september-25-2013/) - Transcept And Shin Nippon Biomedical Laboratories Announce Global Licensing Agreement For Advanced Acute Migraine Treatment TO-2070 is new migraine treatment with a profile promising meaningful therapeutic advantages in an easy-to-use, self-administered dosage form POINT RICHMOND, Calif. and TOKYO, Sept. 25, 2013 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. (NASDAQ: TSPT), and Shin Nippon Biomedical Laboratories, Ltd ("SNBL"),
- [News | September 24, 2013](https://www.nlvpartners.com/news-september-24-2013-2/) - Chronic Wounds and High Risk Surgical Incisions Successfully Treated with Spiracur’s Ultraportable Negative Pressure Wound Therapy System Research Presented at SAWC Highlights Value of Spiracur’s Proprietary SNaP System for Optimized Healing SUNNYVALE, Calif., September 24, 2013 – Spiracur Inc., developer of the only mechanically powered advanced wound care solution with the proven efficacy of Negative
- [News | September 23, 2013](https://www.nlvpartners.com/news-september-23-2013/) - NxStage Introduces Web-Based Dosing Calculator Automated online tool helps physicians to prescribe hemodialysis treatment plans designed to fit patients' lifestyles LAWRENCE, Mass., Sept. 23, 2013 /PRNewswire/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced the immediate availability of the NxStage Dosing Calculator. Designed for use with the NxStage®
- [News | September 18, 2013](https://www.nlvpartners.com/news-september-18-2013/) - Oxford Immunotec Wins Place Again on The Sunday Times Hiscox Tech Track 100 Oxford, UK and Marlborough, MA; 18 September 2013 – Oxford Immunotec has been awarded a place on the prestigious Sunday Times Tech Track 100 league table for the second year running. Ranking Britain's 100 private technology companies with the fastest-growing sales over
- [News | September 11, 2013](https://www.nlvpartners.com/news-september-11-2013/) - Chimerix Presents Brincidofovir (CMX001) Adenovirus Phase 2 Results Positive Phase 2 Study Results Presented as Late Breaker at ICAAC DURHAM, N.C., Sept. 11, 2013 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced the results from its exploratory Phase 2 Study 202
- [News | September 10, 2013](https://www.nlvpartners.com/news-september-10-2013/) - First Patient Enrolls in U.S. Salus Trial Evaluating Direct Flow Medical® Transcatheter Aortic Heart Valve System SANTA ROSA, Calif., September 10, 2013 - Direct Flow Medical®, Inc., a transcatheter heart valve company focused on improving patient outcomes, today announced the first patient enrollment in the U.S. SALUS clinical trial. The trial will study the Direct
- [News | September 9, 2013](https://www.nlvpartners.com/news-september-9-2013/) - Chimerix Initiates Phase 3 SUPPRESS Trial of Brincidofovir (CMX001) for Prevention of CMV in HCT Recipients DURHAM, N.C., Sept. 9, 2013 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced initiation of dosing in the Phase 3 SUPPRESS trial (ClinicalTrials.gov ID: NCT01769170).
- [News | September 6, 2013](https://www.nlvpartners.com/news-september-6-2013/) - Whisper App User Engagement Jumps 140% with TigerText’s In-App Messaging Anonymous Confession App, Whisper Increases User Engagement and Improves Retention by 50% after Integrating TigerText’s Secure Messaging API, TigerConnect SANTA MONICA, CA (September 6, 2013) – TigerText, the leader in secure, real-time messaging for the enterprise, today announced popular anonymous confession app, Whisper saw a
- [News | August 27, 2013](https://www.nlvpartners.com/news-august-27-2013/) - IlluminOss Medical Appoints Dwayne Montgomery as Senior VP of Sales and Marketing Industry Veteran has Proven Track Record of Delivering Revenue Gains within Highly Competitive Orthopedic, Spine, and Cardiac Markets East Providence, RI. (August 27, 2013) – IlluminOss Medical, a privately held commercial stage medical device company in East Providence, Rhode Island, today announced that
- [News | August 22, 2013](https://www.nlvpartners.com/news-august-22-2013/) - TigerText Sees Record Growth in First Half of 2013; Number of Paid Users Quadruples as Enterprise and Healthcare Adoption Jumps Secure Messaging Company’s Success Fueled by Market Acceleration and Recognized Leadership Position; Company Added More Than 1,500 facilities in First 6 Months of 2013; New Customers Include Hoag Health Network, Adventist Health and Doylestown Hospital.
- [News | August 15, 2013](https://www.nlvpartners.com/news-august-15-2013/) - TigerText Expands Partnership with AMiON; Provides Healthcare Professionals with Easier and More Secure Way to Coordinate Care Updated integration now enables AMiON and TigerText users to quickly view their on-call schedules, contact colleagues, and view other department schedules within the TigerText secure messaging app SANTA MONICA, CALIF. (August 15, 2013) – TigerText, the leader in
- [News | August 14, 2013](https://www.nlvpartners.com/news-august-14-2013/) - Chimerix Announces Top Line Data From CMX001 Phase 2 Adenovirus Study and Late-Breaker Presentation at ICAAC -Encouraging results from the first proof-of-concept study for adenovirus infection support continued clinical development of CMX001 as a first-in-class broad-spectrum antiviral for prevention of double-stranded DNA viral infections -Data accepted for oral late-breaker presentation at the ICAAC Annual Meeting
- [News | July 16, 2013](https://www.nlvpartners.com/news-july-16-2013/) - Kit Check Raises $10.4 million from New Leaf, Sands, Easton and LionBird Washington, DC – July 16, 2013 - Kit Check™, provider of automated pharmacy kit processing software for hospitals, today announced a $10.4 million Series A funding round led by New Leaf Venture Partners. Sands Capital Ventures, Easton Capital Investment Group and LionBird also
- [News | June 28, 2013](https://www.nlvpartners.com/news-june-28-2013/) - AstraZeneca Completes Acquisition of Pearl Therapeutics June 28, 2013 - AstraZeneca today announced that on 27 June 2013 it completed its acquisition of Pearl Therapeutics, a privately held company based in Redwood City, California, focused on the development of inhaled small-molecule therapeutics for respiratory disease. Upon completion of the merger, AstraZeneca acquired 100% of Pearl’s
- [News | June 24, 2013](https://www.nlvpartners.com/news-june-24-2013/) - Sprint Launches Secure Messaging Solutions to Enable HIPAA Compliance Sprint and TigerText to deliver a full suite of secure messaging solutions for healthcare professionals OVERLAND PARK, Kan. – June 24, 2013 - Text messaging has become a popular way to communicate at home and in the office. Each year, more and more people send short
- [News | June 10, 2013](https://www.nlvpartners.com/news-june-10-2013/) - Concert Pharmaceuticals Initiates Phase 1 Clinical Trial of CTP-354, a Potential Treatment for Spasticity and Pain LEXINGTON, MA – June 10, 2013 - Concert Pharmaceuticals today announced that it has initiated a Phase 1 clinical trial with CTP-354. CTP-354 is a novel GABA(A) receptor subtype-selective modulator that has demonstrated no sedation at therapeutic doses in
- [News | June 3, 2013](https://www.nlvpartners.com/news-june-3-2013/) - Chimerix and BARDA Continue Collaboration on Development of CMX001 as a Medical Countermeasure Against Smallpox DURHAM, N.C., June 3, 2013 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced the extension of its contract with the Biomedical Advanced Research and Development Authority
- [News | May 22, 2013](https://www.nlvpartners.com/news-may-22-2013/) - CardioKinetix Announces Positive Clinical Data Showing Consistent Compelling Positive Results for Patients Treated with Minimally Invasive Structural Heart Device for Heart Failure Meta-Analysis Presented at EuroPCR Substantiate Potential of Breakthrough Treatment for Heart Failure Patients; Largest Group Studied to Date Paris and Menlo Park, Calif. — May 22, 2013 - CardioKinetix Inc., a medical device
- [News | May 16, 2013](https://www.nlvpartners.com/news-may-16-2013/) - TigerText and AirWatch Partner to Offer Comprehensive Mobile Security Solution for Healthcare Device management and secure messaging solution has been selected by Community Hospice of Texas SANTA MONICA, CALIF. May 16, 2013 -TigerText, the leader in secure, real-time messaging for health care and enterprise and AirWatch, the global leader and innovator in mobile device security
- [News | May 15, 2013](https://www.nlvpartners.com/news-may-15-2013/) - Relypsa Announces Appointment of John Orwin as Chief Executive Officer Industry Veteran Brings Extensive Senior Biopharma Background from Firms including Genentech and Johnson & Johnson Redwood City, CA, May 15, 2013 – Relypsa, Inc., a biopharmaceutical company advancing lead product candidate, patiromer (RLY5016) for the treatment of hyperkalemia, in a pivotal Phase 3 clinical study,
- [News | May 13, 2013](https://www.nlvpartners.com/news-may-13-2013/) - Pearl Therapeutics Initiates PT003 Phase 3 Program for the Treatment of Individuals with Moderate-to-Severe COPD The "PINNACLE" Program will Assess Long-term Efficacy and Safety of PT003 REDWOOD CITY, CALIF., May 13, 2013 - Pearl Therapeutics Inc. today announced the initiation of PINNACLE, a global Phase 3 program of PT003, the Company’s fixed-dose combination of glycopyrrolate,
- [News | May 6, 2013](https://www.nlvpartners.com/news-may-6-2013/) - Concert Pharmaceuticals Announces Strategic Collaboration with Celgene Corporation to Develop Deuterium-Modified Compounds LEXINGTON, MA – May 6, 2013 - Concert Pharmaceuticals, Inc. today announced that it has entered into a strategic collaboration with Celgene Corporation directed towards deuterium-modified compounds targeting cancer and inflammation. The collaboration will initially focus on one program, but has the potential
- [News | April 29, 2013](https://www.nlvpartners.com/news-april-29-2013/) - Spine Wave Announces U.S. FDA’s 510K Clearance of the StaXx® IB System, an Intervertebral Body Fusion Device The StaXx® IB System expands the StaXx® product portfolio and offers the advantage of an Expandable Intervertebral Body Fusion Device with Bone Graft Chambers SHELTON, CT – April 29, 2013 – Spine Wave, Inc. a privately held medical
- [News | April 23, 2013](https://www.nlvpartners.com/news-april-23-2013/) - Treato Raises $14.5m from OrbiMed, New Leaf and Reed Elsevier Proceeds to Expedite Commercialization of Treato Pharma Offering and US Expansion, Bringing ‘Voice of the Patient’ to Healthcare Stakeholders Yehud, Israel - April 23, 2013 - Treato, the social health patient intelligence provider, announced today that it has secured $14.5 million in funding. The round
- [News | April 17, 2013](https://www.nlvpartners.com/news-april-17-2013/) - Durata Therapeutics Closes Public Offering of Common Stock CHICAGO, April 17, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today announced the closing of its public offering of 8,222,500 shares of common stock at a public offering price of $7.00 per share, before underwriting discounts, including 1,072,500 shares of common stock issued upon the exercise
- [News | April 11, 2013](https://www.nlvpartners.com/news-april-11-2013/) - Oxford Immunotec wins 2013 Red Herring Top 100 Award Oxford, UK and Marlborough, MA - 11 April 2013 – Oxford Immunotec is pleased to announce today that it has won a place in Red Herring‘s Top 100 Europe list for 2013. Red Herring’s Top 100 Europe list has become a mark of distinction for identifying
- [News | April 10, 2013](https://www.nlvpartners.com/news-april-10-2013/) - iRhythm Secures $16 Million in Funding Led by Norwest Venture Partners to Fuel Continued Market and Technology Expansion Adoption of Zio Patch System Reaches New Milestone - Greater Than 20 Million Patient Hours of Monitoring SAN FRANCISCO – April 10, 2013 – iRhythm Technologies, Inc., a medical device, service and technology company that develops and
- [News | April 8, 2013](https://www.nlvpartners.com/news-april-8-2013/) - NxStage Completes Move to Direct Sales In UK Company to Leverage Recent CE Mark Approvals for System One Innovations LAWRENCE, Mass., April 8, 2013 /PRNewswire/ -- NxStage® Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, announced today that it has completed its move to a direct sales model in the United Kingdom.
- [News | April 5, 2013](https://www.nlvpartners.com/news-april-5-2013/) - MEI Pharma Announces $15.2 Million Registered Offering of Common Stock San Diego – April 5, 2013 - MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today an underwritten registered offering of 2,030,000 shares of its common stock at a price per share of $7.50.
- [News | April 4, 2013](https://www.nlvpartners.com/news-april-4-2013/) - VaxInnate Awarded U.S. Government Grant to Develop Dengue Vaccine Mosquito-borne disease identified as emerging public health threat for Americans CRANBURY, NJ, April 4, 2013 – VaxInnate Corporation announced today that it has been awarded a grant by the National Institute of Allergy and Infectious Diseases (NIAID) to fund the development of a recombinant vaccine for
- [News | March 21, 2013](https://www.nlvpartners.com/news-march-21-2013/) - Array BioPharma Names Michael N. Needle, M.D. As Chief Medical Officer Hematology / oncology industry expert to lead promising development pipeline BOULDER, Colo., March 21, 2013 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY), a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer, today
- [News | March 19, 2013](https://www.nlvpartners.com/news-march-19-2013-2/) - Douglas Harrington, MD Addresses Select Group of Physicans Regarding Latest Advances in Cardiovascular Risk Assessment MARCH 19, 2013 (San Francisco, CA) – Aviir Inc., a biotechnology company dedicated to enhanced detection and prevention of cardiovascular disease through innovative diagnostic tests, announced that Douglas Harrington, MD, Clinical Professor of Pathology at USC and Aviir, Inc. CEO,
- [News | March 14, 2013](https://www.nlvpartners.com/news-march-14-2013/) - Pearl Therapeutics Receives Award for Innovative Co-Suspension Technology Leading drug delivery companies and scientists recognize Pearl’s technical innovation REDWOOD CITY, CALIF., March 14, 2013 - Pearl Therapeutics Inc. today announced their receipt of the 2013 Drug Delivery Partnerships™ (DDP) Innovation Award for the Company’s novel co-suspension formulation technology. These awards honor companies that have demonstrated
- [News | March 12, 2013](https://www.nlvpartners.com/news-march-12-2013/) - Direct Flow Medical® Transcatheter Aortic Valve System Demonstrates Excellent Six-Month Outcomes In Discover Trial Results Presented on Podium at American College of Cardiology Annual Meeting SAN FRANCISCO, Calif., March 12, 2013 - Direct Flow Medical®, Inc., a transcatheter heart valve innovator focused on improving patient outcomes, announced that the DISCOVER Trial results presented Sunday at
- [News | March 5, 2013](https://www.nlvpartners.com/news-march-5-2013/) - Array Biopharma and Global Blood Therapeutics Announce Drug Discovery Collaboration Focused on Hematology BOULDER, Colo. and SOUTH SAN FRANCISCO, Calif., March 5, 2013 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY) and Global Blood Therapeutics today announced a multi-target drug discovery collaboration agreement to identify small molecule lead compounds targeting chronic blood-based diseases. Array will develop
- [News | February 27, 2013](https://www.nlvpartners.com/news-february-27-2013/) - AccessClosure, Inc. Launches MynxGrip™ Vascular Closure Device New Grip Technology™ Sealant Redefines Active Closure Mountain View, CA (February 27, 2012) – AccessClosure, Inc., the market leader in extravascular closure devices, announced today the FDA approval and US launch of the MynxGrip Vascular Closure Device (VCD). Built on the proven Mynx platform, the MynxGrip VCD offers
- [News | February 25, 2013](https://www.nlvpartners.com/news-february-25-2013-3/) - NxStage Announces CE Mark Approval, First Clinical Use of its Single Needle for Dialysis Patients Elegant Solution Enhances Company's Recent Nocturnal Clearance in Europe LAWRENCE, Mass., Feb. 25, 2013 /PRNewswire/ -- NxStage® Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced its single needle technology, OneSite™, has received CE Mark approval.
- [News | February 20, 2013](https://www.nlvpartners.com/news-february-20-2013/) - Relypsa Enrolls Initial Patient in Pivotal Phase 3 Program for the Treatment of Hyperkalemia Redwood City, CA, February 20, 2013 – Relypsa, Inc., a clinical-stage biopharmaceutical company, announced that he first patient has been enrolled in the company’s pivotal Phase 3 clinical study evaluating the efficacy and safety of patiromer for the treatment of hyperkalemia
- [News | January 29, 2013](https://www.nlvpartners.com/news-january-29-2013/) - Oxford Immunotec and Lophius Biosciences sign licensing and collaboration agreements Oxford, UK; January 29th, 2013 – Oxford Immunotec, a medical diagnostic company developing tests in the fields of infectious and immunological disease and Lophius Biosciences, a leader in the field of novel T-cell based diagnostic test systems, announced today that the companies have signed agreements
- [News | January 17, 2013](https://www.nlvpartners.com/news-january-17-2013/) - Pearl Therapeutics Strengthens Its Organization by Hiring Dr. Michael Riebe, an Industry Veteran in Respiratory Product Development REDWOOD CITY, CALIF., January 17, 2013 - Pearl Therapeutics Inc. today announced that Michael Riebe, Ph.D. has joined Pearl Therapeutics as vice president, pharmaceutical development and research, effective immediately. Chuck Bramlage, Pearl’s president and CEO commented on the
- [News | January 7, 2013](https://www.nlvpartners.com/mews-january-7-2013/) - athenahealth to Acquire Mobile Health Leader Epocrates Acquisition will accelerate athenahealth’s vision to build the nation’s health information backbone; companies will combine forces to redefine physician mobile experience and point-of-care toolset San Mateo, CA and Watertown, MA, January 7, 2013 – athenahealth, Inc,(NASDAQ: ATHN), a leading provider of cloud-based electronic health record (EHR), practice management,
- [News | January 2, 2013](https://www.nlvpartners.com/news-january-2-2013/) - Relypsa Announces Agreement with FDA on Special Protocol Assessment for Patiromer Phase 3 Trial for the Treatment of Hyperkalemia According to data reported at Kidney Week 2012, an ongoing Phase 2b study of patiromer met the interim analysis primary endpoint of mean reduction in serum potassium after four weeks of treatment Redwood City, CA, January
- [News | March 27, 2014](https://www.nlvpartners.com/news-march-27-2014/) - Kit Check adds Medi-Span Integration, New Safety Features for Pharmacy Kit Processing Washington, DC – March 27, 2014 - Kit Check™ (http://kitcheck.com), the leader in hospital pharmacy kit processing software, today announced two new features in a March software update: Medi-Span integration and enhancements to Trusted Pharmacist Medication Checks. Since Kit Check is a cloud-based
- [News | June 15, 2015](https://www.nlvpartners.com/news-june-15-2015/) - Advanced Cell Diagnostics and Indica Labs Partner to Provide Quantitative RNA ISH Analysis Through ACD’s Pharma Assay Services New Mexico, USA 06/15/2015 –Indica Labs, Inc. and Advanced Cell Diagnostics (ACD) announce the signing of a co-marketing partnership agreement to advance quantitative analysis in ACD’s RNAscope Pharma Assay Services. Under the terms of the agreement, ACD
- [News | June 18, 2015](https://www.nlvpartners.com/new-june-18-2015/) - Advanced Cell Diagnostics Completes $22 Million Series C Equity Financing Proceeds Will Accelerate Commercialization and Launch of New Technology Platforms Hayward, CA – June 18, 2015 – Advanced Cell Diagnostics, Inc. (ACD), a world leader in the field of in situ nucleic acid detection for life science research and clinical diagnostics, announced today that it
- [News | March 31, 2015](https://www.nlvpartners.com/news-march-31-2015/) - Oxford Immunotec Announces Availability of the T-SPOT.CMV Test in the United States OXFORD, UK and MARLBOROUGH, MA, March 31, 2015 (GLOBE NEWSWIRE) – Oxford Immunotec Global PLC (Nasdaq: OXFD), a global, commercial-stage diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced the availability in the United States
- [News | March 24, 2015](https://www.nlvpartners.com/news-march-24-2015/) - CardioKinetix Announces Excellent Results of Chinese Trial Evaluating Parachute Heart Failure Device Menlo Park, Calif. and Beijing, China — March 24, 2015 — CardioKinetix Inc., a medical device company pioneering a catheter-based treatment for heart failure, today announced three-month clinical and echocardiographic results of PARACHUTE China, a study of 31 Chinese patients treated consecutively with
- [News | March 19, 2015](https://www.nlvpartners.com/news-march-19-2015/) - Intarcia and Numab Sign Multi-Asset Collaboration to Develop Once-Yearly Therapies in Diabetes, Obesity, and Autoimmune Indications Collaboration combines Intarcia’s proprietary delivery technologies with Numab’s novel multi-specific antibody technology to broaden and strengthen Intarcia’s pipeline Boston, MA, and Wädenswil, Switzerland, March 19, 2015 – Intarcia Therapeutics, Inc. and Numab AG today announced a strategic collaboration focused
- [News | March 17, 2015](https://www.nlvpartners.com/news-march-17-2015/) - Truveris Launches Pharmacy Stop Loss Insurance Platform to Protect Employers from Rising Benefit Costs Brokers and Advisors Can Now Run Stop Loss Quotes in Minutes Using the RxChoice® Self-Service Marketplace NEW YORK, NY – March 17, 2015 - With employers seeking to minimize pharmacy benefit risk amid skyrocketing drug prices, Truveris has introduced a new
- [News | March 14, 2015](https://www.nlvpartners.com/news-march-14-2015/) - Relypsa Announces Phase 2 Data Showing Efficacy of Patiromer FOS in Heart Failure Patients With Chronic Kidney Disease at ACC Scientific Session - Sub-group Analysis of AMETHYST-DN Trial Results Led by Bertram Pitt, M.D. - Sponsored Panel at ACC Led by Prominent Thought Leader, Dr. Ileana L. Piña, will Review the Latest Data in Management
- [News | March 3, 2015](https://www.nlvpartners.com/news-march-3-2015/) - TigerText Launches TigerConnect Secure Messaging Platform Platform enables software developers to build and integrate secure messaging capabilities into any application via the TigerText SDK. SANTA MONICA, Calif. (March 3, 2015) – TigerText, a provider of secure, real-time messaging for the enterprise, today announced the launch of its TigerConnect platform-as-a-service (PaaS), which allows developers to seamlessly
- [News | February 17, 2015](https://www.nlvpartners.com/news-february-17-2015/) - VaxInnate Receives Extension of Contract from BARDA for Development of Seasonal and Pandemic Influenza Vaccines Allows for Non-Dilutive Funding of $53 Million CRANBURY, NJ – February 17, 2015 – VaxInnate Corporation, a biotechnology firm pioneering a breakthrough vaccine technology, today announced that it has executed a contract modification with the U.S. Department of Health and
- [News | January 30, 2015](https://www.nlvpartners.com/news-january-30-2015/) - Oxford Immunotec Global PLC Announces Pricing of Underwritten Offering of Ordinary Shares OXFORD, United Kingdom and MARLBOROUGH, Mass., Jan. 30, 2015 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), a global, commercial-stage diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced its underwritten offering of
- [News | January 21, 2015](https://www.nlvpartners.com/news-january-21-2015/) - Versartis Announces Pricing of Follow-On Offering MENLO PARK, Calif., Jan. 21, 2015 (GLOBE NEWSWIRE) -- Versartis, Inc. (Nasdaq:VSAR), an endocrine-focused biopharmaceutical company, today announced the pricing of an underwritten public offering of 4,347,826 shares of its common stock at a price to the public of $17.25 per share. In addition, Versartis has granted the underwriters
- [News | January 12, 2015](https://www.nlvpartners.com/news-january-12-2015-2/) - Chimerix Receives Notice of Allowance for Brincidofovir Composition of Matter Patent Extending Exclusivity to 2034 Opportunity to pursue multiple additional indications for brincidofovir DURHAM, N.C., Jan. 12, 2015 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced that the United States Patent
- [News | January 11, 2015](https://www.nlvpartners.com/news-january-11-2015/) - Biogen Idec to Expand Neuropathic Pain Portfolio with the Acquisition of Convergence Pharmaceuticals CAMBRIDGE, Mass. -- January 11, 2015 -- Biogen Idec (NASDAQ: BIIB) announced today that it has agreed to acquire U.K.-based Convergence Pharmaceuticals, a clinical-stage biopharmaceutical company with an innovative portfolio of ion channel-modulating product candidates for neuropathic pain. Biogen Idec plans to
- [News | January 6, 2015](https://www.nlvpartners.com/news-january-6-2015/) - Oxford Immunotec Announces Completion of Re-Registration in China for T-SPOT.TB Test OXFORD, United Kingdom and MARLBOROUGH, Mass., Jan. 6, 2015 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, commercial-stage diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced that the company's T-SPOT®.TB test has completed
- [News | January 5, 2015](https://www.nlvpartners.com/news-january-5-2015-2/) - Versartis Announces Positive 12 Month Data for VRS-317 from Ongoing Extension Study Successful Dose Response Further Confirms Phase 3 Trial Design Company to Hold Conference Call at 8:30 a.m. ET on Monday, January 5, 2015 MENLO PARK, Calif., Jan. 5, 2015 /PRNewswire/ -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing a novel,
- [News |December 15, 2014](https://www.nlvpartners.com/news-december-15-2014-2/) - Relypsa Announces FDA Acceptance of New Drug Application for Patiromer for Oral Suspension to Treat Hyperkalemia REDWOOD CITY, Calif., Dec. 15, 2014 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for Patiromer for Oral Suspension (Patiromer FOS) for
- [News | December 10, 2014](https://www.nlvpartners.com/news-december-10-2014/) - IlluminOss Medical Caps off Flagship Year with Addition of New Patents to Bone Fixation Portfolio 2014 Marked by Continued Success in International Orthopedics Markets and Conditional Clearance for First U.S. Clinical Trial to Begin in 2015 East Providence, RI (December 10, 2014) – IlluminOss Medical, a commercial stage medical device company focused on minimally invasive
- [News | December 9, 2014](https://www.nlvpartners.com/news-december-9-2014/) - CardioKinetix Completes $50 Million Financing and Signs Agreement with Edwards Lifesciences, Including Exclusive Option to Purchase Menlo Park, Calif. — December 9, 2014 — CardioKinetix, Inc., a medical device company pioneering a catheter-based treatment for heart failure, announced today that it has completed a $50 million financing led by Edwards Lifesciences Corporation, with participation from
- [News | December 8, 2014](https://www.nlvpartners.com/news-december-8-2014-3/) - MEI Pharma Reports Significant Clinical Activity in Phase II Study of Pracinostat in Front Line Acute Myeloid Leukemia Company Outlines Plans for Phase III Registration Study San Diego, Dec. 8, 2014 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, reported significant clinical activity
- [News | December 2, 2014](https://www.nlvpartners.com/news-december-2-2014-2/) - James R. Tobin, Former CEO of Boston Scientific, Joins Oxford Immunotec Board of Directors OXFORD, United Kingdom and MARLBOROUGH, Mass., Dec. 2, 2014 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, commercial-stage diagnostics company committed to improving patient care by providing advanced, innovative tests in the field of immunology, today announced the appointment
- [News | November 18, 2014](https://www.nlvpartners.com/news-november-18-2014/) - IlluminOss Medical Announces Conditional FDA Approval for Clinical Trials of Groundbreaking Photodynamic Bone Stabilization System in the U.S. Currently Recruiting Clinical Sites for Trial that May Offer Significant Advantages to Surgeons Treating Impending and Pathologic Fractures East Providence, RI (November 18, 2014) – IlluminOss Medical, a privately-held, commercial stage medical device company focused on minimally
- [News | November 17, 2014](https://www.nlvpartners.com/news-november-17-2014/) - Relypsa Announces Key Data Presented at ASN on Long-Term Chronic Treatment and Early Onset of Action With Patiromer for Oral Suspension Pre-Specified Sub-Analysis of Patients With Type II Diabetes From Phase 3 Trial Also Presented REDWOOD CITY, Calif., Nov. 17, 2014 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that data from
- [News | November 13, 2014](https://www.nlvpartners.com/news-november-13-2014/) - Chimerix's Brincidofovir Selected for Use in Ebola Clinical Trial in West Africa by International Consortium DURHAM, N.C., Nov. 13, 2014 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced that its investigational broad-spectrum antiviral brincidofovir has been selected as one of two
- [News | November 12, 2014](https://www.nlvpartners.com/news-november-12-2014/) - Kit Check Install Stories: Children’s Hospital of The King’s Daughters Kit Check Product Delivery Manager Scott Kinsky shares the story behind the installation of Kit Check at Children’s Hospital of The King’s Daughters in Norfolk, Virginia. November 12, 2014 Briefly describe the activities leading up to the install. Two weeks prior to our arrival in
- [News | November 11, 2014](https://www.nlvpartners.com/news-november-11-2014/) - VaxInnate Quadrivalent Seasonal Influenza Vaccine Candidate, VAX2012Q, Meets Phase 1 Seasonal Influenza Endpoints Top-Line Seroprotection Rates Exceed 90% in each of Four Vaccine Components; VAX2012Q to Proceed into Phase 2 Evaluation in 2015 VAX2012QCRANBURY, NJ, November 11, 2014 – VaxInnate Corporation, a biotechnology firm pioneering next-generation vaccine technology, announced today that enrollment has concluded in
- [News | November 10, 2014](https://www.nlvpartners.com/news-november-10-2014/) - Awarepoint Names New CEO Nov 10, 2014 - Awarepoint Corporation, the largest real-time location system (RTLS) provider dedicated exclusively to healthcare, today announced the promotion of Tim Roche, formerly the company’s chief financial officer, to the position of chief executive officer. Roche has served as chief financial officer of Awarepoint since November 2011, and has
- [News | November 4, 2014](https://www.nlvpartners.com/news-november-4-2014-2/) - Relypsa Announces Multiple Patiromer for Oral Suspension Abstracts to be Presented at American Society of Nephrology Annual Meeting 2014 Long-Term, Chronic Treatment Results Accepted for Late Breaking Poster Presentation REDWOOD CITY, Calif., Nov. 4, 2014 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that data from clinical trials of the company's lead
- [News | November 3, 2014](https://www.nlvpartners.com/news-november-3-2014/) - Relypsa Names Scott Garland Senior Vice President and Chief Commercial Officer REDWOOD CITY, Calif., Nov. 3, 2014 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), today announced that Scott Garland has joined the company as senior vice president and chief commercial officer. Garland, a seasoned executive with over 20 years of biotechnology and pharmaceutical experience, has extensive
- [News | October 16, 2014](https://www.nlvpartners.com/news-october-16-2014/) - Chimerix Provides Update on Research and Development Progress Highlights Advancement of Second Clinical Candidate, CMX16669, for CMV and BK Virus DURHAM, N.C., Oct. 16, 2014 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today provided an update on the company's R&D programs, including
- [News | October 13, 2014](https://www.nlvpartners.com/news-october-13-2014/) - Concert Pharmaceuticals Presents Positive Data from Multiple Dose Phase 1 Clinical Trial of CTP-354, Lead Candidate for the Treatment of Spasticity - No sedation or ataxia observed and treatment was well tolerated - Company plans to initiate a Phase 2 trial this year - Data presented at the American Neurological Association Annual Meeting LEXINGTON, Mass.--(Oct
- [News | October 8, 2014](https://www.nlvpartners.com/news-october-8-2014/) - Kit Check Announces RFID Seal Tags in Collaboration with Health Care Logistics for Hospital Pharmacy Kit Safety Chicago, IL – October 08, 2014 - Kit Check™ (http://kitcheck.com), the leader in hospital pharmacy kit processing and medication tracking software, today announced the availability of serialized RFID seal tags for pharmacy kits. Produced in collaboration with Health
- [News | October 7, 2014](https://www.nlvpartners.com/news-october-7-2014/) - Solaris Hospice Replaces Unsecure Email and Voicemail with TigerText Secure Messaging SANTA MONICA, CA (October 7, 2014) – TigerText, the leader in secure, real-time messaging for the enterprise, today announced that Solaris Hospice, a hospice care organization serving the rural communities of Texas, has selected TigerText as its secure messaging provider. TigerText has been incorporated
- [News | October 6, 2014](https://www.nlvpartners.com/news-october-6-2014-2/) - Chimerix Announces Emergency Investigational New Drug Applications for Brincidofovir Authorized by FDA for Patients With Ebola Virus Disease DURHAM, N.C., Oct. 6, 2014 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced that brincidofovir has been provided for potential use in patients
- [News | October 1, 2014](https://www.nlvpartners.com/news-october-1-2014/) - Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results - FREEDOM-1 study showed that ITCA 650 demonstrated positive results when added to standard oral diabetes medications. All endpoints were met regarding HbA1c and weight reductions, as well as the percent of patients
- [News | September 17, 2014](https://www.nlvpartners.com/news-september-17-2014/) - Intarcia Reveals New Insights at EASD Meeting Characterizing the Burden of Poor Control and Non-Adherence to Anti-Diabetic Therapies - Data indicate 58% non-adherence to second-line treatments in T2D patients, significantly higher than patients report and prescribers perceive - Non-adherent T2D patients are at a 50% greater risk of experiencing severe hypoglycemia and other complications resulting
- [News | September 16, 2014](https://www.nlvpartners.com/news-september-16-2014/) - Relypsa Announces New Employment Inducement Grants REDWOOD CITY, Calif., Sept. 16, 2014 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on September 15, 2014, the compensation committee of the company's board of directors granted seven new employees options to purchase an aggregate of 63,500 shares of the company's common stock with
- [News | September 15, 2014](https://www.nlvpartners.com/news-september-15-2014/) - Relypsa Announces New Analysis of Phase 3 Data Demonstrating Patiromer's Ability to Rapidly Correct, and Prevent Recurrence of, Hyperkalemia in Heart Failure and Non-Heart Failure Patients REDWOOD CITY, Calif., Sept. 15, 2014 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that data in heart failure (HF) patients from its pivotal Phase 3
- [News | September 12, 2014](https://www.nlvpartners.com/news-september-12-2014/) - Becker's Health IT & CIO Review, 7 recent vendor contracts Written by Akanksha Jayanthi (Twitter | Google+) | September 12, 2014 The following vendor contracts were announced within the past week. 1. Henry Mayo Newhall Hospital in Valencia, Calif., selected Mobile Heartbeat's CURE (Clinical Urgent Response) smartphone app to enhance clinical communications. 2. Dallas-based Baylor
- [News | September 9, 2014](https://www.nlvpartners.com/news-september-9-2014-2/) - Ventura County Medical Center Selects TigerText for HIPAA Compliant Nurse-to-Physician Communication Ventura County Medical Center adopts TigerText’s secure messaging platform to deliver more efficient care to patients. SANTA MONICA, CA (September 9, 2014) – TigerText, the leader in secure, real-time messaging for the enterprise, today announced Ventura County Medical Center (VCMC), comprised of a 180-bed
- [News | September 4, 2014](https://www.nlvpartners.com/news-september-4-2014/) - Spiracur’s SNaP Wound Care System Awarded Coverage by Health Care Services Corporation SUNNYVALE, Calif., Sept. 4, 2014 – Spiracur, the developer of the only mechanically powered advanced wound care solution that delivers the proven efficacy of Negative Pressure Wound Therapy (NPWT), today announced that Health Care Services Corporation (HCSC) has approved reimbursement coverage of the
- [News | September 3, 2014](https://www.nlvpartners.com/news-september-3-2014/) - Chimerix's Brincidofovir Has in Vitro Activity Against Ebola Chimerix Attending World Health Organization Conference in Geneva DURHAM, N.C., Sept. 3, 2014 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced in vitro activity of its investigational antiviral brincidofovir (BCV) against the Ebola
- [News | September 2, 2014](https://www.nlvpartners.com/news-september-2-2014/) - Chimerix's Brincidofovir Selected for Two Oral Presentations Highlighting Resistance Data in CMV and Adenovirus at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) DURHAM, N.C., Sept. 2, 2014 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced that new data
- [News | August 27, 2014](https://www.nlvpartners.com/news-august-27-2014/) - TigerText Growth Accelerates in First Half of 2014 as Message Volume Surges 750% Five of the top ten largest For-Profit U.S. Health Systems now rely on TigerText for secure messaging SANTA MONICA, CALIF. (August 27, 2014) – TigerText, the leader in secure, real-time messaging for the enterprise, marked the first half of 2014 with record
- [News | August 26, 2014](https://www.nlvpartners.com/new-august-26-2014/) - Concert Pharmaceuticals Achieves $2 Million Milestone for AVP-786 Under Avanir Pharmaceuticals Collaboration LEXINGTON, Mass.--(Aug 26, 2014)-- Concert Pharmaceuticals, Inc. (NASDQ: CNCE) today announced that it has achieved a $2 million milestone under its development and license agreement with Avanir Pharmaceuticals, Inc. for the clinical progression of AVP-786. The milestone is a result of Avanir initiating
- [News | August 7, 2014](https://www.nlvpartners.com/news-august-7-2014-4/) - Spiracur Announces Renewal Contract with Novation for Advanced, Mechanically-Powered, Disposable Negative Pressure Wound Care Products SUNNYVALE, Calif., August 7, 2014 – Spiracur, the developer of the only mechanically powered advanced wound care solution that delivers the proven efficacy of Negative Pressure Wound Therapy (NPWT), today announced it has been awarded a three-year contract renewal with
- [News | August 6, 2014](https://www.nlvpartners.com/news-august-6-2014/) - Kit Check Adds Medication Shortage Management Features To Improve Pharmacy Kit Processing Efficiency Washington, DC – August 6, 2014 – Kit Check™ (http://kitcheck.com), the leader in hospital pharmacy kit processing software, today announced new shortage management features for medications used in hospital pharmacy kits. The recent increase in medication shortages has added time and complexity
- [News | August 5, 2014](https://www.nlvpartners.com/news-august-5-2014/) - Oxford Immunotec Announces Purchase Of Assets Of Boulder Diagnostics Inc. OXFORD, United Kingdom and MARLBOROUGH, Mass., August 5, 2014 (GLOBE NEWSWIRE) - Oxford Immunotec Global PLC (NASDAQ: OXFD), a global, commercial-stage diagnostics company committed to improving patient care by providing advanced, innovative tests in the field of immunology, today announced that it has acquired substantially
- [News | July 31, 2014](https://www.nlvpartners.com/news-july-31-2014/) - New Data on Chimerix's Brincidofovir Supports Safety and Antiviral Activity Against Multiple Life-Threatening DNA Viruses in Organ Transplant Recipients Three Abstracts Presented at 2014 World Transplant Congress DURHAM, N.C., July 31, 2014 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, presented new data
- [News | July 30, 2014](https://www.nlvpartners.com/news-july-30-2014/) - Durata Therapeutics Enters Into an Exclusive License and Supply Agreement With Angelini to Commercialize Dalbavancin in Certain European Territories, Russia and Turkey Approximately $80M in Upfront and Milestone Payments CHICAGO, July 30, 2014 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) announced today that its Dutch subsidiary, Durata Therapeutics International B.V., has entered into a license
- [News | July 22, 2014](https://www.nlvpartners.com/news-july-22-2014/) - LifePoint Hospitals' Fauquier Health, Selects TigerText as its Facility-Wide Secure Messaging Solution Fauquier Health chooses TigerText's secure messaging platform to streamline internal communication and provide more efficient care to patients. SANTA MONICA, CA (July 22, 2014) – TigerText, the leader in secure, real-time messaging for the enterprise, today announced that Fauquier Health, a community health
- [News | July 21, 2014](https://www.nlvpartners.com/news-july-21-2014/) - Jazz Pharmaceuticals and Concert Pharmaceuticals Provide a Phase 1 Clinical Trial Update on JZP-386 DUBLIN & LEXINGTON, Mass.--July 21, 2014-- Jazz Pharmaceuticals plc (NASDAQ: JAZZ) and Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the initiation of the first Phase 1 clinical trial of JZP-386, a deuterium-containing analog of sodium oxybate—the active ingredient in Xyrem® (sodium
- [News | July 18, 2014](https://www.nlvpartners.com/news-july-18-2014/) - Durata Therapeutics Announces the U.S. Launch of DALVANCE™ CHICAGO, July 18, 2014 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) announced today that Dalvance (dalbavancin) for injection is now available for use to treat adult patients with acute bacterial skin and skin structure infections (ABSSSI). Dalvance was approved by the U.S. Food and Drug Administration (FDA)
- [News | July 17, 2014](https://www.nlvpartners.com/news-july-17-2014/) - CareDx Announces Pricing of its IPO and Completion of its First Day of Trading Brisbane, CA - July 17, 2014 - CareDx, Inc. (NASDAQ: CDNA) announced the pricing of its initial public offering of 4,000,000 shares of its common stock at a price to the public of $10 per share, before underwriter discounts. In addition,
- [News | July 16, 2014](https://www.nlvpartners.com/news-july-16-2014/) - Concert Pharmaceuticals Announces FDA Lifts Partial Clinical Hold for CTP-354, A Novel Drug Candidate for Spasticity LEXINGTON, Mass.--(July 16, 2014)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that the FDA has provided notification that the Company has completed the necessary preclinical toxicology testing in order to administer repeated doses of CTP-354 in excess of 6
- [News | July 8, 2014](https://www.nlvpartners.com/news-july-8-2014-3/) - Concert Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for CTP-499 Provides Direction for Phase 3 Development in Diabetic Nephropathy LEXINGTON, Mass.--(July 8, 2014)-- Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced the successful completion of an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) for CTP-499, its investigational therapy targeting diabetic nephropathy. During
- [News | July 1, 2014](https://www.nlvpartners.com/news-july-1-2014/) - ReShape Medical® Submits PMA Application to FDA for Non-Surgical Weight Loss Device ReShape™ Integrated Dual Balloon System to Fill Significant Gap in Obesity Treatment Spectrum SAN CLEMENTE, Calif., July 1, 2014 – ReShape Medical® today announced that the Company has submitted a Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for
- [News | June 27, 2014](https://www.nlvpartners.com/news-june-27-2014/) - Pharmacy Pricing & Benefits Analysis Platform Truveris Raised Another $12.75M Series C Round Financing led by Canaan Partners NEW YORK, June 27, 2014 -- Truveris, a leading platform for pharmacy pricing and benefits analysis, today announced it raised $12.75 million in a Series C Round financing. Canaan Partners led the investment and was joined by
- [News | June 23, 2014](https://www.nlvpartners.com/news-june-23-2014/) - Versartis Presents Positive Six Month VRS-317 Phase 2a Clinical Study Results - Long-Acting VRS-317 Efficacy and Safety Comparable to Daily Growth Hormone Therapies - Company to Hold Conference Call at 5:00 p.m. EDT (4:00 p.m. CDT) CHICAGO, June 23, 2014 (GLOBE NEWSWIRE) -- Versartis, Inc. (Nasdaq:VSAR), an endocrine-focused biopharmaceutical company that is developing a novel,
- [News | June 17, 2014](https://www.nlvpartners.com/news-june-17-2014/) - HIPAA Encryption for iPhones and Android Phones June 17, 2014 Sending Encrypted ePHI to Mobile Devices When new regulations were enacted in the Health Insurance Portability and Accountability Act (HIPAA) in March 2013, healthcare organizations had to decide how to efficiently and inexpensively facilitate HIPAA encryption for iPhone and Android phones. Due to the increased
- [News | June 15, 2014](https://www.nlvpartners.com/news-june-15-2014/) - Intarcia Presents Interim Phase 3 Data at ADA Showing ITCA 650, A Once Yearly GLP-1, Markedly Reduces Blood Sugar in Patients With Very Poorly Controlled Diabetes - The average HbA1C reductions in patients treated with ITCA 650 for 6 months at the time of the interim analysis were -3.2%; patients at baseline had HbA1C levels
- [News | June 10, 2014](https://www.nlvpartners.com/news-june-10-2014/) - MEI Pharma Reports High Response Rates In Phase II Study Of Pracinostat In Front Line Acute Myeloid Leukemia Study Meets Pre-Specified CR/CRi Rate in First Nine Patients SAN DIEGO, June 10, 2014 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, today announced preliminary
- [News | June 2, 2014](https://www.nlvpartners.com/news-june-2-2014/) - Kit Check Announces New RFID Scanning Station, Little Blue Box is Smaller, Lighter, Provided Free for Users Las Vegas, NV – June 2, 2014 - Kit Check today announced at the ASHP Annual Meeting the release of a new RFID scanning station which is used to verify hospital pharmacy kits in five seconds and reduce
- [News | May 27, 2014](https://www.nlvpartners.com/news-may-27-2014/) - Chimerix Announces Completion of Public Offering of Common Stock and Exercise in Full of Option to Purchase Additional Shares of Common Stock DURHAM, N.C., May 27, 2014 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced the completion of an underwritten public
- [News | May 16, 2014](https://www.nlvpartners.com/news-may-16-2014/) - Chimerix Regains Worldwide Rights to CMX157 DURHAM, N.C., May 16, 2014 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced that it has regained the worldwide rights to CMX157, Chimerix's novel lipid acyclic nucleoside phosphonate, from Merck, known as MSD outside the
- [News | May 6, 2014](https://www.nlvpartners.com/news-may-6-2014/) - QPID Health Secures $12.3M Series B Funding New Leaf Venture Partners leads round to accelerate company’s growth and meet market demand for its clinical intelligence solution Boston – May 6, 2014 – QPID Health, which has committed to bringing clinical intelligence to healthcare providers to improve outcomes and lower costs, today announced a $12.3M Series
- [News | April 25, 2014](https://www.nlvpartners.com/news-april-25-2014/) - Concert Pharmaceuticals Presents Positive 48-Week Results from Phase 2 Clinical Trial of CTP-499 in Diabetic Kidney Disease - CTP-499 observed to protect against large increases in serum creatinine - CTP-499 reduced biomarkers of fibrosis - Data presented at late-breaking session at the National Kidney Foundation Spring Clinical Meeting LAS VEGAS--April 25, 2014-- Concert Pharmaceuticals, Inc.
- [News | April 16, 2014](https://www.nlvpartners.com/news-april-16-2014/) - Relypsa, Inc. Announces Closing of Public Offering of Common Stock REDWOOD CITY, Calif., April 16, 2014 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced the closing of its public offering of 4,130,611 shares of its common stock at a price to the public of $24.50 per share for gross proceeds of approximately
- [News | April 15, 2014](https://www.nlvpartners.com/news-april-15-2014/) - Awarepoint Humidity-Sensing Tag Now Available Healthcare RTLS leader announces humidity tag general availability, benefits and support of compliance requirements SAN DIEGO – April 15, 2014 – Awarepoint Corporation, the largest real-time location system (RTLS) corporation dedicated exclusively to healthcare, announced the availability of a humidity-sensing tag after the completion of beta testing at UCSF Medical
- [News | April 9, 2014](https://www.nlvpartners.com/news-april-9-2014/) - Chimerix Announces Appointment of M. Michelle Berrey, M.D., M.P.H. as Chief Executive Officer DURHAM, N.C., April 9, 2014 -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced the appointment of M. Michelle Berrey, M.D., M.P.H. to the position of President and Chief Executive Officer.
- [News | April 7, 2014](https://www.nlvpartners.com/news-april-7-2014/) - CardioKinetix Releases One-Year Clinical Data Showing Consistent, Compelling Positive Results for Patients Treated with Minimally Invasive Structural Heart Device for Heart Failure Analysis from 111 Consecutive Patients Presented at ACC 2014 Substantiate Potential of Breakthrough Treatment for Heart Failure Patients Menlo Park, Calif. – April 7, 2014 – CardioKinetix Inc., a medical device company pioneering
- [News | April 2, 2014](https://www.nlvpartners.com/news-april-2-2014/) - Relypsa Names Sylvia R. Wheeler V.P. Investor Relations and Corporate Affairs REDWOOD CITY, Calif., April 2, 2014 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced the appointment of Sylvia R. Wheeler to the position of Vice President, Investor Relations and Corporate Affairs. Ms. Wheeler, a veteran biopharmaceutical executive, joins Relypsa with over
- [News | April 1, 2014](https://www.nlvpartners.com/news-april-1-2014-3/) - Chimerix Appoints Lisa Ricciardi to Board of Directors DURHAM, N.C., April 1, 2014 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced the appointment of Lisa Ricciardi to the Company's Board of Directors. Ms. Ricciardi has a broad range of experience in
- [News | March 31, 2014](https://www.nlvpartners.com/news-march-31-2014/) - TigerText Dangles $1M Guarantee Against HIPAA Violations Featured on socalTECH - Benjamin Kuo - March 31, 2014 - Santa Monica-based TigerText, which develops secure, text-messaging tools for enterprise customers–and in particular, the healthcare industry–is putting its money where its mouth is, saying Monday that it will offer up a $1 million indemnification against violations from
- [News | June 5, 2015](https://www.nlvpartners.com/news-june-5-2015/) - Intarcia’s Kurt Graves Named an EY Entrepreneur Of The Year® 2015 Boston, MA – June 5, 2015 – Intarcia Therapeutics, Inc. today announced that Kurt Graves, Chairman, President and CEO of Intarcia, has been named an EY Entrepreneur Of The Year® 2015 in New England. The award recognizes top executives from a variety of industries
- [News | June 11, 2015](https://www.nlvpartners.com/news-june-11-2015/) - Oxford Immunotec Announces First Patient Enrolled in REACT Trial for T-SPOT.CMV OXFORD, United Kingdom and MARLBOROUGH, Mass., June 11, 2015 (GLOBE NEWSWIRE) — Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, commercial-stage diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced the first patient has been enrolled in
- [News | April 9, 2015](https://www.nlvpartners.com/news-april-9-2015/) - Edge Therapeutics Raises $72.5 Million Through Successive Series C-1 and C-2 Financings Proceeds to Advance Development of EG-1962 and Earlier Stage Pipeline BERKELEY HEIGHTS, N.J., April 9, 2015 – Edge Therapeutics, a clinical-stage biotechnology company that discovers, develops and seeks to commercialize novel, hospital-based therapies for acute, life-threatening neurological conditions, today announced that it has
- [Hello world!](https://www.nlvpartners.com/hello-world/) - Welcome to WordPress. This is your first post. Edit or delete it, then start blogging!
- [News | May 28, 2015](https://www.nlvpartners.com/news-may-28-2015-2/) - Kit Check Tracks Five Million Hospital Medications with RFID and Cloud Software Solution Burlington, VT – May 28, 2015 - Kit Check™ (http://kitcheck.com), the leader in hospital pharmacy kit processing and medication tracking software, today announced that five million medications have been tracked using the company’s cloud software and RFID-based solution. A vial of Glycopyrrolate
- [News | April 27, 2015](https://www.nlvpartners.com/news-april-27-2015/) - Oxford Immunotec Announces CE Mark Approval for T-SPOT.CMV Test Product to be featured at a symposium at the European Congress of Clinical Microbiology and Infectious Disease OXFORD, UK and MARLBOROUGH, MA, April 27th, 2015 (GLOBE NEWSWIRE) – Oxford Immunotec Global PLC (Nasdaq: OXFD), a global, commercial-stage diagnostics company focused on developing and commercializing proprietary tests
- [News | April 27, 2015](https://www.nlvpartners.com/news-april-27-2015-2/) - For Wall Street Journal coverage of this financing, click here. Intarcia Therapeutics Closes Novel $225 Million Synthetic Royalty Financing with Equity Conversion Option at $5.5 Billion Valuation - Company secures $225M financing in exchange for 1.5% of future global net sales of ITCA 650, a novel once or twice yearly and injection-free GLP-1 therapy currently
- [News | April 27, 2015](https://www.nlvpartners.com/news-april-27-2015-3/) - Neuronetics Closes $34 Million in Series F Financing with GE Ventures and Current Investors Additional investment will help fund the company’s growing commercial development and plans to initiate a new clinical study of NeuroStar TMS Therapy in adolescent patients with Major Depressive Disorder (MDD) MALVERN, PA, United States, April 27, 2015 – Neuronetics, Inc., the
- [News | April 21, 2015](https://www.nlvpartners.com/news-april-21-2015/) - Banner Health to Offer iRhythm ZIO Service for Continuous Cardiac Monitoring SAN FRANCISCO – April 21, 2015 – iRhythm Technologies, Inc., a leading digital healthcare solutions company focusing on the advancement of cardiac care, announced today that Banner Health, one of the largest nonprofit health care systems in the U.S., will now be offering iRhythm’s
- [News | April 13, 2015](https://www.nlvpartners.com/news-april-13-2015/) - Versartis Initiates Phase 2/3 Trial of VRS-317 in Japan for Children With Growth Hormone Deficiency MENLO PARK, Calif., April 13, 2015 (GLOBE NEWSWIRE) -- Versartis, Inc. (Nasdaq:VSAR), an endocrine-focused biopharmaceutical company that is developing a novel, long-acting form of recombinant human growth hormone (rhGH), today announced the initiation of its Phase 2/3 study of VRS-317
- [News | April 7, 2015](https://www.nlvpartners.com/news-2/) - Amerinet Offers Kit Check to 3,000 Member Hospitals April 7, 2015 - Amerinet Contracted SupplierAmerinet, a leading group purchasing organization (GPO) that serves over 3,000 acute care hospitals, Tuesday announced that it is now offering Kit Check and Anesthesia Check to its members. The announcement stated: “Through this agreement, Amerinet members will receive negotiated pricing
- [News | June 3, 2015](https://www.nlvpartners.com/vaxinnate/) - VaxInnate Advances Quadrivalent Seasonal Influenza Vaccine Candidate, VAX2012Q, into Phase 2 Study Top-line results expected in second half of 2015 Cranbury, NJ, June 3, 2015 – VaxInnate Corporation, a biotechnology firm pioneering a breakthrough vaccine technology platform, today announced the initiation of a double-blind, randomized, active comparator controlled Phase 2 study to evaluate the safety
- [News | June 2, 2015](https://www.nlvpartners.com/news-june-2-2015/) - Spiracur Expands Global Reach with the Release of New International Clinical Data and the Introduction of the SNaP Plus Therapy System New Clinical Data Reaffirms Better Wound Healing, Cost Savings and Improved Patient Quality of Life with Spiracur’s Smart Negative Pressure (SNaP) Therapy System SUNNYVALE, Calif., June 2, 2015– Spiracur today announced that results from
- [News | May 28, 2015](https://www.nlvpartners.com/news-may-28-2015/) - Edge Therapeutics Completes Enrollment in Phase 1/2 NEWTON Study of EG-1962 for Patients with Ruptured Brain Aneurysm Favorable Outcomes Reported in 67% of EG-1962 Treated Patients at Study Mid-point BERKELEY HEIGHTS, N.J.-- May 28, 2015 -- Edge Therapeutics today announced that it has completed patient enrollment in all six cohorts of its ongoing Phase 1/2
- [News | June 2, 2015](https://www.nlvpartners.com/news-june-2-2015-2/) - Spiracur Expands Global Reach with the Release of New International Clinical Data and the Introduction of the SNaP Plus Therapy System New Clinical Data Reaffirms Better Wound Healing, Cost Savings and Improved Patient Quality of Life with Spiracur’s Smart Negative Pressure (SNaP) Therapy System SUNNYVALE, Calif., June 2, 2015– Spiracur today announced that results from
- [News | April 21, 2015](https://www.nlvpartners.com/news-april-21-2015-2/) - Dimension Therapeutics Secures $65 Million in Oversubscribed Series B Financing Dimension Is Advancing Liver-Directed Gene Therapy Treatments for Rare Metabolic Disorders and Hemophilia Based on Innovative AAV technologies and a Proprietary Manufacturing Platform CAMBRIDGE, MASS., April 21, 2015 – Dimension Therapeutics, Inc. (“Dimension” or the “Company”), a rare disease company advancing novel, liver-directed treatments for
- [News | April 14, 2015](https://www.nlvpartners.com/news/) - TigerText Introduces First Secure Enterprise Messaging App for the Apple Watch TigerText’s Apple Watch app enables enterprises to work securely – directly from their wrists Santa Monica, CA (April 14, 2015) – TigerText, a provider of secure, real-time messaging for the enterprise, today announced the launch of TigerText for the Apple Watch. TigerText for the
- [News | April 9, 2015](https://www.nlvpartners.com/news-april-9-2015-2/) - Group Message Confirmations Are Here! April 9, 2015 - With HIMSS just around the corner, we’re pleased to share we’ve made some great improvements to our iOS app and added a few features that will save you even more time. If you’re planning to attend HIMSS in Chicago next week, we’ll be showing off these

## Pages

- [Index](https://www.nlvpartners.com/) - [et_pb_section fb_built=”1″ custom_padding_last_edited=”on|desktop” admin_label=”section” module_class=”notonmobile” _builder_version=”4.16″ background_color=”rgba(255,255,255,0)” custom_padding=”2px|0px|5px|0px” custom_padding_tablet=”50px|0|50px|0″ custom_padding_phone=”” transparent_background=”on” global_colors_info=”{}”][et_pb_row column_padding_mobile=”on” admin_label=”row” module_class=”notonmobile” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” custom_padding=”30px|0px|18px|0px” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text module_class=”notonmobile” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” text_orientation=”center” module_alignment=”center” global_colors_info=”{}”] NEW LEAF VENTURE PARTNERS [/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section][et_pb_section fb_built=”1″ custom_padding_last_edited=”on|desktop” admin_label=”Background” module_class=”homepage_link pointer” _builder_version=”4.23″ background_image=”https://www.nlvpartners.com/wp-content/uploads/2024/03/Landing_companies_3-25-24-scaled.jpg” custom_padding=”36px|0px|10%|0px” custom_padding_tablet=”50px|0|50px|0″ custom_padding_phone=”” hover_enabled=”0″ custom_css_main_element=” ” transparent_background=”off” global_colors_info=”{}” alt=”New
- [News 2026](https://www.nlvpartners.com/news-2026/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ background_color=”#ffffff” background_image=”https://www.nlvpartners.com/wp-content/uploads/2015/06/News_header_back1.jpg” transparent_background=”off” global_colors_info=”{}”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”Press Releases 2025″ _builder_version=”4.27.0″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” module_alignment=”left” global_colors_info=”{}”] 2026 Press Releases [/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section][et_pb_section fb_built=”1″ custom_padding_last_edited=”on|desktop” admin_label=”section” module_id=”remove_padding” _builder_version=”3.0.83″ background_color=”#ffffff” custom_padding=”10px|0px|5px|0px” custom_padding_tablet=”50px|0|50px|0″ custom_padding_phone=”” transparent_background=”off” global_module=”6029″ global_colors_info=”{}”][et_pb_row column_structure=”1_3,1_3,1_3″ admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” custom_padding=”7px|0px|8px|0px” global_colors_info=”{}”][et_pb_column type=”1_3″ _builder_version=”4.16″ custom_padding=”|||”
- [News 2025](https://www.nlvpartners.com/news-2025/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ background_color=”#ffffff” background_image=”https://www.nlvpartners.com/wp-content/uploads/2015/06/News_header_back1.jpg” transparent_background=”off” global_colors_info=”{}”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”Press Releases 2025″ _builder_version=”4.27.0″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” module_alignment=”left” global_colors_info=”{}”] 2025 Press Releases [/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section][et_pb_section fb_built=”1″ custom_padding_last_edited=”on|desktop” admin_label=”section” module_id=”remove_padding” _builder_version=”3.0.83″ background_color=”#ffffff” custom_padding=”10px|0px|5px|0px” custom_padding_tablet=”50px|0|50px|0″ custom_padding_phone=”” transparent_background=”off” global_module=”6029″ global_colors_info=”{}”][et_pb_row column_structure=”1_3,1_3,1_3″ admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” custom_padding=”7px|0px|8px|0px” global_colors_info=”{}”][et_pb_column type=”1_3″ _builder_version=”4.16″ custom_padding=”|||”
- [Home](https://www.nlvpartners.com/home/) - [et_pb_section fb_built=”1″ fullwidth=”on” _builder_version=”4.16″ _module_preset=”default” custom_margin=”||2%||false|false” global_colors_info=”{}”][et_pb_fullwidth_code _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”] [/et_pb_fullwidth_code][/et_pb_section][et_pb_section fb_built=”1″ custom_padding_last_edited=”on|desktop” admin_label=”section” _builder_version=”4.16″ custom_padding=”0px||3px|” custom_padding_tablet=”50px|0|50px|0″ custom_padding_phone=”” transparent_background=”off” global_colors_info=”{}”][et_pb_row column_padding_mobile=”on” admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” custom_padding=”0px||7px|” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”Revolutionizing healthcare with exceptional entrepreneurs” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” module_alignment=”left” global_colors_info=”{}”] Revolutionizing healthcare with exceptional entrepreneurs New Leaf Venture Partners believes in
- [Privacy](https://www.nlvpartners.com/privacy/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ background_color=”#ffffff” background_image=”https://www.nlvpartners.com/wp-content/uploads/2015/06/Approach_header_back.jpg” transparent_background=”off” global_colors_info=”{}”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”Privacy Policy” _builder_version=”4.27.0″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” text_orientation=”center” module_alignment=”center” use_border_color=”off” border_color=”#ffffff” border_style=”solid” global_colors_info=”{}”] Privacy [/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section][et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ background_color=”#ffffff” transparent_background=”off” global_colors_info=”{}”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”Privacy Policy” _builder_version=”4.27.0″
- [News 2024](https://www.nlvpartners.com/news-2024/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ background_color=”#ffffff” background_image=”https://www.nlvpartners.com/wp-content/uploads/2015/06/News_header_back1.jpg” transparent_background=”off” global_colors_info=”{}”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”Press Releases 2024″ _builder_version=”4.25.0″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” module_alignment=”left” global_colors_info=”{}”] 2024 Press Releases [/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section][et_pb_section fb_built=”1″ custom_padding_last_edited=”on|desktop” admin_label=”section” module_id=”remove_padding” _builder_version=”3.0.83″ background_color=”#ffffff” custom_padding=”10px|0px|5px|0px” custom_padding_tablet=”50px|0|50px|0″ custom_padding_phone=”” transparent_background=”off” global_module=”6029″ global_colors_info=”{}”][et_pb_row column_structure=”1_3,1_3,1_3″ admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” custom_padding=”7px|0px|8px|0px” global_colors_info=”{}”][et_pb_column type=”1_3″ _builder_version=”4.16″ custom_padding=”|||”
- [News 2020](https://www.nlvpartners.com/news-2020/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ background_color=”#ffffff” background_image=”https://www.nlvpartners.com/wp-content/uploads/2015/06/News_header_back1.jpg” transparent_background=”off” global_colors_info=”{}”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”Press Releases 2020″ _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” module_alignment=”left” global_colors_info=”{}”] 2020 Press Releases [/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section][et_pb_section fb_built=”1″ custom_padding_last_edited=”on|desktop” admin_label=”section” module_id=”remove_padding” _builder_version=”3.0.83″ background_color=”#ffffff” custom_padding=”10px|0px|5px|0px” custom_padding_tablet=”50px|0|50px|0″ custom_padding_phone=”” transparent_background=”off” global_module=”6029″ global_colors_info=”{}”][et_pb_row column_structure=”1_3,1_3,1_3″ admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” custom_padding=”7px|0px|8px|0px” global_colors_info=”{}”][et_pb_column type=”1_3″ _builder_version=”4.16″ custom_padding=”|||”
- [News 2022](https://www.nlvpartners.com/news-2022/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ background_color=”#ffffff” background_image=”https://www.nlvpartners.com/wp-content/uploads/2015/06/News_header_back1.jpg” transparent_background=”off” global_colors_info=”{}”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”Press Releases 2022″ _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” module_alignment=”left” global_colors_info=”{}”] 2022 Press Releases [/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section][et_pb_section fb_built=”1″ custom_padding_last_edited=”on|desktop” admin_label=”section” module_id=”remove_padding” _builder_version=”3.0.83″ background_color=”#ffffff” custom_padding=”10px|0px|5px|0px” custom_padding_tablet=”50px|0|50px|0″ custom_padding_phone=”” transparent_background=”off” global_module=”6029″ global_colors_info=”{}”][et_pb_row column_structure=”1_3,1_3,1_3″ admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” custom_padding=”7px|0px|8px|0px” global_colors_info=”{}”][et_pb_column type=”1_3″ _builder_version=”4.16″ custom_padding=”|||”
- [Portfolio Company News](https://www.nlvpartners.com/portfolio-company-news/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ background_color=”#ffffff” background_image=”https://www.nlvpartners.com/wp-content/uploads/2015/06/News_header_back1.jpg” transparent_background=”off” global_colors_info=”{}”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”Portfolio Company News” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” module_alignment=”left” use_border_color=”off” border_color=”#ffffff” border_style=”solid” global_colors_info=”{}”] Portfolio Company News [/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section][et_pb_section fb_built=”1″ custom_padding_last_edited=”on|desktop” admin_label=”section” module_id=”remove_padding” _builder_version=”3.0.83″ background_color=”#ffffff” custom_padding=”10px|0px|5px|0px” custom_padding_tablet=”50px|0|50px|0″ custom_padding_phone=”” transparent_background=”off” global_module=”6029″ global_colors_info=”{}”][et_pb_row column_structure=”1_3,1_3,1_3″ admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” custom_padding=”7px|0px|8px|0px” global_colors_info=”{}”][et_pb_column
- [Portfolio](https://www.nlvpartners.com/portfolio/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ background_color=”#ffffff” background_image=”https://www.nlvpartners.com/wp-content/uploads/2015/06/portfolio_header_back.jpg” transparent_background=”off” global_colors_info=”{}”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”With the success of our entrepreneurs our portfolio has…” _builder_version=”4.27.0″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” module_alignment=”left” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″] With the success of our entrepreneurs our portfolio has 30 billion-dollar companies, 44 acquired companies, and 54 companies taken
- [Team](https://www.nlvpartners.com/team/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ background_color=”#ffffff” background_image=”https://www.nlvpartners.com/wp-content/uploads/2015/07/Team_header_back.jpg” custom_padding=”54px|0px|5px|0px” transparent_background=”off” global_colors_info=”{}”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” custom_padding=”27px|0px|8px|0px” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”] Our team has experience investing in leading-edge companies that are driving innovation in healthcare [/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.16″ _module_preset=”default” background_color=”RGBA(0,0,0,0)” global_colors_info=”{}”][et_pb_row column_structure=”1_3,1_3,1_3″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_3″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text admin_label=”Photo”
- [News 2023](https://www.nlvpartners.com/news-2023/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ background_color=”#ffffff” background_image=”https://www.nlvpartners.com/wp-content/uploads/2015/06/News_header_back1.jpg” transparent_background=”off” global_colors_info=”{}”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”Press Releases 2023″ _builder_version=”4.19.5″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” module_alignment=”left” global_colors_info=”{}”] 2023 Press Releases [/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section][et_pb_section fb_built=”1″ custom_padding_last_edited=”on|desktop” admin_label=”section” module_id=”remove_padding” _builder_version=”3.0.83″ background_color=”#ffffff” custom_padding=”10px|0px|5px|0px” custom_padding_tablet=”50px|0|50px|0″ custom_padding_phone=”” transparent_background=”off” global_module=”6029″ global_colors_info=”{}”][et_pb_row column_structure=”1_3,1_3,1_3″ admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” custom_padding=”7px|0px|8px|0px” global_colors_info=”{}”][et_pb_column type=”1_3″ _builder_version=”4.16″ custom_padding=”|||”
- [Contact](https://www.nlvpartners.com/contact/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”3.22″ background_color=”#ffffff” background_image=”https://www.nlvpartners.com/wp-content/uploads/2015/06/network_header_back1.jpg” transparent_background=”off” global_colors_info=”{}”][et_pb_row admin_label=”row” _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text _builder_version=”3.27.4″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” module_alignment=”left” global_colors_info=”{}”] Contact [/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section][et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”3.22″ global_colors_info=”{}”][et_pb_row admin_label=”row” _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”NYC” module_class=”address_back” _builder_version=”4.14.7″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” module_alignment=”left” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″] New York City
- [Approach](https://www.nlvpartners.com/approach/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”3.22″ background_color=”#ffffff” background_image=”https://www.nlvpartners.com/wp-content/uploads/2015/06/Approach_header_back.jpg” custom_padding=”80px|0px|80px|0px” transparent_background=”off” global_colors_info=”{}”][et_pb_row admin_label=”row” _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”The healthcare industry is ripe for disruption” _builder_version=”3.27.4″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” module_alignment=”left” global_colors_info=”{}”] The healthcare industry is ripe for disruption And we are partnering with the disruptors [/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section][et_pb_section fb_built=”1″ custom_padding_last_edited=”on|desktop” admin_label=”section” _builder_version=”3.22″ background_color=”#ffffff” custom_padding=”5px|0px|54px|0px” custom_padding_tablet=”50px|0|50px|0″
- [News 2021](https://www.nlvpartners.com/news-2021/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”3.22″ background_color=”#ffffff” background_image=”https://www.nlvpartners.com/wp-content/uploads/2015/06/News_header_back1.jpg” transparent_background=”off”][et_pb_row admin_label=”row” _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text admin_label=”Press Releases 2020″ _builder_version=”4.5.1″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” module_alignment=”left”] 2021 Press Releases [/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section][et_pb_section fb_built=”1″ custom_padding_last_edited=”on|desktop” admin_label=”section” module_id=”remove_padding” _builder_version=”3.0.83″ background_color=”#ffffff” custom_padding=”10px|0px|5px|0px” custom_padding_tablet=”50px|0|50px|0″ custom_padding_phone=”” transparent_background=”off” global_module=”6029″][et_pb_row column_structure=”1_3,1_3,1_3″ admin_label=”row” _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” custom_padding=”7px|0px|8px|0px”][et_pb_column type=”1_3″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text admin_label=”Press release navigation” module_id=”nav_wrapper” _builder_version=”4.5.1″
- [About](https://www.nlvpartners.com/about/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”3.22″ background_color=”#ffffff” background_image=”https://www.nlvpartners.com/wp-content/uploads/2015/06/Approach_header_back.jpg” transparent_background=”off”][et_pb_row admin_label=”row” _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text admin_label=”We’re funding the healthcare revolution” _builder_version=”3.27.4″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” text_orientation=”center” module_alignment=”center” use_border_color=”off” border_color=”#ffffff” border_style=”solid”] We’re funding the healthcare revolution [/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section][et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”3.22″ background_color=”#ffffff” transparent_background=”off”][et_pb_row admin_label=”row” _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.9.5″ background_size=”initial” background_position=”top_left”
- [Divi Filterable portfolio](https://www.nlvpartners.com/divi-filterable-portfolio/) - [et_pb_section fb_built=”1″ _builder_version=”4.9.5″ _module_preset=”default”][et_pb_row _builder_version=”4.9.5″ _module_preset=”default”][et_pb_column type=”4_4″ _builder_version=”4.9.5″ _module_preset=”default”][et_pb_text _builder_version=”4.9.5″ _module_preset=”default”] Investment Board Seat Board Seat Board Seat Investment [/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section]
- [Portfolio News](https://www.nlvpartners.com/portfolio-news/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”3.22″ background_color=”#ffffff” background_image=”https://www.nlvpartners.com/wp-content/uploads/2015/06/News_header_back1.jpg” transparent_background=”off”][et_pb_row admin_label=”row” _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text admin_label=”Portfolio Company News” _builder_version=”3.27.4″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” module_alignment=”left” use_border_color=”off” border_color=”#ffffff” border_style=”solid”] Portfolio Company News [/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section][et_pb_section fb_built=”1″ custom_padding_last_edited=”on|desktop” admin_label=”section” module_id=”remove_padding” _builder_version=”3.0.83″ background_color=”#ffffff” custom_padding=”10px|0px|5px|0px” custom_padding_tablet=”50px|0|50px|0″ custom_padding_phone=”” transparent_background=”off” global_module=”6029″][et_pb_row column_structure=”1_3,1_3,1_3″ admin_label=”row” _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” custom_padding=”7px|0px|8px|0px”][et_pb_column type=”1_3″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text admin_label=”Press release
- [News 2019](https://www.nlvpartners.com/news-2019/) - [et_pb_section bb_built=”1″ admin_label=”section” background_color=”#ffffff” _builder_version=”3.0.47″ background_image=”https://www.nlvpartners.com/wp-content/uploads/2015/06/News_header_back1.jpg” transparent_background=”off” next_background_color=”#ffffff”][et_pb_row admin_label=”row” _builder_version=”3.0.47″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” _i=”0″ _address=”0.0″][et_pb_column type=”4_4″][et_pb_text admin_label=”Press Releases 2019″ _builder_version=”3.19.13″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” module_alignment=”left” _i=”0″ _address=”0.0.0.0″] 2019 Press Releases [/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section][et_pb_section bb_built=”1″ admin_label=”section” background_color=”#ffffff” module_id=”remove_padding” custom_padding_last_edited=”on|desktop” _builder_version=”3.0.83″ custom_padding_tablet=”50px|0|50px|0″ transparent_background=”off” custom_padding=”10px|0px|5px|0px” prev_background_color=”#000000″ next_background_color=”#000000″ global_module=”6029″][et_pb_row admin_label=”row” global_parent=”6029″ _builder_version=”3.0.83″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” _i=”0″ _address=”1.0″ custom_padding=”7px|0px|8px|0px”][et_pb_column type=”1_3″][et_pb_text admin_label=”Press release navigation”
- [404](https://www.nlvpartners.com/404-2/) - [et_pb_section bb_built=”1″ fullwidth=”off” specialty=”off” background_image=”https://www.nlvpartners.com/wp-content/uploads/2015/05/approach21.jpg” transparent_background=”off” allow_player_pause=”off” inner_shadow=”off” parallax=”off” parallax_method=”off” padding_mobile=”off” make_fullwidth=”off” use_custom_width=”off” width_unit=”on” make_equal=”off” use_custom_gutter=”off” custom_padding_tablet=”50px|0|50px|0″ custom_padding_last_edited=”on|desktop” _builder_version=”3.19.13″ next_background_color=”#ffffff”][et_pb_row][et_pb_column type=”4_4″][et_pb_text background_layout=”light” text_orientation=”left” use_border_color=”off” border_color=”#ffffff” border_style=”solid” background_position=”top_left” background_repeat=”repeat” background_size=”initial”] Page Not Found [/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section][et_pb_section bb_built=”1″ prev_background_color=”#000000″][et_pb_row][et_pb_column type=”4_4″][et_pb_text background_layout=”light” text_orientation=”left” use_border_color=”off” border_color=”#ffffff” border_style=”solid” background_position=”top_left” background_repeat=”repeat” background_size=”initial”] Looks like the page you were looking for doesn’t exit.
- [test page](https://www.nlvpartners.com/test-page/)
- [LP Log-in](https://www.nlvpartners.com/lp-log-in/) - [et_pb_section bb_built=”1″ specialty=”off” background_image=”https://www.nlvpartners.com/wp-content/uploads/2015/06/network_header_back1.jpg” transparent_background=”off” parallax=”on” parallax_method=”off” custom_padding_tablet=”50px|0|50px|0″ custom_padding_last_edited=”on|desktop” _builder_version=”3.19.13″ module_class=”section”][et_pb_row background_position=”top_left” background_repeat=”repeat” background_size=”initial”][et_pb_column type=”4_4″][et_pb_text admin_label=”LP log-in” background_layout=”light” text_orientation=”left” use_border_color=”off” border_color=”#ffffff” border_style=”solid” module_alignment=”left” background_position=”top_left” background_repeat=”repeat” background_size=”initial”] LP Log-in [/et_pb_text][/et_pb_column][/et_pb_row][et_pb_row background_position=”top_left” background_repeat=”repeat” background_size=”initial” _builder_version=”3.19.13″ custom_padding=”10%|||”][et_pb_column type=”4_4″][et_pb_text text_orientation=”center” use_border_color=”off” module_alignment=”center” background_position=”top_left” background_repeat=”repeat” background_size=”initial” _builder_version=”3.19.13″] Click here for access to our investor portal. LP Log-in You will be
- [News 2018](https://www.nlvpartners.com/news-2018/) - [et_pb_section bb_built=”1″ admin_label=”section” background_color=”#ffffff” _builder_version=”3.0.47″ background_image=”https://www.nlvpartners.com/wp-content/uploads/2015/06/News_header_back1.jpg” transparent_background=”off” next_background_color=”#ffffff”][et_pb_row admin_label=”row” _builder_version=”3.0.47″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” _i=”0″ _address=”0.0″][et_pb_column type=”4_4″][et_pb_text admin_label=”Press Releases 2018″ _builder_version=”3.0.83″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” module_alignment=”left” _i=”0″ _address=”0.0.0.0″] 2018 Press Releases [/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section][et_pb_section bb_built=”1″ admin_label=”section” background_color=”#ffffff” module_id=”remove_padding” custom_padding_last_edited=”on|desktop” _builder_version=”3.0.83″ custom_padding_tablet=”50px|0|50px|0″ transparent_background=”off” custom_padding=”10px|0px|5px|0px” prev_background_color=”#000000″ next_background_color=”#000000″ global_module=”6029″][et_pb_row admin_label=”row” global_parent=”6029″ _builder_version=”3.0.83″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” _i=”0″ _address=”1.0″ custom_padding=”7px|0px|8px|0px”][et_pb_column type=”1_3″][et_pb_text admin_label=”Press release navigation”
- [New Leaf News](https://www.nlvpartners.com/new-leaf-news/) - [et_pb_section bb_built=”1″ admin_label=”section” fullwidth=”off” specialty=”off” transparent_background=”off” background_color=”#ffffff” inner_shadow=”off” parallax=”off” parallax_method=”off” background_image=”https://www.nlvpartners.com/wp-content/uploads/2015/06/News_header_back1.jpg”][et_pb_row admin_label=”row” background_position=”top_left” background_repeat=”repeat” background_size=”initial”][et_pb_column type=”4_4″][et_pb_text admin_label=”New Leaf News” background_layout=”light” text_orientation=”left” use_border_color=”off” border_color=”#ffffff” border_style=”solid” module_alignment=”left” background_position=”top_left” background_repeat=”repeat” background_size=”initial”] New Leaf News [/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section][et_pb_section bb_built=”1″ admin_label=”section” background_color=”#ffffff” module_id=”remove_padding” custom_padding_last_edited=”on|desktop” _builder_version=”3.0.83″ custom_padding_tablet=”50px|0|50px|0″ transparent_background=”off” custom_padding=”10px|0px|5px|0px” global_module=”6029″][et_pb_row admin_label=”row” global_parent=”6029″ _builder_version=”3.0.83″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” _i=”0″ _address=”1.0″ custom_padding=”7px|0px|8px|0px”][et_pb_column type=”1_3″][et_pb_text admin_label=”Press release navigation”
- [Portfolio Company Blogs](https://www.nlvpartners.com/blogs/) - [et_pb_section bb_built=”1″ admin_label=”section” fullwidth=”off” specialty=”off” transparent_background=”off” background_color=”#ffffff” inner_shadow=”off” parallax=”off” parallax_method=”off” background_image=”https://www.nlvpartners.com/wp-content/uploads/2015/06/News_header_back1.jpg”][et_pb_row admin_label=”row” background_position=”top_left” background_repeat=”repeat” background_size=”initial”][et_pb_column type=”4_4″][et_pb_text admin_label=”Blogs” background_layout=”light” text_orientation=”left” use_border_color=”off” border_color=”#ffffff” border_style=”solid” module_alignment=”left” background_position=”top_left” background_repeat=”repeat” background_size=”initial”] Portfolio Company Blogs [/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section][et_pb_section bb_built=”1″ admin_label=”section” background_color=”#ffffff” module_id=”remove_padding” custom_padding_last_edited=”on|desktop” _builder_version=”3.0.83″ custom_padding_tablet=”50px|0|50px|0″ transparent_background=”off” custom_padding=”10px|0px|5px|0px” global_module=”6029″][et_pb_row admin_label=”row” global_parent=”6029″ _builder_version=”3.0.83″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” _i=”0″ _address=”1.0″ custom_padding=”7px|0px|8px|0px”][et_pb_column type=”1_3″][et_pb_text admin_label=”Press release navigation” global_parent=”6029″ module_id=”nav_wrapper”
- [News 2014](https://www.nlvpartners.com/news-2014/) - [et_pb_section bb_built=”1″ admin_label=”section” fullwidth=”off” specialty=”off” transparent_background=”off” background_color=”#ffffff” inner_shadow=”off” parallax=”off” parallax_method=”off” background_image=”https://www.nlvpartners.com/wp-content/uploads/2015/06/News_header_back1.jpg”][et_pb_row admin_label=”row” background_position=”top_left” background_repeat=”repeat” background_size=”initial”][et_pb_column type=”4_4″][et_pb_text admin_label=”Press Releases 2014″ background_layout=”light” text_orientation=”left” use_border_color=”off” border_color=”#ffffff” border_style=”solid” module_alignment=”left” background_position=”top_left” background_repeat=”repeat” background_size=”initial”] 2014 Press Releases [/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section][et_pb_section bb_built=”1″ admin_label=”section” background_color=”#ffffff” module_id=”remove_padding” custom_padding_last_edited=”on|desktop” _builder_version=”3.0.83″ custom_padding_tablet=”50px|0|50px|0″ transparent_background=”off” custom_padding=”10px|0px|5px|0px” global_module=”6029″][et_pb_row admin_label=”row” global_parent=”6029″ _builder_version=”3.0.83″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” _i=”0″ _address=”1.0″ custom_padding=”7px|0px|8px|0px”][et_pb_column type=”1_3″][et_pb_text admin_label=”Press release navigation”
- [News 2015](https://www.nlvpartners.com/news-2015/) - [et_pb_section bb_built=”1″ admin_label=”section” fullwidth=”off” specialty=”off” transparent_background=”off” background_color=”#ffffff” inner_shadow=”off” parallax=”off” parallax_method=”off” background_image=”https://www.nlvpartners.com/wp-content/uploads/2015/06/News_header_back1.jpg”][et_pb_row admin_label=”row” background_position=”top_left” background_repeat=”repeat” background_size=”initial”][et_pb_column type=”4_4″][et_pb_text admin_label=”Press Releases 2015″ background_layout=”light” text_orientation=”left” use_border_color=”off” border_color=”#ffffff” border_style=”solid” module_alignment=”left” background_position=”top_left” background_repeat=”repeat” background_size=”initial”] 2015 Press Releases [/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section][et_pb_section bb_built=”1″ admin_label=”section” background_color=”#ffffff” module_id=”remove_padding” custom_padding_last_edited=”on|desktop” _builder_version=”3.0.83″ custom_padding_tablet=”50px|0|50px|0″ transparent_background=”off” custom_padding=”10px|0px|5px|0px” global_module=”6029″][et_pb_row admin_label=”row” global_parent=”6029″ _builder_version=”3.0.83″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” _i=”0″ _address=”1.0″ custom_padding=”7px|0px|8px|0px”][et_pb_column type=”1_3″][et_pb_text admin_label=”Press release navigation”
- [News 2016](https://www.nlvpartners.com/news-2016/) - [et_pb_section bb_built=”1″ admin_label=”section” fullwidth=”off” specialty=”off” transparent_background=”off” background_color=”#ffffff” inner_shadow=”off” parallax=”off” parallax_method=”off” background_image=”https://www.nlvpartners.com/wp-content/uploads/2015/06/News_header_back1.jpg”][et_pb_row admin_label=”row” background_position=”top_left” background_repeat=”repeat” background_size=”initial”][et_pb_column type=”4_4″][et_pb_text admin_label=”Press Releases 2016″ background_layout=”light” text_orientation=”left” use_border_color=”off” border_color=”#ffffff” border_style=”solid” module_alignment=”left” background_position=”top_left” background_repeat=”repeat” background_size=”initial”] 2016 Press Releases [/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section][et_pb_section bb_built=”1″ admin_label=”section” background_color=”#ffffff” module_id=”remove_padding” custom_padding_last_edited=”on|desktop” _builder_version=”3.0.83″ custom_padding_tablet=”50px|0|50px|0″ transparent_background=”off” custom_padding=”10px|0px|5px|0px” global_module=”6029″][et_pb_row admin_label=”row” global_parent=”6029″ _builder_version=”3.0.83″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” _i=”0″ _address=”1.0″ custom_padding=”7px|0px|8px|0px”][et_pb_column type=”1_3″][et_pb_text admin_label=”Press release navigation”
- [News 2017](https://www.nlvpartners.com/news-2017/) - [et_pb_section bb_built=”1″ admin_label=”section” background_color=”#ffffff” _builder_version=”3.0.47″ background_image=”https://www.nlvpartners.com/wp-content/uploads/2015/06/News_header_back1.jpg” transparent_background=”off”][et_pb_row admin_label=”row” _builder_version=”3.0.47″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” _i=”0″ _address=”0.0″][et_pb_column type=”4_4″][et_pb_text admin_label=”Press Releases 2017″ _builder_version=”3.0.47″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” module_alignment=”left” _i=”0″ _address=”0.0.0.0″] 2017 Press Releases [/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section][et_pb_section bb_built=”1″ admin_label=”section” background_color=”#ffffff” module_id=”remove_padding” custom_padding_last_edited=”on|desktop” _builder_version=”3.0.83″ custom_padding_tablet=”50px|0|50px|0″ transparent_background=”off” custom_padding=”10px|0px|5px|0px” global_module=”6029″][et_pb_row admin_label=”row” global_parent=”6029″ _builder_version=”3.0.83″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” _i=”0″ _address=”1.0″ custom_padding=”7px|0px|8px|0px”][et_pb_column type=”1_3″][et_pb_text admin_label=”Press release navigation” global_parent=”6029″ module_id=”nav_wrapper” _builder_version=”3.0.83″
- [Dan Becker](https://www.nlvpartners.com/dan-becker/) - [et_pb_section bb_built=”1″ admin_label=”section” background_color=”#a1a0a4″ custom_padding_last_edited=”on|desktop” _builder_version=”3.0.78″ custom_padding_tablet=”50px|0|50px|0″ transparent_background=”off”][et_pb_row _builder_version=”3.0.78″ background_position=”top_center” background_image=”https://www.nlvpartners.com/wp-content/uploads/2015/06/Portfolio_squares_white.png” module_alignment=”center” make_fullwidth=”on”][et_pb_column type=”4_4″][et_pb_image src=”https://www.nlvpartners.com/wp-content/uploads/2015/06/DAn_700x500.png” align=”center” _builder_version=”3.0.78″ max_width=”500px” animation=”off” show_in_lightbox=”off” url_new_window=”off” use_overlay=”off” always_center_on_mobile=”on” border_style=”solid” force_fullwidth=”off” module_alignment=”center” show_bottom_space=”on” /][/et_pb_column][/et_pb_row][/et_pb_section][et_pb_section bb_built=”1″ admin_label=”section” background_color=”#ffffff” module_id=”remove_padding” _builder_version=”3.0.78″ parallax=”on” parallax_method=”off” transparent_background=”off” custom_padding=”7px|0px|54px|0px”][et_pb_row admin_label=”row” _builder_version=”3.0.78″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” custom_padding=”7px|0px|27px|0px”][et_pb_column type=”4_4″][et_pb_text admin_label=”Nav” module_id=”nav_wrapper” _builder_version=”3.0.78″ text_orientation=”center” module_alignment=”center”] Team NLV Advisors [/et_pb_text][et_pb_text admin_label=”Contact ”
- [News 2013](https://www.nlvpartners.com/news-2013/) - [et_pb_section admin_label=”section” fullwidth=”off” specialty=”off” transparent_background=”off” background_color=”#ffffff” inner_shadow=”off” parallax=”off” parallax_method=”off” background_image=”https://www.nlvpartners.com/wp-content/uploads/2015/06/News_header_back1.jpg”][et_pb_row admin_label=”row”][et_pb_column type=”4_4″][et_pb_text admin_label=”Press Releases 2013″ background_layout=”light” text_orientation=”left” use_border_color=”off” border_color=”#ffffff” border_style=”solid”] 2013 Press Releases [/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section][et_pb_section admin_label=”section” fullwidth=”off” specialty=”off” transparent_background=”off” background_color=”#ffffff” inner_shadow=”off” parallax=”off” parallax_method=”off” module_id=”remove_padding” allow_player_pause=”off” padding_mobile=”off” make_fullwidth=”off” use_custom_width=”off” width_unit=”on” make_equal=”off” use_custom_gutter=”off”][et_pb_row admin_label=”row”][et_pb_column type=”1_3″][et_pb_text admin_label=”Press release navigation” background_layout=”light” text_orientation=”left” use_border_color=”off” border_color=”#ffffff” border_style=”solid” module_id=”nav_wrapper”] 2017 2016 2015 2014
- [Portfolio Life Sciences Tools](https://www.nlvpartners.com/portfolio-life-sciences-tools/) - [et_pb_section admin_label=”section” fullwidth=”off” specialty=”off” background_image=”https://www.nlvpartners.com/wp-content/uploads/2015/06/portfolio_header_back.jpg” transparent_background=”off” background_color=”#ffffff” inner_shadow=”off” parallax=”off” parallax_method=”off”][et_pb_row admin_label=”row”][et_pb_column type=”4_4″][et_pb_text admin_label=”Text” background_layout=”light” text_orientation=”left” use_border_color=”off” border_color=”#ffffff” border_style=”solid”] Our Portfolio Life Science Tools [/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section][et_pb_section admin_label=”section” fullwidth=”off” specialty=”off” transparent_background=”off” background_color=”#ffffff” inner_shadow=”off” parallax=”off” parallax_method=”off”][et_pb_row admin_label=”row”][et_pb_column type=”4_4″][et_pb_text admin_label=”Text” background_layout=”light” text_orientation=”center” module_id=”nav_wrapper” use_border_color=”off” border_color=”#ffffff” border_style=”solid”] Life Science Tools All Companies [/et_pb_text][et_pb_text admin_label=”Text” background_layout=”light” text_orientation=”left”] Boston, MA Sunnyvale, CA NASDAQ:
- [Portfolio Information Convergence](https://www.nlvpartners.com/portfolio-information-convergence/) - [et_pb_section admin_label=”section” fullwidth=”off” specialty=”off” background_image=”https://www.nlvpartners.com/wp-content/uploads/2015/06/portfolio_header_back.jpg” transparent_background=”off” background_color=”#ffffff” inner_shadow=”off” parallax=”off” parallax_method=”off”][et_pb_row admin_label=”row”][et_pb_column type=”4_4″][et_pb_text admin_label=”Text” background_layout=”light” text_orientation=”left”] Our Portfolio Information Convergence [/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section][et_pb_section admin_label=”section” fullwidth=”off” specialty=”off” transparent_background=”off” background_color=”#ffffff” inner_shadow=”off” parallax=”off” parallax_method=”off”][et_pb_row admin_label=”row”][et_pb_column type=”4_4″][et_pb_text admin_label=”Text” background_layout=”light” text_orientation=”center” module_id=”nav_wrapper” use_border_color=”off” border_color=”#ffffff” border_style=”solid”] Information Convergence All Companies [/et_pb_text][et_pb_text admin_label=”Text” background_layout=”light” text_orientation=”left”] Ontario, Canada Chicago, IL Cambridge, MA New York, NY San
- [Portfolio Medical Devices](https://www.nlvpartners.com/portfolio-medical-devices/) - [et_pb_section admin_label=”section” fullwidth=”off” specialty=”off” background_image=”https://www.nlvpartners.com/wp-content/uploads/2015/06/portfolio_header_back.jpg” transparent_background=”off” background_color=”#ffffff” inner_shadow=”off” parallax=”off” parallax_method=”off”][et_pb_row admin_label=”row”][et_pb_column type=”4_4″][et_pb_text admin_label=”Text” background_layout=”light” text_orientation=”left”] Our Portfolio Medical Devices [/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section][et_pb_section admin_label=”section” fullwidth=”off” specialty=”off” transparent_background=”off” background_color=”#ffffff” inner_shadow=”off” parallax=”off” parallax_method=”off”][et_pb_row admin_label=”row”][et_pb_column type=”4_4″][et_pb_text admin_label=”Text” background_layout=”light” text_orientation=”center” module_id=”nav_wrapper” use_border_color=”off” border_color=”#ffffff” border_style=”solid”] Medical Devices All Companies [/et_pb_text][et_pb_text admin_label=”Text” background_layout=”light” text_orientation=”left” use_border_color=”off” border_color=”#ffffff” border_style=”solid”] South San Francisco, CA NASDAQ: DICE South
- [Portfolio Biopharmaceuticals](https://www.nlvpartners.com/portfolio-biopharmaceuticals/) - [et_pb_section admin_label=”section” fullwidth=”off” specialty=”off” background_image=”https://www.nlvpartners.com/wp-content/uploads/2015/06/portfolio_header_back.jpg” transparent_background=”off” background_color=”#ffffff” inner_shadow=”off” parallax=”off” parallax_method=”off”][et_pb_row admin_label=”row”][et_pb_column type=”4_4″][et_pb_text admin_label=”Text” background_layout=”light” text_orientation=”left”] Our Portfolio Biopharmaceuticals [/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section][et_pb_section admin_label=”section” fullwidth=”off” specialty=”off” transparent_background=”off” background_color=”#ffffff” inner_shadow=”off” parallax=”off” parallax_method=”off”][et_pb_row admin_label=”row”][et_pb_column type=”4_4″][et_pb_text admin_label=”Text” background_layout=”light” text_orientation=”center” module_id=”nav_wrapper” use_border_color=”off” border_color=”#ffffff” border_style=”solid”] Biopharmaceuticals All Companies [/et_pb_text][et_pb_text admin_label=”Text” background_layout=”light” text_orientation=”left”] Newton, MA South San Francisco, CA Cambridge NASDAQ: COGT South San Francisco,

## Projects

- [Ron Hunt](https://www.nlvpartners.com/project/ron-hunt/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ background_color=”#a1a0a4″ background_image=”https://www.nlvpartners.com/wp-content/uploads/2015/06/Portfolio_squares_white.png” custom_padding=”||0px|” transparent_background=”off” global_colors_info=”{}”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”Photo” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” max_width=”510px” module_alignment=”center” global_colors_info=”{}”] [/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section][et_pb_section fb_built=”1″ admin_label=”section” module_id=”remove_padding” _builder_version=”4.16″ background_color=”#ffffff” parallax=”on” parallax_method=”off” custom_padding=”0px|||” transparent_background=”off” global_colors_info=”{}”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”Nav” module_id=”nav_wrapper” _builder_version=”4.16″ background_size=”initial” background_position=”top_left”
- [Flosonics Medical](https://www.nlvpartners.com/project/flosonics-medical/)
- [Vijay Lathi](https://www.nlvpartners.com/project/vijay-lathi/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ background_color=”#a2bc89″ background_image=”https://www.nlvpartners.com/wp-content/uploads/2015/06/Portfolio_squares_white.png” custom_padding=”||0px|” transparent_background=”off” global_colors_info=”{}”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”Photo” _builder_version=”4.16″ header_text_align=”center” background_size=”initial” background_position=”top_left” background_repeat=”repeat” text_orientation=”center” max_width=”510px” module_alignment=”center” global_colors_info=”{}”] [/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section][et_pb_section fb_built=”1″ admin_label=”section” module_id=”remove_padding” _builder_version=”4.16″ background_color=”#ffffff” parallax=”on” parallax_method=”off” custom_padding=”0px|||” transparent_background=”off” global_colors_info=”{}”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”Nav” module_id=”nav_wrapper” _builder_version=”4.16″
- [Kyruss](https://www.nlvpartners.com/project/kyruss/)
- [Abcuro](https://www.nlvpartners.com/project/arvinas-2-2/)
- [Kalderos](https://www.nlvpartners.com/project/bluesight-2/)
- [Bluesight](https://www.nlvpartners.com/project/bluesight/)
- [Electra Therappeutics](https://www.nlvpartners.com/project/cogent-2-2/) - Therapies for systemic mastocytosis and gastrointestinal stromal tumors (GIST) Cambridge NASDAQ: COGT
- [Star Therapeutics](https://www.nlvpartners.com/project/kyruss-2/)
- [Anthony Ford](https://www.nlvpartners.com/project/anthony-ford/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”3.22″ background_color=”#a1a0a4″ background_image=”https://www.nlvpartners.com/wp-content/uploads/2015/06/Portfolio_squares_white.png” custom_padding=”||0px|” transparent_background=”off”][et_pb_row admin_label=”row” _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text admin_label=”Photo” _builder_version=”3.27.4″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” max_width=”510px” module_alignment=”center”] [/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section][et_pb_section fb_built=”1″ admin_label=”section” module_id=”remove_padding” _builder_version=”3.22″ background_color=”#ffffff” parallax=”on” parallax_method=”off” custom_padding=”0px|||” transparent_background=”off”][et_pb_row admin_label=”row” _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text admin_label=”Nav” module_id=”nav_wrapper” _builder_version=”4.9.5″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” text_orientation=”center” module_alignment=”center” hover_enabled=”0″ use_border_color=”off” border_color=”#ffffff” border_style=”solid”
- [Craig Slutzkin](https://www.nlvpartners.com/project/craig-slutzkin/) - [et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”3.22″ background_color=”#ededed” background_image=”https://www.nlvpartners.com/wp-content/uploads/2015/06/Team_header_back2.jpg” custom_padding=”||0px|” transparent_background=”off”][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_image src=”https://www.nlvpartners.com/wp-content/uploads/2015/07/Craig_700x500_2021.jpg” alt=”Craig Sultzkin” title_text=”Craig_700x500_2021″ align=”center” align_tablet=”center” align_phone=”” align_last_edited=”on|desktop” _builder_version=”4.9.5″ max_width=”510px” animation=”off” sticky=”off” use_border_color=”off” border_color=”#ffffff” border_style=”solid” always_center_on_mobile=”on”][/et_pb_image][/et_pb_column][/et_pb_row][/et_pb_section][et_pb_section fb_built=”1″ admin_label=”section” module_id=”remove_padding” _builder_version=”3.22″ background_color=”#ffffff” parallax=”on” parallax_method=”off” custom_padding=”0px|||” transparent_background=”off”][et_pb_row admin_label=”row” _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text admin_label=”Nav” _builder_version=”4.9.5″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”
- [Cleerly](https://www.nlvpartners.com/project/cogent-2/) - Therapies for systemic mastocytosis and gastrointestinal stromal tumors (GIST) Cambridge NASDAQ: COGT
- [Arvinas](https://www.nlvpartners.com/project/arvinas-2/)
- [Qlaris Bio](https://www.nlvpartners.com/project/qlaris-bio/)
- [BrightInsight](https://www.nlvpartners.com/project/brightinsight/)
- [Renovacor](https://www.nlvpartners.com/project/renovacor/)
- [Edgewise Therapeutics](https://www.nlvpartners.com/project/edgewise-therapeutics/)
- [Curasen](https://www.nlvpartners.com/project/curasen/)
- [Rallybio](https://www.nlvpartners.com/project/rallybio/)
- [Truveris](https://www.nlvpartners.com/project/truveris/)
- [TigerConnect](https://www.nlvpartners.com/project/tigertext/)
- [Arvinas](https://www.nlvpartners.com/project/arvinas/)
- [NY Digital Health Accelerator](https://www.nlvpartners.com/project/ny-digital-health-accelerator/)
- [Rock Health](https://www.nlvpartners.com/project/rock-health/)
- [Team Member Template](https://www.nlvpartners.com/project/jeani-6/) - [et_pb_section fullwidth=”off” specialty=”off” transparent_background=”off” background_color=”#ffffff” inner_shadow=”off” parallax=”on” parallax_method=”off” module_id=”remove_padding”][et_pb_row][et_pb_column type=”4_4″][et_pb_text admin_label=”Text” background_layout=”light” text_orientation=”center”][/et_pb_text][et_pb_text admin_label=”Text” background_layout=”light” text_orientation=”left” module_id=”remove_padding”] Jeani Delagardelle Managing Director San Mateo jeani@nlvpartners.com (650) 234-2700 Jeani Delagardelle is a Managing Director and leads our medical device practice, with almost 30 years of experience in that industry. Jeani joined Sprout in August 2000 and

## Ess. Grid Posts

- [Cogent Biosciences](https://www.nlvpartners.com/essential_grid/cogent-biosciences/) - NLV-III/Opportunities I
- [Iterum Therapeutics](https://www.nlvpartners.com/essential_grid/iterum-therapeutics/) - NLV-III / OPPORTUNITIES-II
- [Passage Bio, Inc.](https://www.nlvpartners.com/essential_grid/passage-bio-inc/) - NLV-III/OPPORTUNITIES-II
- [Observer Star Therapeutics](https://www.nlvpartners.com/essential_grid/observer-star-therapeutics-vijay/)
- [Rocket Pharma](https://www.nlvpartners.com/essential_grid/rocket-pharma/) - BPO-II
- [Board Seat](https://www.nlvpartners.com/essential_grid/board-seat-11/) - NLV-IV, NLV-III
- [Board Seat](https://www.nlvpartners.com/essential_grid/board-seat-18-2/)
- [Board Seat Flosonics Medical](https://www.nlvpartners.com/essential_grid/board-seat-6-2-2/)
- [Investment Sunbird Bio](https://www.nlvpartners.com/essential_grid/investment-3/)
- [Investment Cleerly](https://www.nlvpartners.com/essential_grid/board-seat-6-2/)
- [Cleerly](https://www.nlvpartners.com/essential_grid/cleerly/) - NLV-III/NLV-IV
- [Qlaris Bio](https://www.nlvpartners.com/essential_grid/qlaris-bio/) - NLV-III/NLV-IV/Opportunities II
- [Observer](https://www.nlvpartners.com/essential_grid/investment-3-2/)
- [Deciphera](https://www.nlvpartners.com/essential_grid/deciphera/) - NLV–III / OPPORTUNITIES-I
- [Kalderos Blog](https://www.nlvpartners.com/essential_grid/kalderos-blog/) - NLV-III/NLV-IV
- [Kalderos](https://www.nlvpartners.com/essential_grid/kalderos/) - NLV–IV
- [Truveris Blog](https://www.nlvpartners.com/essential_grid/truveris-2/)
- [Cleerly Blog](https://www.nlvpartners.com/essential_grid/cleerly-2/) - NLV-III/NLV-IV
- [Flosonics Blog](https://www.nlvpartners.com/essential_grid/flosonics-blog/) - NLV-III/NLV-IV
- [Observer Kyruus](https://www.nlvpartners.com/essential_grid/board-seat-4/)
- [Observer Electra Therapeutics](https://www.nlvpartners.com/essential_grid/board-seat-4-2/)
- [Board Seat Truveris](https://www.nlvpartners.com/essential_grid/investmenttruveris/)
- [Investment TigerConnect](https://www.nlvpartners.com/essential_grid/board-seat-2/)
- [Board Seat Bluesight](https://www.nlvpartners.com/essential_grid/board-seat_bluesight-inc/)
- [Board Seat BrightInsight](https://www.nlvpartners.com/essential_grid/board-seat-17/) - NLV-IV, NLV-III
- [Flosonics](https://www.nlvpartners.com/essential_grid/flosonics/) - NLV–IV
- [Electra Therapeutics](https://www.nlvpartners.com/essential_grid/star-therapeutics-2/) - NLV-IV / Opportunities-II
- [Star Therapeutics](https://www.nlvpartners.com/essential_grid/star-therapeutics/) - NLV-IV / Opportunities-II
- [Sunbird Bio](https://www.nlvpartners.com/essential_grid/sunbird-bio/) - NLV-IV
- [Dice Therapeutics](https://www.nlvpartners.com/essential_grid/dice-molecules/) - Opportunities-II
- [Harpoon Therapeutics](https://www.nlvpartners.com/essential_grid/harpoon-therapeutics/) - NLV-III, OPPORTUNITIES-II
- [Kyruus](https://www.nlvpartners.com/essential_grid/kyruus/) - NLV–III
- [Kyruus Blog](https://www.nlvpartners.com/essential_grid/kyruus-blog/)
- [Investment](https://www.nlvpartners.com/essential_grid/investment-3-3/)
- [Abcuro](https://www.nlvpartners.com/essential_grid/star-therapeutics-2-2/) - Opportunities-II
- [Bluesight  Blog](https://www.nlvpartners.com/essential_grid/kitcheck/)
- [Addex Therapeutics](https://www.nlvpartners.com/essential_grid/addex-therapeutics/) - OPPORUTNITIES-I
- [Bluesight](https://www.nlvpartners.com/essential_grid/bluesight/) - NLV–II
- [CuraSen Therapeutics, Inc.](https://www.nlvpartners.com/essential_grid/curasen-therapeutics-inc/) - NLV-IV/OPPORTUNITIES-II
- [PDS Biotechnology](https://www.nlvpartners.com/essential_grid/pds-biotechnology/) - NLV–III / OPPORTUNITIES-I
- [Braeburn Pharmaceuticals](https://www.nlvpartners.com/essential_grid/braeburn-pharmaceuticals/) - NLV-III / OPPORTUNITIES-I
- [Escape Bio](https://www.nlvpartners.com/essential_grid/escape-bio/) - NLV-IV
- [Aptinyx](https://www.nlvpartners.com/essential_grid/aptinyx/) - NLV-III / OPPORTUNITIES-I
- [Sierra Oncology](https://www.nlvpartners.com/essential_grid/reviral-2/) - NLV-IV / OPPORTUNITIES-I
- [ReViral](https://www.nlvpartners.com/essential_grid/reviral/) - NLV-IV / OPPORTUNITIES-II
- [James Niedel](https://www.nlvpartners.com/essential_grid/james-niedel/) - Advisor
- [Neurana Pharmaceuticals](https://www.nlvpartners.com/essential_grid/neurana-pharmaceuticals/) - NLV-III
- [Investment](https://www.nlvpartners.com/essential_grid/observer-2/)
- [Karus Therapeutics](https://www.nlvpartners.com/essential_grid/karus-therapeutics/) - NLV–II
- [Saniona](https://www.nlvpartners.com/essential_grid/saniona/) - NLV-IV
- [Ron Hunt](https://www.nlvpartners.com/essential_grid/ron-hunt/) - Co-Founder/Managing Director New York
- [Vijay Lathi](https://www.nlvpartners.com/essential_grid/vijay-lathi/) - Co-Founder/Managing Director Menlo Park
- [Rallybio](https://www.nlvpartners.com/essential_grid/rallybio/) - NLV–III/Opportunities II
- [Edgewise Therapeutics](https://www.nlvpartners.com/essential_grid/edgewise-therapeutics/) - OPPORTUNITIES-II
- [Intarcia Therapeutics](https://www.nlvpartners.com/essential_grid/intarcia-therapeutics/) - NLV–I / OPPORTUNITIES-I
- [LabCyte](https://www.nlvpartners.com/essential_grid/labcyte-2/) - Sprout
- [Principia Biopharma](https://www.nlvpartners.com/essential_grid/principia-biopharma/) - NLV–II/OPPORTUNITIES–II
- [Calchan](https://www.nlvpartners.com/essential_grid/calchan-holdings-limited/) - NLV–II
- [Neuronetics](https://www.nlvpartners.com/essential_grid/neuronetics/) - NLV–II
- [Investment](https://www.nlvpartners.com/essential_grid/investment-2/)
- [Craig Slutzkin](https://www.nlvpartners.com/essential_grid/craig-slutzkin/) - Chief Operating Officer / Chief Financial Officer New York
- [Board Observer](https://www.nlvpartners.com/essential_grid/observer/) - BPO-II
- [Board Observer](https://www.nlvpartners.com/essential_grid/board-seat-15/)
- [BrightInsight Blog](https://www.nlvpartners.com/essential_grid/brightinsight-blog/)
- [BrightInsight](https://www.nlvpartners.com/essential_grid/brightinsight/) - NLV-IV, NLV-III
- [Anthony Ford](https://www.nlvpartners.com/essential_grid/anthony-ford/) - Biopharmaceuticals Menlo Park
- [Board Seat](https://www.nlvpartners.com/essential_grid/board-seat/)
- [Board Seat](https://www.nlvpartners.com/essential_grid/board-seat-14/)
- [Dermira](https://www.nlvpartners.com/essential_grid/dermira/) - NLV–OPPORTUNITIES-I
- [CRISPR Therapeutics](https://www.nlvpartners.com/essential_grid/crispr-therapeutics/) - NLV-OPPORTUNITIES-I
- [Investment](https://www.nlvpartners.com/essential_grid/board-seat-5/)
- [ReShape Lifesciences](https://www.nlvpartners.com/essential_grid/reshape-medical/) - NLV–I
- [WAVE Life Sciences](https://www.nlvpartners.com/essential_grid/wave-life-sciences/) - NLV–OPPORTUNITIES-I
- [Epizyme](https://www.nlvpartners.com/essential_grid/epizyme/) - NLV-II
- [Relypsa](https://www.nlvpartners.com/essential_grid/relypsa/) - NLV–I
- [Arvinas](https://www.nlvpartners.com/essential_grid/arvinas/) - NLV–III/Opportunities-II
- [Chimerix](https://www.nlvpartners.com/essential_grid/chimerix/) - NLV–II
- [Oxford Immunotec](https://www.nlvpartners.com/essential_grid/oxford-immunotec/) - NLV–II
- [Awarepoint](https://www.nlvpartners.com/essential_grid/awarepoint-corporation/) - NLV–II
- [Martin Mackay](https://www.nlvpartners.com/essential_grid/martin-mackay/) - Advisor
- [Board Seat](https://www.nlvpartners.com/essential_grid/board-seat-13/)
- [Board Seat](https://www.nlvpartners.com/essential_grid/board-seat-12/)
- [Karyopharm Therapeutics](https://www.nlvpartners.com/essential_grid/karyopharm-therapeutics/) - NLV-II / OPPORTUNITIES-I
- [Afferent Pharmaceuticals](https://www.nlvpartners.com/essential_grid/afferent-pharmaceuticals/) - NLV–II / OPPORTUNITIES-I
- [True North Therapeutics](https://www.nlvpartners.com/essential_grid/true-north-therapeutics/) - NLV-OPPORTUNITIES-I
- [Marinus](https://www.nlvpartners.com/essential_grid/marinus/) - NLV–OPPORTUNITIES-I
- [Dynavax](https://www.nlvpartners.com/essential_grid/dynavax/) - NLV–OPPORTUNITIES-I
- [Alder](https://www.nlvpartners.com/essential_grid/alder/) - NLV–OPPORTUNITIES-I
- [Dimension Therapeutics](https://www.nlvpartners.com/essential_grid/dimension-therapeutics/) - NLV–III / OPPORTUNITIES-I
- [TigerText Blog](https://www.nlvpartners.com/essential_grid/tigertext-2/)
- [Tioga Pharmaceuticals](https://www.nlvpartners.com/essential_grid/tioga-pharmaceuticals/) - NLV–I
- [TigerConnect](https://www.nlvpartners.com/essential_grid/tigertext/) - NLV–II
- [Board Observer](https://www.nlvpartners.com/essential_grid/board-observer/)
- [iRhythm Technologies](https://www.nlvpartners.com/essential_grid/irhythm-technologies/) - NLV–II
- [Investment](https://www.nlvpartners.com/essential_grid/investmenttreato/)
- [Investment](https://www.nlvpartners.com/essential_grid/investment/)
- [Truveris](https://www.nlvpartners.com/essential_grid/truveris/) - NLV–II
- [Advanced Cell Diagnostics](https://www.nlvpartners.com/essential_grid/advanced-cell-diagnostics/) - NLV–II
- [Karos Pharmaceuticals](https://www.nlvpartners.com/essential_grid/karos-pharmaceuticals/) - NLV–II
- [Versartis](https://www.nlvpartners.com/essential_grid/versartis/) - NLV–II
- [CardioKinetix](https://www.nlvpartners.com/essential_grid/cardiokinetix-inc/) - NLV–II
- [Altura Medical](https://www.nlvpartners.com/essential_grid/altura-medical/) - NLV–II
- [Direct Flow](https://www.nlvpartners.com/essential_grid/direct-flow/) - NLV–I
- [Investment](https://www.nlvpartners.com/essential_grid/investmentintarcia-therapeutics-inc/)
- [Vaxinnate](https://www.nlvpartners.com/essential_grid/vaxinnate-corporation/) - NLV–I
- [Illuminoss Medical](https://www.nlvpartners.com/essential_grid/illuminoss-medical/) - NLV–I
- [Board Seat](https://www.nlvpartners.com/essential_grid/board-seatprincipia-biopharma-inc/)
- [Board Seat](https://www.nlvpartners.com/essential_grid/investmentedge-therapeutics/)
- [Calithera Biosciences](https://www.nlvpartners.com/essential_grid/calithera-biosciences/) - NLV–II
- [Board Seat](https://www.nlvpartners.com/essential_grid/board-seat-10/)
- [QPID Health](https://www.nlvpartners.com/essential_grid/qpid-health/) - NLV–II
- [Investment](https://www.nlvpartners.com/essential_grid/board-seatilluminoss-medical/)
- [Spiracur](https://www.nlvpartners.com/essential_grid/spiracur/) - NLV–II
- [Board Seat](https://www.nlvpartners.com/essential_grid/board-seat-7/)
- [VNUS Medical Technologies](https://www.nlvpartners.com/essential_grid/vnus-medical-technologies/) - Sprout
- [Tripath Imaging](https://www.nlvpartners.com/essential_grid/tripath-imaging-fka-autocyte/) - Sprout
- [SGX Pharmaceuticals](https://www.nlvpartners.com/essential_grid/sgx-pharmaceuticals-inc/) - Sprout
- [Sapient](https://www.nlvpartners.com/essential_grid/sapient/) - Sprout
- [Phase Forward](https://www.nlvpartners.com/essential_grid/phase-forward/) - Sprout
- [Pharsight](https://www.nlvpartners.com/essential_grid/pharsight/) - Sprout
- [Onyx Pharmaceuticals](https://www.nlvpartners.com/essential_grid/onyx-pharmaceutical/) - Sprout
- [NxStage Medical](https://www.nlvpartners.com/essential_grid/nxstage-medical/) - Sprout
- [Nuvelo](https://www.nlvpartners.com/essential_grid/nuvelo-inc/) - Sprout
- [ISTA Pharmaceuticals](https://www.nlvpartners.com/essential_grid/ista-pharmaceuticals-inc/) - Sprout
- [IntraBiotics Pharmaceuticals](https://www.nlvpartners.com/essential_grid/intrabiotics-pharmaceuticals/) - Sprout
- [ePocrates](https://www.nlvpartners.com/essential_grid/epocrates/) - Sprout
- [eHealth](https://www.nlvpartners.com/essential_grid/ehealth/) - Sprout
- [Connetics](https://www.nlvpartners.com/essential_grid/connetics/) - Sprout
- [Charles River Laboratories](https://www.nlvpartners.com/essential_grid/charles-river-laboratories/) - Sprout
- [Cephalon](https://www.nlvpartners.com/essential_grid/cephalon/) - Sprout
- [Catalyst Pharmaceutical Partners](https://www.nlvpartners.com/essential_grid/catalyst-pharmaceutical-partners/) - Sprout
- [CareDX](https://www.nlvpartners.com/essential_grid/caredx-inc/) - Sprout
- [Auxilium Pharmaceuticals](https://www.nlvpartners.com/essential_grid/auxilium-pharmaceuticals/) - Sprout
- [Atherogenics](https://www.nlvpartners.com/essential_grid/atherogenics/) - Sprout
- [Aspreva](https://www.nlvpartners.com/essential_grid/aspreva/) - Sprout
- [Aradigm](https://www.nlvpartners.com/essential_grid/aradigm/) - Sprout
- [Allos Therapeutics](https://www.nlvpartners.com/essential_grid/allos-therapeutics/) - Sprout
- [AffyMax](https://www.nlvpartners.com/essential_grid/affymax/) - Sprout
- [Adolor](https://www.nlvpartners.com/essential_grid/adolor/) - Sprout
- [Adeza Biomedical](https://www.nlvpartners.com/essential_grid/adeza-biomedical/) - Sprout
- [Transcept Pharmaceuticals](https://www.nlvpartners.com/essential_grid/transcept-pharmaceuticals/) - NLV–I
- [Concert Pharmaceuticals Inc.](https://www.nlvpartners.com/essential_grid/concert-pharmaceuticals-inc/) - NLV–I
- [Barrier Therapeutics](https://www.nlvpartners.com/essential_grid/barrier-therapeutics/) - NLV–I
- [World Heart](https://www.nlvpartners.com/essential_grid/world-heart-corporation/) - NLV–II
- [Synageva BioPharma](https://www.nlvpartners.com/essential_grid/synageva-biopharma-corp/) - NLV–II
- [MEI Pharma](https://www.nlvpartners.com/essential_grid/mei-pharma/) - NLV–II
- [Intercept Pharmaceuticals](https://www.nlvpartners.com/essential_grid/intercept-pharmaceuticals/) - NLV–II
- [Durata Therapeutics](https://www.nlvpartners.com/essential_grid/durata-therapeutics-inc/) - NLV–II
- [Array Biopharma](https://www.nlvpartners.com/essential_grid/array-biopharma/) - NLV–II
- [Acadia Pharmacuuticals](https://www.nlvpartners.com/essential_grid/acadia-pharmacuuticals/) - NLV–II
- [Convergence Pharmaceuticals](https://www.nlvpartners.com/essential_grid/convergence-pharmaceuticals/) - NLV–II
- [NY Digital Health Accelerator](https://www.nlvpartners.com/essential_grid/ny-digital-health-accelerator/) - NLV–III
- [Investment](https://www.nlvpartners.com/essential_grid/board-seatneuronetics/)
- [Sequana Therapeutics](https://www.nlvpartners.com/essential_grid/sequana-therapeutics/) - Sprout
- [Oriel Therapeutics](https://www.nlvpartners.com/essential_grid/oriel-therapeutics/) - NLV–I
- [Visiogen](https://www.nlvpartners.com/essential_grid/visiogen/) - Sprout
- [Spotfire](https://www.nlvpartners.com/essential_grid/spotfire/) - Sprout
- [Spiration](https://www.nlvpartners.com/essential_grid/spiration/) - Sprout
- [Spine Wave](https://www.nlvpartners.com/essential_grid/spinewave-inc/) - Sprout
- [Sopherion Therapeutics, Inc.](https://www.nlvpartners.com/essential_grid/sopherion-therapeutics-inc/) - Sprout
- [Sirna Therapeutics](https://www.nlvpartners.com/essential_grid/sirna-therapeutics/) - Sprout
- [Selective Genetics](https://www.nlvpartners.com/essential_grid/selective-genetics/) - Sprout
- [Radiant Medical](https://www.nlvpartners.com/essential_grid/radiant-medical/) - Sprout
- [Protedyne](https://www.nlvpartners.com/essential_grid/protedyne/) - Sprout
- [Prometheus Laboratories](https://www.nlvpartners.com/essential_grid/prometheus-laboratories/) - Sprout
- [Point Biomedical](https://www.nlvpartners.com/essential_grid/point-biomedical/) - Sprout
- [Pathology Partners](https://www.nlvpartners.com/essential_grid/pathology-partners/) - Sprout
- [Orquest](https://www.nlvpartners.com/essential_grid/orquest/) - Sprout
- [Nycomed](https://www.nlvpartners.com/essential_grid/nycomed/) - Sprout
- [Lathian Systems](https://www.nlvpartners.com/essential_grid/lathian-systems/) - Sprout
- [Kalypsys](https://www.nlvpartners.com/essential_grid/kalypsys/) - Sprout
- [Intrinsic Therapeutics](https://www.nlvpartners.com/essential_grid/intrinsic-therapeutics/) - Sprout
- [Ilypsa](https://www.nlvpartners.com/essential_grid/ilypsa-inc/) - Sprout
- [Fougera Pharmaceuticals](https://www.nlvpartners.com/essential_grid/fougera-pharmaceuticals-inc/) - Sprout
- [Focus Diagnostics](https://www.nlvpartners.com/essential_grid/focus-diagnostics/) - Sprout
- [Epicor](https://www.nlvpartners.com/essential_grid/epicor/) - Sprout
- [Endocardial Solutions](https://www.nlvpartners.com/essential_grid/endocardial-solutions/) - Sprout
- [Corixa](https://www.nlvpartners.com/essential_grid/corixa/) - Sprout
- [Cellgate](https://www.nlvpartners.com/essential_grid/cellgate-inc/) - Sprout
- [Aspire Medical](https://www.nlvpartners.com/essential_grid/aspire-medical-inc/) - Sprout
- [Stromedix](https://www.nlvpartners.com/essential_grid/stromedix-inc/) - NLV–I
- [Pearl Therapeutics](https://www.nlvpartners.com/essential_grid/pearl-therapeutics/) - NLV–I
- [Interlace Medical](https://www.nlvpartners.com/essential_grid/interlace-medical/) - NLV–I
- [Cerexa](https://www.nlvpartners.com/essential_grid/cerexa/) - NLV–I
- [Biorelix](https://www.nlvpartners.com/essential_grid/biorelix/) - NLV–I
- [Access Closure](https://www.nlvpartners.com/essential_grid/access-closure-inc/) - NLV–I
- [Audax Health Solutions](https://www.nlvpartners.com/essential_grid/audax-health-solutions-inc/) - NLV–II
- [Rock Health](https://www.nlvpartners.com/essential_grid/rock-health/) - NLV–III
- [Investment](https://www.nlvpartners.com/essential_grid/board-seat-altura/)
- [Rock Health Blog](https://www.nlvpartners.com/essential_grid/rock-health-blog/)
- [Board Seat](https://www.nlvpartners.com/essential_grid/board-seatunum-therapeutics/)
- [June 3, 2015](https://www.nlvpartners.com/essential_grid/vaxinnate-advances-quadrivalent-seasonal-influenza-vaccine-candidate-vax2012q-into-phase-2-study-june-3-2015/) - VaxInnate Advances Quadrivalent Seasonal Influenza Vaccine Candidate, VAX2012Q, into Phase 2 Study June 3, 2015
- [June 2, 2015](https://www.nlvpartners.com/essential_grid/june-2-2015spiracur-expands-global-reach-with-the-release-of-new-international-clinical-data-and-the-introduction-of-the-snap-plus-therapy-system/) - Spiracur Expands Global Reach with the Release of New International Clinical Data and the Introduction of the SNaP Plus Therapy System

## Categories

- [Uncategorized](https://www.nlvpartners.com/category/uncategorized/)
- [News 2015](https://www.nlvpartners.com/category/news-2015/)
- [News 2014](https://www.nlvpartners.com/category/news-2014/)
- [News 2013](https://www.nlvpartners.com/category/news-2013/)
- [New Leaf News](https://www.nlvpartners.com/category/new-leaf-news/)
- [Portfolio News](https://www.nlvpartners.com/category/portfolio-news/)
- [News 2016](https://www.nlvpartners.com/category/news-2016/)
- [News 2017](https://www.nlvpartners.com/category/news-2017/)
- [News 2018](https://www.nlvpartners.com/category/news-2018/)
- [News 2019](https://www.nlvpartners.com/category/news-2019/)
- [News 2020](https://www.nlvpartners.com/category/news-2020/)
- [News 2021](https://www.nlvpartners.com/category/nnews-2011/)
- [News 2022](https://www.nlvpartners.com/category/news-2022/)
- [News 2023](https://www.nlvpartners.com/category/news-2023/)
- [News 2024](https://www.nlvpartners.com/category/news-2024/)
- [News 2025](https://www.nlvpartners.com/category/news-2025/)
- [News 2026](https://www.nlvpartners.com/category/news-2026/)

## Project Categories

- [Team Members](https://www.nlvpartners.com/project_category/team-members/)
- [New York City Team](https://www.nlvpartners.com/project_category/new-york-city-team/)
- [San Mateo Team](https://www.nlvpartners.com/project_category/san-mateo-team-team-members/)
- [Vijay Lathi](https://www.nlvpartners.com/project_category/vijay-lathi/)
- [Craig Slutzkin](https://www.nlvpartners.com/project_category/craig-slutzkin/)
- [Ron Hunt](https://www.nlvpartners.com/project_category/ron-hunt/)
- [Active](https://www.nlvpartners.com/project_category/active/)
- [Kyruus](https://www.nlvpartners.com/project_category/kyruus/)
- [Truveris](https://www.nlvpartners.com/project_category/truveris/)
- [TIgerConnect](https://www.nlvpartners.com/project_category/tigerconnect/)
- [Rock Health](https://www.nlvpartners.com/project_category/rock-health/)
- [NY Digital Health Accelerator](https://www.nlvpartners.com/project_category/ny-digital-health-accelerator/)
- [Arvinas](https://www.nlvpartners.com/project_category/arvinas/)
- [Rallybio](https://www.nlvpartners.com/project_category/rallybio/)
- [Anthony Ford](https://www.nlvpartners.com/project_category/anthony-ford/)
- [Star Therapeutics](https://www.nlvpartners.com/project_category/star-therapeutics/)
- [Curasen](https://www.nlvpartners.com/project_category/curasen/)
- [Edgewise Therapeutics](https://www.nlvpartners.com/project_category/edgewise-therapeutics/)
- [BrightInsight](https://www.nlvpartners.com/project_category/brightinsight/)
- [Qlaris Bio](https://www.nlvpartners.com/project_category/qlaris-bio/)
- [Cleerly](https://www.nlvpartners.com/project_category/cleerly/)
- [Electra Therapeutics](https://www.nlvpartners.com/project_category/electra-therapeutics/)
- [Bluesight](https://www.nlvpartners.com/project_category/bluesight/)
- [Kalderos](https://www.nlvpartners.com/project_category/kalderos/)

## Categories

- [All Life Sciences Tools](https://www.nlvpartners.com/essential_grid_category/life-sciences-tools/)
- [All Information Convergence](https://www.nlvpartners.com/essential_grid_category/information-convergence/)
- [All Biopharmaceuticals](https://www.nlvpartners.com/essential_grid_category/biopharmaceuticals/)
- [All Active Companies](https://www.nlvpartners.com/essential_grid_category/active/)
- [All Companies](https://www.nlvpartners.com/essential_grid_category/all-companies/)
- [All Alumni Companies](https://www.nlvpartners.com/essential_grid_category/alumni/)
- [Portfolio Jeani](https://www.nlvpartners.com/essential_grid_category/portfolio-jeani/)
- [Jeani Altura](https://www.nlvpartners.com/essential_grid_category/jeani-altura/)
- [Jeani Reshape](https://www.nlvpartners.com/essential_grid_category/jeani-reshape/)
- [Portfolio Vijay](https://www.nlvpartners.com/essential_grid_category/portfolio-vijay/)
- [Vijay Bluesight](https://www.nlvpartners.com/essential_grid_category/vijay-bluesight/)
- [Vijay TigerConnect](https://www.nlvpartners.com/essential_grid_category/vijay-tigertext/)
- [2015 News](https://www.nlvpartners.com/essential_grid_category/2015-news/)
- [2015 June](https://www.nlvpartners.com/essential_grid_category/2015-june/)
- [Team](https://www.nlvpartners.com/essential_grid_category/team/)
- [Ron Hunt](https://www.nlvpartners.com/essential_grid_category/ron-hunt/)
- [James Niedel](https://www.nlvpartners.com/essential_grid_category/james-niedel/)
- [Craig Slutzkin](https://www.nlvpartners.com/essential_grid_category/craig-slutzkin/)
- [Vijay Lathi](https://www.nlvpartners.com/essential_grid_category/vijay-lathi/)
- [Blogs](https://www.nlvpartners.com/essential_grid_category/blogs/)
- [Bluesight Blog](https://www.nlvpartners.com/essential_grid_category/kitcheck-blog/)
- [TigerText Blog](https://www.nlvpartners.com/essential_grid_category/tigertext-blog/)
- [Truveris Blog](https://www.nlvpartners.com/essential_grid_category/truveris-blog/)
- [Alumni Biopharmaceuticals](https://www.nlvpartners.com/essential_grid_category/alumni-biopharmaceuticals/)
- [Alumni Medical Devices](https://www.nlvpartners.com/essential_grid_category/alumni-medical-devices/)
- [Alumni Information Convergence](https://www.nlvpartners.com/essential_grid_category/alumni-information-convergence/)
- [Alumni Life Sciences Tools](https://www.nlvpartners.com/essential_grid_category/alumni-life-sciences-tools/)
- [Portfolio Ron](https://www.nlvpartners.com/essential_grid_category/portfolio-ron/)
- [Portfolio Isaac](https://www.nlvpartners.com/essential_grid_category/portfolio-isaac/)
- [Portfolio Jim](https://www.nlvpartners.com/essential_grid_category/portfolio-jim/)
- [Portfolio Liam](https://www.nlvpartners.com/essential_grid_category/portfolio-liam/)
- [Liam Neuronetics](https://www.nlvpartners.com/essential_grid_category/liam-neuronetics/)
- [Liam UNUM](https://www.nlvpartners.com/essential_grid_category/liam-unum/)
- [Liam Edge](https://www.nlvpartners.com/essential_grid_category/liam-edge/)
- [Rock Health Blog](https://www.nlvpartners.com/essential_grid_category/rock-health-blog/)
- [Active Biopharmaceuticals](https://www.nlvpartners.com/essential_grid_category/active-biopharmaceuticals/)
- [Active Information Convergence](https://www.nlvpartners.com/essential_grid_category/active-information-convergence/)
- [All](https://www.nlvpartners.com/essential_grid_category/medical-devices/)
- [Kryuus](https://www.nlvpartners.com/essential_grid_category/kryuus/)
- [Deciphera](https://www.nlvpartners.com/essential_grid_category/deciphera/)
- [Liam Arvinas](https://www.nlvpartners.com/essential_grid_category/liam-arvinas/)
- [Liam Aptinyx](https://www.nlvpartners.com/essential_grid_category/liam-aptinyx/)
- [Vijay Kyruus](https://www.nlvpartners.com/essential_grid_category/vijay-kyruus/)
- [Portfolio Dan](https://www.nlvpartners.com/essential_grid_category/portfolio-dan/)
- [Dan Principia](https://www.nlvpartners.com/essential_grid_category/dan-principia/)
- [Portfolio Eric](https://www.nlvpartners.com/essential_grid_category/portfolio-eric/)
- [Eric Treato](https://www.nlvpartners.com/essential_grid_category/eric-treato/)
- [Vijay Truveris](https://www.nlvpartners.com/essential_grid_category/vijay-truveris/)
- [Isaac Braeburn](https://www.nlvpartners.com/essential_grid_category/isaac-braeburn/)
- [Issac Addex](https://www.nlvpartners.com/essential_grid_category/issac-addex/)
- [Isaac ReViral](https://www.nlvpartners.com/essential_grid_category/isaac-reviral/)
- [Martin Mackay](https://www.nlvpartners.com/essential_grid_category/martin-mackay/)
- [Anthony Ford](https://www.nlvpartners.com/essential_grid_category/anthony-ford/)
- [Isaac Passage Bio](https://www.nlvpartners.com/essential_grid_category/isaac-passage-bio/)
- [Portfolio Jeff](https://www.nlvpartners.com/essential_grid_category/portfolio-jeff/)
- [Jeff Curasen](https://www.nlvpartners.com/essential_grid_category/jeff-curasen/)
- [Ron Rallybio](https://www.nlvpartners.com/essential_grid_category/ron-rallybio/)
- [Ron Qlaris Bio](https://www.nlvpartners.com/essential_grid_category/ron-qlaris-bio/)
- [Vijay BrightInsight](https://www.nlvpartners.com/essential_grid_category/vijay-brightinsight/)
- [Isaac Renovacor](https://www.nlvpartners.com/essential_grid_category/isaac-renovacor/)
- [BrightInsight Blog](https://www.nlvpartners.com/essential_grid_category/brightinsight-blog/)
- [Isaac Edgewise](https://www.nlvpartners.com/essential_grid_category/isaac-edgewise/)
- [Vijay Sunbird Bio](https://www.nlvpartners.com/essential_grid_category/vijay-sunbird-bio/)
- [Ron Edgewise](https://www.nlvpartners.com/essential_grid_category/ron-edgewise/)
- [Vijay Star](https://www.nlvpartners.com/essential_grid_category/vijay-star/)
- [Vijay Cleerly](https://www.nlvpartners.com/essential_grid_category/vijay-cleerly/)
- [Ron Curasen](https://www.nlvpartners.com/essential_grid_category/ron-curasen/)
- [Vijay Electra Therapeutics](https://www.nlvpartners.com/essential_grid_category/vijay-electra-therapeutics/)
- [Cleerly Blog](https://www.nlvpartners.com/essential_grid_category/cleerly-blog/)
- [Ron Abcuro](https://www.nlvpartners.com/essential_grid_category/ron-abcuro/)
- [Vijay Flosonics Medical](https://www.nlvpartners.com/essential_grid_category/vijay-flosonics-medical/)
- [Flosonics Blog](https://www.nlvpartners.com/essential_grid_category/flosonics-blog/)
- [Vijay Kalderos](https://www.nlvpartners.com/essential_grid_category/vijay-kalderos/)